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Abstract
Colorectal cancer (CRC) is the fourth most common cause of death from cancer in
the world and second most common (behind lung cancer) in developed countries. In
recent years there has been much interest in the potential use of prebiotics, probiotics
and synbiotics in the prevention and treatment of CRC. We have previously shown
that synbiotic consumption in Azoxymethane treated rats modulates the immune
system, influences the genotoxic potential of caecal contents and reduces the number
of colonic tumours compared to control rats who did not receive the synbiotic. The
aim of the current study was to identify biomarkers suitable for use as cancer risk
markers and as intervention markers. A second aim was to determine the influence
of synbiotic consumption on cancer risk biomarkers such as in vivo colonic mucosal
proliferation and genotoxic damage along with examining the genotoxic, cytotoxic
and tumour promoting potential of faecal water (FW).
Synbiotic consumption altered the composition of the gastrointestinal flora and
reduced in vivo genotoxic damage and the genotoxic potential of FW in cancer and
polyp subjects. Synbiotic consumption also reduced the proliferative activity in the
colonic mucosa in polyp subjects. In both cancer and polyp subjects gene expression
in the colonic mucosa was modulated in synbiotic consuming subjects.
In this and other studies the activity of natural killer cells, the level of PGE2 in FW,
IL-12 production by PBMCs, genotoxic damage in the colonic mucosa and the
tumour promoting activities of FW have been identified as possible biomarkers of
cancer risk. Future large scale studies investigating these parameters in healthy and
diseased individuals are needed to confirm the suitability of these markers in
assessing cancer risk and the role of synbiotics in modulating them.
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1 Introduction
Colorectal cancer (CRC) is the fourth most common cause of death from cancer in
the world and second most common (behind lung cancer) in developed countries
(Figures 1 & 2). The incidence of colorectal cancer increases steeply after the age of
40 and exponentially thereafter. An individual's lifetime risk of developing
colorectal cancer is estimated at five percent but this figure rises rapidly with age: by
the age of 70, approximately half of the Western population will have developed an
adenoma (Fodde et a/. 2001). Individuals with first-degree relatives diagnosed with
colon cancer or adenomatous polyps, have a risk two to three times greater than this.
Colorectal cancer is much more common in developed countries than in developing
countries (Figures 3 & 4). Most recently available statistics show that the incidence /
mortality of CRC in developed countries is 40.0 / 17.7 (males) and 36.6 / 12.3
(females) per 100,000 people compared to rates in developing countries of 10.2 /6.2
(males) and 7.7 / 4.7 (females), (Ferlay et al. 2004). Several hypotheses exist to
explain this dramatic difference, including dietary intake and infectious challenges in
childhood. The interaction of bacterial endotoxins and enterotoxins with the
intestinal epithelium in early life is thought to influence colon carcinogenesis,
reducing the risk in later life and this may explain the differences between these
populations, (Pitari et a/. 2003).
EUCAN statistics from 1998 show the European Union age standardised
(standardised to world figures) incidence of colorectal cancer at 29.36 cases per
100,000 and mortality at 13.63 per 100,000 cases. UK rates were 27.61 (incidence)
and 13.52 (mortality) per 100,000 cases while in Ireland rates were above the EU
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Table 1: Genetic syndromes carrying an increased risk for colorectal cancer
ReferenceCharacteristics
or
LYnch
SYndrome
cancer
(HNPCC)
Hereditary
nonpolyposis
colorectal
polyposis
(FAP)
adenomatous
~'--'-._'.----'---'----------------------r------------,
Syndrome
------.-.-- -----+-----------------------+-----------1
Familial An autosomal dominant syndrome caused by germline Nishisho et al. (1991)
mutation of APC (adenomatous polyposis coli) gene. Kinzler et al. (1991)
Multiple colonic adenomas occur at an early age, Groden et al. (1991)
occasionally during the preteen years, and proliferate
throughout the colon, with malignant degeneration in
most patients by the age of40 to 50 years.
1-------+---_._------ .-.-...-------------+---------~
An autosomal dominant disorder accounts for about 3- Mecklin (1987); Jass &
5% of all CRC cases, caused by mutation of one of the Stewart (1992); LYnch et
DNA mismatch repair genes. Colorectal cancer usually al. (1993); Scapoli et al.
arises from a single colorectallesion in the absence of (1994); Vasen et al.
polyposis. Individuals with a HNPCC gene mutation (1995, 1996) Rodriguez-
have approx. a 70-80% lifetime risk of developing Bigas et al. (1997);
colon or rectal cancer. Accelerated carcinogenesis Boland (1998); Aaltonen
occurs where colonic adenomas may emerge as et al. (1998); Lynch & de
carcinomas within 2-3 YrS, compared to 8-10 YrS. la Chapelle (1999)
Li-Fraumeni
SYndrome
(LFS)
Familial dominantly inherited cancer syndrome Srivastava et al. (1990)
characterised by a wide spectrum of neoplasms Li & Fraumeni (1969
occurring in children and young adults. Cancer may Li et al. (1988)
develop at a very young age, individuals often develop
multiple primary tumours, and there is a high
frequency of cancer within the family. Germline
mutations in the p53 gene are the major cause of the
predisposition to cancer in LFS. It is rare that colon
cancers are the first tumour to develop, however, they
may occur as second or third cancers
f-......... . -..•.•-.__ •.....•..... • --- -.------------- -1- -1
Hamartomatous Peutz-Jeghers syndrome consists of perioral Hemminki et al. (1998)
polyposis pigmentation, upper and lower gastrointestinal
syndromes hamartomatous lesions, small bowel and pancreatic
cancers, colorectal cancer and sex-cord tumours of the
ovary. The mutant gene is LKBI. Other SYndromes of
this type are familial juvenile polyposis, Cowden's
disease, and Bannayan-Ruvalcaba-Riley SYndrome.
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average at 34.12 (incidence) and 15.22 (mortality) per 100,000 cases (Ferlay et ale
1999).
Despite progress in chemotherapy, radiation therapy, and surgery, little change has
occurred in the survival of patients with colorectal cancer. Currently the 5-year
survival rate in Europe is approximately 50%, (Campo el ale 2004). This has lead to
increased research into the aetiology of colorectal cancer with the aim of improving
and developing early detection and prevention strategies.
2 Aetiology of Colorectal Cancer (CRC)
Genetic, experimental and epidemiological studies suggest that colorectal cancer
results from a complex interaction between inherited susceptibility and
environmental factors. Epidemiological studies have shown that changes in cancer
incidence occur in migrant populations moving from environments of low cancer
incidence to high cancer incidence, clearly demonstrating that environmental factors
play an extremely important role in the aetiology of colorectal cancer, (Grandics
2003). The influence of genetic factors is equally well documented as colorectal
cancers occur more frequently in certain families and there are several rare genetic
syndromes that carry a markedly increased risk for CRC (Table 1), (Potter 1999).
In the 1980's the adenoma-carcinoma sequence was first postulated by Vogelstein,
in which the steps required for the development of cancer involve the mutational
activation of an oncogene or oncogenes coupled with the loss of several genes that
normally suppress tumourigenesis. This process was thought to account for up to
4
Figure 5: h ad n rna- ar in rna
an r. dapt d fr rn
Dr th d I pm nt of lor tal
10 inzl r (1993 .
Fi ure 5: h ad n ma- ar in rna
an r. dapt d fr m
fI r th d 1 pm nt
10 inzl r 1993.
90% of cases of colorectal cancer, (Vogelstein et oJ. 1988). This cascade which
describes the multi-step progression from normal epithelium to hyperproliferative
epithelium, to focally dysplastic crypts, to tubular adenoma, to dysplastic or villous
adenoma and finally onto invasive carcinoma and metastasis gave credence to the
commonly held theory that most if not all malignant carcinomas arise from pre-
existing benign tumours. The US National Polyp Study provided evidence
supporting the Vogelstein sequence. This evidence included; the common finding of
foci of cancer in adenomatous polyps, the similar colonic distribution of adenomas
and cancer, the high correlation between the incidence of cancer and the prevalence
of adenomas, and the reduction in the incidence of colon cancer seen following
adenoma removal, (Winawer et aJ. 1993).
Following on from their initial work on the adenoma-carcinoma sequence, Fearon &
Vogelstein (1990) identified the adenomatous polyposis coli (APe) gene, other
genes on chromosome 18q, and the p53 gene as the genes in which mutations or
epigenetic dysregulation contribute to evolution of colon cancer. Based on these
findings they proposed the multi-gene clonal evolution and selection model for the
initiation and progression of colon cancer. This multi-step model involves biallelic
inactivation mutations in the APe tumour suppressor gene as an early event leading
to the development of polyps, followed by inactivating mutations in the oncogene K-
ras in the advancing adenoma, and biallelic inactivating mutations of p53 during the
transition to malignancy in most colorectal cancers (Figure 5), (Fearon & Vogelstein
1990; Vogelstein et oJ. 1988). The types of genomic alterations included point
mutations, and allelic loss events known as loss of heterozygosity (LOH). This
cascade is the classical sequence of events, however, not all mutations are necessary
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for tumour formation and although genetic alterations often occur according to a
preferred sequence it is the total accumulation of these changes, rather than their
order with respect to one other, which determines the biological properties of the
tumour.
As mentioned earlier the aetiology of colorectal cancer is heterogeneous, with
environmental or genetic factors playing varying key roles in different patients,
(Potter 1999). Using the Swedish Family-Cancer Database containing 9.6 million
individuals, Czene et ale (2002) estimated the genetic and environmental components
in fifteen common cancers. They estimated that 13% of colon cancer could be
associated with genetic effects. Thyroid cancer was by far the most associated with
genetics at 53%. The results of this study showed that environment plays a principal
causative role in cancer in all studied sites except for thYroid.
2.1 Microsatellite instability (MSI)
Exogenous and endogenous reagents constantly modify the genomic DNA of all
organisms, (Friedberg et ale 1995). This modification often occurs during the process
of DNA metabolism, commonly during DNA replication where errors may be
introduced into newly SYnthesized DNA strands. Over time numerous processes
aimed at maintaining the integrity of the genome have evolved including base
excision repair, nucleotide excision repair, mismatch repair or recombination repair.
Aaltonen et ale (1993) described a malfunction of the mismatch repair mechanism in
tumours of the colon, endometrium, ovary and other organs targeted by the
hereditary non-polyPOsis SYndrome in humans. Faults in the mismatch repair process
leads to microsatellite instability (MSI). A microsatellite is a rePeated DNA
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sequence in which the length of the core sequence that is repeated is small (one to
five nucleotides). During DNA replication repetitive subunits may be misaligned
leading to elongation or contraction and these abnormalities are usually repaired by
the mismatch repair mechanism. When errors occur in the mismatch repair process
new microsatellite alleles emerge which have lengths that differ from the host's two
parent (Le. normal tissue) alleles for that microsatellite. MSI is found in virtually all
hereditary nonPOlyposis colorectal tumours, (Aaltonen et al. 1994). Most
microsatellites occur in non-coding DNA; therefore, contractions or elongations are
believed to have little or no effect on protein function. However, there are genes that
have microsatellites in their coding regions, and MSI will thus lead to altered
proteins.
Studies have shown that in patients with sporadic cancer, high-frequency
microsatellite instability in CRC is independently predictive of a relatively
favourable outcome and, in addition, reduces the likelihood of metastases, (Gryfe et
ale 2000; Halling et al. 1999). An interesting study by Elsaleh et al. (2000) found
that adjuvant chemotherapy lead to a significantly greater survival rate in patients
with MSI-POsitive tumours.
2.2 Sporadic cancer
Although the genetic process of sporadic cancer is not understood, genes described
in the Fearon and Vogelstein cascade (APC, genes on 18q, ras, and p53), have been
confirmed as affected in sporadic cancers. But mismatch repair genes have also been
implicated, (LYnch & de la Chapelle 2003). The average age of onset of sporadic
cancer is 63 years whereas for hereditary nonPOlyposis colorectal cancer (HNPCC),
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a cancer syndrome characterised by microsatellite instability it is 45 years. It may
well be that in these cancers the accumulation of frame shift mutations in coding
microsatellites leads to a loss of function, further affecting, and perhaps speeding up
the evolution ofcancer.
Genetics also seems to play a role in determining the site at which a tumour will
develop. Proximal colorectal cancers are more likely to have diploid DNA, possess
microsatellite instability; harbour mutations in mismatch repair (MMR) genes, and
behave less aggressively, as in HNPCC. Colorectal cancers involving the distal colon
are more likely to have aneuploid DNA, harbour mutations in the APC, p53 or K-ras
genes and behave more aggressively as in sporadic cancer and also FAP, (Lynch &
de la Chapelle 1999).
2.3 p53
p53 was first identified in 1979 as a protein that complexes with viral oncogenes
such as SV40 large T-antigen, adenovirus E1B and papilloma virus E6, (Levine
1990). p53, or part of it's regulatory circuit, is functionally inactivated in almost all
cancers highlighting it's importance in preventing tumourigenesis (Jin & Levine
2001), and p53 is referred to as the 'guardian of the genome' because of it's role in
checkpoint control following DNA damage (Lane 1992).
DNA may be damaged due to UV radiation, (sunlight) or chemical carcinogens (e.g.
diet). Such damage causes p53 induction and the levels of p53 protein in the cell
increases. Increased p53 halts cell division in the late G 1 phase, allowing the cell
time to repair its DNA, and to ensure that a correct copy of each gene is present
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before allowing the cell cycle to continue, (Kuerbitz et al. 1992). Increased p53 has
been shown to cause aPOptosis in some cells however the reason for this is not yet
understood, (Yonish-Rouach et al. 1991). p53 therefore ensures that the correct
genetic information is present in the cell before allowing the cell to replicate.
The role of p53 in tumourigenesis is highlighted in the Li-Fraumeni SYndrome
(LFS), where the major cause of the predisposition to cancer in LFS families has
been identified as germline mutations in the p53 gene, (Srivastava et al. 1990). p53
itself is not mutated in all cancers; however mutations may be present in genes
involved in the p53 regulatory circuit. p53 regulates its own expression through
feedback loops. One such regulatory mechanism works through a gene called mdm2.
Following DNA repair p53 activates mdm2, and the mdm2 protein product binds to
and inhibits p53 allowing the cell cycle to continue, (Wu et al. 1993). To induce
aPOptosis p53 transactivates the bax gene. There are many genes involved in the p53
functional circuit, the impairment of whose function may play a part in
tumourigenesis, (Miyashita & Reed 1995).
2.4 Multiple Drug Resistance (MDR)
Efflux mechanisms have become the subject ofconsiderable interest in recent studies
ofgut mucosal defence and the pharmacokinetics ofdrugs. The multi-drug resistance
pump (MDR1), also known as P- glycoprotein 170 mediates the efflux mechanism in
the intestinal epithelium. The MDR1 gene may have an important role in the
tumourigenesis of colorectal cancer. It is hypothesised that over-expression of
MDR1 may influence apoptotic pathways by secreting endogenous or xenobiotic
toxic substances into the lumen or by mediating a more generic anti-apoptotic
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function. The MDR1 gene product, P-glycoprotein, protects the cell against a wide
variety of caspase-dependent death stimuli including fas ligand, tumour necrosis
factor, and ultraviolet radiation, (Smith 1998; Smyth 1999). In colorectal tumours
the expression of P- glycoprotein correlates with pathological grading of tumours,
being most intense in the well-differentiated tumours and low in the poorly
differentiated ones, (Potocnik et ale 2002).
2.5 Colonic crypt homeostasis
Homeostasis of the normal colonic mucosa relies on a balance between proliferation
at the base of the crypt and aPOptosis at the surface epithelium. Normal colonic
epithelium is organised in crypts where cell proliferation, migration, differentiation
and aPOptosis are topographically organised in a linear fashion along the crypt axis.
Normal colonic crypts are composed of stem cells at the base, a proliferation and a
differentiation zone in the lower third of the crypt, a migration zone in the upper two
thirds, and the surface epithelium where senescent cells are eliminated by aPOptosis.
Colonic epithelial cells migrate from the base of the crypt to the surface epithelium
in six to seven days.
The stem cells at the base of the crypt are susceptible to somatic mutations and these
mutations persist during migration along the crypt axis but will be eliminated by
aPOptosis at the surface epithelium. However, genes directly involved in the normal
aPOptotic process can themselves be mutated causing a malfunction in the aPOptotic
pathways, (Abdel-Rahman et ale 1999). Dysregulation of aPOptosis in colorectal
adenomas and carcinomas has been correlated with abnormal Bak expression, (Partik
et ale 1998). Studies have also shown dysregulation and mutations in the caspase
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family in colon cancer, especially caspases 3 and 5, (Leonardos et al. 1999;
Schwartz et al. 1999). As a result, cells with mutations in the aPOptotic machinery
will accumulate at the top of the crypt and surface epithelium, be unable to detach
and die, and contribute to neoplastic transformation.
Alternatively genes encoding for cell-cell and cell matrix adhesion proteins can also
be over- or under expressed, or undergo mutations causing resistance to anoikis
(detachment of epithelial cells from the basement membrane). As a result of these
alterations, cells will be unable to undergo the timely detachment and apoptotic
process normally found at the surface colonic epithelium, (Kim et al. 1994).
2.6 Mucins
Mucins are high molecular weight glycoproteins that represent the major secreted
products of the gastrointestinal tract. They are a major component of the mucus
layer, which guards the epithelium of the gastrointestinal tract from mechanical,
chemical, enzymatic, and microbial damage. Mucins are secreted in large quantities
by colon cancer cells, and alterations in mucin expression and glycosylation occur
during tumourigenesis and tumour progression in the colon, (Bresalier et al. 1991,
1996, 1998; Chang et al. 1994; Hanski et al. 1997).
MUC 2 mucin is the major product of the goblet cells in the small and large intestine
in humans and is the principle mucin produced by most colon cancers. Previous
studies have shown that mucins are frequently altered in colon cancers. Such
alterations include differences in mucin-associated antigen expression between
normal colon, preneoplastic adenomas and dysplasia, primary colon cancers, and
12
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metastatic disease, (Bresalier, 1996; Hanisch, 1992; Itzkowitz, 1990; Nakamori,
1993). Studies in athymic mice have shown that mucin production by human colon
cancer cells is correlated with their metastatic potential, (Bresalier et al. 1991) and
specific inhibition of MUC 2 mucin synthesis by antisense technology in cultured
colon cancer cells inhibited colon cancer metastasis and liver colonisation,
(Sternberg et al. 1999). Also, alterations in cellular behaviour such as proliferation,
aPOptosis, and cell migration occur with loss of MUC2 mucin and this could playa
part in the early stages ofcarcinogenesis in the intestine, (Velcich et al. 2002).
3 Risk Factors & Prevention of Colorectal Cancer
Despite advances in surgical techniques and adjuvant therapy, there has only been a
modest improvement in survival for patients who present with advanced neoplasms.
Most colorectal cancers arise from precursor adenomatous polyps that develop into
invasive carcinoma, typically over a five to ten year period or longer. Hence,
effective primary and secondary preventive approaches must be developed to reduce
the morbidity and mortality from CRC. Central to this is the identification of at risk
subjects, who can be targeted for prevention strategies such as chemoprevention
coupled with modification of lifestyle.
• Diet and excess weight
In the case of colorectal cancer diet has long been regarded as the most important
environmental influence and this is reflected in the volume of studies testing the
dietary hypothesis. International variation in the incidence and mortality of
colorectal cancer (Figures 3 & 4), rapid increases in colorectal cancer in several
countries and data on migration patterns and colon cancer support a role for diet in
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the genesis of colon cancer. Many studies of various dietary components have
yielded some evidence for the association of certain dietary habits with CRC while
the evidence on other types ofdiet is conflicting.
A comprehensive epidemiological meta-analysis by Bergstrom et al. (2001) found
consistent evidence of a positive association with obesity. A 2002 report from the
World Health Organisation's International Agency for Research on Cancer
documented that 20-33% of all breast, kidney, colon and endometrial cancers are
related to obesity, (Vainio & Bianchini 2002). A high total fat intake is associated
with increased colon cancer rates whereas rates are lower in populations consuming
less fat, (Rose et al. 1986).
A possible explanation for the association of obesity with cancer has been generated
by epidemiological studies, which demonstrate a close association between colon
cancer risk and insulin resistance. Consumption of high-risk diets provides excess
dietary energy, in response to which intravascular levels of insulin and energy
substrates accumulate leading to increased cell proliferation, (Bruce et al. 2000). If
cells were under normal cell cycle control this proliferative stimulus would have
little effect, however, cells with defective cell cycle control will be stimulated to
proliferate possibly giving rise to tumours. It is not known whether increased insulin
resistance alone leads to increased proliferation or whether other factors are also
involved. Higginbotham et al. (2004) found that diets with high glycemic quantities
(i.e. processed foods such as white bread, white rice, cakes etc.) were associated with
an increased risk of colorectal cancer.
IS
Many studies have shown an inverse association between vegetable intake and colon
cancer, the most convincing evidence being for cruciferous vegetables, (Potter
1997). However there are some cohort studies where the frequent consumption of
vegetables did not appear to confer protection from colon or rectal cancer, (Michels
et al. 2000). The role of dietary fibre in colon cancer was first proposed by Burkitt
(1969) and has been widely studied since then. Some studies have shown a
protective effect against colon cancer, (Trock et al. 1990; Giovannucci et al. 1992;
Howe et al. 1992 ) while other more recent large scale studies, such as the Polyp
Prevention Trial have found no effect of dietary fibre on adenoma recurrence,
(Alberts et al. 2000; Schatzkin et al. 2000). However authors point out that the lack
of effect may be attributed to the age of the study population, the type of fibre,
compliance, and the duration of follow up. So, although the evidence is inconsistent
we cannot definitively say that dietary fibre is not protective against colorectal
cancer and as there are many other health benefits, diets rich in fibre should be
encouraged in subjects considered at risk ofcolon cancer.
Total meat consumption has been studied in two meta-analyses that showed no
statistically significant overall association (Norat et al. 2002; Sandhu et al. 2001).
The same studies found a positive association of red meat and processed meat with
the risk of colorectal cancer. The Nurses' Health Study found that women who
consumed red meat frequently had a 2.5 fold increase in colon cancer risk compared
with women who consumed red meat rarely, (Willett et al. 1990). Overall, the
evidence suggests a strong association of red meat and colorectal cancer.
16
• Physical activity
The relationship between physical activity and reduced risk of colon cancer is among
the most consistent findings in the literature. Studies indicate a consistent inverse
relationship, with a 50% reduction in risk among those with the highest level of
exercise, (Araya et al. 2002; Kiningham, 1998; Colditz et oJ. 1997; Friedenreich,
2001).
• Smoking
Although earlier studies of smoking and colorectal cancer showed no association,
more recent studies have shown long-term smokers to be at elevated risk, with
relative risks typically in the range of 1.5 to 3.0, (Giovannucci et al. 2001). Most
recently interest has focused on the possibility that risk associated with smoking is
modified by polymorphisms in metabolising enzymes (Welfare et oJ. 1997).
• Alcohol
The association between colorectal cancer and alcohol is not clear. Although the
majority of studies suggest a positive association between alcohol consumption and
colorectal cancer, a substantial portion of studies show no association, (potter 1997).
• Hormone therapy
Protective effects against CRC of both hormone replacement therapy (HRT) and oral
contraceptives (OC) have been postulated. The majority of evidence shows an
inverse relationship between postmenopausal HRT and colorectal cancer (Crandall
1999; Potter 1997; Rossouw et al. 2002).
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• Chemoprevention e.g. nonsteroidal anti-inflammatory drugs (NSAIDs)
The sequential process of tumourigenesis provides opportunities for the development
and testing of both primary and secondary prevention strategies. Chemoprevention is
defined as the use of natural or synthetic agents to reverse the process of
carcinogenesis.
Epidemiological studies have consistently shown that chronic intake of nonsteroidal
anti-inflammatory drugs (NSAIDs), principally aspirin, can reduce the incidence of
colorectal adenomas and carcinomas, (Giovannucci et al. 1995; Thun et al. 2002). In
a randomised trial of 1121 subjects with a previous history of adenoma, Baron et al.
(2003) reported a reduction in adenoma recurrence in subjects taking aspirin
compared to subjects in the placebo group. Another randomized trial of 635 CRC
patients who had undergone curative resection, showed that taking 325mg of aspirin
daily led to fewer adenomas and delayed the time of adenoma development
compared to placebo (Sandler et al. 2003).
The cyclooxygenase (COX) family ofenzymes which are involved in the conversion
of arachadonic acid to prostaglandins are believed to be one of the most important
enzyme classes associated with colon cancer. COX-2 has been found to be over
expressed in the hamartomatous polyps of patients with Peutz-Jeghers Syndrome, a
genetic syndrome that carries a markedly increased risk for CRC (McGarrity et al.
2003). Inhibition of COX-2 increases arachadonic acid, which, in tum stimulates the
conversion of sphingomyelin to ceramide, a mediator of apoptosis (Sheng et aI.
1998). COX-2 inhibition may also cause apoptosis by altering prostaglandin
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production and by decreasing angiogenic factors, (Chan et al. 1998; Tsujii et ale
1998).
Waddell & Loughry, (1983) reported that sulindac, an indene acetic analogue of the
NSAID indomethacin, caused the regression of adenomatous polyps in three of four
members of a Gardner's SYndrome family. This observation was confirmed in
uncontrolled studies, case reports, and controlled trials. In a placebo-controlled,
randomised study of 22 patients with familial adenomatous polyposis and
established adenomatous polyps, the effect of 150 mg of sulindac, orally twice a day,
was greater after six months of treatment than after nine months, suggesting the
emergence of resistance to sulindac, (Giardiello et ale 1993). This effect may have
been mediated by a decrease in the expression of COX-2 or other molecular events
such as a mutation in the K- ras gene, (Keller et al. 2001).
More recently, the selective Cox-2 inhibitor Celebrex was also shown to be effective
in familial adenomatous polyposis (Steinbach et ale 2000) and was approved by the
Food and Drug Administration as an adjunct to usual care in these patients. In
addition to demonstrating efficacy, chemopreventive agents must be safe and well
tolerated for chronic administration and should be relatively cost-effective. In
September 2004 the Adenomatous Polyp Prevention on Vioxx (APPROVe)
randomised, placebo-controlled clinical trial, designed to evaluate the efficacy of a
Cox-2 inhibitor marketed as Vioxx in preventing recurrence of colorectal polyps in
patients with a history of colorectal adenomas was stopped. In this study, there was
an increased relative risk for cardiovascular events, such as heart attack and stroke,
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beginning after 18 months of treatment in the patients taking Vioxx compared to
those taking placebo.
Other chemopreventive agents which have been assessed include folate, calcium,
and oestrogens. In the Nurses' Health Study,. supplementation with folate was
protective against colorectal cancer, with the greatest risk reduction among women
taking high daily doses of folate; this reduction became significant only after 15
years of use, (Giovannucci et ale 1998). The long time period required for clinical
benefit suggests that folate acts early in colon carcinogenesis.
Some, but not all, studies of humans consuming high calcium diets or receiving
calcium supplements have shown protective effects against colon carcinogenesis due
to decreased proliferation of colorectal epithelial cells, changes in bile acid
composition, or decreased cytotoxicity of faecal water, (Baron et ale 1995; Bostick et
ale 1995; Holt et ale 1998; Lapre et ale 1993; Lipkin & Newmark 1985).
4 Screening & Diagnosis
Early diagnosis of colorectal cancer is often difficult clinically, as sYmPtoms and
signs only present late in the disease. The presenting features ofcolon cancer include
rectal bleeding, changes in bowel habit, abdominal pain, tenesmus, iron deficiency
anaemia, emergency presentation with large bowel obstruction or perforation and
sYmptoms of malignancy such as weight loss and anorexia. However, screening of
asYmptomatic individuals can lead to detection of the disease at an early stage when
it is more amenable to treatment.
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4.1 Screening
The most widely investigated screening modality has been faecal occult blood
testing (FOBT), a meta-analysis of around 443,000 people aged 40 or over in five
countries concluded that FOBT resulted in a 16% reduction in colorectal cancer
mortality, and when adjusted for attendance for screening, this improved to a 23%
reduction (Towler et aI. 1998). Sigmoidoscopy, colonoscopy or double contrast
barium enema are also commonly used for screening.
The age at which screening is begun and the technique employed is dependant on the
patients' history. The American Gastroenterological Association guidelines for
screening recommends beginning screening in average risk people who are >50
years old, to stratify patients by risk, to offer various options for screening, to follow
up a positive screening test with a colonoscopy, and appropriate and timely surgery
for detected cancers, and follow up surveillance is required after polypectomy and
surgery. Screening begins at a younger age and occurs at more regular intervals in
HNPCC, familial adenomatous polyposis (FAP), inflammatory bowel disease (IBD)
and patients with a family history ofcolon cancer, (Winawer, et al. 2003).
It is obvious that screening leads to earlier diagnosis and reduces the mortality of
colorectal cancer, however, there are many issues regarding the relative cost
effectiveness of the various tests, and specifically whether routine colonoscopic
screening should be the test ofchoice. Further studies are required in this area.
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4.2 Diagnosis
Colonoscopy is an extremely sensitive diagnostic test for colorectal cancer and has
the major advantages ofallowing both biopsy and polyPectomy and does not involve
exposure to ionising radiation. There are some disadvantages however: failure to
reach the caecum in 5-30% of cases, (Theoni & Laufer 1994), intravenous sedation
is nearly always required, tumour localisation can be inaccurate, and there is a small
but significant risk of complications (Atkin 1999; Waye et aJ. 1996). The procedure
related mortality is approximately 1 in 5,000 for colonoscopy and 1 in 50,000 for
sigmoidoscopy and for double contrast barium enema.
In 1981, an Israeli physician, Dr. Gavriel Iddan, began development of a video
camera that would fit inside a pill and now this wireless capsule endoscopy is being
used in clinical settings. The capsule is about the size of a large vitamin capsule and
is resistant to stomach acid and digestive enzymes. It relays video pictures of the
gastrointestinal (GI) tract, via a wireless radiofrequency transmitter, as it moves
naturally via peristalsis. Its main role is in the diagnosis of small bowel disorders and
it is not useful in large bowel lesions as the folds of the lower intestine make
visualisation of the entire colon difficult.
Double contrast barium enema is a radiological procedure using air and barium as
contrast to highlight the lining of the large bowel. It may be employed as a sensitive,
safe alternative to colonoscopy. Combining double contrast barium enema and
sigmoidoscopy results in a sensitivity of 94% and specificity of 99%, (Jensen et aJ.
1990).
22
Computed tomography (Cn colonography is a sensitive method for detection of
colorectal cancer, but not for polyps less than 10mm. Thin section, helical, CT is
followed by off line processing ("virtual colonoscopy") which yields high resolution,
three-dimensional images of the colon, (Miao et 01.2000).
4.3 Tumour markers
Biochemical markers for colorectal cancer are potentially useful in screening for
early disease, aiding diagnosis, predicting likely responses to specific therapies,
surveillance of patients undergoing curative resection, and monitoring the treatment
of advanced disease. Although multiple markers have been described, confusion
remains about how best to use these factors.
Carcinoembryonic antigen (CEA) has been in use for approximately 30 years and is
one of the most widely used tumour markers worldwide. It is a high molecular
weight glycoprotein belonging to the immunoglobulin superfamily of molecules and
is thought to playa role in a number of biological processes including cell adhesion,
immunity and aPOptosis, (Duffy, 2001; Hammarstrom 1999). Inadequate sensitivity
severely limits the value of CEA for the diagnosis of early or low stage colorectal
cancer and the specificity of CEA is also impaired as it is elevated in the absence of
malignancy (e.g. patients with benign liver disease and in cigarette smokers).
A study by Harrison et al. (1997) in 572 node negative colon cancer patients found
that preoperative serum CEA levels may be useful in identifying a subgroup of node-
negative or Dukes' B colon cancer patients that have a poor prognosis, and might
therefore benefit from adjuvant chemotherapy. However there is no current evidence
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that selecting patients for adjuvant chemotherapy based on an elevated preoperative
CEA level is associated with a better prognosis.
An elevated preoperative CEA concentration should return to normal within
approximately 6 weeks following complete surgical resection of a colorectal cancer,
(Filella et 01. 1994). Failure to do so suggests residual or metastatic disease. Serial
monitoring with CEA has been shown to detect recurrent or metastatic disease with a
sensitivity of approximately 80% and specificity of approximately 70%, (Duffy,
2001; Fletcher 1986). CEA is most useful for the early detection of liver metastasis
in patients with diagnosed colorectal cancer.
Although the oldest, CEA is still the best available serum marker for CRC. One of its
major limitations in monitoring, however, is that 20-30% of patients fail to produce
elevated serum levels, despite the presence of advanced disease. For follow up of
these patients, other markers are therefore necessary.
After CEA, Carbohydrate antigen 19.9 (Ca 19.9) is the most widely used tumour
marker. It is the best available marker for pancreatic cancer but it is less sensitive
than CEA for detecting colorectal carcinoma (Duffy, 1998). Elevated preoperative
levels of CA 19.9 have been found to correlate with adverse patient outcome,
(Lindmark et ale 1995; Nakayama et ale 1997; Reiter et 01. 1997, 2000) despite being
of little value in early diagnosis of the disease, (Moertel et 01. 1993).
Other newer markers have been identified, but there is insufficient data available to
recommend their use in the early detection of colorectal cancer. Studies suggest that
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they may provide independent prognostic information. These markers include the
following:
Carbohydrate antigen 242 (CA242) does not detect early stage colorectal cancer.
However this marker may be useful when employed in combination with CEA in the
surveillance of patients diagnosed with cancer, (Hall et al. 1994). TPA (tissue
polypeptide antigen) measures fragments of cytokeratin 8, 18, and 19 and TPS
(tissue polypeptide-specific antigen) and detects fragments of cytokeratin 18. These
have been subjected to limited evaluation in colon cancer. Tissue inhibitor of
metalloproteinase I (TIMP-I) is a multifunctional glycoprotein that inhibits
metalloproteinase activity, stimulates cell growth and inhibits apoptosis, (Chambers
& Matrisian 1997). In a study of TIMP-I levels in blood from healthy individuals,
IBD patients, breast, colon and rectal cancer patients, TIMP-I levels were elevated
in the colon cancer patients only. The specificity / sensitivity of TIMP-I for colon
cancer were 95% / 65% and 95% / 42% for rectal cancer, (Holten-Andersen et al.
2002). Combining CEA and TIMP-l measurements increased the sensitivities above
those obtained for TIMP-l measurements alone.
None of the biochemical tumour markers currently available have the ability to
detect early stage colorectal cancers nor are they 100% specific or sensitive.
Combining markers may provide stronger prognostic information but further work is
needed to validate the use of such combinations. However it should be remembered
that these markers may be elevated in benign conditions such as cirrhosis and
pancreatitis, (Duffy. et al. 2000).
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S Treatment
Treatment depends mainly on the size, location, and extent of the tumour, and on the
patients' general health. Several different types of treatment are used to treat
colorectal cancer and sometimes the treatments are combined.
5.1 Surgery
Surgery remains the definitive treatment for apparently localised colorectal cancer,
offering the only chance of cure. The colon and the rectum are anatomically distinct
and present different difficulties to the surgeon. The principles of radical surgical
resection for colonic tumours have generally remained unchanged in the past few
decades. In patients with colon cancer there is no evidence that radicality of excision
has an effect on outcomes. Rouffet et al. (1994), compared survival in 270 colon
cancer patients. They found that there was no difference in survival in patients who
had undergone segmental colectomy compared to patients who had undergone the
more radical procedure hemicolectomy. Total mesorectal excision (TME) is
recommended for most rectal cancers where the patient is fit for radical surgery,
(Heald et al. 1998; Wiig et al. 1998). As with all surgical procedures there are
complications associated with colorectal cancer surgery. Anastomotic leakage is an
important and potentially fatal complication of CRC surgery, and measures to
minimise it should be taken.
Certain rectal cancers are amenable to local excision. A randomised trial of local
resection for early rectal carcinomas compared outcomes using the gold standard
method ofanterior resection (AR) and the newer, less invasive technique oftransanal
endoscopic microsurgery (TEM). Lower morbidity, shorter operation time and
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hospital stay, less blood loss and less opiate analgesia were associated with TEM,
while local recurrence and survival rates were similar to AR, (Winde et al. 1996).
Evidence from several randomised controlled trials, case control studies, and cohorts
indicate that laparoscopic surgery for colorectal cancer is feasible, and can reduce
postoperative pain, analgesia use, hospital stay and blood loss in the short term,
(Maxwell-Armstrong et al. 2000). But these have the potential for bias as blinding is
impractical. Reliable outcomes are also lacking.
5.2 Staging
Following surgery, pathological investigation of the resected tumour is performed to
assess prognosis and the need for adjuvant therapy. Staging identifies patients who
might benefit from adjuvant chemotherapy, and circumferential resection margin
(CRM) helps select patients with rectal cancer that might benefit from postoperative
radiotherapy, (Adam et al. 1994). Pathological investigation allows tumours to be
classified according to two different staging systems Dukes' and TNM, based on the
extent of local invasion and the presence ofdisease in the lYmph nodes.
The American Joint Committee on Cancer (AJCC) has designated staging by the
TNM classification (AJCC, 1997). T refers to the primary tumour and TX, TO, Tis,
TI, T2, T3 and T4 refers to status of the tumour (invasive, metastatic etc.). N refers
to lYmph nodes, where NX, NO, NI and N2 refers to the presence, absence and
number of lYmph node metastases. Similarly M refers to distant metastasis and MX,
MO, MI refer to the presence, absence and number. Staging is as follows; Stage 0 is
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Tis, NO, MO; Stage 1 is Tl, NO, MO, T2, NO, MO; Stage 2 is T3, NO, MO, T4, NO,
MO; Stage 3 is any T, N1, MO or any T, N2, MO; Stage 4 is any T, any N, MI.
Dukes' staging was created in 1929 by Sir Cuthbert E. Dukes, a pathologist in St.
Mark's Hospital in London and originally described for rectal cancer but is now
applied to all colorectal adenocarcinomas. Dukes' A is where the tumour is confined
to the bowel wall, B is tumour invasion through the bowel wall into the surrounding
tissue, C is lymph node involvement, with C1 where the tumour has not reached the
apical (highest) regional lymph node, and C2 where the apical node is involved.
Dukes himself did not describe a D, but this was later added to refer to distant
metastases. Approximately 10% of patients will present with Dukes A, 20-30% ~ith
Dukes B, 30-40% with Dukes C and the remainder with Dukes D, (Mcleod et ale
2000). Five year treated survival according to Dukes staging is 90% for A, 65% for
B, 30% for C, with 5 year survival of only 5% if distant metastases are present
(Dukes'D).
5.3 Radiotherapy & Chemotherapy
Both radiotherapy and chemotherapy can improve survival rates after potentially
curative surgery, and chemotherapy prolongs overall survival of patients with
advanced disease. The anatomical differences between colon and rectal cancer and
the ease of surgical intervention determine the pattern of recurrence, which defines
the most appropriate adjuvant and relapse treatments. About 50% of recurrences of
rectal cancer occur in the pelvis and are, therefore, amenable to local radiotherapy.
By contrast, relapse of colon cancer is generally at distant sites - liver, lungs and
bone and systemic chemotherapy seems more appropriate. In fact the use ofadjuvant
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radiotherapy in colon cancer has not been shown to improve outcome, (Martenson et
al. 1999).
Fluorouracil has remained the cornerstone chemotherapy for colorectal cancer for
over 40 years. It is a pro-drug that is converted intracellularly to various metabolites
that bind to the enzyme thYmidylate synthase, inhibiting SYnthesis of thYmidine,
DNA, and RNA. The decision to use adjuvant chemotherapy is influenced by the
tumour stage. The absolute survival benefit from adjuvant chemotherapy in Dukes'
C colon cancer is 4% to 13% at five years and the evidence for Dukes' B tumours,
shows no overall benefit from adjuvant chemotherapy (Figueredo et al. 1997;
Marsoni 1995; O'Connell et al. 1997).
Efforts to improve the efficacy of 5-fluorouracil have confirmed the benefit of
including folinic acid. Preliminary results of the SAFFA study (short course adjuvant
5-flurouracil, 5-fluorouracil plus folinic acid) appear to at least support the reduced
toxicity of this regimen in the adjuvant setting (Saini et al. 2000).
There is evidence from two systematic reviews that chemotherapy for metastatic
colorectal cancer can improve survival, and should be considered in all cases (Jonker
et al. 2000; Simmonds 2000). This form of treatment is given with palliative intent,
and a major aim should be to alleviate sYmptoms or delay their onset.
Up to 20% of patients who relapse after apparently curative resection of colorectal
cancer present with disease macroscopically confined to the liver. Studies have
shown that response rates are higher with hepatic artery infusion (HAl) of
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fluorouracil but improvements in survival are meagre (Harmantas et al. 1996;
Kemeny et al. 1999; Lorenz & Muller 2000). Any advantages achieved through the
use of HAl are offset by technical difficulties associated with the technique.
The Swedish Rectal Cancer Trial found that a short-term regimen of high-dose
preoperative radiotherapy reduced the rates of local recurrence and improved
survival among patients with resectable rectal cancer. Patients received either
radiotherapy prior to surgery or surgery alone. After five years of follow-up, the rate
of local recurrence was significantly lower in the radiotherapy group (II %) than in
the group treated with surgery alone (27%). The overall five-year survival rate was
improved in the radiotherapy group (58%) compared to the surgery group (48%) and
the cancer-specific survival rates at nine years were 74% (radiotherapy) and 65%
(surgery), (Renehan et aI. 2002; 1997). In cases of advanced disease, radiotherapy
has the potential to improve operability of unresectable disease, in the curative
treatment of inoperable disease, (Habr-Gama et al. 1998), and in palliative
management of symptoms in patients with persistent or locally recurrent disease,
(Spanos et al. 1993).
5.4 Follow -up
Patients who have undergone curative resection for colorectal cancer should undergo
formal follow up in order to facilitate the early detection of metastatic disease.
Interval CT scanning and CEA estimation may be of value in follow up of patients
who have undergone curative resection for colorectal cancer but further studies are
required to define an optimum approach, (Jeffery et al. 2002; Renehan et al. 2002;
Rosen et al. 1998). Colonoscopy after curative resection for colorectal cancer should
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be carried out as for adenomatous polyps. Clinicians should investigate promptly any
symptoms or signs of recurrence.
6 Need for New Markers
Recent years have seen much research into the aetiology and management of
colorectal cancer and some progress has been made in the areas of therapy, surgery
and follow-up. However the long time period between exposure to a carcinogen and
tumour formation poses a difficult problem when studying the relationship between
suspected aetiological agents of colon cancer and the end point of tumour formation.
In identification of at risk subjects, early detection methods, and methods to monitor
patients during and after treatment, only modest improvements have occurred. The
currently available biochemical markers for CRC discussed earlier are not markers
ofcancer risk and therefore are not particularly useful in cancer risk lowering studies
or in evaluating the effectiveness of prevention strategies. There is a real need for the
development of new, non-invasive, reliable markers predictive of tumour formation,
which are altered by changing risk.
The expression of a biomarker, which is to be used in surveillance or early diagnosis
of cancer should correlate with early stage of the disease, Le. it should be
differentially expressed in normal, pre-malignant and malignant stages. Such
biomarkers have been proposed and developed from an understanding of the chain of
events leading to colon cancer and an understanding of the changes, which occur in
the colon before the manifestation of cancer. With regard to colon cancer there are
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two main types of biomarkers (I) cell and tissue biomarkers and (2) biochemical
biomarkers.
6.1 Cell Biomarkers
As discussed earlier it is now known that during the transition from normal mucosa
to invasive carcinoma multiple molecular alterations occur at the genome level,
(Fearon & Vogelstein 1990). It seems logical to hypothesise that these genes, which
undergo mutation during the carcinogenesis process, might provide markers that are
relatively specific to malignant and premalignant disease and also aid early
diagnosis. Cells containing these abnormal DNA (e.g. mutant p53 or ras genes)
sequences are shed into the lumen by exfoliation and can be detected in the stools of
colorectal cancer patients, urine in bladder cancer patients and sputum in lung cancer
patients, (Duffy, 1995).
The presence of DNA adducts in the colonic mucosa is associated with increased
risk ofcolon cancer, (Pfohl-Leszkowicz et al. 1995). DNA adducts are formed when
carcinogenic or mutagenic substances (from the diet or environment e.g. polycyclic
aromatic hydrocarbons PeA) covalently bind to DNA. Oxidative DNA adducts have
been shown to be increased in all stages of colorectal carcinogenesis and also in
polyps of FAP patients, (Hendrickse et al. 1994; Schmid et al. 2000). Mucosal cells,
which have been sloughed off in the colon, are excreted in the faeces. DNA adducts
can be measured in faecal samples and as such seem a promising choice as a non-
invasive biomarker.
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6.2 Tissue Biomarkers
There are many different types of tissue parameters, which have been proposed as
possible biomarkers. Tissue biomarkers are analysed in tissue biopsies, which may
be obtained by a number oftechniques ofvarying levels of invasiveness.
6.2.1 Proliferation
As discussed earlier dysregulation of colonic crypt homeostasis is associated with
increased risk of CRC. In the normal colonic mucosa proliferation occurs in the
lower third of the crypt, and as cells mature they move to the top of the crypt where
they are eliminated by aPOptosis and eventually sloughed off. However in the
abnormal situation, e.g. polyp or tumour formation, proliferation occurs throughout
the entire crypt often with the zone of maximum activity occurring at the top of the
crypt (Figure 6).
Proliferative activity is one of the most commonly used biomarkers to assess cancer
risk and to monitor the effectiveness of risk lowering strategies. Studies have shown
that subjects at high risk ofcolon cancer, such as subjects with familial adenomatous
polyposis (Mills et al. 2001), ulcerative colitis (Shinozaki et al. 2000) or sporadic
colon cancer (Roy et aI. 1999) have a high mucosal proliferative activity as
compared to controls. de Leon et al. (1988) reported that proliferation in the upper
crypt was significantly increased in patients with polyps and colorectal cancer
compared to healthy controls. In animal models of carcinogenesis, the carcinogen
often increases cell proliferation and causes a shift in the zone of proliferation.
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In human populations different geographic zones with variable colon cancer
incidence show different proliferation patterns in the colorectal mucosa e.g., in
Trieste, northern Italy, which has a colon cancer incidence of 30.9 / 100,000
proliferation is higher than in Florence in central Italy where colon cancer incidence
(21.9/ 100,000) is lower, (Dolara et oJ. 2000).
Caderni et oJ. (1999) investigated the influence ofdifferent diets in subjects who had
previously had at least two sporadic colonic adenomas removed. They found that
subjects reporting a diet rich in fish, starch, and p-carotene and low in red meat had
lower colorectal mucosa proliferation and a normal pattern of proliferation along the
crypt. Also patients who had had villous adenomas (considered to have higher
malignant potential) tended to have a higher proliferative activity than patients who
had had tubular adenomas and that proliferation was higher in the upper
compartment in subjects who ate the most red meat.
Mucosal cell proliferation is easily measured in biopsy samples. A commonly
employed method to measure the proliferative activity in tissue sections is
immunostaining for proliferating cell nuclear antigen (PCNA). Another commonly
used method involves incubating a biopsy sample with 3[H]-thymidine and the level
of thymidine incorporation being measured by autoradiography where tissue sections
are dipped in photographic emulsion containing a dense suspension of very small
grains. Slides are then developed by standard photographic procedures, stained with
haematoxylin-eosin and radiolabelled cells are visualized due to an accumulation of
dark grains. An advantage of this method is that it determines the rate as well as the
zone of proliferation. To date studies assessing the association of proliferation and
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cancer risk have produced variable results and the usefulness of proliferation as a
biomarker is still under consideration, (Mills et 01. 200 I; Sandler et 01. 2000).
However, inclusion of apoptosis and differentiation markers in studies assessing
proliferative activity may strengthen this parameter as a biomarker.
6.2.2 Genotoxic Damage
The human colon is continually exposed to a complex mixture of compounds, which
are either of direct dietary origin or the result of digestive, microbial and excretory
processes. It is therefore useful to develop methods to analyse the mutagenic burden
to which the colonic mucosa is exposed, and develop strategies to reduce this
burden. The mutagenic potential of a compound has traditionally been measured
using the Ames test. Mutagenicity is determined based on the ability of the test
substance to induce mutations in Salmonella typhimurium. Bruce et al. (1977) first
reported on the mutagenicity oforganic faecal extracts using this assay. However the
usefulness of this method is limited as the mutagenic potential of a substance is
evaluated using prokaryotic cells, limiting the ability of this method to identify
human carcinogens. In recent years, the use of methods, which measure genotoxic
damage in eukaryotic cells, have proven to be more promising as an indicator of
cancer risk.
One class of mutagenic agent of particular interest in the area of CRC are genotoxic
agents. Genotoxic agents cause cellular DNA damage but are not cytotoxic to the
cell. One of the most commonly used methods to assess genotoxic damage is the
single cell microgelelectrophoresis assay or comet assay, which was developed by
(Ostling & Johanson 1984), and modified by (Singh et al. 1988), as the alkaline
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comet assay. Briefly, a single cell suspension is prepared either from a cell line or
cells isolated from the target organ and treated with the agent under investigation.
Cell numbers and viabilities are assessed. The cells are then immobilised in agarose
on a glass slide and treated to lyse the cell membrane. This is followed by a period of
alkaline treatment to allow unwinding of DNA. An electric current is then applied to
the DNA and broken DNA fragments (damaged DNA) migrate away from the
nucleus producing tail lengths, which vary based on the amount of DNA damage.
This method has been used to study the genotoxic potential of substances (e.g.
heterocyclic amines) associated with cancer risk in freshly derived colon cells from
healthy subjects (Pool-Zobel & Leucht 1997). Hambly et al. (1997) investigated the
influence of diets containing high and low risk factors for colon cancer on 1,2-
dimethylhydrazine (DMH) induced carcinogenesis in human flora-associated (HFA)
rats using DNA damage as one of the end point markers. DNA damage was
significantly higher in colon cells from animals on the high-risk diet.
(Schaeferhenrich et al. 2003) described a novel in vitro method in genetic toxicology
using the comet assay to detect DNA damage connected with altered migration of
the tumour protein p53 in primary human co1onocYtes. Further refinement of this
method may perhaps generate another biomarker for genotoxicity and cancer risk.
6.2.3 Gene expression
Studies of the gene expression profiles of tumours, polyps and normal tissues help to
identify genes involved in the carcinogenic process and to determine their potential
usefulness as risk I diagnostic markers or as intervention biomarkers. As previously
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discussed the expression of oncogenes, tumour suppressor genes and DNA repair
genes are often altered in cancer. Using molecular techniques such as gene array
analysis, the expression of these genes can be investigated and alterations in normal
gene expression levels can be identified. Polymorphisms of certain genes have been
associated with CRC risk. Some polymorphisms in genes, which encode the
cytochrome P450 enzyme family lead to altered expression of the active enzyme and
their increased expression is found in individuals with a history of CRC, (Kiss et al.
2000; Martinez et al. 2001).
The Glutathione S-transferase (GST) enzyme family are important detoxification
enzymes, which catalyse the conjugation of xenobiotics with glutathione. GSTJ.1
enzymes are more effective at detoxifying potential cytotoxic and genotoxic
epoxides than other GSTs. Polymorphisms in the GSTJ.1 gene leading to loss of or
decreased enzyme function have been characterised in healthy individuals who later
went on to develop colorectal and gastric cancers, (Chenevix-Trench et al. 1995).
It must be remembered that cancer arises from an accumulation of mutations in a
single cell. Therefore genotyping of neoplasms has proven useful in detecting
mutated genes whose loss or altered function may contribute to the carcinogenic
process and which may prove useful as diagnostic / intervention biomarkers.
6.3 Biochemical marken
Biochemical markers can be measured in blood, urine and faeces and samples are
obtained by less invasive methods than for tissue biomarkers. There are two types of
biochemical markers (1) gut flora associated biomarkers which include bacterial
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enzymes and faecal metabolites and (2) mammalian enzymes for example GSTs and
the Cytochrome P450 family.
6.3.1 Gut flora associated markers
The use of gut flora associated biomarkers is not a new concept. The normal colonic
microflora produces enzymes such as J3-glucuronidase, J3-glucosidase, nitrate
reductase, nitroreductase and azoreductase, the activities of which have been
implicated in colon carcinogenesis.
The liver is the site where metabolism of many toxic and carcinogenic compounds
occurs. These compounds are conjugated with glucuronic acid and are then excreted
via the bile into the small intestine. However bacteria in the colon produce J3-
glucuronidases which hydrolyse the glucuronide conjugates and release potential
carcinogens and mutagens into the lumen thereby increasing the risk of tumour
formation.
Many studies have confirmed the role of bacterial derived colonic J3-glucuronidases
in colorectal cancer. Reddy et al. (1974) found that germ free rats treated with the
carcinogen 1,2-dimethylhydrazine (DMH) or Methylazoxymethanol (MAM)-
glucuronic acid, which is formed following bacterial deconjugation of DMH, had
fewer colonic tumours than rats with a normal flora, confirming the role of this
enzyme in the promotion of carcinogenesis. The activity of J3-glucuronidases in the
gastrointestinal tract is influenced by diet. Diets considered high risk for CRC have
been associated with increased J3-glucuronidase activity compared to low risk diets,
(Eriyamremu & Adamson 1995; Hambly et oJ. 1997b). Kim & Jin (2001) reported
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that faecal ~-glucuronidase activity was 1.7 fold higher in patients with colon cancer
than in controls. However when these faecal samples were sonicated the enzyme
activity of patients with colon cancer was 12.1 fold higher than that of healthy
controls.
Diets high in fruit and vegetables are considered low risk for colon cancer. However
fruit, vegetables and drinks produced from plants (e.g. wine), contain plant
glycosides, which consist of low-molecular weight substances linked to sugar
moieties. Plant glycosides are poorly digested in the upper GI tract and reach the
colon in their safe glycosidic form. ~-glucosidases produced by the colonic flora
cleave the sugar moieties releasing toxic, mutagenic or carcinogenic aglycones,
(Hughes & Rowland 2000). The breakdown of plant glycosides to aglycones is
influenced by the composition and metabolic activity of the gut flora.
Nitroreductases reduce aromatic and heterocyclic nitrocompounds, which are found
in cigarette smoke and diesel exhaust, to potentially toxic N-nitroso and N-hydroxy
compounds. Bacterial nitrate reductases produced in the colon convert nitrate
ingested in food and water to nitrite. Oxides of nitrogen derived from nitrite may
further react with amines and amides to produce N-nitroso compounds many of
which are highly carcinogenic. Red meat increases colonic N-nitrosation, which may
explain the positive association between red meat intake and CRC risk. Hughes et al.
(2002) reported that excretion ofN-nitroso compounds was reduced by consumption
of soy in seven male volunteers consuming a high red meat diet.
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Another bacterial derived enzyme associated with cancer is azoreductase, which
promotes the reduction of azo food dyes to substituted phenyl and naphthyl amines,
which are potent carcinogens.
6.3.2 Mammalian enzymes
One of the most important phase II detoxifying enzYmes are the glutathione-S-
transferase (GST) family (alpha [al, pi [1tl and mu [J.1]) which are known to
inactivate a number of genotoxic and carcinogenic risk factors by catalysing their
conjugation with Glutathione and a reduction in their activity is associated with an
increased risk of colon cancer (Szarka et al. 1995). Thus the inducibility of GSTs in
normal tissues is a marker of chemoprevention. In contrast, human colonic tumours
express high levels of GST, and especially GST placental enzyme pi tyPe (GST-P);
this characteristic is associated with failure of cancer chemotherapy and poor patient
survival, (Sutoh et 01. 2000).
Szarka et al. (1995) measured the GST activity of blood lymphocytes of healthy
control individuals and individuals at high risk for colon cancer. They found that the
GST activity of blood lYmphocytes from high-risk individuals was significantly
lower than that of blood lYmphocytes from control individuals. They also measured
GST activity in colon tissue from the high-risk individuals and paired analysis
indicated a strong correlation between the GST activity of blood lymphocytes and
colon tissue. Further work is needed, but the use of GST activity as a biomarker for
cancer risk and to monitor responsiveness to treatment is a promising prospect.
(Hengstler et al. 1998) reported that the expression ofGST a and 1t was significantly
increased in tumour tissue compared to adjacent normal tissue in the colon.
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6.4 Faecal water activity
The colonic mucosa is continually exposed to the end products of diet, digestive and
excretory processes as well as the metabolic activities of the gut flora many of which
are carcinogenic and mutagenic. Colonic tumours arise from damage to the colonic
mucosa, which is as a result of interactions with damaging components in the gut
luminal contents. The aqueous phase of faeces called faecal water (FW) contains
most of the free reactive and soluble factors, which interact with the mucosa in vivo,
Rafter et aJ. (1987). The genotoxic and cytotoxic potentials of FW are considered as
measures of the potential of the dissolved factors to induce damage in the colonic
mucosa and have become popular intervention biomarkers in recent years.
6.4.1 FW Genotoxicity
Venturi et aJ. (1997) were the first to use the comet assay to assess the ability of FW
from healthy individuals to induce genotoxic damage in Caco-2 cells. More recent
studies have shown that there is an inter- and intra-individual variation of faecal
water genotoxicity even in subjects consuming the same diet (OJ3wald et oJ. 2000;
Woods et oJ. 2002). Despite this variation, OJ3wald et oJ. (2000), have suggested that
FW genotoxicity is suitable as a biomarker for application in intervention studies
when each subject is analysed as his or her own control.
A study by Rieger et al. (1999) in which healthy volunteers consumed a diet high in
fat and meat, but low in fibre for twelve days (high CRC risk) followed by a high
vegetable and wholemeal, low fat and meat diet (low CRC risk) for another twelve
days found that the genotoxic damage induced by FWs from the high risk diet was
approximately twice as high as damage induced by the low risk diet.
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6.4.2 FW Cytotoxicity
Many of the substances to which the colonic mucosa is exposed induce cytotoxic
damage leading to cell death. Stimulation of proliferation in the colon is, in part, to
compensate for the loss of cells due to cytotoxic mechanisms, causing an increase in
mitotic activity, increasing the risk of colon cancer. The cytotoxic potential of faecal
water is now accepted as a risk marker for colon cancer, (Lapre & Vander Meer
1992; Lipkin 1991) and in vitro faecal water cytotoxicity towards colon cells is often
employed as a biomarker in intervention studies.
van Muster et 01. (1994) demonstrated that the consumption of resistant starch (a
prebiotic) significantly decreased proliferation in rectal biopsies and the cytotoxicity
of faecal water in healthy volunteers. Glinghammar et 01. (1997) demonstrated that a
shift from a dairy-product rich diet (low cancer risk) to a dairy product-free diet
(high risk) increased cytotoxicity of FW from healthy volunteers; however the
genotoxic potential of FW was unaltered. The exact mechanism by which dairy
products lower cancer risk is unknown however it may be speculated that, in this
study, the increase in cytotoxicity may have been due to the reduction of calcium in
the diet.
6.4.3 Gene modulation by FW
Zeng & Davis (2003) reported that incubation of HT-29 cells with human FW
induced apoptosis, reduced cell growth, decreased the mRNA levels of cyclin A and
PCNA, and increased the levels of cyclin-dependent kinase inhibitor gene, p21 waft •
Further investigation of the influence of FW on these parameters may lead to the
development ofa novel approach for assessing the effect ofdiet on colon cancer risk
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7. Gut Microflora
As discussed previously diets high in fat and low in fibre are associated with a high
risk of colon cancer whereas diets high in fibre, fruit and vegetables and low in red
meat are considered low risk for colon cancer. It is not certain how diet affects
cancer risk but it is likely that a combination of diet and host genetic factors
influences the composition and metabolic activity of the gut flora therefore
influencing the carcinogenesis process.
7.1 The Gastrointestinal. (GI) Tract
The 01 tract harbours a rich flora of greater than 500 different bacterial species; the
human body contains 10 times more bacteria than it does eukaryotic cells. After the
respiratory tract the 01 tract constitutes the second largest body surface area. The
human gastrointestinal tract consists of the oral cavity, oesophagus, stomach, small
intestine (duodenum, jejunum, ileum), large intestine (caecum, colon) and the
rectum.
The mucosal surface of the adult human gastrointestinal tract measures up to 300 m2,
making it the largest body area in contact with the external environment. In
comparison the skin surface measures only 2m2• Only a single cell layer thick, the
large surface area in the gastrointestinal tract is achieved by different degrees of
folding (villi and microvilli) of the mucosal surface, Holzapfel et ale (1998). This
large surface area provides the required space for the interactions of the digestive
process and allows bacterial adhesion to the mucosal wall and colonisation. During a
normal lifetime 60 tonnes of food pass through this canal, which is essential for
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health, but also poses a significant threat to the integrity of the digestive tract and the
body as a whole, (Bengmark 1998).
Savage (1977), described the nonnal flora as being composed of the autochthonous
and allochtonous flora. The autochthonous flora refers to microorganisms that
natively colonize a particular habitat or environmental niche and are present in all
communities of a particular animal species. The allochtonous flora refers to
microorganisms that cannot colonize a particular habitat, except under abnonnal
circumstances. However these tenns are little used today and the tenns nonnal and
indigenous flora are used interchangeably to describe the microorganisms, which
nonnally inhabit the gastrointestinal tract, (Berg 1996).
7.2 Development of the gastrointestinal flora
Colonisation of the GI tract of newborns begins immediately after birth and bacteria
can be found in the faeces within a few hours of birth. Certain microorganisms
colonize particular intestinal habitats at various times following birth, which are
characteristic of that particular habitat and host. This is a process known as bacterial
succession. Bacterial populations develop during the first day of life and the
composition of the gut flora in newborns is influenced by the delivery method
(passage through the birth canal versus caesarean section) and also by the diet (breast
fed versus fonnula fed). Breast-fed infants have been shown to have a lower risk of
gastrointestinal infections than fonnula-fed infants. Infants delivered by caesarean
section have far fewer lactobacilli in the early stages of life than those delivered
vaginally (Collins & Gibson 1999).
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Cooperstock & Zedd (1983) divided the development of the intestinal microflora in
infants into four phases, 1) weeks 1-2, initial acquisition, 2) breast-feeding alone, 3)
introduction of supplementation and cessation of breast-feeding and 4) cessation of
breast-feeding and conversion to adult like flora.
Initially the facultative anaerobes such as E. coli and streptococci are dominant, and
produce a reduced environment allowing the establishment of anaerobic bacteria
such as Bacteroides, bifidobacteria and clostridia, generally by day 4-7, (Stark & Lee
1982). In breast fed infants bifidobacterial numbers increase sharply, while E. coli
and streptococci decrease, and clostridia and Bacteroides are low or absent. This
change does not occur in formula fed infants and the composition of the
gastrointestinal flora becomes rather complex with high numbers of Bacteroides,
clostridium and streptococci, and bifidobacteria, although present, are in much lower
numbers than in breast fed infants. During phases 3 and 4, following the introduction
of solid food and weaning, the flora becomes similar to the normal adult flora, and
the composition of the flora while being distinct for each individual, remains
relatively stable throughout life, (Holzapfel et oJ. 1998).
7.3 Microbial distribution in the gastrointestinal tract
Mackie et 01. (1999) stated that "indigenous bacteria are not distributed randomly
throughout the gastrointestinal tract but instead are found at population levels and in
species distribution that are characteristic of specific regions of the tract". The
distribution of the normal flora of an adult human is shown in Figure 7. The oral
cavity contains an indigenous flora of about 200 species, however, most of these are
washed into the stomach with saliva and most research of 01 tract flora centres
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around the stomach, small and large intestines and faecal matter.
After the relatively neutral environment of the oral cavity the low pH of the stomach
(pH 2.5 to pH 3.5) is destructive to most microorganisms and bacterial numbers are
low (l01 and 103 cfu/ml of contents). Following a meal bacterial numbers in this
region may increase temporarily 100 to 1000-fold due to increases in pH, (Lambert
& Hull 1996). Acid tolerant Gram-positive species such as streptococci and
lactobacilli predominate in the stomach and duodenum. Helicobacter pylori a
significant causative agent of gastritis in adults, thrives on the mucosa of the
stomach (Berg 1996). Bacterial numbers are also low in the duodenum due to the
detrimental effects of biliary and pancreatic secretions and also the short transit
times.
The concentration and variety of microorganisms increase significantly in the distal
small intestine (Ileum). Here bacterial numbers of 108 cfu/ml of intestinal contents
are found, consisting mainly of species of streptococci, lactobacilli, bifidobacteria,
bacteroides, fusobacteria and enterobacteriaceae, (Nielsen et al. 1994).
The primary site of microbial colonisation in humans and animals is the large
intestine, possibly due to the low oxidation-reduction potentials and the slow
intestinal motility in this area (transit times up to 60hr), (Tannock 1995). Bacterial
numbers exceed 1010_1012 cfu/g and represent 40-55% of luminal contents. It is
thought that greater than 400 different species inhabit the colon, however a
considerable number of these remain unculturable using existing culture techniques.
It is also important to note that 99.90.4 of the indigenous flora of the large intestine
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are obligate anaerobes. Genera such as Bacteroides, Eubacterium, Bifidobacterium
and Peptostreptococcus dominate at levels of approximately IOlO-I011cfulg.
Enterobacteriaceae, streptococci and lactobacilli are also present at levels of
I08cfulg, (Naidu et al. 1999).
Faecal samples are most often used to study the colonic flora. However, the bacteria
found in faecal samples represent the luminal environment and may differ greatly
from the flora of the mucosa. The faecal flora may indicate the bacteria present in
the distal colon but is not a true indication of the flora of the transverse and
ascending colon and certainly not of the flora of the small intestine. Investigation of
faecal samples alone may underestimate true bacterial numbers, and many
researchers suggest that microbiological investigation of biopsy samples may give a
truer indication of the diversity of the colonic flora, however this approach is much
more difficult.
Within the GI tract bacteria are found in different microhabitats stretching from the
gut lumen to the mucosal epithelium, (Freter 1992). These microhabitats are;
1. Surface of the cells of the epithelium
2. Crypts of the ileum, caecum and colon
3. Mucus gel that overlays the epithelium
4. Lumen of the intestine
Certain bacteria reside freely in the gut lumen possibly associated with the surface of
particles. Others colonize the crypts or adhere to the mucus layer or to the surface of
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epithelial cells. The obligate anaerobes associate intimately with the gut wall to form
layers on the mucosal epithelium (Berg 1996).
7.4 Unculturables
Of the 400 different species of bacteria inhabiting the colon, a considerable number
are unculturable using existing culture techniques. Traditional culture techniques
depend on the use of selective media for the enumeration of bacterial genera or
species of interest and are limited in their potential to reproduce the complex mixture
of gases and nutrients present in the colon. Therefore such techniques provide a
limited view of the diversity of the flora and comparison of results from electron
microscopic investigation of the gastrointestinal flora and traditional culture counts
has demonstrated that culture methods yield only between 50 to 80% of the total
microscopic counts, (Tannock 2001).
Recent years have produced major advances in the area of molecular biology and the
development of the tools required to study the diversity of complex bacterial
environments without the use of traditional culture methods. Molecular methods
have indicated that 60-80% of the organisms in the total human microflora have not
been cultivated, (Langendijk et ale 1995). These molecular techniques are based on
16S ribosomal RNA (l6S rRNA) gene sequences which contain regions that are
conserved across all bacterial SPecies and are interspersed with regions in which
sequences are variable among bacterial types, (Stackebrandt & Rainey 1995).
Microbial DNA is extracted from faecal samples and from the OJ tract and the 16S
rRNA gene sequences are amplified by polYmerase chain reaction (PeR). Two
methods for analysing the PeR products are denaturing gradient gel electrophoresis
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(DGGE) and temperature gradient gel electrophoresis (TOOE). DGGE is based on
electrophoresis of peR-amplified 16S rONA fragments in polyacrylamide gels
containing linearly increasing gradients of denaturants allowing DNA fragments of
the same length but with different base-pair sequences to separate, (Muyzer et ale
1993). TGGE separates rONA fragments in polyacrylamide gels with a temperature
gradient. With both DGGE and TOOE specific DNA fragments can be excised from
the gel and sequenced to identify the bacterial species represented by the particular
band.
Fluorescent in situ hybridisation (FISH) is also based on the 16S rRNA region. With
this method rRNA targeted oligonucleotide probes specific for phylogenetic groups,
are used for the in situ identification of individual bacterial cells in a complex
environment, (Amann et ale 1995).
Suau et al. (1999), investigated the bacterial diversity within an adult-male faecal
sample using comparative analysis ofcloned 16S rRNA gene sequences. They found
that the majority of the generated rONA sequences (76%) did not correspond to
known organisms. The use of these molecular methods is greatly contributing to our
understanding of the diversity of the gastrointestinal ecosystem and with further
developments in methods the possibility of identifying all components of the gut
microflora no longer seems an impossible dream.
7.S Functions of the Gut Microflora
With more bacterial cells in the gut than eukaryotic cells in the entire body, the gut
has often been described as the forgotten organ. The collective metabolic activity of
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the normal flora would rival that of the activity of the liver, (Berg 1996; Bocci
1992). The functions of the intestinal microflora contribute to the health of the host
in many ways.
The important effects that the gut microflora exerts on its host have been revealed
through the comparative studies of animals bred under germ-free conditions and
conventional animals with a normal indigenous flora. Such studies have shown that
the microflora has an influence on the physiological and immunological
characteristics of the host. Germ-free animals have been found to have:
• No intestinal plasma cells
• Smaller Peyer's patches
• A slower intestinal passage
• A lower intestinal motility
• A retarded gastric emptying
• An accelerated carbohydrate absorption
• An enlarged caecum
(Schaafsma 1997)
The beneficial activities of the normal gut flora include vitamin synthesis, and
improved absorption of minerals by the host e.g. calcium, magnesium and iron,
(Younes et a/. 2001). The flora is also involved in the conversion of pro-drugs to
their active form and the metabolism of carcinogens ingested in the diet to both
active and inactive compounds. It is thought that the composition of the flora
influences whether ingested carcinogens are converted to active or inactive forms.
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7.5.1 Metabolism
A major metabolic activity of the colonic microflora is the fermentation of non-
digestible dietary residues and endogenous mucus produced by epithelial cells,
which results in the production of absorbable substrates and energy for the host, and
a supply of energy and nutrients for bacterial growth, (Guarner & Malagelda 2003).
The major source of energy within the colon is the fermentation of carbohydrates by
the colonic flora, the endpoint of which is the production of short-chain fatty acids
(SCFA). SCFAs provide between 10-30% of basal metabolic requirements
(including energy for liver cells, colonocYtes and peripheral tissues) and only 5% of
SCFA is excreted in the faeces, (Dunne 2001). Acetate, propionate and butyrate are
the principal SCFA produced in the colon.
Acetate traverses the liver and enters the peripheral circulation. Propionate is
extracted by the liver and effects lipid metabolism, (Bridges et aJ. 1992). Butyrate is
a major source of energy for colonocytes and is almost completely consumed by the
colonic epithelium. Only a portion of butyrate leaves the colon for extraction by the
liver. Butyrate has been associated with many biological properties in the colon and
is thought to directly enhance cell proliferation in normal cells and suppress
proliferation in transformed cells. In addition, apoptosis may be increased in
transformed cells but inhibited in normal cells when butyrate is present, (Hague et aI.
1995; Hass et aI. 1997; Marchetti et aI. 1997). Butyrate is known to reduce risk
factors involved in the aetiology of colon cancer and adenoma development, (Smith
et aJ. 1998).
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7.5.2 Barrier to infection
The normal flora plays a major role as a physical barrier against pathogenic and
opportunistic infection. Germ-free animals, which lack a gut flora, are very
susceptible to infections. In humans the importance of this barrier effect or
colonisation resistance is best demonstrated when the composition of the normal
flora is altered by broad-spectrum antibiotic therapy. In such cases the use of
antibiotics disturbs the normal balance allowing the overgrowth of opportunistic
bacteria, which are normally resident in the gut but have restricted growth, leading to
diarrhoea and other symptoms. Clostridium difficile overgrowth is often an unwanted
side effect ofantibiotic therapy.
7.5.3 Immune education
The gut-associated lYmphoid tissue (GALT) transforms the gastrointestinal tract into
the largest immune organ in the human body. Approximately 1010 immunoglobulin
producing cells per meter of small bowel are suggested to be present, accounting for
approximately 80% of all immunoglobulin producing cells in the body, (Targan &
Shanahan 1994). The antigens of the gut are derived from the diet and the resident
microbiota. Without the microflora, mucosal associated lYmphoid tissue is
underdeveloped and cell mediated immunity is defective. In order to prevent
unnecessary and potentially harmful reactions, the gut immune system must be able
to distinguish the normal microflora and dietary antigens from pathogens (oral
tolerance). However the immune system must be ready for an immediate response in
the presence of a pathogen. One of the mechanisms for the rapid discrimination
between potential pathogens, commensal bacteria, and food antigens is via a
restricted number of preformed receptors. A newly discovered class of cell surface
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receptors, the Toll-like receptors, specifically interact with bacterial walls or
antigens, (Krutzik et al. 2001).
Dendritic cells are crucial in detennining the local development of an adaptive
immune response. Two subsets of monocyte-derived dendritic cells (MOC) exist;
MDC 1, which responds to lipopolysaccharide, Iipotechoic acid or CpG DNA by
means of the Toll mannose receptor, which leads to NF-KB activation and
potentiates Th1 responses, whereas MDC2 responds to immune complexes and
cellular factors and leads to a Th2 response, (Hemmi et al. 2000). Hence, according
to the nature of the antigen a Thlffh2 polarisation will occur.
Th1 type responses are characterised by production of pro-inflammatory cytokines;
interferon-gamma (IFN-y), tumour necrosis factor-alpha (TNF-a), Interleukin-12
(IL-12), and IL-2. Th2 cells mediate humoral immunity through the action of IL-4,
IL-5, and IL-6. It is important to maintain a balance between Th1 and Th2 responses
in relation to oral tolerance to ingested antigens. Inappropriate polarisation can
eventually lead to disease, for example, allergy (Th2) or autoimmunity (Th1).
The involvement of regulatory T cells which produce anti-inflammatory cytokines
like tumour growth factor-~ (TGF-~) and IL-IO is an area of increased research
interest. The Th3 cell subset is generated in the gut-associated lYmphoid tissue
(GALn and suppresses the function of effector cells by releasing the inhibitory
cytokine TGF-~. Th3 cells are also implicated in IgA production and in the
regulation oforal tolerance by blocking the Th1 or Th2 response.
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Figure 8: Factors affecting the stability of the gastrointestinal flora.
Adapted from (Kleessen et al. 2000).
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7.6 Stability of the Gut Microtlora
Studies of the faecal flora have shown that individuals tend to maintain their own
distinctive flora compositions and although many bacterial species are shared,
individuals generally have their own distinct predominant species combinations,
even after drastic changes in diet, (Kleessen et al. 2000). McCartney et al. (1996)
investigated the bifidobacterial and lactobacillus populations of faecal samples from
two human subjects over a 12-month period. They discovered that while stability in
species composition may be a feature of the normal microflora, stability at the level
of bacterial strains was less common.
Although the composition of the GI flora is rather stable in healthy individuals it can
be altered by many endogenous and exogenous factors such as antimicrobial agents,
radiation therapy, emotional stress, GI surgical procedures, peristalsis disorders,
inflammatory bowel diseases, cancer, immune disorders and age. The variety of
factors relating to the host, the bacteria and the environment, which affect the
composition, and function of the flora in the GI tract is shown in Figure 8.
7.7 The Role of the Microtlora in Colon Cancer
Imbalance in the composition of the GI flora has been associated with increased risk
ofcolon cancer, (Gorbach & Goldin, 1990). A study of the composition of the faecal
flora of human subjects at varying risks of colon cancer found that the presence of
two Bacteroides species, Bacteroides vulgatus and Bacteroides stercoris were
associated with high risk. Low risk was associated with the presence of
Lactobacillus acidophilus, Lactobacillus S06 and Eubacterium aerofaciens, (Moore
& Moore 1995). Contrary to popular opinion, this study found that Bifidobacterium
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longum and Bifidobacterium angulatum were associated with a high risk of colon
cancer. Bifidobacterial counts are low and clostridia counts high in elderly subjects
with colon cancer (Benno et al. 1991). Although not conclusive, the evidence does
show that the colonic flora plays a major role in modulating cancer risk in humans.
Reddy et al. (1974) showed that treatment with the carcinogen DMH or MAM-
glucuronic acid, (formed following bacterial deconjugation of DMH), produced less
colonic tumours in germ-free rats than in rats with a normal flora. Treptow-van
Lishaut et 01. (1999) reported that the level of GST expression in colon cells from
germ-free rats is much lower than that observed in rats with a conventional flora,
indicating the importance of the gut flora in inducing the expression of enzymes
protective against colon cancer.
Hirayama et al. (2000), compared the effect of three mutagens associated with colon
cancer on DNA adduct formation in the colons of germ-free and human flora
associated rats. They found that the microbial flora played an essential role in DNA
adduct formation and that the role played by the flora was dependent on the type of
mutagen. The formation of DNA adducts is a possible mechanism by which the gut
flora influences the carcinogenic process.
It is now accepted that the normal microflora plays a role in the onset and
progression of colon cancer. Therefore it is logical to propose that altering the
intestinal microflora may influence tumour development. The consumption of
functional foods in an effort to alter the gastrointestinal flora is considered an
attractive alternative to the use ofantibiotic / pharmaceutical based treatments.
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8. Probiotics, prebiotics and synbiotics
A food can be said to be functional if it contains a component (which mayor may
not be a nutrient) that affects one or a limited number of functions in the body in a
targeted way so as to have positive effects on health, or it has a physiologic or
psychologic effect beyond the traditional nutritional effect. As such pre-, pro- and
synbiotics are considered functional foods as they have been shown to exert positive
health effects, (Roberfroid 2000).
8.1 Probiotics
It was at the beginning of the 20th century that Metchnikoff first suggested the
concept ofwhat we now know as probiotics (Metchnikoff 1907). His hypothesis was
that the long, healthy life of Bulgarian peasants resulted from their consumption of
fermented milk products, which he suggested modified the activity of the colonic
microflora suppressing the putrefactive-type fermentation of the intestinal flora in a
health promoting way.
In the early 1900's there was much interest in the health benefits of consumption of
fermented dairy products. In fact, it was during this period that some of the
companies still associated with the production of yoghurt and fermented milk
products (Danone & Yakult) were founded (www.yakult.co.uk,
www.danoneinstitute.org).
8.1.1 Definition
The word probiotic is derived from the Greek meaning 'for life'. The term was first
used in 1965 by Lilly & Stillwell (1965), to describe substances secreted by one
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protozoan to stimulate the growth of another. Over the years the definition of a
probiotic has evolved with the advancement of research in the area. In 1989 Fuller
defined a probiotic as a 'live microbial feed supplement, which beneficially affects
the host animal by improving its intestinal microbial balance', (Fuller 1989). The
definition was again revised in 1992 by Havenaar & Huis In't Veld (1992), who
defined a probiotic as 'a mono- or mixed-culture of live microorganisms which when
applied to man or animal affects beneficially the host by improving the properties of
the indigenous microflora'. However, the most accurate definition of a probiotic was
proposed by Salminen et oJ. (1999): 'Probiotics are microbial cell preparations or
components of microbial cells that have a beneficial effect on the health and well-
being of the host.' This definition was based on research, which showed that
probiotics need not be viable in order to exert an effect and also that some beneficial
probiotic effects were non-microflora mediated.
8.1.2 Selection criteria
Fermented dairy products have traditionally been produced using combinations of
microorganisms often Lactobacillus and Streptococcus species because of their
supposed positive health effects. However many people, especially some members
of the scientific community have remained sceptical of these products and their
associated probiotic claims. In order to overcome this problem much effort has been
expended in recent years to remove the myth from probiotic research and to replace
it with confirmed facts. Participants involved in the Lactic Acid Bacteria Industrial
Platform (LABIP) workshop on probiotics concluded that 'probiotics may be
consumed either as a food component or as a non-food preparation'. Criteria,
outlined by others, for use in the assessment of potential probiotics were summarised
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Table 2: Microorganisms considered as probiotics adapted from Holzapfel et al. (2001)
Lactobacillus species Bifidobacterium species Other lactic acid bacteria Nonlactic acid bacteria
L. acidophilus
L. amylovorus
L. casei
L. crispatus
L. delbrueckii subsp. bulgaricrd
L. gal/inarum'
L. gasseri
L. johnsonii
L. paracasei
L. plantarum
L. reuteri
L. rhamnosus
I Main application for animals.
B. adolescentis
B. animalis
B. bifidum
B. breve
B. infantis
B. lactis4
B.longum
Enterococcus faeca/isT Bacilluscereus var. toyo;J'z
Enterococcus faecium Escherichia coli strain nissle
Lactococcus lactis3 Propionibacterium freudenreichii" 2
Leuconstoc mesenteroides Saccharomyces cerevisiae2
Pediococcus acidilacticl Saccharomyces boulardi;2
Sporolactobacil/us inu/inus'
Streptococcus thermophilus3
2 Applied mainly as pharmaceutical preparations.
3 There is either little known about the probiotic properties or the microorganism is nonprobiotic.
4 Probably synonymous with B. animalis
by Dunne et al. (1999), and a definitive set of selection criteria for probiotics was put
forward.
Probiotic microorganisms should:
• Be of human origin
• Demonstrate non-pathogenic behaviour
• Exhibit resistance to technological processes (Le., viability and activity in
delivery vehicles)
• Prove resistant to gastric acid and bile
• Adhere to gut epithelial tissue
• Be able to persist, albeit for short periods, in the gastrointestinal tract
• Produce antimicrobial substances
• Modulate immune responses
• Have the ability to influence metabolic activities (e.g. cholesterol
assimilation, lactase activity, vitamin production).
Most recently the joint Food and Agriculture Organization (FAO) / World Health
Organization (WHO) working group on drafting guidelines for the evaluation of
probiotics in food recommended that probiotics be defined as 'live microorganisms
which when administered in adequate amounts confer a health benefit on the host'
(Araya et al. 2002).
Probiotics are generally lactic acid producing bacteria (LAB), and are primarily of
the genus Lactobacillus and Bifidobacterium. However some non-LAB bacteria and
yeasts are considered as having probiotic properties (Table 2).
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8.1.3 Beneficial health effects
Numerous health-promoting properties have been associated with probiotics over the
years. Probiotics have been shown to lower the frequency and duration of diarrhoea
associated with antibiotic therapy, (D'Souza et al. 2002; Pochapin 2000), rotavirus
infection, (Vanderhoof & Young, 1998; Guandalini et ale 2000), chemotherapy, and,
to a lesser extent, traveller's diarrhoea, (Hilton et ale 1997; Katelaris et ale 1995).
Probiotics have been shown to have a positive effect on urogenital health. Reid et ale
(2001) demonstrated a reduced recurrence rate of urinary tract infections with oral
consumption of lactobacilli. Lactobacilli have also proven useful in the treatment
and prevention of bacterial vaginitis, (Sieber & Dietz 1998). Di Benedetto et ale
(1998) reported a reduction in infections and abdominal pain and an increase in
weight in children with cystic fibrosis when Lactobacillus rhamnosus GG was
administered as an adjunct to standard treatment.
Probiotics have also been extensively investigated as possible treatments of
inflammatory bowel disease. VSL#3 which is a combination of eight strains (4
lactobacilli, 3 bifidobacteria, 1 streptococcus) has been shown to successfully
maintain remission in pouchitis, ulcerative colitis and Crohn's disease, (Friedman &
George 2000; Gionchetti et ale 2000; Gupta et ale 2000). Escherichia coli Nissle
1917 has been found to be as effective as mesalazine (standard treatment) for
maintaining remission in ulcerative colitis, (Kruis et ale 2004).
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Figure 9: Health benefits associated with probiotic consumption
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Probiotics when administered subcutaneously or orally in animal models of colitis
and arthritis show efficacy in attenuating disease. This suggests a role for probiotic
bacteria in treating gastrointestinal and systemic autoimmune diseases. Probiotics
have also demonstrated the ability to stimulate the host immune system, (Schiffrin et
aJ. 1997; Erickson & Hubbard, 2000) to improve gut barrier function, (Isolauri et aJ.
1993; Madsen et aJ. 2001), alleviate symptoms of lactose intolerance (de Vrese et al.
2001; Montes et ale 1995; Shermak et aJ. 1995) reduce blood pressure in
hyPertensive subjects (Hata et al. 1996; Takano 1998), reduce cholesterol and
triacylglycerol plasma concentrations, (Kiessling et aJ. 2002; Taranto et aJ. 1998)
and playa part in cancer prevention, (Wollowski et aJ. 2001; Rafter, 2002; Gallaher
& Khil, 1999). Figure 9 shows the many health promoting activities associated with
probiotics.
8.1.4 Lactobacillus rhamnosus GG
Lactobacillus rhamnosus OG (LGG) is one of the most thoroughly studied probiotic
strains, (Salminen et ale 1993). LOG has been shown to adhere to the human Caco-2
cell line and the adherence was significantly better than that of other dairy strains of
lactobacilli and bifidobacteria, (Elo et aJ. 1991), to adhere in vitro to both human
colonic mucosa, (Sarem-Damerdji et al. 1995) and human intestinal mucus,
(Kirjavainen et aJ. 1998). LOG also survives and colonises the gastrointestinal tract
of adults and children, (Goldin et aJ. 1992; Millar et al. 1993). A study in which 20
healthy volunteers consumed LOG for 7 days at 1.2 x 1010 cfu/day in gelatine
capsules resulted in faecal recovery of 1.2 x lOs cfu/ gram of faeces, (Saxelin et aJ.
1995).
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As all previous studies had investigated the numbers of LGG recoverable from
faeces as an indication of strain survival and transit in the GI tract, Alander et al.
(1997) fed five human subjects with a whey drink containing LGG for 12 days and
investigated the presence of LOG in both faeces and colonic biopsies. In all subjects
LGG was the dominant lactic acid bacterium recovered from faeces and was also
detected in biopsies in four of the five subjects (one subject was diagnosed with
ulcerative colitis during study), demonstrating the ability of LOG to adhere in vivo
to the colon.
In another study by the same group, subjects were again fed the whey drink
containing LOG and at the cessation of feeding were split into 3 groups, 1) subjects
biopsied immediately after cessation, 2) subjects biopsied 7 days after cessation 3)
subjects biopsied 14 days after cessation, (Alander et al. 1999). The presence of
LGG in faeces was also investigated at these time points. Results show that LGG can
persist on the colonic mucosa after cessation of feeding and even after the strain's
disappearance from faecal samples, and that the study of probiotic numbers in faecal
samples may actually underestimate colonisation by probiotic strains.
Consumption of LGG has been shown to reduce the activities of bacterial enzymes
implicated in carcinogenesis, (Ling et al. 1994), reduce the accumulation of
alfatoxins in the intestine, (Kankaapaa et al. 2000) improve the immunogenicity of
an oral rotavirus vaccine, (Isolauri et al. 1995), treat and prevent diarrhoea
associated with antibiotic use, (Vanderhoof et al. 1999), rotavirus infection,
(Majamaa et al. 1995), Clostridium difficile overgrowth, (Pochapin 2000), and
traveller's diarrhoea, (Hilton et al. 1997). LOG consumption has also proven
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effective in the treatment and management of food allergy in infants, (Majamaa &
lsolauri 1997).
8.1.5 Bijidobacterium lactis Bb12
The most commonly studied probiotic Bifidobacterium strain is Bifidobacterium
lactis Bb12 (Bb12). Bb12 has the ability to survive in the human GJ tract, (Alander
et ale 2001), to adhere to human intestinal mucus, (Kirjavainen et ale 1998) and to
human ileostomy glycoproteins, (Ouwehand et al. 2000). The adherence of Bb12 to
ileostomy glycoproteins and to the intestinal mucus of infants was enhanced in the
presence of LGG, indicating that simultaneous use of these strains may be more
efficacious than individual use, (Juntunen et al. 2001; Ouwehand et ale 2000). The
ability of Bb12 to adhere to the intestinal mucus of infants was unaltered during or
after rotavirus diarrhoea compared to healthy infants, (Juntunen et al. 2001).
An in vitro study by Fooks & Gibson (2002) on the ability of probiotic strains to
inhibit pathogen growth found that Bb12 inhibited the growth of pathogens,
eSPeCially E. coli, to a greater extent than that observed for the other probiotic strains
tested. They also found that this inhibition was influenced by the tyPe of
carbohydrate which was provided in vitro, the most significant results were from
inulin and fructo-oligosaccharide containing carbohydrates. Bb12 has been shown to
exert an inhibitory effect against Helicobacter pylori (H pylon) in vitro and in a
human intervention study when administered as a yoghurt which also contained
Lactobacillus acidophilus LA5, Lactobacillus bulgaricus and Streptococcus
thermophilus, (Wang et al. 2004).
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Consumption of Bb12 in a fermented milk product by healthy volunteers for three
weeks enhanced the phagocytic activity of peripheral blood leukocytes as well as
increasing the numbers of faecal bifidobacteria, (Schiffrin et al. 1997). In a six-
month placebo controlled trial Bb12 consumption resulted in a significant reduction
in atopic eczema in infants with severe food allergy compared to the control group,
(Mattila-Sandholm et aJ. 1999).
A double-blind placebo controlled trial to evaluate the efficacy of a formula
containing Bb12 and S. thermophilus for the prevention of acute diarrhoea in infants
admitted to hospital was conducted by (Saavedra et al. 1994). Significantly fewer
infants receiving probiotic formula than receiving control formula developed acute
diarrhoea during their hospital stay. The prevalence and the rate of rotavirus
shedding was significantly less in the probiotic group compared to control.
8.2 Prebiotics
Oligosaccharides ofvarious types are found as natural components in many common
foods including fruit, vegetables, milk and honey. The use of oligosaccharides as
food ingredients has risen rapidly over the past 20 years especially in Europe and
Japan, (Crittenden & PlaYne 1996). In 1991 the Japanese government legislated for
'foods for specified health use' (FOSHU): fructo., galacto-, soybean and palatinose
oligosaccharides are among the foods currently listed. Most dietary oligosaccharides
are hydrolysed in the upper part of the gastrointestinal tract, however some
oligosaccharides resist the digestive process and reach the colon in an intact form
where they are hydrolysed to small oligomers and monomers, which are further
metabolised by the microtlora. One such class of dietary oligosaccharides are the
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non-digestible oligosaccharides (NOOs), which are of short (degree of
polymerisation (DP) >10) or medium length (DP >60).
8.2.1 Definition
Delzenne & Roberfroid (1994) proposed the term prebiotics for certain types of non-
digestible oligosaccharides (NDOs) used as food ingredients to modify the
composition of endogenous gut flora. The definition was further develoPed by
Gibson & Roberfroid (1995) who defined a prebiotic 'as a non-digestible food
ingredient that benefits the host by selectively stimulating the growth or activity of
one or a limited number of bacteria in the colon'. Therefore any food ingredient that
enters the large intestine may be considered a candidate prebiotic; however it is the
selectivity of the fermentation in the presence of the diverse microflora that is the
defining feature.
Collins & Gibson (1999), stated that in order to classify a food ingredient as a
prebiotic, it must be
1) neither hydrolysed nor absorbed in the upper part of the gastrointestinal tract;
2) a selective substrate for one or a limited number of potentially beneficial
commensal bacteria in the colon, thus stimulating the bacteria to grow,
become metabolically activated, or both
3) able as a consequence to alter the colonic microflora toward a healthier
composition.
Examples of prebiotics are specific oligosaccharides, starch fractions (resistant
starch), pectins, lactose, lactulose, lactitol, sorbitol and xylitol. In the European
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market some of the most extensively researched prebiotics are the fructo-
oligosaccharides (FOS) especially those which are derived from the chicory root,
(inulin and it's enzymatic hydrolysate oligofructose). The average daily consumption
of inulin and oligofructose has been estimated to be one to four grams in the USA
and three to eleven grams in Europe, (Van Loo et al. 1995).
8.2.2 Health benefits
Prebiotics exhibit a dietary fibre-like action. Fermentation of prebiotics lowers the
intestinal pH. This leads to a decreased activity of the enzyme 7a-hydroxylase
responsible for the formation of secondary bile acids. Secondary bile acids comprise
over 80% of faecal bile acids and are thought to play an important role in colon
carcinogenesis by acting as promoters in tumour formation, (Nagengast et al. 1995).
One of the most interesting aspects of prebiotics is that they enhance the growth of
bifidobacteria and other Gram-positive bacteria but are not fermented by the
majority of Gram-negative bacteria in the colon. Effective bifidogenic doses appear
to vary among the different oligosaccharide types. However, most oligosaccharides
have been demonstrated to increase bifidobacteria numbers in the colon at doses of
<15grams/day, (Crittenden & PlaYne 1996) although some prebiotics have
demonstrated an effective bifidogenic effect at lower doses. Most in vivo human
studies suggest that the log increase in the number of bifidobacteria depends on the
initial number of bifidobacteria, irrespective of the dose of the FOS, (Rao 2001;
Roberfroid et al. 1998), although a study by Bouhnik et al. (1999), found a linear
relationship between the increase in bifidobacterial counts and FOS consumption
and also found the optimal daily dose of FOS to be 1ograms.
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Prebiotic consumption is associated with many beneficial effects. van den Heuvel et
01. (1999), demonstrated that oligofructose consumption (15grams/day) stimulated
calcium absorption in male adolescents. In rats consumption of inulin or resistant
starch or a combination of the two significantly increased the intestinal absorption
and balance of calcium and magnesium compared to placebo, (Younes et 01. 2001).
Scheppach et a/. (2001) described the influence of prebiotics on sugar digestion and
absorption, glucose and lipid metabolism and protection against known risk factors
ofcardiovascular disease.
Prebiotics have laxative properties similar to carbohydrates. Carbohydrates that
reach the large intestine, such as non-starchy polysaccharides and resistant starch,
are known to have a laxative effect on bowel function. Stimulation of microbial
growth leads to increased bacterial mass and bowel content, which in tum stimulates
peristalsis, decreases transit times and prevents constipation. Consumption of
chicory inulin was shown to relieve constipation in elderly subjects, (Kleessen et al.
1997) and in healthy volunteers, (Hond et al. 2000). Prebiotics may also influence
the host's natural defence against pathogens by enhancing bacterial colonisation
resistance. Hopkins & MacFarlane (2003), demonstrated that NOOs enhanced
colonisation resistance against Clostridium difficile in vitro.
8.3 Synbiotics
In general if a probiotic is to exert a beneficial effect on the host, the bacterium must
be metabolically active in the gut. Within the colon the supply of fermentable
carbohydrate is a growth-limiting factor for bacteria. The bacterial species, which
occur in the greatest numbers, are those which utilise the available nutrients most
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effectively. As discussed previously, prebiotics resist digestion in the upper GI tract
and reach the colon intact, where they are available as nutrients for the colonic flora.
Current research indicates that consumption of prebiotics with probiotic strains
enhances the growth of the introduced strain in the gut. This is known as the
sYnbiotic effect and the term sYnbiotic is applied to a product, which contains both
prebiotics and probiotics.
8.3.1 Definition
In defining a sYnbiotic, Schrezenmeir & de Vrese (2001) stated, 'because the word
alludes to SYnergism, this term should be reserved for products in which the prebiotic
compound selectively favours the probiotic compound'. In the strictest sense,
therefore, a product containing oligofructose as a prebiotic and bifidobacteria as a
probiotic would fit the definition of a sYnbiotic but a product containing
oligofructose and a lactobacillus strain would not. However, it may be argued that
promotion of the growth of indigenous bifidobacteria in vivo, combined with the
introduction of a lactobacillus strain and subsequent beneficial effects on the health
ofthe host fulfils the definition of synergism.
8.3.2 Health Benefits
One of the principal benefits of sYnbiotics is believed to be the increased persistence
of the probiotic in the GI tract. Consumption of a prebiotic in a sYnbiotic compound
provides a readily fermentable carbohydrate source for the introduced probiotic
strain, giving the probiotic a competitive advantage over the indigenous flora. This
advantage increases the persistence of the probiotic in the GI tract increasing the
time period in which the probiotic strain can exert its influence.
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This synbiotic effect has been proven in human studies. Morelli et al. (2003),
investigated the effect of a synbiotic preparation of two Lactobacillus paracasei
strains, a Lactobacillus gasseri strain and inulin, glutamin, zinc and vitamin B6 on
the flora of twelve healthy individuals. After fifteen days Lactobacillus paracasei
counts had increased by at least one log in all subjects, with a 2-3 log increase in
subjects who had low counts of this group at baseline. Lactobacillus paracasei
persisted after cessation of feeding with counts three days after cessation of feeding
similar to or slightly lower than these counts at the end of treatment but higher than
at baseline. Bifidobacterial numbers also increased but no consistent effects were
seen on enterobacteria, enterococci or Clostridium perfringens.
Gallaher & Khil (1999) demonstrated that feeding rats, treated with the chemical
carcinogen DMH, either bifidobacteria or oligofructose alone had no influence on
the number of aberrant crypts compared to controls. However in five of six
experiments, the combination of oligofructose and bifidobacteria led to a reduction
in aberrant crypt numbers compared to controls indicating an additive or synbiotic
effect of oligofructose and bifidobacteria for reduction of colon cancer risk in
carcinogen-treated rats.
An interesting application of synbiotics as a supportive therapy for critically ill
patients in intensive care units has been suggested by Kanarnori et al. (2002). They
fed a synbiotic combination of B. breve, L. casei and galacto-oligosaccharides to a 9-
month old baby born with laryngotracheo-eosophageal cleft, who had undergone her
initial surgery at 3 months, had suffered repetitive episodes of pneumonia and whose
growth remained unsatisfactory. Abdominal x-ray had shown no gas in the large
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bowel and lactobacilli and bifidobacteria were not detected in the faeces. Bowel
movements were restored just 1 day after commencement of syobiotic treatment and
a dramatic increase in faecal short-chain fatty acids (SCFAs) was achieved within 1
month. Pneumonia developed only once after the beginning of syobiotic treatment,
body weight doubled after 11 months treatment and final curative surgery was
performed at this time. The authors suggest that the dramatic effectiveness of
syobiotic therapy in such cases may be due to improved nutrition, prevention of
bacterial translocation due to the presence of the probiotics and also modulation of
the immune system. Such therapies should be considered as an immunonutritional
therapy for critically ill patients in intensive care units.
8.4 Influence of pre-pro and synbiotics on carcinogenesis
As discussed earlier it is an accepted fact that the normal microflora plays a role in
the onset and / or promotion of colon cancer. Therefore it is not unexpected that
there has been much interest in the development of methods to alter the composition
or the metabolic activity of the intestinal microflora in an attempt to influence the
carcinogenic process.
A protective role for pre-, pro- and syobiotics has been shown in animal studies,
(Gallaher & Khil 1999; Wollowski et aJ. 2001). The exact mechanisms by which
pre-, pro- and syobiotics may inhibit colon carcinogenisis are as yet uncertain.
However, based on results from the vast amount of in vitro and in vivo studies
performed to date, it is possible to speculate on some potential mechanisms.
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(Rafter, 2002) suggested the following mechanisms by which lactic acid bacteria
may inhibit colon cancer:
• Altering the physicochemical environment in the colon
• Enhancement of the host's immune response
• Inactivating potential carcinogens and mutagens
• Altering the composition of the intestinal flora to a more beneficial flora
• Anti-mutagenic or anti-tumourigenic activities
• Altering the metabolic activity of the flora
• Increase activities of protective enzymes and reduce activities of enzymes
involved in carcinogenesis
8.4.1 Altering the physicochemical environment in the colon
Modler et oJ. (2001) suggested that large bowel cancer may be influenced directly by
reducing the intestinal pH, causing the growth of putrefactive bacteria to be reduced.
Silvi et oJ. (1999) reported that resistant starch selectively increased the levels of
lactobacilli and bifidobacteria by ten to one hundred fold in faecal samples from rats
associated with a human flora, while decreasing enterobacteria, caecal ammonia
concentrations, caecal pH and J3-glucuronidase. Rowland et oJ. (1998) demonstrated
the co-administration of Blf. /ongum and inulin significantly reduced the pH of
caecal contents and the number of aberrant crypt foci (ACF) in the colon of
azoxymethane (AOM) induced rats comPared to controls. Challa et oJ. (1997) found
that administration of a synbiotic combination of Blf. /ongum and lactulose reduced
the numbers of ACF in the colon and the caecal pH as well as inducing the activity
of colonic glutathione S - transferase ( a phase II detoxifying enzyme). However pH
has not been consistently reduced in studies of probiotic and synbiotic consumption.
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8.4.2 Enhancement of the host's immune response
The presence ofa normal healthy microflora is essential for the proper functioning of
the host's immune system. The gastrointestinal immune system (GALT etc.) is
responsible for distinguishing between the normal flora and potential pathogens,
which are ingested in the diet. As probiotic bacteria originate from the normal gut
flora their consumption does not induce an immune response of the type, which
occurs in the presence of a pathogen. However probiotics have been shown to exert
various immune enhancing effects following oral consumption. These include
enhanced macrophage phagocytosis, (Perdigon et al. 1988), promotion of 19A
responses, (Isolauri et al. 1993; Link-Amster et al. 1994; Malin et al. 1996), and
altered cytokine production, (Miettinen et al. 1998), leading to a shift in the balance
between Th1 and Th2 immune responses.
Natural killer (NK) cells are a sub-population of lymphocytes important for the
recognition and elimination of virally infected cells and tumour cells. NK cells are
thought to playa role in the non-specific mechanism in immuno-surveillance for
cancer. Studies have suggested that low NK cell activity is associated with an
unfavourable prognosis, (Tartter et al. 1987). Imai et al. (2000) investigated NK cell
activity in 3625 Japanese people mostly older than forty and carried out a follow-up
survey of cancer incidence for eleven years. Their results indicate that medium and
high NK cell activity of PBMCs is associated with reduced cancer risk, whereas low
activity is associated with increased cancer risk. Probiotic supplementation has been
shown to enhance NK cell activity, (Takagi et al. 2001; Gill et al. 2001). Matsuzaki
& Chin (2000) demonstrated that in adult mice fed the probiotic Lactobacillus case;
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strain Shirota for five days the NK activity of spleen cells was significantly higher
than the NK activity of spleen cells from mice not fed the probiotic.
One of the most interesting aspects of probiotic modulation of the immune response
is through its influence on cytokine production, and many studies have shown that
probiotics can alter cytokine expression profiles in healthy and diseased states in
both animals and humans. Miettinen et ale (1998) stimulated human peripheral blood
mononuclear cells with three non-pathogenic Lactobacillus strains and one
pathogenic Streptococcus pyogenes strain. All bacteria strongly induced IL-I p, IL-6
and TNF-a mRNA and secretion of the cytokine protein. IL-12 and IFN-y
production was greatest following stimulation with Strep. pyogenes but was also
induced by two Lactobacillus strains. All strains induced IL-18 protein secretion.
Schultz et ale (2003) investigated the effect of five-week oral consumption of
Lactobacillus rhamnosus GG in ten healthy volunteers on the cytokine secretion
profile of peripheral blood mononuclear cells (PBMCs) following stimulation with
'self' and 'non-self intestinal organisms and whole stool preparations. Probiotic
consumption increased the activational response of CD4+ T-lymphocytes towards
heat-inactivated E.coli and Bacteroides fragilis group isolated from faecal samples.
The secretion ofTNF-a, IL-6 and IFN-y by PBMCs was decreased, while the IL-IO
and IL-4 secretion was increased following probiotic consumption irrespective of the
origin of the antigen (self or non-self).
Sheih et ale (2001) conducted a three-stage intervention study where fifty-four
healthy volunteers consumed reconstituted low fat milk (LFM) for a three-week run
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in period (stage I) followed by three-weeks consuming Lactobacillus rhamnosus
HNOOI in either LFM or reconstituted lactose-hydrolysed LFM (stage 2) and a
follow up period of three weeks consuming reconstituted LFM alone (stage 3). They
found that immune responses were unaltered in the run-in period (stage I).
Phagocytic activity of polymorphonuclear cells isolated from whole blood and the
NK cell activity of mononuclear cells was significantly increased by HNOO1
consumption irrespective of the delivery method (stage 2). These immune responses
declined three weeks after cessation of HNOOI consumption (stage 3), but remained
elevated compared to baseline. This study confirms that probiotic consumption can
enhance natural cellular immunity in healthy individuals and this enhancement can
persist after cessation of probiotic consumption. Delivery of the probiotic in lactose
hydrolysed LFM results in immune enhancing effects comparable to those yielded
by normal LFM indicating that this delivery method may prove useful in designing
probiotic products targeted to lactose intolerant individuals.
The ability of the probiotics LGG and Bb12 (probiotic group), the inulin enriched
oligofructose prebiotic called SynergyO1 (prebiotic group) and a sYnbiotic
combination of Bb12, LGG and SynergyOI (sYnbiotic group) to modulate the
immune system of healthy rats consuming a high fat low fibre diet (western style
diet) was investigated by Roller et aJ. (2004). In the prebiotic fed group IL-IO
production in the Peyer's patches was enhanced and secretory IgA production was
increased in the caecum compared to the control group receiving a standard, non-
supplemented diet. The synbiotic combination increased secretory IgA production in
the ileum and NK cell activity in peripheral blood, while it reduced the oxidative
burst activity of blood neutrophils. Immune markers were unaltered in the group fed
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probiotics (Bb12 & LGG) alone, however this may in part be due to the use of a high
fat low fibre diet. This study indicates that combining probiotics and prebiotics in a
synbiotic formulation does not simply result in an additive effect but in an enhanced
effect greater than the combined effects of the individual components.
Probiotics have been shown to influence the balance between the arms of the T
helper cell response. When fed probiotics Lactobacillus salivarius spp sa/ivarius
VCC 118 and Bifidobacterium in/antis 35624, Interleukin-IO (IL-IO) knockout mice,
had reduced levels of IL-12 and TNF-a both systemically and mucosally, and TGF-
~ levels were maintained, (McCarthy et al. 2003). IL-IO knockout mice develop
colitis, which is similar to Crohn's disease in humans (Th I type disease), and this
study illustrates that probiotic consumption reduced production of Th I type
cytokines with an associated attenuation in colitis.
The modulation of cytokine production may also be mediated by constituents of
probiotic bacteria and may not necessarily require whole bacteria. Lammers et al.
(2003) showed that bifidobacterium genomic DNA induced secretion of IL-IO by
PBMCs. Total bacterial DNA from faeces collected after probiotic administration
modulated the immune response by a decrease of IL-I ~ and an increase in IL-IO.
It is postulated that the immune response to pre-, pro- and synbiotics depends on the
host's immune status and for example, in atopic individuals, consumption may lead
to an improved Th1 response. Pierre et al. (1997) reported that six week
consumption of short chain fructo-oligosaccharides by multiple intestinal neoplasias
(Min) mice significantly reduced the incidence of colon tumours and as well as
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developing gut-associated lymphoid tissue compared to controls. Following on from
this work this group reported that fructo-oligosaccharide fed to CD4+/CDS+ depleted
Min mice resulted in twice as many colonic and caecal tumours as fructo-
oligosaccharide fed immunocompetent Min mice, (Pierre et al. 1999), suggesting
that prebiotic consumption stimulates a mechanism of tumour immuno-surveillance
in which T cell status plays a primary role.
The immune response may also vary with different strains of probiotic, types of
prebiotic and synbiotic combinations. Specific products with immuno-regulatory
and/or anticancer effects need to be clearly identified and their mechanism of action
characterised.
8.4.3 Inactivating potential carcinogens and mutagens
Mutagens and potential carcinogens are ingested every day as part of the normal
diet. One possible mechanism by which pre-, pro- and syobiotics may protect against
colon cancer is by binding and degrading potential mutagens and carcinogens. High
meat consumption is considered a risk factor for colon cancer due to the production
of mutagenic heterocyclic amines (HCA), which are formed during cooking, (Sinha
& Rothman 1999). Common HCAs are 2-amino-3- methylimidazo [4,5:f] quinoline
(IQ), 2-amino-3,4-dimethylimidazo [4,5:f] quinoline (MeIQ), 2-amino-l-methyl-6
phenylimidazo [4,5-b] pyridine (PhIP), the tryptophan pYrolysis products Trp-P-l
and Trp-P-2 and the glutamic acid pyrolysis products Glu-P-l and Glu-P-2. HCAs
themselves are not mutagenic but, like most chemical carcinogens, require metabolic
activation. The metabolism of HCA is under genetic control, (Potter 1996).
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Lactic acid bacteria have been shown to bind HCA in vitro dependent on the pH of
the culture medium, (Morotomi & Mutai 1986; Orrhage et a/. 1994; Zhang &
Yoshiyuki 1991). L.casei YIT 9018 has been shown to bind in vitro to the mutagenic
pyrolysate Trp-P-2 formed in cooked meat, and consequentially to prevent the
mutagenic effect of Trp-P-2 in the Salmonella mutagenicity assay, (Morotomi &
Mutai 1986). Consumption of lactobacilli in healthy human feeding studies has been
shown to reduce the mutagenicity of faeces and urine associated with the ingestion
ofcarcinogens in cooked meat, (Hayatsu & Hayatsu 1993; Lidbeck et a/. 1992).
A lyophilised culture of Blf. /ongum has been shown to have a 100% inhibitory
effect on IQ induced colon carcinogenesis in male colon cancer and to lesser extent
(50% inhibition) in mammary carcinogenesis in female rats, (Reddy & Rivenson
1993). A possible explanation for the complete inhibition in colon carcinogenesis in
this model may be that the Blf. /ongum binds the IQ in the lumen preventing
interaction of the mutagen with the mucosa. Rowland & Grasso (1975) demonstrated
that lactobacilli have the ability to degrade nitrosamines, mutagens associated with
cooked meat. Wollowski et a/. (200 I) showed that Lactobacillus bu/garis 191 R fed
to rats reduced DMH induced DNA damage in colon cells as measured in the comet
assay.
8.4.4 Altering the composition of the intestinal flora
Imbalance in the composition of the GI flora has been associated with increased risk
of colon cancer, (Gorbach & Goldin, 1990). The consumption of pre-, pro- and
synbiotics has been reported to shift the composition of the gut flora to a more
beneficial composition. Most studies in this area have shown that pre-, pro or
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synbiotic consumption increases bifidobacteria and lactobacilli numbers, (Kruse et
al. 1999; Tuohy et al. 200 I). However some studies have demonstrated that pre-,
pro- or synbiotic consumption can affect other members of the gut flora.
Spanhaak et al. (1998), demonstrated that consumption of a milk fermented by
Lactobacillus casei strain shirota significantly increased lactobacilli and
bifidobacteria and decreased the numbers of clostridium although not significantly.
Gibson et al. (1995) demonstrated that consumption of the prebiotics, oligofructose
and inulin, significantly increased the numbers of faecal bifidobacteria, while
decreasing the numbers of Bacteroides, clostridia, fusobacteria and Gram positive
cocci.
Fujiwara et al. (200 I) fed seven healthy volunteers a rifampicin-streptomycin-
resistant variant of the probiotic Bifidobacteriun /ongum SBT2928 for seven days
with a run in period of three days and a follow up period of thirty days. They found
that the introduced probiotic strain was recovered in high numbers from the faeces of
all the volunteers during the seven-day administration period and was detectable in
the faeces of two volunteers up to thirty days after cessation of administration. The
numbers of Enterobacteriaceae, lecithinase-negative Clostridium spp and C.
perfringens were significantly reduced after seven days administration of the
probiotic, however numbers increased towards baseline levels thirty days after
cessation of feeding.
In a study investigating the influence of the probiotic Lactobacillus salivarius spp
salivarius Dee118 (Dee118) on inflammation and tumour development in IL-IO
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knockout mice, the numbers of coliforms and enterococci recovered from faeces
were decreased in the mice fed UCCI18 (n=IO) for sixteen weeks compared to the
control mice (n=IO). Total lactobacilli, bifidobacteria and bacteroides levels were
unchanged in both the control and probiotic fed groups. The prevalence of colon
cancer and mucosal inflammatory activity was significantly reduced in the mice fed
UCC118 compared to control mice, (O'Mahony et al. 200I).
8.4.5 Anti-mutagenic or anti-tumourigenic activities
The antimutagenic potential of pre-, pro- and sYnbiotics has been confirmed in
numerous studies. Klinder et al. (2004b) carried out in vitro fermentations of
various combinations of a prebiotic (SYnergyOI), Bb12 and GG (probiotics) and the
sYnbiotic combination (BbI2, GG and SYnergyol) either alone (pure culture
fermentations) or in the presence of faecal slurries. Control fermentations where
glucose replaced SYnergyCI as the sole carbon source were also performed.
Supernatants from the fermentations containing SynergyCI (prebiotic and sYnbiotic)
were less cytotoxic to HT-29 and Caco-2 cells, compared to supernatants derived
from control fermentations. The reduced cytotoxic potential of the supernatants
seems to be associated with the increased butyrate concentrations in the prebiotic
containing fermentations compared to controls and probiotics.
Zsivkovits et al. (2003) reported that Lactobacillus bulgaricus 291, Streptococcus
thermophilus F4, S. thermophilus V3 and Bifidobacterium longum BB536, strains
commonly used in yoghurt production, completely inhibited genotoxic damage in the
colons of rats induced by hetero-cyclic amines of the type found in cooked beef.
Other studies have shown that some lactic acid bacteria inhibit N-Methyl-N'-Nitro-
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N-Nitrosoguanidine (MNNG) and DMH induced genotoxicity in colon cells isolated
from rats, (Pool-Zobel et al. 1996; Wollowski et al. 1999).
Klinder et al. (2004a) reported that the genotoxic potential of FW from rats treated
with AOM was significantly reduced in animals fed both SYnergyOl and a synbiotic
(SynergyOl, Bbl2 and GG). Bums & Rowland (2004) investigated the effect of
incubating a genotoxic faecal water sample from a human subject with six different
strains of lactic acid bacteria on the DNA damaging potential of the FW. They found
that DNA damage in HT-29 cells was significantly reduced by all strains except
Strep. thermophilus and that Lactobacillus plantarum and Bb12 showed the greatest
protective effect. The bacterial strains were also fermented in the presence of
prebiotics and the ability of the resultant supernatant to protect against FW induced
DNA damage investigated. Incubations involving Lactobacillus plantarum and
fructo-oligosaccharide based prebiotics were most effective in preventing genotoxic
damage. Reduction in FW induced DNA damage was also seen with supernatants
from fermentations of Bb12 and prebiotics.
In animal studies co-administration of pre-, pro- or sYnbiotics with a chemical
carcinogen reduces the incidence of both pre-cancerous lesions (aberrant crypt foci)
and colonic tumours. Aberrant crypt foci (ACF) are early preneoplastic lesions in the
colon from which adenomas and carcinomas may develop. ACF have consistently
been observed in experimentally induced colon carcinogenesis in laboratory animals
and have also been shown in the colonic mucosa of patients with colon cancer,
(Mclellan et al. 1991; Pretlow et al. 1992; Wargovich et al. 1996). ACF express
mutations in the ape and ras oncogenes, which are involved in cancer development,
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(Vivona et al. 1993). ACF fonnation is often used in animal studies as an end point
for investigating potential anti-tumourigenic agents and several inhibitors of ACF
fonnation have been shown to reduce the incidence of colonic tumours in laboratory
animals, (Wargovich et al. 1996). The multiplicity of aberrant crypts is also
measured in many studies and ACF with four or more crypts is considered predictive
of tumour incidence, (Pretlow et al. 1992).
Prebiotics have demonstrated an inhibitory effect on ACF and tumour fonnation.
Reddy et al. (1997) demonstrated that consumption of inulin or oligofructose inhibits
ACF fonnation and multiplicity in the colons of rats treated with the chemical
carcinogen AOM. The degree of ACF inhibition was more pronounced in rats fed
inulin than in those fed oligofructose. Taper et al. (1997) reported that the
consumption of oligOfructose or inulin significantly inhibited the growth of
transplantable mouse tumours, EMT6 and TLT in mice.
Prebiotics have also been shown to stimulate apoptosis in the colons of rats,
consuming a high fat western type diet and treated with the carcinogen DMH,
(Hughes & Rowland 2001). Apoptosis was significantly higher in the colon of rats
fed diets supplemented with either oligofructose or inulin compared to rats fed the
basal diet. Induction ofapoptosis and the resultant effect on proliferation may be one
ofthe mechanisms by which prebiotics exert cancer protecting effects.
Probiotics have also been shown to inhibit colon cancer. Lactobacillus acidophilus
feeding has been shown to decrease the incidence of colon tumours in rats
challenged with the colon carcinogen DMH from 77% to 40%, (Goldin & Gorbach
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1980). Reddy & Rivenson (1993) demonstrated that Bit Iongum consumption
inhibited the IQ-induced incidence of colon (100%) and liver (80%) tumours and
multiplicity (tumours/animal) of colon, liver, and small intestinal tumours in male
rats. In female rats, IQ-induced mammary carcinogenesis was inhibited (although
not significantly) to 50% and liver carcinogenesis to 27% compared to control
animals, however, the mammary tumour multiplicity (tumours/animal) was
significantly inhibited in female rats fed Bit longum. A possible explanation for the
complete inhibition of colon carcinogenesis in this model may be that the Bit
longum binds the IQ in the lumen preventing interaction of the mutagen with the
mucosa. Singh et ale (1997) demonstrated that consumption of lyophilised Bit
longum significantly inhibited tumour incidence and multiplicity in AOM treated
animals compared to controls.
Consumption of Lactobacillus salivarius ssp. salivarius VCC 118 in interleukin-IO
knockout mice (colitis model) was associated with a trend towards reduced tumour
development and attenuation of gastrointestinal inflammation. Gastrointestinal
neoplastic transformation was evident in 50% of mice from the placebo group while
only 10% of the probiotic group demonstrated any evidence of neoplastic change,
(O'Mahony et ale 2001).
The anti-tumourigenic potential of probiotics has also been shown in animal studies
although research in this area is limited. Biasco et ale (1991) reported that elevated
cell proliferation in the colonic mucosa was decreased by probiotic consumption in
some patients with benign tumours in the colon.
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Synbiotics have demonstrated similar anti-tumourigenic properties. Rowland et al.
(1998) investigated the effect of a derivative of inulin (Raftiline HP) alone and in
combination with Blf. longum on ACF induction by AOM. Blf. longum consumption
alone resulted in a 26% reduction in small ACF (one to three aberrant crypts per
focus), and inulin alone inhibited ACF formation by 41 % compared to control.
However when administered together as a synbiotic, small ACF formation was
inhibited by 80%. This synergistic effect was particularly evident as the synbiotic
inhibited large ACF formation (>4 aberrant crypts/focus) by 59% while inulin and
Blf. longum alone were ineffective.
Many animal studies designed to investigate the effect of pre-, pro- or synbiotics on
colon carcinogenesis are short-term experiments where intervention is carried out for
approximately 12 weeks and use the formation of ACF as a marker. There is very
little data available for pre-, pro- or synbiotics in long term carcinogenesis
experiments. Femia et al. (2002) investigated the effect of consumption of a
prebiotic SynergyCl, the probiotics Lactobacillus rhamnosus 00 (00) and
Bifidobacterium lactis Bb12 (Bb12), and a synbiotic containing the prebiotic and
both probiotics for 31 weeks on AOM induced carcinogenesis in rats. The results
show that the prebiotic and the synbiotic fed groups, but not the probiotic fed group,
had significantly reduced tumour incidence in the colon compared to the control
group. The synbiotic fed group also had fewer tumour bearing rats than the prebiotic,
probiotic or control groups.
87
8.4.6 Altering the metabolic activity of the flora
The normal colonic microflora produces enzymes such as ~-glucuronidase, ~
glucosidase, nitrate reductase, nitroreductase and azoreductase, the activities of
which have been implicated in colon carcinogenesis. Bifidobacteria and lactobacilli
have lower activities of these xenobiotic-metabolising enzymes than do Bacteroides,
clostridia and enterobacteriaceae. Decreasing the numbers of bacteria with high
activities of theses enzymes and increasing the numbers of bacteria with lower
activities is a potential mechanism for cancer prevention. Pre-, pro- and sYfibiotics
can alter the composition of the gut flora however the activities of bacterial enzymes
are not always altered.
Consumption of pre- and probiotics has been shown to decrease the activity of ~
glucuronidase. Ling et al. (1994) demonstrated that consumption of LGG alone or
LGG with fibre for two or four weeks significantly reduced faecal ~-glucuronidase
and nitroreductase activities as well as glycocholic acid hydrolase activities in
healthy volunteers. Activities of these enzymes returned to baseline levels following
cessation of feeding. ~glucosidase activities were not significantly altered by
intervention. Fujiwara et al. (2001) demonstrated that seven-day consumption of Blf.
longum SBT2928 significantly decreased ~-glucuronidase and ~-glucosidase levels
and was associated with decreases in the numbers of Enterobacteriaceae and C.
perfringens.
Marteau et a/. (1990) reported that three-week consumption of a dairy product
fermented with L. acidophilus, B. bifidum, S. lactis and S. cremoris reduced faecal
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nitroreductase and increased ~-glucosidase activities. ~-glucuronidase, ~
galactosidase and azoreductase activities were unaltered.
Azoreductase promotes the reduction of azo food dyes to substituted phenyl and
naphthyl amines, which are potent carcinogens. Laboratory rats, which have been
experimentally, fed beef and lactobacilli have reduced faecal amounts of beta-
glucuronidase, azoreductase, and nitroreductase, (Goldin & Gorbach 1984; Simon &
Gorbach 1986).
Bouhnik et 01. (1996) investigated the effect of bifidobacteria fermented milk with or
without fructo-oligosaccharide (inulin) on the activity of pro-carcinogenic enzYmes
in twelve healthy subjects. The results showed that consumption of bifidobacteria
fermented milk increased the number of total bifidobacteria and decreased ~
glucuronidase, while nitrate reductase, nitroreductase and azoreductase were
unaltered. Co-administration of inulin also increased the total number of
bifidobacteria but had no influence on enzyme levels. Rowland et 01. (1998) found
that co-administration ofBlf. Iongum and inulin significantly reduced the number of
ACF in the colon, the concentration of ammonia in caecal samples as well as caecal
~glucuronidase activities. Caecal ~-glucosidase activities however were increased.
However as mentioned by Rafter (2002), 'it is important to note that the studies to
date do not always find reductions in the same enzymes, although findings with ~
glucuronidase and nitroreductase are the most consistent'.
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8.4.7 Modulating the activity of host enzymes
The activity of detoxifying enzymes plays an important role in the protection of the
colonic mucosa from carcinogens and mutagens. The Glutathione-S-transferase
(GST) and VDP-glucuronosyl transferase (VGT) superfamilies play an important
role in the conversion of the reactive intermediate back to the parent amine therefore
protecting epithelial DNA from adduction by activated HCA, (Airoldi et aI. 2004).
Treptow-van Lishaut et al. (1999), demonstrated that resistant starch (a prebiotic),
increased levels of GST 1t in the rat colon. Consumption of the prebiotic lactulose,
either alone, or in conjunction with Blf. longum reduced the number of ACFs, and
significantly increased GST levels in the rat colon compared to controls, (Challa et
al. 1997). SCFAs, the main fermentation products of the microflora have been
shown to induce GST 1t in a Caco-2 cancer cell line. It is also interesting to note an
increase in GST in rectal biopsies following consumption of Brussels sprouts was
mirrored by an increase in GST activity in blood lymphocytes. GST levels in
lYmphocytes may be used as a marker for cancer risk or to assess the effect of
intervention on cancer progression.
The genes hepatic cytochrome P4501A2, (CYPIA2) and acetyltransferase-2 (NAT-
2), which are polYmorphic in humans have been implicated in the metabolic
activation of heterocyclic amines to colon carcinogens which readily form DNA
adducts, (Gooderham et al. 1996; Sawada & Kamataki 1998). NADPH-cytochrome
P-450 reductase (CYC) is a phase I xenobiotic metabolising enzyme involved in the
biotransformation of noxious xenobiotics before excretion. Lactic acid bacteria have
been shown to increase CYC activity in the colon, (Pool-Zobel et al. 1996).
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Ornithine decarboxylase (ODe) is the first and rate-limiting enzyme in the synthesis
of polyamines. Polyamines are involved in cell proliferation and differentiation and
in macromolecular synthesis. In humans ODe levels are elevated in neoplastic
colonic mucosa compared to normal appearing mucosa, in dysplastic polyps
compared to nondysplastic polyps and in colonic adenocarcinomas compared to
adjacent non-involved mucosa, (Reddy 1999). Studies have shown that probiotic
administration in animal models of chemically induced colon carcinogenesis reduce
the levels ofODe, (Singh et al. 1997).
Ras activation is one of the earliest and most frequently occurring genetic alterations
associated with human cancers, especially colon cancer, (Barbacid 1990). Bif.
longum consumption has been shown to reduce ras-p21 expression and cell
proliferation in AOM induced carcinogenesis in rats (Reddy 1998; Singh et ale
1997).
The evidence outlined suggests possible mechanisms by which pre-, pro- or
synbiotics may protect against colon cancer. However it must be noted that there is
no direct experimental evidence that pre-, pro- or synbiotics play a role in cancer
suppression in man.
9. Future Trends
Many studies have shown that the co-administration of pre- and probiotics in a
synbiotic combination leads to a greater effect than that achieved with either
component alone. However, many of these studies did not screen candidate pre- and
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probiotics in order to determine the optimal synbiotic combination. In general there
is a lack of studies concentrating on the optimal formulation of synbiotics from
thoroughly characterised prebiotics and probiotics followed by confirmation of their
effectiveness both in vitro and most importantly in vivo. When selecting a synbiotic
combination for clinical use the synbiotic formulation should be targeted towards the
disease, as a synbiotic combination effective, for example, in ameliorating antibiotic
associated diarrhoea may be ineffective in lowering cancer risk.
The design of effective synbiotics may further be improved by targeting prebiotics
for a specific probiotic. Rabiu et al. (200 I) isolated J3-galactosidases from five
bifidobacterium strains and used these enzymes in glycosyl transfer reactions to
synthesize oligosaccharides from lactose. Fermentation tests showed an increased
growth rate compared to oligomate 55, a commercial prebiotic galacto-
oligosaccharide, for four out of five of the bifidobacterium strains on the product
derived using their own enzyme. One of the novel prebiotics was further tested in the
presence of mixed populations of intestinal bacteria and was seen to have an
equivalent prebiotic activity to that of Oligomate 55. However, this novel prebiotic
exhibited a lower stimulatory effect on Bacteroides and lactobacilli than did
Oligomate 55, suggesting that it is more selective. The potential of plant cell wall
polysaccharides as sources of novel prebiotics has recently been investigated.
Specific glycanases can be used to produce novel oligosaccharides from plant cell
wall polysaccharides, (Van Laere et al. 2000).
The tolerance of the immune system to pre-, pro- and synbiotics has led to much
research in their use as delivery methods for vaccines and treatments. Attenuated
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pathogens are effective vaccines against the pathogen itself, however these
organisms are often strongly immunogenic and are therefore not suitable for use in
immunocompromised individuals for whom they may be potentially pathogenic. As
lactic acid bacteria have been consumed by large numbers of people for many years
without causing health problems, they are an attractive vehicle for the delivery of
vaccines.
Isolauri et ale (1995) administered LGG concomitantly with the 0 x RRV reassortant
rotavirus vaccine to young infants and evaluated the immune response following
vaccination. Results suggested that the immunogenicity of an oral live rotavirus
vaccine may be improved by concomitant and subsequent administration of LGG.
Kruisselbrink et ale (2001) used a recombinant lactobacillus to induce tolerance in
mice against a component of the house dust mite, demonstrating the usefulness of
probiotic bacteria in the treatment of allergic and autoimmune diseases. Steidler et
ale (2000) engineered a Lactococcus lactis strain to secrete an anti-inflammatory
cytokine (IL-IO). The therapeutic effect of the engineered strain was comparable to
conventional steroid treatment in murine models of inflammatory bowel disease. The
potential of probiotic bacteria to be used as delivery vehicles seems very promising.
The multistage carcinogenesis process occurs over a long time period and makes it
difficult to assess the effectiveness of pre-, pro- and synbiotic intervention without a
lengthy follow-up period. An attractive alternative to time consuming, labour
intensive follow-up studies is the use of validated cancer risk biomarkers as
endpoints in intervention studies. Information on the ability of pre-, pro. and
synbiotics to modulate many different biological parameters has been generated
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from studies investigating the efficacy or pre-, pro- and synbiotics in the treatment or
prevention of many different disease processes. This information has and will
continue to prove invaluable in the development of a strategy for their application in
colorectal cancer.
Analysis of the gene expression profiles of normal tissue, polyps, tumour tissue and
normal tissue adjacent to tumours has identified many genes which may be involved
in the promotion or progression of colon cancer. Gene array analysis has already led
to the development of several new methods for use in diagnosis, patient stratification
and therapy. All factors of the genetic pathway in colorectal cancer are potential
targets for therapy and further work is needed to determine if pre-, pro- or syobiotic
intervention can effectively target specific genes with an associated beneficial effect.
10. Concluding Remarks
Symptoms of colorectal cancer present at a late stage in the disease process and
therefore, early prevention and detection of preneoplastic changes should be the
main area of focus in the coming years. Non-invasive cancer risk biomarkers, similar
to those discussed earlier, which herald early events in the cancer process, can be
used to identify individuals at risk of colon cancer and also to assess efficacy of
preventative measures.
Syobiotics offer great potential as a preventative strategy. Syobiotic intervention in
animal models of colon carcinogenesis has yielded very promising results. Current
studies in humans should further elucidate the mechanisms involved in their
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preventative action and their possible role in an early intervention strategy. In this
area there is a need for well-designed and executed intervention studies. The
synbiotic combination should be selected from well characterised pre- and probiotics
and based on its ability to affect the disease process. The study design should be
double-blinded and placebo controlled and should investigate a well-defined
population. The use of proven biomarkers is essential in assessing the efficacy of the
intervention.
Progress in the area of detection of cancer and the development of early preventive
measures, such as sYnbiotics, will lead to a dramatic change in the morbidity and
mortality pattern ofcolorectal cancer in the developed world.
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Chapter 2
General Methods
Study Outline
A twelve week randomised, double blind, placebo controlled trial ofa synbiotic food
supplement, containing a synbiotic mixture of Lactobacillus rhamnosus GG (LGG)
and Bifidobacterium lactis Bb12 (Bb12) and the inulin-type prebiotic Raftilose~
SynergyOI (inulin) for reduction in cancer risk biomarkers was carried out in The
Mercy University Hospital, Cork, Ireland. This study was evaluated and approved by
the Cork University Hospitals Ethics Committee.
The strains selected for this study were Lactobacillus rhamnosus GG (Valio,
Finland) and Bifidobacterium lactis Bb12 (Christian Hansen Labs, Sweden) the
properties of which were discussed previously (chapter 1 sections: 8.1.4 & 8.1.5). It
was thought that a combination of two probiotic strains would be more effective than
a single strain alone. Studies have shown that adherence of Bb12 to ileostomy
glycoproteins and to the intestinal mucus of infants is enhanced in the presence of
LGG indicating that simultaneous use of these strains may be more efficacious than
individual use (Juntunen et al. 2001; Ouwehand et ale 2000). From a practical point
of view it was decided to use existing commercial strains with a history ofanticancer
properties in experimental models.
The prebiotic selected for use in this study is a I: I mixture of long chain and short
chain fractions of inulin extracted from chicory roots (Cichorium Inrybus) and
known as oligofructose-enriched inulin or 'SynergyOI' (Raftilose SynergyOI, Orafti,
Belgium). One fraction is composed of linear 13 (2-1) fructans with a degree of
polymerisation (DP) ranging between ten and sixty-five (average DP 25) and the
other fraction contains similar molecules but with chain length varying between two
128
Inclusion Criteria:
Subjects must, within the last 5 years, have
• had a biopsy- and histologically-confirmed adenomatous polyp
or
• undergone resection for histologically-confirmed colon cancer
Both retrospective and prospective polypectomy and colon carcinoma resected
subjects may be enrolled.
Exclusion Criteria:
• Subjects over 75 years ofage.
• Pregnancy or a desire to become pregnant during the study period
• Subjects with known lactose intolerance and subjects with clinically
significant immunodeficiency
• Subjects who are considered to be poor clinic attendees or unlikely for any
reason to be able to comply with the trial
• Concomitant Drug usage - subjects will be excluded if they require COX-2
inhibitors or other selected NSAIDs
• Subjects who have been on antibiotics within the previous month or are
likely to require antibiotics during the trial period will be excluded
• Subjects with additional gastrointestinal disorders, (e.g. Crohn's disease or
ulcerative colitis)
• Malignancy or any concomitant end-stage organ disease
Figure 1: Study inclusion and exclusion criteria
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and eight (average DP 4). The latter molecules are rapidly fermented by the colonic
flora leading to a modification of the composition of the intestinal flora in the
proximal part of the colon. The longer chains are typically fermented at a slower
rate, but more selectively than the short-chains. This longer chain fraction has the
ability to maintain the metabolic activity of the improved flora for a lengthy time
period, or spatially, in more distal parts of the intestine. In experimental models this
mixture of inulin-type fructans reduces the incidence of aberrant crypt foci
significantly more than its individual components alone, (Verghese et al. 2003).
A dedicated study nurse was employed to identify subjects from the patient lists of
consultant gastroenterologists in The Mercy University Hospital, Cork, Ireland, who
fulfilled the inclusion and exclusion criteria of the study, (Figure 1). The study nurse
then contacted potential subjects and outlined the study protocol. Interested subjects
met with the study nurse in her consulting room, and a full patient history and
informed written consent were obtained at least one week before the subject began
the intervention.
The outline of the study was as follows:
Study-Outline:
~ Phase I (6 Weeks) I Phase 2 (6 Weeks) L---...
.,~-------I~-----~
Tl T2 T3
Faeces & blood Faeces & blood Faeces & blood
Biopsies (rectal) Biopsies (rectal)
The subjects attended appointments with the study nurse at Tl (before intervention),
T2 (following six weeks intervention) and T3 (following twelve weeks intervention).
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Figure 2: Faecal parameters investigated
Faeces
II Microbiology I
I
Standard plate count
• Totallactobacilli
• Total bifidobacteria
• Total enterococci
• Total coliforms
• Total Bacteroides
• Clostridium perjringens
Molecular Analysis
Calprotectin I II Faecal Water I
I
Mutagenic potential
• Genotoxic potential
• Cytotoxic potential
Tumour promoting potential
• Tight junction integrity
• Invasive potential
Immunology
• PGE2
• TGF-J3
Figure 3: Blood parameters investigated
Blood
I I
I Serum I Phagocytic & Respiratory I Lymphocytes I
I Burst activities I
Tumour markers
Cholesterol Cytokine production
• Total cholesterol Natural killer cell activity
• HDL cholesterol Genotoxic damage
• LDL cholesterol GST activity
• Triglycerides
Figure 4: Biopsy parameters investigated
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Subjects were randomly assigned to two groups. One group received the synbiotic
product consisting of encapsulated probiotic bacteria (1010 cfu LGG and 1010 cfu
Bb12) and a 12g sachet of SynergyCI and the other group received the placebo
product, consisting of encapsulated maltodextrin and a 12g sachet of maltodextrin.
Subjects kept a six-week diary detailing general health, appetite, smoking and
alcohol consumption for each phase of the intervention. At TI and T2 the subjects
received a box containing sufficient product for six-weeks. At T2 and T3 subjects
were interviewed by the study nurse, and reactions to the product, medications taken
and any adverse events, which had occurred in each six-week period were recorded.
The amount of product returned was also recorded to confirm compliance.
Subjects provided samples at three time points. Faecal (Figure 2) and blood (Figure
3) samples were provided at the beginning of intervention (week 0), mid-way
through intervention (week 6) and at the end of intervention (week 12) and numerous
parameters were investigated.
Biopsy samples (Figure 4) were provided at the beginning of intervention (week 0)
and at the end of intervention (week 12). Because bowel preparations (Le. enemas
and laxatives) used before endoscopic examinations have been reported to affect
colon proliferation, (Kleibeuker et al. 1995) patients were instructed not to take any
laxatives or enemas before endoscopy, which was performed in either the morning or
afternoon (between lOam and 3 pm). Rectal biopsies were obtained without
sedation, by rigid sigmoidoscopy from normal-appearing mucosa at 10 to 15 cm
from the anal verge and transferred immediately to appropriate storage media.
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Figure 5: Recruitment and randomisation process
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Figure 5 shows the recruitment and randomisation processes. A total of eighty
subjects (forty three polyp, thirty seven cancer) were recruited to the intervention
study from which six patients subsequently withdrew. Overall, thirty four cancer
subjects completed the trial, of which thirteen were female and twenty one were
male, with an average age of 60.1 ± 5.8 and 62.1 ± 5.3 (mean ± SD), respectively. In
this group, fifteen subjects consumed placebo and nineteen consumed syobiotic. A
total of forty polyp subjects successfully completed the trial, eighteen were female
and twenty-two were male, with an average age of 56.0 ± 9.8 and 58.0 ± 9.7 (mean ±
SD), respectively. In the group of polyp subjects, twenty-one subjects consumed
placebo and nineteen subjects consumed syobiotic.
There were no adverse effects of intervention, however some subjects consuming the
syobiotic reported a feeling of fullness and excessive bloating, both of which are
commonly associated with prebiotic consumption, (Cummings et oJ. 2001).
Feedback from most subjects was positive with many patients expressing the wish to
continue on the product after intervention was completed.
Blinding of the Study
The study was conducted in a double-blinded manner. Subjects were coded from
Syo-O1 to Syn-80 and each time point was coded either X, Y or Z. Coded samples
were processed and analysed in a blinded manner. For the duration of the study the
code was stored by one individual and following completion of all analyses was
disclosed.
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Product Transit
A common criticism of probiotic research is that the fate of the introduced bacterium
in the GI tract is not always investigated. It is important to confirm that introduced
probiotic strains transit the GI tract so that any observed effect may be associated
with probiotic consumption. In the human intervention study subjects consumed wild
type probiotic strains, which cannot be selectively isolated from the faeces of
subjects. Therefore spontaneously occurring rifampicin-resistant (rif) mutants
(50f,lglml) were selected from Bb12 and LGG. Previous experience in humans
demonstrated that such rif strains were not normally present in stool samples, and
that rifampicin resistance is a suitable marker to allow selective isolation and
enumeration of introduced probiotic strains from faeces, (Dunne et al. 1999, 2001).
The rifampicin resistant strains were freeze-dried and the resultant freeze-dried
product was checked for purity.
Briefly a 1.5L fermenter containing modified De Man, Rogosa, Sharpe (MRS) broth
[0.4% yeast extract, 2% glucose, 0.2% K2HP04, 0.5% Na-acetate, 0.2% (N~)3
citrate, 0.02% MgS04, 0.0046% MnS04 and 1.8% peptone] for LOG rif or
modified MRS broth containing 0.05% cysteine for Bb12 rif was inoculated with
overnight cultures of rif R strains. Fermentation was allowed to proceed for sixteen
hours at 3'tC and constant pH 5.5 with agitation. The suspension was centrifuged,
the pelleted bacteria resuspended in 10% skim milk, 2% sucrose and ascorbic acid
and frozen at -80°C for at least one hour. The bacteria were freeze-dried for 48 hours
and viable bacteria per gram of freeze-dried product were enumerated. Freeze-dried
powder was serially diluted 10-fold in sterile PBS /0.05% cysteine and appropriate
dilutions were spread-plated on rifampicin containing MRS agar (LOG) and
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modified raffinose bifidobacterium agar, (Hartemink et al. 1996), where raffinose
was replaced with lactose, in order to exclude the growth of LGG and isolate Bb12.
Bbl2 rit freeze-dried powder was found to contain 5.9 xl010 c.f.u.lg and LGG rit
powder contained 4.7x I010 c.f.u.lg.
The freeze-dried rit strains and the wild-type parent strains were found to be
identical using API (a rapid biochemical test). In this project it was considered
desirable that the probiotics reach the colon in a viable form in order to exert
beneficial health effects. As the acid environment in the stomach is the main reason
for bacteria not surviving passage through the upper intestinal tract, the probiotics
were administered in a coated capsule. The coating resists the acid conditions in the
stomach, and releases it's contents in the small intestine. The probiotic strains
selected have previously been shown to resist the bile acids that are secreted in the
small intestine.
The freeze-dried strains were encapsulated and a pilot study to confirm probiotic
transit was conducted with three healthy volunteers who consumed one capsule
containing 1010 cfu of both LGG rit and Bbl2 rit with a sachet ofSynergyCI (l2g)
every day for a seven-day period. The volunteers provided faecal samples before
feeding and at the end of feeding. The number of rit bacteria present in faeces
before and after seven days of feeding were enumerated using standard plate count
techniques. Total stool from one passage was collected in a plastic container and
mixed using a sterile wooden spatula. An aliquot was used to make a faecal slurry
with sterile 60% phosphate buffered saline solution (PBS) / 40% Glycerol / 0.05%
cysteine which was serially diluted 10-fold in sterile PBS / 0.05% cysteine.
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Product Quality & Stability
Before beginning the intervention study and during the study period product quality
and stability was investigated. Batches of synbiotic and placebo product were
received from Orafti, (Tienen, Belgium), as required throughout the intervention.
Microbial analysis was performed on each new batch and the numbers of probiotic
bacteria in the synbiotic capsules was consistently found to be 1010 cfu of each
bacterial strain. The sachets of SynergyCl and maltodextrin as well as the
maltodextrin capsules were free from detectable contaminants.
In the intervention study, subjects in the synbiotic group consumed probiotic
capsules every day for a twelve-week period. Subjects received a six-week supply of
product at the beginning of the study and again after the first six weeks of feeding. It
was recommended to store the capsules in a domestic freezer, however, it became
apparent that this might not be possible for all subjects. Therefore the effect of
storage at -20°C, 4°C and room temperature (Rn on the numbers of bacteria in the
probiotic capsules over a six-week period was investigated.
The number of viable bacteria was determined by resuspending the freeze-dried
contents of a capsule in PBS / 0.050/0 cysteine and serially diluting 10-fold in sterile
PBS / 0.05% cysteine. Appropriate dilutions were spread plated on MRS agar (LGG)
and modified raffinose bifidobacterium agar (BbI2) as described previously.
It was found that the optimal temperature for storage of the probiotic capsules was at
-200 C, however, storage at 4°C or room temperature did not result in a significant
decrease in numbers as counts remained above 9.8 x 109 cfu / capsule irrespective of
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Faecal Water (FW) Isolation
The method employed for the isolation of FW in this study was developed in
collaboration with Dr. Annett Klinder and Prof. Beatrice Pool-Zobel at the
Department of Nutritional Toxicology, Friedrich-Schiller University of Jena, Jena,
Germany.
Total stool from one passage was collected in a plastic container. The faecal sample
was weighed, mixed using a sterile wooden spatula and an aliquot taken for faecal
water preparation. The aliquot was diluted I: I with OMEM [lOx OMEM powder
(Gibco cat no. 52100) 10L H20, 2.9g L-Glutamine (Sigma), 1.1 g sodium pyruvate
(Sigma), 37g sodium bicarbonate (Sigma), Ig streptomycin sulphate (Sigma), 1
million units benzyl penicillin (Sigma), 40f..l.l Beta-2-mercaptoethanol (Merck)] in a
sterile stomacher bag (Seward), and was homogenised twice for three minutes. The
homogenate was then centrifuged at 60,000 x g for 2 hours at 4°C. The resultant
supernatant was filtered through a 0.2).101 filter (Nalgene; 155-0020) with glass pre-
filter (Nalgene, OS0281-5000). Iml aliquots were stored at -80°C. FW levels of
Prostaglandin E2 (PGE2) and transforming growth factor - beta I (TGF-J3), (chapter
3), and the tumour promoting (chapter 4), genotoxic (chapter 5) and cytotoxic
(chapter 6) potential of FW were determined. We have previously shown that this
method yields a large sample volume allowing the determination of many parameters
without influencing the properties of the FW (Klinder et oJ. 2005).
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Peripheral Blood Mononuclear Cell (PBMC) Isolation
Whole blood (9ml to 30ml) was collected in heparin treated collection tubes
(Sarstedt) and PBMCs isolated by density gradient centrifugation. Briefly blood was
diluted 5:3 with PBS, (Gibco Life Sciences). The PBS-blood mixture was carefully
layered onto Histopaque-I077 (Sigma) and centrifuged at 400 x g for 30 min. The
buffy layer containing the PBMCs was removed and transferred to a 15ml centrifuge
tube and washed twice by centrifuging at 400 x g for 10 mins in serum free RPMI-
1640 (Gibco Life Sciences) containing L-glutamine (2mmol/L), penicillin (100,000
UIL) and streptomycin (lOOmg/L). The resultant pellet was resuspended in 3ml
complete RPMI-1640 [RPMI-I640 containing 10% heat-inactivated foetal bovine
serum (FBS)] and cell number and viability was determined in a haemocytometer
(improved nuebauer) using trypan blue exclusion.
Cell concentration was adjusted to Ixl06 cells/ml of complete RPMI-I640. The
isolated PBMCs were stimulated for cytokine production (chapter 3), the remaining
PBMCs were cryopreserved for analysis of Natural Killer Cell (NK cell) activity
(chapter 3), for determination of GST activity (chapter 4) and genotoxic damage
(chapter 5).
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Chapter 3
The systemic immune system in cancer and
polyp subjects and the influence of synbiotic
consumption on immune function
Abstract
Probiotics and prebiotics are known to modulate the immune system in animals and
humans and to inhibit colon carcinogenesis in experimental animal models, but the
influence of synbiotics in these processes is not well documented. We have
previously shown in Azoxymethane (AOM) treated rats that consumption of a
synbiotic combination of Lactobacillus rhamnosus GG (LGG), Bifidobacterium
lactis Bb12 (Bb 12) and SynergyOl for 31 weeks modulated the immune system with
a concomitant reduction in the incidence of colonic tumours and a stimulation of
natural killer cytotoxicity with increased IL-I0 production in the Peyer's patches
(Femia et ale 2002). The aim of this study was to investigate the influence of twelve-
week consumption ofa synbiotic combination ofLGG, Bbl2 and SynergyOI on the
systemic immune system in cancer subjects who had undergone previous curative
resection, and in polypectomised subjects, and to identify immune biomarkers
suitable for use in intervention studies. A secondary aim was to investigate if the
functioning of the systemic immune system was different in cancer as compared to
polyp subjects and to identify putative immune biomarkers which may be useful as
cancer risk biomarkers. We found that synbiotic consumption did not significantly
modulate the systemic immune system in cancer and polyp subjects. We did
however identify significant differences between cancer and polyp subjects in
phagocytic activity, natural killer cell activity, IL-12 production by PBMCs and
PGE2 levels in FW at the beginning of the study. Further work is needed to confirm
the usefulness of these markers as biomarkers for cancer risk.
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Introduction
The gastrointestinal tract is the largest immune organ and is also home to the largest
concentration and diversity of resident microbial antigens in the human body. The
antigens of the gut are derived from the diet and the resident microbiota. In order to
prevent unnecessary and potentially harmful reactions, the gut immune system must
be able to distinguish the normal microflora and dietary antigens from pathogens
(oral tolerance).
It is known that there is a lifelong dialogue between the commensal microflora and
the host immune system, which is initiated at birth. Evidence from studies with germ
free animals show that in the absence of the commensal microflora, mucosal
associated lymphoid tissue is underdeveloped and cell mediated immunity is
defective, (Schaafsma 1997). The normal flora also acts as a physical barrier against
pathogenic and opportunistic infection by a process called colonisation resistance.
Germ-free animals, which lack a gut flora, are very susceptible to infections.
The importance of the commensal flora in stimulation of non-damaging immune
responses has become more evident recently. Increases in observed incidence and
severity of allergies as well as conditions such as inflammatory bowel disease in the
Western world have been linked with increases in standards of hygiene and
sanitation, concomitant with a decrease in the number and range of infectious
challenges encountered by the growing and developing host. This lack of immune
education may cause the host immune system to over-react to antigens of the non-
pathogenic normal flora resulting in inflammation, allergy and autoimmunity,
(Dunne et ale 1999).
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The commensal microflora influences the immune response through signalling with
the gut epithelium (Shanahan 2000). Certain members of the gut flora have been
shown to beneficially influence this intracellular signalling in in vitro studies (Haller
et al. 2000). Interactions with Toll-like receptors and dendritic cells in the gut are
believed to be involved in this process (Marteau et al. 2002; Shanahan 2002).
The normal microflora plays a central role in the initiation and maintenance of
appropriate immune function. Therefore modification of the composition and
metabolic activity of the flora seems a sensible means to beneficially enhance host
health. Probiotics, prebiotics and sYnbiotics have proven effective in altering the
composition of the flora and modulating the immune system in a health-promoting
manner.
One of the selection criteria for probiotic bacteria is that they exhibit the ability to
modulate the immune system, (Dunne et al. 1999). Although there is clear evidence
from experimental and human studies that probiotics influence host resistance
against intestinal infections as well as a number of immune cell functions, not all
studies report effective immune modulation by probiotics. In addition, the
underlying mechanisms by which probiotics exert their immunological effects are
not well defined. Several recent reviews summarise the available experimental
evidence of the immuno-modulatory effects of probiotics (Blum & Schiffrin 2003;
Cross 2002; Erickson & Hubbard 2000; Meydani & Ha 2000). Immune enhancing
effects associated with probiotics include enhanced macrophage phagocytosis
(Perdigon et 01. 1988), promotion of IgA responses (Isolauri et al. 1993; Link-
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Amster et al. 1994; Malin et al. 1996), and altered cytokine production (Miettinen et
al. 1996).
Current research indicates that consumption of prebiotics with probiotic strains
enhances the growth of the introduced strain in the gut. This is known as the
synbiotic effect and the term synbiotic is applied to a product, which contains both
prebiotics and probiotics. A synbiotic is defined as 'a mixture of a probiotic and a
prebiotic that beneficially affects the host by improving the survival and the
implantation of live microbial dietary supplements in the gastrointestinal tract, by
selectively stimulating the growth and/or by activating the metabolism of one or a
limited number of health-promoting bacteria', (Roberfroid 1998).
Consumption of lactic acid bacteria has been reported to increase the phagocytic and
respiratory burst activities of human peripheral blood cells. Schiffrin et al. (1995)
found that administration of milk fermented by Lactobacillus johnsonii La1 or
Bifidobacterium Iactis Bbl2 enhanced phagocytosis of E.coli compared to pre-
feeding levels. The same fermented milk product was found to increase phagocytic
and respiratory burst activities in humans consuming milk fermented with 109 cfu
but was unaltered in the group consuming milk fermented with 108 (Donnet-Hughes
et aI. 1999). Results from studies investigating the influence of probiotic
consumption on these parameters are not always consistent. Spanhaak et al. (1998)
reported that consumption of milk fermented with Lactobacillus casei Shirota did
not influence the phagocytic activity of blood cells.
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Cytokines are biologically active signalling proteins that function as intercellular
communicators. They act in the local environment by interacting with specific
receptors on the surface of cells and are involved in pro- and anti-inflammatory
responses mediating the immune response to pathogenic and commensal bacteria
and antigens. They also have an important role in the development of the immune
system. Studies have shown that probiotics can alter cytokine expression profiles in
healthy and diseased states in both animals and humans, (McCarthy et al. 2003;
Miettinen et al. 1996 & 1998; Sheil et al. 2004).
The modulation of cytokine production may also be mediated by constituents of
probiotic bacteria and may not necessarily require whole bacteria. Lammers et al.
(2003) showed that bifidobacterium genomic DNA induced secretion of 1L-10 by
PBMCs. Total bacterial DNA from faeces collected after probiotic administration
modulated the immune response with a decrease of IL-l (3 and an increase of IL-l0
production being recorded.
Many studies have identified the prostaglandin SYnthesis pathway as a potential
target for the treatment or prevention of colorectal cancer (Gupta & Dubois 2001;
Ota et al. 2002). The two isoforms of the cyclooxygenase (COX-l and COX-2)
enzyme catalyse the initial step in the formation of biologically important
prostanoids. The predominant prostaglandin species in benign and malignant
colorectal tumours is Prostaglandin E2 (PGE2). Several studies have shown that
levels of PGE2 are significantly higher in benign and malignant colorectal tumours
compared with paired histologically normal mucosa (Pugh & Thomas 1994; Yang et
al. 1998). A study by Narisawa et al. (1990) found high levels of PGE2 in the
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carcinoma tissue, the local venous blood draining the carcinoma and in the
peripheral blood in cases with liver or lung metastasis in 44 subjects with colorectal
cancer. Pugh & Thomas (1994) investigated the levels of colonic mucosal PGE2 in
subjects with adenomatous polyps and carcinomas as well as in normal healthy
subjects. Polyp and cancer subjects were found to express significantly higher
amounts of PGE2 than normal subjects.
Measuring PGE2 levels in faecal water (FW) may provide a useful non-invasive
biomarker for monitoring colorectal cancer risk and the effectiveness of
treatment/prevention strategies. Lauritsen et al. (1984) reported that PGE2 levels in
FW from patients with active ulcerative colitis (UC) was significantly higher than
levels in FW from healthy volunteers. They also found in UC patients in complete
remission that withdrawal of sulphasalazine increased PGE2 concentrations to values
above normal levels, which then returned to pre-trial values following treatment with
another salicylic derivative.
Transforming growth factor P(TGF-P) is a multifunctional polypeptide. Its role in
carcinogenesis can be either suppressive or promoting depending on tumour
developmental stages and cellular context. TGF-f3 is regarded as a major tumour
suppressor during early tumour development because it inhibits cell-cycle
progression and tumour growth. However, in late stages of progression, the majority
of transformed cells become either partly or completely resistant to TGF-p growth
inhibition due to inactivation of its signalling pathway or aberrant regulation of cell
cycle machinery and the role of TGF-f3 signalling is often switched from tumour
suppression to promotion. Development of resistance to TGF-f3 growth inhibition
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may also be due to alterations in the Smad-dependant anti-proliferative response
such as early termination of Smad signaling through Smad4 degradation or negative
regulation of Smad2/3 through phosphorylation caused by the presence of oncogenic
Ras (Saha et aJ. 2001).
It has been reported that in the later stages of cancer development TGF-p is actively
secreted by tumour cells and contributes to tumour growth, invasion, and metastasis
and decreases host-tumour immune responses (Pasche 2001). TGF-p has been
reported to be over-expressed in human cancers such as pancreatic, colorectal,
stomach, lung, prostate and breast (Gold 1999). Measurement of TGF-p in FW may
provide a non-invasive biomarker for colorectal cancer.
Natural killer (NK) cells are a sub-population of lYmphocytes important for the
recognition and elimination of virally infected cells and tumour cells. NK cells are
thought to playa role in the non-specific mechanism in immuno-surveillance for
cancer. Studies have suggested that low NK cell activity is associated with an
unfavourable prognosis, (Tartter et ale 1987).
Matsuzaki & Chin (2000) demonstrated that in adult mice fed the probiotic
Lacobacillus casei strain Shirota for five days the natural killer activity of spleen
cells was significantly higher than the NK activity of spleen cells from mice not fed
the probiotic. Takagi et aJ. (200 I) found that consumption of Lactobacillus casei
Shirota by mice treated with a chemical carcinogen enhanced the cytotoxicity ofNK
cells and delayed tumour onset.
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The aims of this study were:
1) To investigate the influence of twelve-week consumption of a synbiotic
combination of Lactobacillus rhamnosus 00, Bifidobacterium lactis Bb12 and
Synergy 1 on the systemic immune system in cancer subjects who had undergone
previous curative resection and in polypectomised subjects.
2) To investigate if the functioning of the systemic immune system in cancer
subjects who had undergone previous curative resection is different from that of
polypectomised subjects.
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Methods
The work described in this chapter was conducted in collaboration with Dr Monika
Roller, Dr Bernhard Watzl and Prof Gerhard Rechkemmer of the Institute of
Nutritional Physiology, Federal Research Centre for Nutrition and Food, Karlsruhe,
Gennany.
Phagocytic activity of peripheral blood cells
Leukocyte phagocytosis in human whole blood was assessed using opsinised
fluorescein isothiocyanate (FITC)-labelled E. coli [(lxI09 E. coli / ml), Molecular
Probes] and flow cytometric analysis. Blood was collected in heparin treated
collection tubes (Sarstedt). 100JlI of blood was aliquoted to two flow cytometer tubes
and placed on ice for 10 min. 5JlI of pre-cooled opsinised FITC-Iabelled E. coli, was
added to each tube and one tube was incubated for 10 mins at 3t>C in a waterbath
while the other tube was placed on ice for 10 min.
Following incubation, tubes were placed on ice and 100JlI of ice-cold quenching
solution (I 0% Trypan blue in PBS) was added to quench extracellular bacteria. 3ml of
washing solution (PBS) was then added and the tubes were centrifuged at 250 x g for
5 min. The supernatant was removed and the pellet washed again. 2ml of 1 x FACS-
Lysing Solution, (Becton Dickinson) was added to lyse red blood cells, tubes were
then incubated at room temperature for 20 min protected from light.
Following incubation tubes were centrifuged at 250 x g for 5 min and the supernatant
removed. Cells were then washed in 3ml of PBS and centrifuged at 250 x g for 5 min.
The supernatant was removed and leukocyte DNA was stained by
152
Fi lire fa i IIrefb
~ .
I mph = granulo t
ba d n m rph Iand ranul
ntr I (Fi ure la) and t t ( ioure 1b) ampl b in a a d
r pr nt d a a d t pi t f f; ard att r
t around m n
11 p pulati n in a
f; r pha
att r. R
pr nt dar nta t .
adding 100,...1 of propidium iodide (0.5,...g/ml Molecular probes) to each tube
followed by incubation on ice protected from light for 10 mins.
Phagocytic activity was measured by flow cytometry in an Epics Elite flow
cytometer fitted with an argon laser at 488nm (Beckman Coulter). During
acquisition a 'Live-Gate' was set in the histogram displaying diploid cell content.
This data was presented as a dot plot of forward scatter versus side scatter. Regions
were set around monocytes and granulocytes based on morphology (Figures la-b,
2a-b). Analysis was performed using the software package Expo Elite32 (Beckman
Coulter). Phagocytic activity was expressed as the percentage of active granulocytes
and monocytes as well as the mean fluorescence intensity, which correlates to the
number of bacteria per individual granulocyte or mononcyte.
Respiratory burst activity of peripheral blood cells
Leukocyte oxidative burst in human whole blood was determined by stimulating
blood cells with fMLP (N-Formyl-Met-Leu-Phe) (Sigma) and PMA (Phorbol-12-
myristat-13-acetat) (Sigma) followed by incubation with DHR (Dihydrorhodamine
123) and analysis by flow cytometry. Blood was collected in heparin treated
collection tubes (Sarstedt). 100,...1 of blood was aliquoted into each of three flow
cytometer tubes and placed on ice for 10 mins.
20,...1 of PBS was added to the first tube (control), 20,...1 of fMLP (mild stimulant) to
the second tube and 20,...1 of PMA (high stimulant) to the third tube. The test tubes
were incubated at 3t>C in a waterbath for 10 mins. Following incubation 1.7,...1 DHR
(final concentration O.4mM), was added to each tube followed by mixing on a vortex
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and a further 10 minute incubation at 3rC was performed. DHR is a non-fluorescent
substrate, which becomes oxidised by cellular enzymes and superoxide ions to a
fluorescent product which binds to the mitochondria of the phagocyte. The
fluorescence emitted gives a measure of respiratory burst activity.
Following incubation 2ml of Ix FACS-Lysing Solution was added, tubes were
mixed on a vortex and incubated at room temperature for 20 minutes protected from
light. Tubes were centrifuged at 250 x g for 5 min and the supernatant removed.
Finally cells were washed in 3ml of PBS, centrifuged at 250 x g for 5 min and
stained by adding 300Jll of propidium iodide (33.3Jlg/ml). Tubes were incubated on
ice protected from light for 10 min.
Respiratory burst activity was measured by flow cytometry in an Epics Elite flow
cytometer fitted with an argon laser at 488nm (Beckman Coulter). During
acquisition a 'Live-Gate' was set in the histogram displaying diploid cell content.
This data was presented as a dot plot of forward scatter versus side scatter. Regions
were set around monocytes and granulocytes based on morphology (Figures 3a-c,
4a-c, 5a-c). Analysis was performed using the software package Expo Elite32
(Beckman Coulter). Respiratory burst activity was expressed as the percentage of
active granulocytes and monocytes as well as the mean fluorescence intensity of
granulocytes and monocytes following stimulation with PMA.
PBMC stimulation
PBMCs were isolated from whole blood by density gradient centrifugation (general
methods). 100Jll ofPBMCs (lxl06 cells/ml) were incubated in complete RPMI-I640
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in a 96 well microtitre plate at 3t>C in a humidified atmosphere containing 5% C~
in air. PBMCs were stimulated in quadruplicate with 100JlI of 10mglL Con A
(Concanavalin A) (Sigma) for the production ofIL-2 and IFN-y, 100JlI of2Jlg/L LPS
(E. coli 0111 :B4) (Sigma) for IL-12 and TNF-(X production and in duplicate with
100fli of 2mg/L PHA (Lectin of Phytolacca Americana) (Sigma) for IL-IO
production. Cells thus treated were incubated for 24 hours. Following incubation the
microtitre plate was centrifuged at 200 x g for 5 min. The resultant supernatants were
harvested and aliquoted and stored at -80°C until analysis for cytokine production by
ELISA (BD Pharmingen) was performed.
Cryopreservation ofPBMCs for Natural Killer (NK) cell activity
Six ml of PBMCs at a concentration of Ixl06 cells/ml in complete RPMI-I640
(RPMI-1640 medium supplemented with 5% foetal bovine serum, 1%
penicillin/streptomycin, 1% L-glutamine) were centrifuged at 400 x g for 8 minutes.
The cell pellet was resuspended in 300JlI of cryoprotective medium [70% RPMI-
1640,20% FBS, 10% DMSO (Dimethyl sulfoxide)], aliquoted into cooled cryogenic
vials (Nunc) and placed overnight at -80°C in a cryopreservation vessel (Bicell). The
cryogenic vials were transferred to liquid nitrogen after 24 hours and stored for
further analysis.
Cytotoxicity of Natural Killer cells
Lytic activity of NK cells was measured using a flow cytometric method (Chang et
aI. 1993). This assay uses a cyanine membrane dye to stain live K562 target cells
and an iodide nuclear dye to quantitate dead cells.
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K562 human myelogenous leukaemia cells (German Cancer Research Centre,
Heidelberg, Germany) at a concentration of Ix106 cells/ml were labelled with 10JlI
of 3,3'-dioctadecyloxacarbocyanine perchlorate (3mmol/L; DiO;Molecular Probes)
and incubated at 3'PC for 20 min. The cell concentration was then adjusted to a
working concentration of I x lOS cellslml
Cryopreserved PBMCs were thawed rapidly in a water bath at 3'PC, then added to
10ml complete RPMI-1640, centrifuged at 400 x g for 8 mins and resuspended in
3ml of fresh medium and incubated for 18 h at 3'PC, then washed with fresh
medium and following counting (Coulter Z2) the cell concentration was adjusted to
2.5 x 106 cellslml.
PBMCs were pipetted in triplicate (IOOJlI) in tubes to which 200JlI of appropriately
diluted DiO-Iabelled target cells were added for final effector: target ratio of 12.5:1.
Finally, to each tube 20JlI propidium iodide (525 mgiL) was added and cells were
incubated for 135 min at 3'PC in a humidified atmosphere.
Damaged target cells appear double-stained as their membranes become permeable
to the nuclear stain, propidium iodide, during incubation. During data acquisition a
live gate is set on DiO-Iabelled target cells, which allows differentiation between
effector and target cells. The percentage ofdouble-stained target cells was quantified
and the lytic activity was calculated as the percentage of dead target cells in the test
samples less the percentage of dead target cells in the control samples without
effector cells.
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Quantification of Prostaglandin Ez (pGEz) in FW
FW was prepared by diluting faeces 1:1 with DMEM followed by ultra-
centrifugation as described in general methods. For this assay faecal water samples
were centrifuged at 2,500 x g, for 5 mins at 20°C. 100J.11 of the supernatant was
diluted 1: 10 with water and passed through a 0.2 J.1m filter. 500J.11 of the filtrate was
added to 500J.11 of an ice cold ethanol solution (1 :4, water:ethanol). 10J.11 glacial
acetic acid was added, gently mixed and incubated for 5 min at room temperature,
followed by centrifugation at 2500 x g for 3 min at 20°C.
The supernatant was applied to a C18 reverse phase minicolumn (Amprep C 18
500mg/2.8 ml RPN1910) (Amersham), which had been primed with 5.6 ml of 10 %
ethanol. The column was washed with 2.8ml of distilled water followed by 2.8ml
hexane and PGE2 was eluted with 3ml ethyl acetate. The ethyl acetate was
evaporated in a vacuum centrifuge and the resultant pellet was resuspended in 250J.11
assay buffer. PGE2 was measured by a commercial enzyme immunoassay
(Amersham), according to the manufacturers instructions.
Quantification of transforming growth factor - beta 1 (TGF-~) in FW
In order to quantify TGF-~ in faecal water, latent TGF-~ was first activated in the
FW sample. FW samples were centrifuged at 2,500 x g for 5 mins at 20°C. 80J.11 of
the supernatant was mixed with 80J.11 of 2.5M acetic acid / 10M urea and incubated
for 10 min at room temperature. The samples were neutralised with 80J.11 of 2.7M
NaOH / 1M HEPES. TGF-~ was measured immediately by ELISA (R&D systems),
according to the manufacturers instructions.
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Results
Phagocytic Activity of Peripheral Blood Cells
Whole blood was incubated with fluorescently labelled E. coli and phagocytic
activity was determined by measuring the percentage of active granulocytes and
monocytes and the mean fluorescence intensity ofgranulocytes and monocytes using
flow cytometry.
Cancer subjects
Phagocytic activity was measured as the percentage of active granulocytes as well as
the mean fluorescence of granulocytes. There was no significant difference of these
parameters at the end of (weekI2) or midway through intervention (week 6) as
compared to the beginning of intervention (week 0) in both the synbiotic (n=13) and
placebo (n=12) group of cancer subjects (Table I(a)). Similarly the percentage of
active monocytes and the mean fluorescence of monocytes were unaltered at all
three time-points in both groups of cancer subjects (Table I(b)).
Polyp subjects
In polyp subjects consuming the synbiotic (n=13) the percentage of active
granulocytes as well as the mean fluorescence of granulocytes was unaltered during
intervention. Unexpectedly the percentage of active granulocytes was significantly
increased at week 12 compared to week 0 (p=0.0175) in the group of polyp subjects
consuming placebo (n=16) (Table 2(a)). In both the synbiotic (n=13) and placebo
(n=16) group of polyp subjects the percentage active monocytes as well as the mean
fluorescence of monocytes were unaltered during the twelve-week intervention
period (Table 2(b)).
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The phagocytic activity of cancer (synbiotic & placebo) subjects and polyp
(synbiotic & placebo) subjects at week 0, was analysed. The phagocytic activity of
granulocytes (% active granulocytes) was significantly higher in cancer subjects
compared to polyp subjects (p=0.0173). However there was no significant difference
in the percentage of phagocytic activity in monocytes or the mean fluorescence of
granulocytes or monocytes (Table 3).
Respiratory Burst Activity of Peripheral Blood Cells
The respiratory burst activity of granulocytes and monocytes in whole blood
following stimulation with phorbol-12-myristat-13-acetat (PMA) was analysed by
flow cytometry.
In cancer subjects consuming synbiotic (n=13) there was an increase although not
significant (p=O.0669) in the percentage ofactive granulocytes at week 12 compared
to week O. The percentage of active granulocytes was unaltered in the placebo group
of cancer subjects (n=12), and both the synbiotic (n=15) and placebo (n=18) group
ofpolyp subjects (Figure 6(a)).
The mean fluorescence of granulocytes was significantly increased at week 12
compared to week 0 in synbiotic consuming cancer (p=O.0090) and polyp
(p=O.0344) subjects as well as in the placebo (p=O.0390) group of cancer subjects.
The mean fluorescence of granulocytes in polyp placebo subjects was unaltered
(Figure 6(b)).
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The respiratory burst activity of cancer (synbiotic & placebo) subjects and polyp
(synbiotic & placebo) subjects at week 0, was analysed. The respiratory burst
activity of granulocytes was not significantly different in cancer and polyp subjects
(Table J).
Cytokine Expression in Supernatants from Mitogen Stimulated PBMCs
Peripheral blood mononuclear cells were isolated from whole blood by density
gradient centrifugation and were then stimulated for 24 hours with a range of
mitogens following which cell free supernatants were analysed by ELISA for the
levels of the cytokines IL-2, IL-] 0, IL-12, IFN-y and TNF-a.
Cancer subjects
Mitogen induced cytokine levels in PBMCs isolated from the cancer synbiotic
(n=19) group at week 0, week 6 and week 12 were analysed by ELISA. Synbiotic
consumption significantly increased the levels of IFN-y at week 12 compared to
week 6 (p=0.0107) and week 0 (p=O.0376). IL-2, IL-I0, IL-12, and TNF-a levels
were unaltered (Figure 7(a)).
In the group of cancer subjects consuming placebo (n=15) cytokine levels were
unaltered during the twelve-week intervention period (Figure 7(b)).
Polyp subjects
Synbiotic intervention did not alter cytokine levels in polyp (n=19) subjects over the
twelve-week intervention period (Figure B(a)). However in the group of polyp
subjects consuming placebo (n=20), IL-2 production was significantly increased at
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week 12 compared to week 6 (p=O.0209) and week 0 (p=0.0022). IL-12 production
was also significantly increased at week 12 compared to week 0 (p=O.0050). IL-I0,
IFN-y and TNF-(X expression was unaltered (Figure 8(b)).
Cytokine expression in PBMCs derived from cancer (synbiotic & placebo) subjects
and polyp (synbiotic & placebo) subjects at week 0, was analysed. IL-12 protein
expression was significantly higher (p=0.0034) in cancer than in polyp subjects. IL-
2, IL-I0, IFN-y and TNF-a. levels were not significantly different (Table 3).
Natural Killer Cell Activity
The natural killer cell activity ofPBMCs was assessed by flow cytometry. There was
no significant change in the lytic activity of natural killer cells in cancer subjects
consuming synbiotic (n=7) or placebo (n=6) as well as polyp subjects consuming
synbiotic (n=5) or placebo (n=6) over the twelve-week intervention period (Table 4).
The natural killer cell activity of PBMCs derived from cancer (synbiotic & placebo)
subjects and polyp (synbiotic & placebo) subjects at week 0, was analysed. The lytic
activity of natural killer cells was significantly higher in polyp subjects than in
cancer subjects (p=0.0178) (Table 3).
Quantification of Prostaglandin E2 (PGE2) in FW
PGE2 was isolated from FW using a C18 reverse phase minicolumn and PGE2 levels
were measured by ELISA. There was no significant change in PGE2 levels in
synbiotic (n=17) and placebo (n=14) cancer subjects or in polyp synbiotic (n=l7)
and placebo (n=19) subjects (Table 5). There was a large inter and intra-individual
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variation in levels of faecal PGE2 in this study suggesting that this marker is not
suitable as an biomarker in an intervention study of this type.
The level of PGE2 in FW derived from cancer (synbiotic & placebo) subjects and
polyp (synbiotic & placebo) subjects at week 0, was analysed. PGE2 levels in FW
was significantly higher in cancer subjects comPared to polyp subjects (p=O.0032)
(Table 3).
Quantification of Transforming Growth Factor- Beta 1 (TGF-~) in FW
The level of TGF-~ in faecal water was measured by ELISA. During the twelve-
week intervention period there was no change in the levels ofTGF-~ in FW in either
cancer (synbiotic n=17, placebo n=14) or polyp (synbiotic n=17, placebo n=20)
subjects (Table 6). Similar to PGE2 there was a large inter and intra-individual
variation in levels of faecal TGF-~ in this study suggesting that this marker is not
suitable as an biomarker in an intervention study ofthis type.
The level of TGF-~ in FW derived from cancer (synbiotic & placebo) subjects and
polyp (synbiotic & placebo) subjects at week 0, was analysed. The level ofTGF-~ in
FW was not significantly different in cancer and polyp subjects (Table 3).
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Table I(a)
Percentage active granulocytes and the mean fluorescence of granulocytes in both
the synbiotic and placebo group of cancer subjects at the beginning of (week 0),
midway through (week 6) and at the end of intervention (weekI2). There was no
influence of synbiotic consumption on the phagocytic activity of granulocytes.
Results are expressed as mean ± standard error.
Table I(b)
Percentage active monocytes and the mean fluorescence of monocytes in both the
synbiotic and placebo group of cancer subjects at week 0, week 6 and at week 12.
There was no influence of synbiotic consumption on the phagocytic activity of
monocytes. Results are expressed as mean ± standard error.
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Table I(a): Granulocyte phagocytic activity in cancer subjects
Group
Synbiotic cancer (n=13)
Placebo cancer (n=12)
% Active Granulocytes
Week 0 Week 6
47.6±4.5 34.1 ±6.0
49.9 ± 6.0 38.3 ± 5.4
Week 12
43.7 ± 4.5
40.4 ± 5.4
P value
D.S.
D.S.
Group
Synbiotic cancer (n=13)
Placebo cancer (n=12)
Mean Fluorescence Granulocytes
Week 0 Week 6 Week 12
21.7 ± 1.4 16.7 ± 2.0 22.1 ± 2.2
22.4 ± 3.4 16.7 ± 1.4 22.8 ± 2.6
P value
D.S.
D.S.
Table 1(b): Monocyte phagocytic activity in cancer subjects
Group
Synbiotic cancer (n=13)
Placebo cancer (n=12)
0A. Active Monocytes
Week 0 Week 6
19.0 ± 2.9 15.6 ± 2.5
21.9 ± 3.2 16.5 ± 2.5
Week 12
18.4 ± 1.9
19.7±3.4
P value
D.S.
D.S.
D.S.
D.S.
P value
Mean Fluorescence Monocytes
Week 0 Week 6 Week 12
21.3±3.0 14.8±1.8 16.0±1.1
27.5 ± 8.4 16.9 ± 3.1 20.1 ± 1.8
Group
Synbiotic cancer (n=13)
Placebo cancer (n=12)
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Table 2(a)
Percentage active granulocytes and mean fluorescence of granulocytes in both the
synbiotic and placebo group of polyp subjects at the beginning of (week 0), midway
through (week 6) and at the end of intervention (week12). In the group of polyp
subjects consuming placebo the percentage of active granulocytes was significantly
increased at week 12 compared to week o. The percentage of active granulocytes
was unaltered in synbiotic consuming subjects. Results are expressed as mean ±
standard error.
Table 2(b)
Percentage active monocytes and the mean fluorescence of monocytes in both the
synbiotic and placebo group of polyp subjects at week 0, week 6 and at week 12.
There was no influence of synbiotic consumption on the phagocytic activity of
monocytes. Results are expressed as mean ± standard error.
167
Table 2(a): Granulocyte phagocytic activity in polyp subjects
Group
Synbiotic polyp (n=13)
Placebo polyp (n=16)
0t'o Active Granulocytes
Week 0 Week 6
37.6 ± 5.2 34.3 ± 3.5
J4.4 ::I: 4.8 34.3 ± 4.8
Week 12
45.2±6.1
45.3:1: 4.'
P value
D.S.
e.0171
Group
Synbiotic polyp (n=13)
Placebo polyp (n=16)
Mean Fluorescence Granulocytes
Week 0 Week 6 Week 12
19.3±1.1 17.9 ±2.4 23.9±4.1
19.0± 1.3 17.4± 1.6 23.1 ±3.1
Table 2(b): Monocyte phagocytic activity in polyp subjects
P value
D.S.
D.S.
Group
Synbiotic polyp (n=13)
Placebo polyp (n=16)
0t'o Active Monocytes
Week 0 Week 6
17.5 ± 2.7 16.1 ± 3.0
15.8 ± 2.1 17.4 ± 2.0
Week 12
15.9 ± 2.3
17.5±2.2
P value
D.S.
D.S.
Group
Synbiotic polyp (n=13)
Placebo polyp (n=16)
Mean Fluorescence Monocytes
Week 0 Week 6 Week 12
23.5 ± 5.9 17.2 ± 2.1 20.8 ± 3.3
18.4 ± 1.2 17.1 ± 1.2 21.8 ± 2.7
P value
D.S.
D.S.
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Table 3
Comparison of immune parameters in all cancer subjects compared to all polyp
subjects at the beginning of intervention. The percentage of active granulocytes,
natural killer cell activity, the expression of IL-12 by PBMCs and the level of PGE2
in FW was significantly different in cancer subjects compared to polyp subjects.
Results are expressed as mean ± standard error. Statistical significance was assessed
by un-paired t-test.
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Table j
Immune function in cancer vs. polyp subjects at the start of intervention
Immune marker
(units)
Cancer Subjects
Week 0
Polyp Subjects
Week 0
P value
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
n.s.
"'0111
'.81"
'.0034
1.0032
'7.63 ± 2.91
(0=39)
20.68 ± 0.93
(n=39)
17.64 ± 1.46
(n=39)
21.05 ± 2.08
(n=39)
IL-2
(pg/ml)
IL-10
(pg/ml)
IL-12
(pg/ml)
IFN-y
(pg/ml)
TNF-a
(pg/ml)
TGF-f3 FW
(pg/ml)
PGE2 FW
(pg/ml)
Phagocytic activity
(% active granulocytes)
Phagocytic activity
(MF granulocytes)
Phagocytic activity
(% active monocytes)
Phagocytic activity
(MF monocytes)
Phagocytic Activity
•.33 ± 3.27
(0=30)
22.58 ± 1.53
(n=30)
21.51 ± 1.96
(n=30)
24.34 ± 3.60
(n=30)
Respiratory Burst Activity
Respiratory burst activity 87.19 ± 1.42 88.44 ± 0.74
(% active granulocytes) (n=30) (n= 39)
Respiratory burst activity 16.12 ± 0.65 17.72 ± 1.43
(MF granulocytes) (n=30) (n=39)
Peripheral Blood Cytokine Expression
245.9 ± 45.7 160.5 ± 23.53
(n=34) (n=39)
146.6 ± 19.1 108.5 ± 18.87
(n=34) (n=39)
195.4 ± 125.1 178.5 ± 67.N
(0=34) (0=39)
723.2 ± 138.4 888.2 ± 146.9
(n=34) (n=39)
9186 ± 1700 6861 ± 1884
(n=34) (n =39)
Natural Killer Cell Activity
Natural Killer cell activity 13.27±1.24 19.93 ± 2.71
(% killed target cells) (8=24) (Ja=lS)
FW Cytokine Expression
1644 ± 313.9 1622 ± 248.9
(n=34) (n=40)
17473 ± 4991 11822 ± 211'
(a=33) (a=39)
170
Figure 6(a)
Respiratory burst activity expressed as the percentage of active granulocytes at week
0, week 6 and at week 12. The percentage ofactive granulocytes was unaltered in the
synbiotic (n=15) and placebo (n=18) groups of polyp subjects and the placebo
(n=12) group of cancer subjects. However the percentage of active granulocytes was
increased, although not significantly (p=0.0669) at week 12 compared to week 0 in
the synbiotic group of cancer subjects (n=13). Results are expressed as mean ±
standard error.
Figure 6(b)
Respiratory burst activity expressed as the mean fluorescence of granulocytes at
week 0, week 6 and at week 12. The mean fluorescence of granulocytes was
significantly increased at week 12 compared to week 0 in synbiotic consuming
cancer (n=13) and polyp (n=15) subjects as well as in the placebo group of cancer
(n=12) subjects. The mean fluorescence of granulocytes in polyp placebo subjects
(n=18) was unaltered. Results are expressed as mean ± standard error.
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Figure 7(a)
Mitogen induced cytokine levels in PBMCs isolated from the cancer synbiotic
(n=19) group at week 0, week 6 and week 12. Synbiotic consumption significantly
increased the levels ofIFN-y at week 12 compared to week 6 (p=0.0107) and week 0
(p=0.0376). IL-2, IL-I0, IL-12 and TNF-a expression was unaltered. Results are
expressed as mean ± standard error.
Figure 7(b)
Mitogen induced cytokine levels in PBMCs isolated from the cancer subjects
consuming placebo (n=15) at week 0, week 6 and week 12. Cytokine protein
expression was unaltered during the twelve-week intervention period this group of
subjects. Results are expressed as mean ± standard error.
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Figure 8(a)
Mitogen induced cytokine levels in PBMCs isolated from the polyp synbiotic (n=19)
group at week 0, week 6 and week 12. Synbiotic intervention did not alter cytokine
protein expression over the twelve-week intervention period. Results are expressed
as mean ± standard error.
Figure 8(b)
Mitogen induced cytokine levels in PBMCs isolated from the polyp subjects
consuming placebo (n=20) at week 0, week 6 and week 12. IL-2 production was
significantly increased at week 12 compared to week 6 (p=0.0209) and week 0
(p=0.0022). IL-12 production was also significantly increased at week 12 compared
to week 0 (p=O.0050). Results are expressed as mean ± standard error.
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Table 4
The natural killer cell activity ofPBMCs was assessed by flow cytometry. There was
no significant change in the lytic activity of natural killer cells over the twelve-week
intervention period in any of the study groups. Results are expressed as mean ±
standard error.
Table 5
PGE2 levels in faecal water were measured by ELISA. There was no significant
change in PGE2 levels over the twelve-week intervention period in any of the study
groups. Results are expressed as mean ± standard error.
Table 6
TGF-J3 levels in faecal water were measured by ELISA. There was no significant
change in TGF-J3 levels over the twelve-week intervention period in any of the study
groups. Results are expressed as mean ± standard error.
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Table 4: Natural killer cell activity (% of dead cells) in all subjects groups
CaDcer subjects Week 0 Week 6 Week 12 P value
Synbiotic (n=7) 12.44±2.307 13.30±2.316 15.32±4.213 D.S.
Placebo (n=6) 13.32 ± 2.844 18.12 ± 3.640 12.95 ± 3.809 D.S.
Polyp subjects
Synbiotic (n=5)
Placebo (n=6)
Week 0
23.34 ± 4.954
24.53 ± 3.609
Week 6
16.65 ± 1.110
20.08 ± 1.830
Week 12
18.65 ± 1.903
27.77 ± 6.451
P value
D.S.
D.S.
Table 5: Prostaglandin E2 (pg/ml) in Faecal Water
CaDcer subjects Week 0 Week 6 Week 12 P value
Synbiotic (n=17) 25106 ± 5926 25171 ± 5782 27095 ± 5590 D.S.
Placebo (n=14) 33817 ± 9062 34077 ± 9046 28192 ± 8515 D.S.
Polyp subjects
Synbiotic (n=17)
Placebo (n=19)
Week 0
10996 ± 2695
13749 ± 3597
Week 6 Week 12
8140 ± 1882 10124 ± 2936
11098 ± 3827 9922 ± 2018
P value
n.s.
n.s.
Table 6: Transforming Growth Factor-J3 (pglml) io Faecal Water
CaDcer subjects Week 0 Week 6 Week 12 P value
Synbiotic (0=17) 1033 ± 224.5 1486 ± 485.9 671.1 ± 129.4 D.S.
Placebo (0=14) 2263 ± 622.5 2397 ± 646.3 2357 ± 570.2 D.S.
Polyp subjects
Synbiotic (n=17)
Placebo (0=20)
Week 0
1405 ± 380.8
1682 ± 353.8
Week 6
1994 ± 477.2
1520 ± 324.9
178
Week 12
1924 ± 493.4
1654 ± 339.2
P value
D.S.
D.S.
Discussion
In the current study we evaluated the ability of a synbiotic combination of
Lactobacillus rhamnosus GG, Bifidobacterium lactis Bb12 and SynergyOl to
modulate the systemic immune system in polypectomised subjects and in cancer
subjects who had previously undergone 'curative resection'. We have previously
shown in Azoxymethane (AOM) treated rats that consumption of this synbiotic
combination for 31 weeks modulated the immune system with a concomitant
reduction in the incidence of colonic tumours (Femia et ale 2002; Roller et ale
2004a). By investigating the influence of synbiotic consumption on the systemic
immune system of subjects considered at risk for colon cancer we hoped to identify
non-invasive biomarkers for use in intervention studies and also biomarkers of
cancer risk.
Consumption of probiotics has been reported to enhance phagocytosis and
respiratory burst activities in human and animal studies (Collins et ale 2001; Mattila-
Sandholm et ale 1999; Perdigon et ale 1995, 1987, 1988). In humans consumption of
milk fermented by Lactobacillus johnsonii Lalor Bifidobacterium lactis Bb12
enhanced phagocytosis of E. coli compared to pre-feeding levels (Donnet-Hughes et
ale 1999; Schiffrin et ale 1995).
In contrast to the studies outlined above synbiotic consumption did not enhance the
phagocytic or respiratory burst activities of granulocytes or monocytes in the current
study. There was a significant increase in the percentage of active granulocytes in
polyp placebo subjects at the end of intervention compared to the beginning
indicating an increase in the number of phagocytosing granulocytes. However there
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was no change in the mean flouresence or the percentage ofactive monocytes in this
group. The increase in the percentage of active granulocytes observed in placebo
polyp subjects might indicate changes occurring in the 01 tract of these subjects,
which did not occur in polyp subjects consuming synbiotic. It may be that synbiotic
consumption prevented these changes, however this study was not designed to ask
this question and further work would be needed to determine the reason for this
increase. The outcome of this study is not unusual as not all studies have shown
enhancement of phagocytic activity in response to probiotics. Spanhaak et al. (1998)
reported that consumption of milk fermented with Lactobacillus casei Shirota did
not influence the phagocytic activity of blood cells.
In the current study there was a significant increase in respiratory burst activity as
measured by mean fluorescence in granulocytes in both synbiotic and placebo cancer
subjects and in synbiotic polyp but not placebo polyp subjects at the end of
intervention compared to the beginning. Interestingly this increase in respiratory
burst activity in three of the four study groups is in contrast to the phagocytosis assay
where placebo polyp subjects were the only group in which the percentage of active
granulocytes was altered. Similar to the phagocytosis assay the enhancement in
respiratory burst activity may be attributable to some other unknown factor. From
these results we conclude that phagocytic and respiratory burst activities are not
suitable biomarkers in an intervention study of this type.
Modulation of cytokine expression following probiotic consumption has been
reported in many studies in healthy and diseased states in both animals and humans,
(McCarthy et al. 2003; Miettinen et al. 1996, 1998; Sheil et al. 2004). Miettinen et
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aI. (1996,1998) reported that PBMCs stimulated with several strains of non-
pathogenic lactobacilli induce higher amounts of TNF-a than PBMCs stimulated
with LPS. IL-6 was also produced. Five-week oral consumption of Lactobacillus
rhamnosus GO in ten healthy human volunteers decreased the secretion of TNF-a,
IL-6 and IFN-y by PBMCs and increased IL-I0 and IL-4 secretion following in vitro
stimulation with self and non-self intestinal organisms and whole stool preparations,
(Schultz et al. 2003). Previous work in our lab has shown that different probiotic
strains induce distinct cytokine responses (Sheil 2003).
In this study synbiotic consumption by cancer subjects increased IFN-y production
by PBMCs but did not alter production of IL-2, IL-I0, IL-12, and TNF-a. In the
polyp placebo group there was a significant increase in IL-2 and IL-12 production,
however there was no alteration in cytokine production by polyp subjects consuming
the synbiotic, suggesting a dampening of the production of the pro-inflammatory
cytokines IL-2 and IL-12 in polyp subjects due to synbiotic consumption. Roller et
al. (2004a) found that consumption of the synbiotic combination used in the current
study increased IL-I0 production in Peyer's patches from AOM treated mice with a
lower incidence ofcolon tumours compared to mice not fed the synbiotic.
Natural killer (NK) cells are thought to playa role in the non-specific mechanism of
immuno-surveillance for cancer. Medium and high NK cell activity of PBMCs is
associated with reduced cancer risk, whereas low activity is associated with
increased cancer risk (lmai et al. 2000). Natural killer cells from probiotic fed mice
have been reported to demonstrate increased activity against tumour cells (Gill 1998;
Kato et al. 1984; Matsuzaki & Chin 2000). In the current study there was no effect
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of synbiotic intervention on the natural killer activity of PBMCs from cancer and
polyp subjects. In contrast Roller et al. (2004b) reported an increase in natural killer
cell activity in Peyer's patches from AOM treated rats fed the same synbiotic as that
used in this study compared to rats not fed the synbiotic.
Prostaglandin E2 (PGE2) and Transforming Growth Factor-p (TGF-P) have been
reported to be over-expressed in human cancers. PGE2 levels are significantly higher
in colorectal tumours compared with paired histologically normal mucosa (Pugh &
Thomas 1994; Yang et al. 1998). TGF-P is actively secreted by tumour cells and
contributes to tumour growth, invasion, and metastasis and decreases host-tumour
immune responses (Pasche 200 I). In the current study there was no influence of
synbiotic consumption on the levels of PGE2 and TGF-p in FW from cancer and
polyp subjects.
We compared the levels of immune parameters in cancer subjects to polyp subjects
at the beginning of intervention. The phagocytic activity of granulocytes (% active
granulocytes) was significantly higher in cancer subjects compared to polyp subjects.
Natural killer cell activity was significantly higher in polyp subjects compared to
cancer subjects. This result agrees with the findings of Imai et aJ. (2000) who
investigated NK cell activity in 3625 Japanese people mostly older than forty and
carried out a follow-up survey of cancer incidence for eleven years. Their results
indicate that medium and high NK cell activity of PBMCs is associated with reduced
cancer risk, whereas low activity is associated with increased cancer risk. Natural
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killer cell activity may be useful as a biomarker of cancer risk but further work is
needed to confirm its' potential in this area.
IL-12 production by PBMCs from cancer subjects was significantly higher than
production by PBMCs from polyp subjects following in vitro stimulation with LPS.
In contrast, studies have shown that CRC patients have lower preoperative levels of
IL-12 compared to healthy controls and lower levels of IL-12 production was
associated with advanced disease (O'Hara et al. 1998a,b).
The level of PGE2 in FW of cancer subjects was significantly higher than in FW
from polyp subjects. This increase may be due to inflammation of the colonic
mucosa. Lauritsen et al. (1984) reported that the level of PGE2 in FW from patients
with active ulcerative colitis is significantly higher than in FW from healthy
volunteers. Further work is needed but measurement of PGE2 in FW is a potential
non-invasive biomarker ofcancer risk.
In conclusion consumption of a synbiotic combination of Lactobacillus rhamnosus
00, Bifidobacterium lactis Bb12 and SynergyOI for twelve weeks did not
significantly modulate the systemic immune system in cancer and polyp subjects.
Previous work by our group has shown that consumption of this synbiotic
combination by AOM treated rats modulated the immune system and reduced
tumour incidence. This apparent paradox may be explained by the fact that in the rat
study immune responses were assessed in tissues of the immune system (i.e. Peyer's
patches, mesenteric lymph nodes) while in the human study we did not have access
to these tissues and so the immune modulating effects of the synbiotic were
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investigated in the systemic immune system. However it may also call into question
the degree to which observations from animal studies can be directly interpreted in
the human context.
Comparison of immune function in cancer and polyp subjects identified significant
differences in phagocytic activity, natural killer cell activity, IL-12 production by
PBMCs and PGE2 levels in FW as possible biomarkers of cancer risk. Further work
however is needed to confirm the efficacy of these biomarkers.
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Chapter 4
Synbiotic consumption reduces the proliferative
activity of the colonic mucosa but does not
influence the tumour promoting activity of
faecal water (FW)
Abstract
Animal and human studies have shown that prebiotics and probiotics influence
cancer risk in a protective manner, however the influence of synbiotic consumption
has not been well studied. We have previously shown in azoxymethane (AOM)
treated rats that consumption of a synbiotic (Lactobacillus rhamnosus 00,
Bifidobacterium lactis BbJ2, SynergyCl) significantly reduced the number of
colonic tumours compared to control rats. In humans cancer develops over a long
time period and currently available tumour markers do not have the ability to detect
early stage colorectal cancers. The aim of this study was to determine if synbiotic
consumption could influence the proliferative activity of the colonic mucosa, the
tumour promoting potential of faecal water (FW), the expression of glutathione-S-
transferases (GSTs) and the levels of CEA and CAI9-9. A secondary aim was to
determine which, if any, of the above markers might be suitable as cancer risk
biomarkers and / or biomarkers suitable for use in intervention studies. We found
that synbiotic consumption significantly reduced the proliferative activity in biopsies
from polyp subjects and increased GST activity in cancer subjects. There was no
change in the tumour promoting activity ofFW as measured by comet assay. Neither
was there an effect of synbiotic consumption on the levels of CEA and CA19-9. The
influence of FW on tight junction integrity in Caco-2 cells was significantly different
for FW derived from polyp subjects compared to FW derived from cancer subjects
indicating that the composition of FW is different in cancer and polyp subjects. In
conclusion synbiotic consumption influences the proliferative activity of the colonic
mucosa and the expression of detoxifying enzymes in a health promoting manner.
The composition of FW derived from cancer subjects is different to FW derived
from polyp subjects at the beginning of intervention and at all time points.
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Proliferative activity, GST expression and the influence of FW on tight junction
integrity may be useful as biomarkers ofcancer risk.
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Introduction
The long time period between exposure to a carcinogen and tumour formation in
humans poses a difficult problem when studying the relationship between suspected
aetiological agents of colon cancer and the end point of tumour formation. The
currently available biochemical markers for colorectal cancer (CRC) are not markers
ofcancer risk and therefore are not particularly useful in cancer risk lowering studies
or in evaluating the effectiveness of prevention strategies. There is a real need for the
development of new non-invasive reliable markers predictive of tumour formation,
which are altered by changing risk.
The colonic epithelium is a homeostatic tissue with strict control of proliferation,
growth, arrest and apoptosis. Disruption of the balance between cell growth and cell
death can result in clonal expansion and development of carcinomas. A gradual
inhibition of apoptosis, leading to increased proliferation has been reported in the
conversion of normal colonic epithelium into carcinomas (Bedi et ale 1995)
Normal colonic epithelium is organised into crypts where cell proliferation,
migration, differentiation and apoptosis are topographically organised in a linear
fashion along the crypt axis. Normal colonic crypts are composed of stem cells at the
base, a proliferation and a differentiation zone in the lower third of the crypt, a
migration zone in the upper two thirds, and the surface epithelium where senescent
cells are eliminated by apoptosis. However in the abnormal situation, e.g. polyp or
tumour formation, proliferation occurs throughout the entire crypt often with the
zone of maximum activity occurring at the top of the crypt.
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Proliferative activity is one of the most commonly used biomarkers to assess cancer
risk and to monitor the effectiveness of risk lowering strategies. Studies have shown
that subjects at high risk ofcolon cancer, such as subjects with familial adenomatous
polyposis (Mills et aJ. 2001), ulcerative colitis (Shinozaki et aJ. 2000) or sporadic
colon cancer (Roy et aI. 1999) have a high mucosal proliferative activity as
compared to controls. de Leon et aJ. (1988) reported that proliferation in the upper
crypt was significantly increased in patients with polyps and colorectal cancer
compared to healthy controls. In animal models of carcinogenesis, the carcinogen
often increases cell proliferation and causes a shift in the zone of proliferation.
Studies have shown that consumption of prebiotics, probiotics and synbiotics
decrease proliferative activity in humans and animals. Biasco et aJ. (1991) reported
that elevated cell proliferation in the colonic mucosa was decreased by probiotic
consumption in some patients with benign tumours in the colon. We have previously
shown that feeding azoxymethane (ADM) treated rats the prebiotic Synergy 1
significantly decreases the proliferative activity of the colonic mucosa. ADM treated
rats fed the probiotics Lactobacillus rhamnosus GG and Bifidobacterium Jactis Bb12
and rats fed a synbiotic combination of both probiotic strains and SynergyCI tended
to have a lower proliferative activity than control ADM treated rats. In synbiotic fed
rats there were significantly less colonic tumours than in control rats (Femia et aI.
2002).
A major function of intestinal epithelial cells is to provide a physical barrier between
the potentially hostile intestinal lumen and the highly immunoreactive subepithelial
tissue. Epithelial barrier function is provided by the epithelial cells and the tight
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junctions (TJs) which connect them. These junctions express a high degree of
plasticity and may be greatly attenuated in disease states.
TJs are critical for the control of paracellular transport between the luminal and the
basolateral fluid compartments (Madara, 1998). Disruption of TJs leads to a 'leaky
gut' with an increase in intestinal paracellular permeability, (Sugi el ale 2001). Soler
et al. (1999) demonstrated the association between increased tight junction
permeability and colonic tumour development. They found that TJs were highly
permeable in both rat and human colon tumours and also in the colonic epithelium of
rats with DMH induced carcinogenesis. This study also found in a limited number of
samples that human colonic polyps of the type more frequently associated with colon
cancer, (e.g. villous adenoma and adenomatous polyps) had more permeable TJs
than hyperplastic polyps which do not increase the risk of colon cancer and whose
TJ permeability was more similar to that ofnormal colonic epithelium.
Intestinal epithelial intercellular junctional integrity can be investigated in vitro by
measuring the transepithelial electrical resistance (TER) across a confluent
monolayer of cells grown on a permeable membrane. Transepithelial resistance to
the flow of an electrical current represents a direct measure of monolayer resistance
to passive ion permeation and is used as a measure ofjunctional permeability. Using
this method resistance is detected using a handheld volt ohm meter. It is also
possible to measure TJ integrity in the same system by measuring the paracellular
transport ofa labeled probe e.g. radiolabelled mannitol 14C.
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Metastasis is the escape of tumour cells from a primary site and their re-
establishment with secondary tumour formation at a distant secondary site. In recent
years there has been much development in the areas of diagnosis, surgery and
adjuvant therapies, however most deaths from cancer are due to metastases which
are resistant to conventional therapies. Metastases may occur in areas far distant
from the primary tumour and often go undetected at surgery.
The metastatic process involves a complex series of interactions between the cancer
and its environment. Fidler & Radinsky (1996) outlined the step leading to cancer
metastasis:
• Escape of the cells from the primary tumour
• Intravasation (entry ofcells into lymphatic or blood circulation)
• Survival and transport in the circulation
• Arrest in distant organs
• Extravasation (escape of cells from the circulation), growth of cells to form
secondary tumours in the new organ or environment
It is well known that the majority of cells within a tumour cannot complete the
multistep process of metastasis and are eliminated. Less than 0.1 % of cells entering
the bloodstream successfully form clinically detectable lesions, (Welch & Rink-
Schaeffer 1999).
The final step of the metastasis process is the development ofa new tumour. In order
to achieve this, the metastatic cells must first invade the tissue, a process which
involves adherence to the basement membrane (BM), production and secretion of
proteolytic enzymes capable of degrading the extracellular matrix (ECM) and basal
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membrane (8M), adherence to and degradation of the ECM components of host cells
and regulation of genes encoding for proteolytic enzymes for ECM degradation and
adhesion. The genes involved in the degredation of the ECM are those coding for the
Matrix Metalloproteinases (MMPs).
The metastatic potential of epithelial cells can be demonstrated in vitro using the
Matrigel Invasion assay (Albibi et a/. 1987; Kermorgant et a/. 2001). The aqueous
phase of faeces called faecal water (FW), contains most of the free reactive and
soluble factors, which interact with the mucosa in vivo (Rafter et a/. 1987).
Investigating the effect of FW on cells in the Matrigel Invasion assay determines the
invasion promoting potential of FW.
One of the most important groups of phase II detoxifying enzymes are the
glutathione-S-transferases (GSTs) which are known to inactivate a number of
genotoxic and carcinogenic substances by catalysing their conjugation with
glutathione. The GST family is divided into two microsomal and several cytosolic
classes (alpha, mu, kappa, pi, sigma, theta and zeta). Several GSTs are polymorphic
and some allelic variants causing impaired enzyme activity are suspected to increase
susceptibility to cancer. Extensive deletions in GSTM 1 and GSITI result in
complete loss of enzyme function, which may influence colorectal cancer
susceptibility (Seow et a/. 2002).
Szarka et a/. (1995) measured the GST activity of blood lymphocytes of healthy
control individuals and individuals at high risk of colon cancer. They found that the
GST activity of blood lymphocytes from high-risk individuals was significantly
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lower than that of blood lymphocytes from control individuals. They also measured
GST activity in colon tissue from the high-risk individuals and paired analysis
indicated a strong correlation between the GST activity of blood lymphocytes and
colon tissue. Dietary intervention can modulate the activity of GSTs. Treptow- van
Lishaut et al. (1999) reported that consumption of a resistant starch, induced GST 7t
in the rat colon and that germ free rats had lower levels of colonic GSTs than
conventional rats. Thus the inducibility of GSTs in normal tissues is a marker of
chemoprevention.
However human colonic tumours have been reported to express high levels of GST.
Hengstler et al. (1998) reported that the expression ofGST a and 7t was significantly
increased in tumour tissue compared to adjacent normal tissue in the colon. Sutoh et
al. (2000) reported increased GST 7t and P-glycoprotein expression was associated
with failure of cancer chemotherapy and poor patient survival. Further work is
needed but the use of GST activity as a biomarker for cancer risk and as a means of
monitoring responsiveness to treatment is a promising prospect.
Carcinoembyronic antigen (CEA) has been in use for approximately 30 years and is
one of the most widely used tumour markers worldwide. It is a high molecular
weight glycoprotein belonging to the immunoglobulin superfamily of molecules. It
has been postulated to playa role in a number of biological processes including cell
adhesion, immunity and apoptosis. After CEA, CA 19-9 is the most widely used
tumour marker. It is the best available marker for pancreatic cancer but it is less
sensitive than CEA for detecting colorectal carcinoma (Duffy et aJ. 2002). As these
markers are the most commonly used tumour markers for colorectal cancer we
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decided to investigate if synbiotic intervention in subjects at risk ofcolorectal cancer
could affect their levels.
The aims of this study were:
1) To investigate the influence of twelve-week consumption of this synbiotic
combination of Lactobacillus rhamnosus 00, Bifidobacterium lactis Bbl2 and
SynergyCI on proliferative activity in the colonic mucosa of polypectomised
subjects.
2) To investigate the influence of twelve-week consumption of a synbiotic
combination on the expression of tumour markers (CEA and CA19-9) as well as
the tumour promoting activities of faecal water in polypectomised subjects and
in cancer subjects who had previously undergone 'curative resection'.
3) To investigate if synbiotic intervention can modulate the activity of glutathione-
S -tl'ansferases
4) To investigate if the expression of tumour markers and the tumour promoting
activities of faecal water in cancer subjects who had undergone previous
curative resection is different from that of polypectomised subjects.
199
Methods
Work described in this chapter was carried out in collaboration with Dr Roisin
Hughes and Prof. Ian Rowland of the Northern Ireland Centre for Food & Health,
University of Ulster, Coleraine, Northern Ireland, Dr Giovanna Caderni, of the
Department of Pharmacology, University of Florence, Italy, Dr Annett Klinder and
Prof. Beatrice L. Pool-Zobel of the Department ofNutritional Toxicology, Friedrich-
Schiller University of Jena, Germany and Dr Tony Fitzgerald of the Biochemistry
Department, The Mercy University Hospital, Cork.
Proliferation Assay
Proliferative activity was assessed in vitro by eHl thymidine incorporation in
colorectal biopsy specimens from polyp subjects. Proliferative activity was not
assessed in cancer subjects due to sample limitation. Because bowel preparations
used before endoscopic examinations have been reported to affect colon proliferation
(Kleibeuker et oJ. 1995), patients were instructed not to take any laxatives or enemas
before endoscopy.
Two rectal biopsies were obtained by sigmoidoscopy from normal appearing mucosa
at about 15 cm from the anal verge of polyp subjects on placebo or sYnbiotic diet and
placed in a collection tube containing DMEM (Gibco). Biopsies were washed well
with sterile saline to remove any faeces and mucus and immediately transferred to a
20 ml sterile vial fitted with a sleeve-style rubber stopper, containing I ml DMEM
(Gibco,) and 5J.11 of 3H-thymidine (specific activity, 41 Ci/mmole; final
concentration, 5J1Ci/ml; Amersham Bioscience). Oxygen (25 ml) was injected into
the vials, which were then incubated in a shaking water-bath at 3t>C for 90 mins.
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At the end of the incubation the pressure in the vial was released with a syringe and
biopsies were washed 10 times with sterile saline to remove any unincorPOrated eH]
thymidine. Biopsies were orientated luminal side up under the microscope, set in a
plastic frame and fixed in this orientation with 2% agar at 40°C. After solidification
of the agar, the biopsies were fixed in 10% buffered formalin, embedded in paraffin
and stored at room temperature until processing for autoradiography.
Samples were processed for authoradiography as follows. Samples were sectioned
on a microtome and a series of sections, 5J,1m in thickness and perpendicular to the
surface of the mucosa were cut, these were dipped, in the dark, in Nuclear Track
Emulsion (NTB-2; Eastman Kodak), diluted 1:1 in distilled water at 40°C, and kept
in the dark at 4°C for 2 weeks. Slides were then developed by standard photographic
procedures and stained with haematoxylin-eosin.
For each subject, only full longitudinal crypt sections (Le. from the base to the top of
the crypt) were scored (Figures I(a-b)). For each subject (n=32) a mean of 14 ± 0.7
(SE) crypts were scored (range: 10-19). The number of cells per crypt column (Le.
number of cells from the bottom to the top of the half crypt appearing in the section)
and the number and position of the labelled cells along the crypt, dividing each crypt
into three equal parts: lower, middle and upper compartment (Figure 1(e)) , was
recorded.
The proliferative activity was expressed as percentage labelling index (LI):
number of labelled cells counted in all the Crypts of the same subject
total number of cells in all the crypt sections of the same subject x 100
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To evaluate the distribution of proliferative activity along the crypt, each crypt was
divided into three equal compartments (lower, middle and upper) and the distribution
of proliferating cells along the crypt (%LI in each compartment of the crypt) was
expressed using the formula:
total number of labelled cells in each compartment of all the Crypts scored
total number of labelled cells scored in the complete crypt
x 100
Slides were coded and read independently by two observers. The Correlation
Coefficient between these two observers on a set of46 LI scores was 0.83 (P<O.OO 1).
Tumour promotion assays: tight junction integrity
The effect of faecal water on two markers of tight junction integrity trans-epithelial
resistance (TER) and 14C mannitol flux in the Caco-2 cell line was measured as an
indictor of tumour promotion. Caco-2 cells are capable of enterocytic differentiation
forming atypical brush border membranes and tight junctions and provide a relevant
model for permeability and transport studies (Pinto et aI. 1983).
All tissue culture media and plastic ware was purchased from Life Technologies
(Paisley, UK). Human Caco-2 cells were obtained from the European Collection of
Animal Cell Cultures (ECACC) and cultured in tissue culture flasks with minimum
essential medium supplemented with foetal bovine serum (10%), non-essential
amino acids (1 %) and penicillin/streptomycin (1 %) in a humidified atmosphere
containing 5% C02 in air until 75% - 85% confluent. Cells between passage 6 and
10 were used.
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Figure 2: Measuring the transepithelial resistance of a cell monolayer grown on
an insert using an epithelial voltohmeter and STX2 electrode.
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Caco-2 cells were seeded onto the apical surface of collagen (rat tail type I, Sigma)
coated polyethylene terephthalate (PEn cell culture inserts (pore size 0.45J.U1l,
surface area 4.2cm2, Becton Dickinson, Falcon), which were kept in six well
companion plates (BD Falcon, Oxford, UK). 2.5 x lOS cells were added to each
insert (Le. 5.95 x 104 cells per cm2) and standard growth medium (1.5ml) was added
to each well. Two inserts contained cell free medium only in order to control for
resistance due to the insert membrane. Spent medium was removed and fresh
medium added to all inserts every forty-eight hours.
Transepithelial Electrical Resistance (TER)
TER readings were taken every 48 hours following eight days of cell culture on the
inserts. TER was measured using an EVOM epithelial voltohmeter and STX2
electrode (World Precision Instruments, Stevenage, Herts, UK) and all
measurements were taken after cells had adapted to room temperature (Figure 2).
TER readings stabilised at 700-800 ohmslcm2 after 14-16 days and cells were then
considered fully differentiated. Cells were then treated with faecal water (10% in
standard growth medium) for a 12-hour period. Changes in tight junction integrity
were assessed over this time by TER and results were expressed as percentage
change over the 12-hour period. Samples were analysed in triplicate. Negative
(standard culture media only) and positive (250 f.1M deoxycholic acid) controls were
included.
14C Mannitol Flux
Using the same system the effect of faecal water on the paracellular transport of
radiolabelled mannitol 14C, was measured following the final TER reading. The
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epithelial layer is nonnally impenneable to the sugar alcohol mannitol however
penneability increases as the selective function of the tight junctions decreases. This
can be measured by monitoring the apical to basolateraI Passage of radiolabelled
mannitol 14C across the monolayer and was used as another marker of tight junction
integrity to confinn TER results. Results were presented as activity of 14C mannitol
transported across monolayer expressed as a percentage of initial activity applied to
cells.
Faecal water was removed from the Caco-2 monolayers and cells were washed in
Hanks Balanced Salt Solution (HBSS). 14C mannitol (1 J.1Ci per ml in standard
growth medium) was then added and cells were incubated at room temperature for
one hour at which time 50~1 of medium was removed from the well of the
companion plate and added to 5ml scintillation fluid (Scintran Cocktail T, BDH).
The scintillation count of the original solution added to the insert was also
detennined. The amount of 14C passing into the well of the companion plate was
counted on a liquid scintillation counter (Wallac) as counts per minute. Results were
expressed as a percentage of the known 14C counts initially added to each insert.
Tumour promotion assays: HTttS cell invasion
The number of invading HTI15 cells was used as a measure of cell invasion
following a 24-hour treatment with faecal water. The HTI15 cell line is a highly
invasive human colon cancer cell line which was obtained from the European
Collection of Animal Cell culture (ECACC, UK). HTI15 cells were routinely
maintained in Dulbeccos minimum essential media (DMEM) supplemented with L-
glutamine (1%), foetal bovine serum (10%) and penicillin/streptomycin (1%). Cells
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were grown in a humidified atmosphere at 37°C containing 5% C~ in air. Cells
were grown to 80% confluence. To test the invasive ability of cells, matrigel protein
(BD Biosciences, Oxford, UK) was diluted with serum free growth medium (l :2).
Cell culture inserts (8J.1m pore size, BD Biosciences, Falcon, UK) were coated with
diluted matrigel and allowed to dry at room temperature to give a final concentration
of 25J.1g1cm2 of matrigel. Chambers were then rehydrated by adding serum free
medium and incubated at 37°C for two hours.
HTl15 cells were then seeded onto the inserts at a density of IxlOs/ml in serum free
growth medium. Inserts were then placed in tissue culture wells containing MRC5
monolayers. MRC5 cells which were obtained from the American Type Culture
Collection (AlTC, USA) are fibroblasts, which produce a hepatocyte growth
factor/scatter factor (HGF/SF), which acts as a chemo-attractant. HT1l5 cells were
immediately treated with faecal water (10% in serum free growth medium) and
incubated in a humidified incubator at 3'PC for 24 hours. HTl15 cells on both sides
of the inserts (Le. non invasive and invasive cells) were then fixed in 80% ethanol
and stained with haematoxylin (Sigma,). Cells were counted in five random fields at
a magnification of 200x (Imagedok, Kinetic Imaging) (Figure 3). The number of
invading cells was expressed as a percentage of the total cells (non invasive +
invasive) counted.
Glutathione-S-Tranferase (GST) activity in PBMCs
PBMCs were isolated by density gradient centrifugation and cell number was
adjusted to Ixl06 cells/ml in RPMI. The cell culture medium was removed by
centrifuging at 400 x g for 8mins and cells were resuspended in cryoprotective
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medium (90% FBS, 10% DMSO), frozen slowly to -80°C and stored under liquid
nitrogen until analysed.
Cryopreserved PBMCs were thawed on ice at 4°C, centrifuged at 400 x g for 8 mins
to remove the cryoprotective medium and resuspended in Iml PBS. Cell numbers
and viabilities were determined by counting in the presence oftrypan blue. Then cell
suspension was again centrifuged (400 x g, 8 mins) and the pellet was resuspended in
0.5 ml sonication buffer (25 mM Tris-HCI, pH 7.8,0.25 M sucrose, I mM EDTA, and
1 mM Pefabloc), and homogenised for 1 min (ultrasound Bandelin Electronics).
Following ultra-centrifugation (32,000 x g, 75 min, 4°C), the supernatant was frozen at
-140°C until analysed.
Total GST activity was determined by measuring spectrophotometrically the
conjugation of 1 mM l-chloro-2,4-dinitrobenzene with reduced 1 mM glutathione in
the presence of cell sonicate at 30°C. Conjugation is accompanied by an increase in
absorbance at 340nm (Habig et al. 1974). The rate of increase is directly
proportional to the GST activity of the sample. Total protein content was measured
according to Bradford (1976), using BSA as standard protein. All values were based
on the number of cells (Treptow-van Lishaut et al. 1999) as well as on total protein
content. Only one determination in each of these assays could be performed, due to
the limited amount of material available.
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CEA and CA19-9
Blood was collected in serum-gel blood collection tubes (Sarstedt). The tubes were
centrifuged at 300 x g for 5mins and the upper serum layer was removed, aliquoted
and stored at -80°C until analysed. Serum CEA and CA19-9 levels were determined
by a microparticle enzyme immunoassay and analysed on an IMx Analyzer,
(Abbott).
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Results
Proliferative Activity in the Colorectal Mucosa
Colorectal biopsies were obtained from polyp subjects at the beginning (week 0) and
the end of intervention (week 12). Proliferative activity was assessed in vitro by [3H]
thymidine incorporation in colorectal biopsy specimens. The total number of cells
(labelled and unlabelled) per crypt, the number of labelled cells per crypt, the
labelling index (number of labelled cells per crypt x cells counted in that crypt x
100) and the distribution of the labelled cells along the crypt were scored
independently by 2 observers.
Synbiotic consumption significantly reduced proliferative activity in the colonic
mucosa of polyp subjects. In polyp subjects consuming the synbiotic (n=14) the
number of labelled cells per crypt at the end of intervention was significantly less
(p=O.0277) than at the beginning of intervention (Figure 4(b)). This change was not
observed in the placebo polyp subjects (n=14) (Figure 4(a)).
The overall labelling index (LI) was also significantly reduced (p=O.0274) at week
12 compared to week 0 in the synbiotic group (Figure 5(b)), but was unaltered in the
placebo group (Figure 5(a)).
The distribution of labelled cells along the crypt in both the synbiotic and placebo
groups was unaltered. The significant reduction in proliferative activity in the
synbiotic group occurred in the lower (1 st) compartment of the crypt (p=O.0052)
(Figures 6 a-b) while proliferative activity in the mid (2nd) and upper (3rd) crypt
compartments was unaltered (Figures 7a-b, 8 a-b).
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The total number of cells/crypt (labelled and unlabelled) was unchanged by
intervention. For syobiotic subjects the total number of cells/crypt (mean ± SE) was
62.25 ± 1.78 before and 61.83 ± 1.89 following intervention. For placebo subjects
the numbers were 62.26 ± 1.73 before and 64.18 ± 1.84 after intervention.
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Figure4(a)
The number of labelled cells per crypt in colorectal biopsies from polyp subjects
(n=14) consuming placebo at the beginning (week 0) and the end of intervention
(week 12). The number of labelled cells per crypt was not significantly different at
week 0 compared to week 12.
Figure4(b)
The number of labelled cells per crypt in colorectal biopsies from polyp subjects
consuming synbiotic (n=14) at week 0 and week 12. The number of labelled cells per
crypt was significantly reduced at week 12 compared to week O.
Figure 5(a)
The overall labelling index (LI) in colorectal biopsies from placebo polyp subjects
(n=14) was not significantly different at week 0 and week 12.
Figure 5(b)
The overall labelling index (LI) in colorectal biopsies from synbiotic polyp subjects
(n=14) was significantly reduced at week 12 compared to week 0
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Figure 6(a)
The percentage labelling index (%LI) in the lower (l5t) crypt compartment in
colorectal biopsies from placebo polyp subjects (n=14). There was no significant
change in the twelve-week intervention period.
Figure 6(b)
The percentage labelling index (%LI) in the lower (l5t) crypt compartment in
colorectal biopsies from synbiotic polyp subjects (n=14) was significantly reduced at
week 12 compared to week O.
Figure 7(a)
The percentage labelling index (%LI) in the mid (2nd) crypt compartment in
colorectal biopsies from placebo polyp subjects (n=14). There was no significant
change in the twelve-week intervention period.
Figure 7(b)
The percentage labelling index (%LI) in the mid (2nd) crypt compartment in
colorectal biopsies from synbiotic polyp subjects (n=14) was significantly reduced at
week 12 compared to week O.
Figure8(a)
The percentage labelling index (%LI) in the upper (3 rd) crypt compartment in
coIorectal biopsies from placebo polyp subjects (n=14). There was no significant
change in the twelve-week intervention period.
Figure8(b)
The percentage labelling index (%LI) in the upper (3M) crypt compartment in
colorectal biopsies from synbiotic polyp subjects (n=14). There was no significant
change in the twelve-week intervention period.
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The Influence of Faecal water on Tumour Promotion
The influence of FW on tumour promotion was assessed by measuring a number of
tumour promoting biomarkers;
I. trans-epithelial resistance (TER) in Caco-2 cells
2.14C mannitol flux in Caco-2 cells
3. Invasive potential of HTIIS cells
Tight junction integrity
1. Trans-epithelial resistance
Changes in paracellular permeability across a Caco-2 monolayer induced by
incubation with FW samples were measured as the resistance to the flow of an
electric current (trans epithelial electrical resistance, TER). There was no significant
difference in the tight junction integrity of Caco-2 cells measured by trans-epithelial
resistance following incubation with FW derived from both cancer and polyp
subjects irrespective of intervention at all time points (Table 1);
The influence of FW derived from cancer (synbiotic and placebo) and polyp
(synbiotic and placebo) subjects at the beginning of intervention (week 0) on tight
junction integrity was measured by TER (Table 2). FW derived from polyp subjects
significantly improved tight junction integrity compared to FW derived from cancer
subjects at the beginning of intervention. In fact TER was significantly higher
following treatment of cells with FW derived from polyp subjects compared to FW
from cancer subjects at all three time points. However FW derived from cancer
subjects did not have an adverse effect on tight junction integrity, which was
generally greater than in cells treated with tissue culture medium alone (100%).
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2. 14C mannitol flux
The influence of FW on paracellular penneability across a Caco-2 monolayer was
also determined by measuring the paracellular transport of 14C mannitol across that
monolayer. The tight junction integrity measured by 14C mannitol flux in Caco-2
cells was unaltered at week 6 and week 12 compared to week 0 for both cancer and
polyp subjects irrespective of intervention (Table 3).
The influence of FW derived from cancer (synbiotic and placebo) and polyp
(synbiotic and placebo) subjects at the beginning of intervention (week 0) on tight
junction integrity was measured by assessing the paracellular transport of 14C
mannitol (Table 2). The paracellular transport of 14C mannitol was not significantly
different in cells treated with FW derived from polyp subjects compared to cells
treated with FW derived from cancer subjects.
3. HTIIS cell invasion
HT liS cells were grown on matrigel coated cell culture inserts and treated with FW.
The number of cells on both sides of the insert, (Le. non invasive and invasive cells)
were counted microscopically and the number of invading cells was expressed as a
percentage of the total cells (non invasive + invasive) counted. The percentage of
invading cells at week 6 and week 12 were not significantly different than at week 0
for all groups of subjects whether consuming the synbiotic or the placebo product
(Table 4).
The influence of FW derived from cancer (synbiotic and placebo) and polyp
(synbiotic and placebo) subjects at the beginning of intervention (week 0) on the
invasive potential of HTI15 cells was analysed by detennining the percentage of
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invasive cells passing through the matrigel (Table 2). There was no significant
difference in invasive potential in cells treated with FW derived from polyp subjects
compared to FW derived from cancer subjects at the beginning of intervention or at
all three time-points.
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Table 1
There was no significant difference in the tight junction integrity of Caco-2 cells
measured by trans-epithelial resistance following incubation with FW derived from
both cancer and polyp subjects irrespective of intervention at all time points. Results
are expressed as mean ± standard error.
Table 2
Comparison of biomarkers in all cancer (sYnbiotic and placebo) subjects compared
to all polyp (sYnbiotic and placebo) subjects. Tight junction integrity (TER) in Caco-
2 cells was significantly higher in cells following incubation with FW derived from
polyp subjects compared to cancer subjects at the beginning of intervention and at all
three time points. Mannitol flux (activity of 14C mannitol transported across
monolayer expressed as a percentage of initial activity applied to cells) was not
significantly different at the beginning of intervention or at all time points. The
percentage of invasive cells [number of invading cells expressed as a percentage of
total cells (non invasive + invasive)] passing through the matrigel was not
significantly different in cells treated with FW derived from polyp subjects
compared to cells treated with FW derived from cancer subjects. Results are
expressed as mean ± standard error. Statistical significance was assessed by un-
paired t-test.
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Table 1: Transepithelial electrical resistance in all subject groups
(0/0 change in TER following treatment with FW)
Cancer subjects Week 0 Week 6 Week 12 P value
Synbiotic (n=16) 113.1 ± 7.019 114.8 ± 10.55 110.2 ± 8.144 n.s.
Placebo (n=12) 101.6 ± 9.063 105.1 ± 9.240 101.8 ± 12.52 n.s.
Polyp subjects Week 0 Week 6 Week 12 P value
Synbiotic (n=14) 126.8 ± 5.433 132.7 ± 7.804 133.5 ± 5.466 n.s.
Placebo (n=20) 133.5 ± 5.239 127.8 ± 7.432 125.2 ± 6.642 n.s.
Table 2: Biomarker levels in cancer vs. polyp subjects at the beginning of
intervention and at all three time points
Biomarker Cancer Polyp P Cancer Polyp P
(units) Subjects Subjects value Subjects Subjects value
Week 0 Week 0 All times All times
Tight Junction Integrity
TER 108.8 ± 5.1 130.5 ± 3.' l.8Oot 108.3:l:5l 127.7± 3.t I.OO~(% ofcontrol) (8=31) (8=35) (8=31) (8=35)
Mannitol flux 6.42 ± 0.83 6.17 ± 0.39 6.21 ± 0.70 5.96 ± 0.39
(% transported) (n=31) (n=35) n.s. (n=31) (n=35) n.s.
Invasive Potential
Invasive cells 6.37 ± 0.65 5.50 ± 0.71 7.10 ± 0.64 6.26 ± 0.60
(% of total cells) (n= 34) n.s. (n=31) (n=35) n.s.(n=25)
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Table 3
The tight junction integrity measured by 14C mannitol flux in Caco-2 (activity of 14C
mannitol transported across the monolayer expressed as a percentage of initial
activity applied to cells) cells was unaltered during the twelve-week intervention for
both cancer and polyp subjects irrespective of intervention. Results are expressed as
mean ± standard error.
Table 4
The percentage of HTl15 cells invading a matrigel coated cell insert following
treatment with FW was not significantly different for FWs derived from all subjects
(cancer and polyp) whether consuming the synbiotic or the placebo product. Results
are expressed as mean ± standard error.
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Table 3: Mannitol flux in all subject groups (% transported)
CaDcer subjects Week 0 Week 6 Week 12 P value
Synbiotic (n=16) 7.356 ± 1.348 6.386 ± 1.123 6.379 ± 1.277 D.S.
Placebo (n=12) 6.190 ±O.999 6.949 ± 1.541 6.897 ± 1.696 D.S.
Polyp subjects Week 0 Week 6 Week 12 P value
Synbiotic (n=14) 6.749 ± 0.573 6.886 ± 0.605 6.640 ± 0.669 D.S.
Placebo (n=20) 5.913 ± 0.531 6.065 ± 0.568 5.656 ± 0.574 D.S.
Table 4: HTI15 Invasion in all subject groups [number of invading cells expressed
as a percentage of total cells (non invasive + invasive)]
Cancer subjects Week 0 Week 6 Week 12 P value
Synbiotic (n=13) 6.564 ± 1.025 7.020 ± 1.086 9.475 ± 2.312 D.S.
Placebo (n=9) 6.446 ± 1.091 8.636 ± 2.105 5.849 ± 1.719 D.S.
Polyp subjects Week 0 Week 6 Week 12 P value
Synbiotic (n=8) 5.689 ± 1.430 8.875 ± 2.155 9.043 ± 2.888 D.S.
Placebo (n=7) 5.419 ± 1.046 5.981 ± 1.110 6.608 ± 1.473 D.S.
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Glutathione -S- Tranferase (GST) Activity in PBMCs
Total GST activity in PBMCs was measured spectrophoretically and expressed as
nmoles GST / min per 106 cells and nmoles GST / min per )J.g total protein.
Cancer subjects
Total GST activity was significantly increased by synbiotic consumption in cancer
subjects. GST activity per 106 cells was significantly increased (p=O.0282) at week 6
compared to week 0 in synbiotic cancer subjects (n=18) (Figure 9(a)). GST activity
per 106 cells was unaltered in placebo cancer subjects (n=14) (Figure 9(b)).
In synbiotic cancer subjects GST activity per )J.g of protein was unaltered during the
twelve week intervention period (Figure lOra)). Again there was no change in the
placebo group of cancer subjects (Figure IO(b)).
Polyp subjects
Total GST activity per 106 cells was unaltered in polyp subjects consuming synbiotic
(n=18) (Figure ll(a)). However in polyp placebo subjects (n=19) GST activity per
106 cells was significantly increased (p=O.0034) at week 12 compared to week 0
(Figure ll(b)).
GST activity per )J.g of protein was increased significantly (p=O.0176) at week 12
compared to week 0 in the synbiotic polyp group (Figure 12(a)). GST activity per
106 cells was unaltered during the twelve week intervention period in the polyp
placebo group (Figure 12(b)).
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GST activity of lymphocytes from cancer (synbiotic and placebo) and polyp
(synbiotic and placebo) subjects at the beginning of intervention was assessed. There
was no significant difference in GST activity in cancer subjects compared to polyp
subjects. GST activity per 106 cells was 1.06 ± 0.11 (cancer) and 0.88 ± 0.09 (polyp)
and GST activity per J.lg of protein was 5.64 ± 0.74 (cancer) and 6.23 ± 0.86 (polyp).
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Figure 9(a)
GST activity per 106 cells in synbiotic cancer subjects (n=18) was significantly increased at week 6 compared to week O.
Figure 9(b)
GST activity per 106 cells in cancer subjects consuming placebo (n=14) was unaltered during the twelve-week intervention period.
Figure lOra)
GST activity per J.lg of protein in synbiotic cancer subjects (n=18) was unaltered during the twelve-week intervention period.
Figure lO(b)
GST activity per J.lg of protein in cancer subjects consuming placebo (n=14) was unaltered during the twelve-week intervention period.
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Figure ll(a)
GST activity per 106 cells in polyp subjects consuming synbiotic (n= 18) was unaltered during the twelve-week intervention period
Figure 11(b)
GST activity per 106 cells in polyp placebo subjects (n=19) was significantly increased at week 12 compared to week O.
Figure 12(a)
GST activity per J.1g of protein in the synbiotic polyp group (n=18) was significantly increased at week 12 compared to week O.
Figure 12(b)
GST activity per Jlg ofprotein in the polyp placebo group (n=19) was unaltered during the twelve-week intervention period.
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Biochemical Tumour Markers:
Carcinoembryonic antigen (CEA) & Carbohydrate antigen 19-9 (CAI9-9)
Serum CEA and CA19-9 levels were determined by microparticle enzyme
immunoassay. CEA and CA19-9 levels were not significantly altered in the cancer
synbiotic subjects (Table 5). In this group one subject (Syn-21) had elevated CEA
and equivocal Ca19-9 at the end of intervention. This subject was diagnosed with
metastatic disease of the liver at the end of intervention. Similarly CEA and CA19-9
levels were not significantly altered in cancer subjects consuming placebo (Table 6).
CEA and CA19-9 levels were unaffected in both the synbiotic (Table 7) and placebo
(Table 8) polyp subjects.
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Table 5
Serum CEA and Cal9-9levels in cancer subjects consuming synbiotic.
CEA
Normal range 0-3 ng/ml
Equivocal 3-10 ng/ml
Elevated > I0 ng/ml
NO = not determined.
CA19-9
Normal range 0-37 Vim I
Equivocal 37-60 U/ml
Elevated >60 U/ml
WD--withdrew from intervention
Table 6
Serum CEA and Ca19-9 levels in cancer subjects consuming placebo.
CEA
Normal range 0-3 ng/ml
Equivocal 3-10 ng/ml
Elevated > I0 ng/m I
NO = not determined.
CA19-9
Normal range 0-37 Vim I
Equivocal 37-60 U/ml
Elevated >60 Uiml
WD=withdrew from intervention
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Table 5
Subject CEA CEA CEA Ca19.9 Ca19.9 Ca19.9
no (week 0) (week 6) (week 12) (week 0) (week 6) (week 12)
Syn-Ol NO 0.6 0.6 NO 9.1 8.2
Syn-03 NO 0.1 0.4 NO 4.7 3.9
Syn-04 0.4 0.4 0.5 6.6 10.0 7.4
Syn-05 3.8 3.0 4.2 2.0 1.5 1.6
Syn-08 0.7 0.9 1.1 0.5 0.8 0.6
Syn-09 0.7 0.6 0.5 10.4 5.8 6.4
Syn-13 1.0 1.0 1.1 0.0 0.0 0.0
Syn-14 0.8 0.8 0.7 5.9 6.0 5.9
Syn-20 1.8 2.0 2.3 19.9 18.0 20.2
Syn-21 NO NO ] 1.8 NO NO 42.8
Syn-25 0.6 0.6 0.3 19.2 21.2 22.7
Syn-26 0.8 1.0 0.8 11.8 10.9 13.5
Syn-39 2.5 2.0 2.5 4.1 3.3 5.0
Syn-43 1.6 1.6 1.8 11.8 14.6 11.7
Syn-51 2.2 1.9 1.9 4.4 3.4 11.9
Syn-58 0.5 0.5 0.6 11.5 9.1 10.4
Syn-71 3.1 2.9 2.6 0.0 0.0 0.0
Syn-75 2.3 1.9 2.0 0.0 0.0 0.0
Syn-76 1.5 2.0 1.7 6.4 4.0 43.0
Table 6
Subject CEA CEA CEA Ca19.9 Ca19.9 Ca19.9
no (week 0) (week 6) (week 12) (week 0) (week 6) (week 12)
Syn-02 NO 3.1 3.5 NO 19.3 19.3
Syn-06 2.3 2.3 2.8 NO NO NO
Syn-07 1.6 1.9 2.2 1.8 2.7 3.1
Syn-l0 1.4 1.6 1.5 3.9 4.2 3.0
Syn-ll 1.6 WO WO NO WO WO
Syn-12 0.7 1.0 0.9 9.2 6.8 7.7
Syn-15 0.2 0.5 0.2 1.2 1.4 1.0
Syn-16 0.4 0.1 0.4 0.9 0.5 0.7
Syn-17 1.7 1.4 1.8 27.4 27.9 25.9
Syn-18 1.0 1.2 1.2 14.5 14.1 12.8
Syn-19 0.7 0.7 1.0 0.7 0.0 1.0
S)'n-30 1.0 1.0 1.2 1.0 1.4 6.4
Syn-38 2.7 2.7 3.1 13.5 15.9 14.8
S1'n-44 1.3 WO WO 21.7 WO WO
Syn-47 0.3 WO WO 9.5 WO WO
Syn-52 1.7 1.5 1.7 12.9 11.3 13.0
_ S)'n-73 0.7 0.7 0.8 3.2 3.8 3.7
S1'n-77 1.9 2.4 2.4 12.7 22.0 19.9
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Table 7
Serum CEA and Ca19-9 levels in polyp subjects consuming synbiotic.
CEA
Nonnal range 0-3 nglml
Equivocal 3-10 ng/ml
Elevated > 10 ng/ml
ND = not determined.
CA19-9
Normal range 0-37 VImI
Equivocal 37-60 Vlml
Elevated >60 Vlml
WD--withdrew from intervention
Table 8
Serum CEA and Ca19-9 levels in polyp subjects consuming placebo.
CEA
Nonnal range 0-3 nglml
Equivocal 3-10 ng/ml
Elevated >10 ng/ml
ND =not determined.
CA19-9
Normal range 0-37 VIm I
Equivocal 37-60 Vlml
Elevated >60 Vlml
WD=withdrew from intervention
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Table 7
Subject CEA CEA CEA Ca19.9 Ca19.9 Ca19.9
no (week 0) (week 6) (week 12) (week 0) (week 6) (week 12)
Syn-23 1.4 1.5 1.4 21.2 26.6 29.8
Syn-27 ND 1.4 0.8 ND 18.2 15.6
Syn-29 1.7 1.6 2.1 2.9 2.3 2.6
Syn-33 0.7 0.8 0.8 2.8 3.0 2.0
Syn-34 0.1 0.2 0.1 3.1 3.6 4.2
Syn-36 1.7 1.5 1.5 2.7 3.0 3.4
Syn-37 3.5 3.3 WD 52.9 42.2 WD
Syn-40 3.1 3.0 2.4 79.7 80.5 81.1
Syn-45 1.8 WD WD 14.0 WD WD
Syn-48 0.9 0.8 0.9 6.9 6.2 6.3
Syn-53 3.0 2.3 2.6 9.5 8.2 8.2
Syn-54 0.4 0.5 0.6 7.9 5.2 4.1
Syn-57 2.1 2.1 2.3 1.3 0.1 0.0
Syn-60 1.3 1.0 0.9 5.7 4.5 3.5
Syn-61 1.4 1.3 1.3 26.8 24.0 25.9
Syn-62 1.6 1.4 IJ 4.7 4.9 5.2
Syn-65 0.4 0.5 0.6 5.6 6.0 5.9
Syn-67 0.9 0.9 1.0 10.9 10.6 16.9
Syn-68 1.8 1.7 1.8 10.6 16.9 10.9
Syn-70 2.4 2.5 2.1 2.1 2.5 1.3
Syn-79 ND 2.0 2.4 NO 32.2 32.6
Table 8
Subject CEA CEA CEA Ca19.9 Ca19.9 Ca19.9
no (week 0) (week 6) (week 12) (week 0) (week 6) (week 12)
Syn-22 1.4 WD WD OJ WD WD
Syn-24 2.5 3.3 3.0 2.5 2.7 3.4
Syn-28 0.9 0.5 0.8 12.5 11.5 22.2
Syn-31 0.4 0.7 0.7 14.1 19.9 27.9
Syn-32 0.5 0.6 0.6 3.9 3.6 3.0
Syn-35 1.1 1.3 1.3 4.5 5.9 3.9
Syn-41 1.9 1.6 1.7 41.0 36.0 38.7
Syn-42 3.8 4.7 4.2 0.0 0.0 0.0
Syn-46 0.6 0.6 0.8 22.7 20.5 20.8
Syn-49 0.7 0.9 0.9 0.0 0.0 0.0
Syn-50 2.0 1.8 1.9 15.8 15.8 14.9
Syn-55 5.5 5.0 5.5 12.7 12.2 15.4
Syn-56 2.3 1.7 2.1 3.9 5.1 4.3
Syn-59 1.7 1.6 1.5 2.6 1.5 1.7
Syn-63 0.9 1.1 1.1 34.0 31.8 35.6
Syn-64 0.7 0.8 0.8 1.1 1.7 1.7
Syn-66 0.9 0.9 1.0 3.5 2.5 2.1
Syn-69 0.8 0.8 0.9 0.8 0.6 0.9
Syn-70 0.9 0.8 0.8 2.2 1.9 2.1
Syn-72 3.2 3.6 4.2 2.4 1.8 4.1
Syn-74 2.5 2.2 1.7 13.6 12.7 10.8
Syn-80 1.9 1.9 1.9 0.0 0.0 0.0
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Discussion
In the current study we evaluated the ability of a synbiotic combination of
Lactobacillus rhamnosus 00, Bifidobacterium lactis Bb12 and SynergyCl to
modulate the proliferative activity of the colonic mucosa in polyPectomised subjects
and to influence the expression of tumour markers and tumour promoting activities
of faecal water in polyPectomised subjects and in cancer subjects who had
previously undergone 'curative resection'.
Epidemiological and experimental studies suggest that a high proliferative activity or
a deregulation of the normal pattern of proliferation along the crypt are risk factors
for colon carcinogenesis. De Leon et al. (1988) reported that proliferation in the
upper crypt was significantly increased in patients with polyps and colorectal cancer
compared to healthy controls. Many studies have shown that dietary intervention can
reduce colorectal mucosal proliferation (Caderni et al. 1988; Holt et al. 1988). In the
present study proliferative activity in the colonic mucosa of polyPectomised subjects
was significantly decreased following a twelve-week intervention with the synbiotic.
The distribution of proliferating cells along the colonic crypt however was not
altered, and the reduction in proliferative activity was found to be most prominent in
the lower compartment of the crypt.
These results correlate with previous work by our group which showed that
consumption of this synbiotic by azoxYmethane treated rats reduced the proliferative
activity as well as the number of colonic tumours in these rats but did not influence
the distribution of proliferating cells in the colon (Femia et al. 2002). These results
suggest a protective effect of synbiotics in colon carcinogenesis. However, further
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work is required to elucidate the mechanisms by which synbiotics mediate their
protective effects.
Within the gastro-intestinal tract tight junctions (TJs) control paracellular transport
between the luminal and the baso-Iateral fluid compartments. Disruption ofTJs leads
to a 'leaky gut' with an increase in intestinal paracellular permeability, (Sugi el ale
2001). Soler el ale (1999) demonstrated the association between increased tight
junction permeability and colonic tumours. Tight junction integrity is influenced by
the components of the gut lumen, with which it is in intimate contact. Human faeces
represents the end products of diet, digestive and excretory processes as well as the
metabolic activities of the gut flora. Therefore investigation of faecal contents
provides a non-invasive method of studying the stresses to which the colorectal
mucosa is exposed.
The influence of faecal water on the integrity of the epithelial barrier function was
assessed by transepithelial electrical resistance (TER) and paracellular transport of
radiolabelled mannitol. There was no significant difference in the trans-epithelial
resistance or mannitol flux in Caco-2 cells following incubation with FW derived
from both the synbiotic and placebo groups of polyp and cancer subjects at the end
of intervention compared to the beginning. Interestingly TER was always
significantly higher in cells treated with FW derived from polyp subjects compared
to cells treated with FW from cancer subjects although there was no detrimental
effect of FW from cancer subjects on tight junction integrity, which was generally
greater than in cells treated with tissue culture medium alone (100%). Therefore
althOUgh FW derived from cancer subjects does not adversely affect tight junction
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integrity it does not have the positive influence on integrity observed with FW
derived from polyp subjects. It may be that FW from polyp subjects contains
substances, which promote tight junction integrity and these substances are either
absent, inactive or present at lower concentrations in FW of cancer subjects. Further
work identifying the substances present in FW of healthy subjects and subjects with
disease e.g. by mass spectrometry, and analysis of their effects, either individually or
in combination, on tight junction integrity will help in designing strategies to alter
the metabolic activity in the colon, to reduce the production of damaging substances,
and increase the production ofcancer protective substances.
In contrast to the TER results the paracellular transport of 14C mannitol, which is
another method to assess tight junction integrity was not significantly different in
cells treated with FW derived from polyp subjects or cancer subjects. TER and
mannitol flux are generally inversely related and this was not observed in this study.
This may be explained by the fact that treatment with FW generally resulted in TER
measurements of the same magnitude or greater than control (100%) indicating that
tight junction integrity was maximal and therefore the paracellular transport of
mannitol is unaltered in this situation.
The influence of FW on the invasion of HTIIS cells across a matrigel barrier was
not significantly different at the end of intervention compared to the beginning of
intervention in any of the study groups. It is interesting however that over the 24
hour incubation period, 20-25% of HTItS cells treated with serum free growth
medium (negative control) typically invade the matrigel coated inserts, but in this
study the majority of FW samples reduced invasion below that of the negative
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control (ranging from 0-19%). Exactly why this occurred is not known but other
factors such as cell loss due to sample toxicity or the induction of expression of
MMPsffIMPs, COX-2, prostaglandin E2 etc., by FW may playa role in modulating
the invasive ability of these cells.
Glutathione-S-transferases (GSTs) are important detoxifying enzYmes, which
inactivate a number of genotoxic and carcinogenic compounds by catalysing their
conjugation with glutathione. GST induction in normal tissue is considered
protective against cancer. In this study GST activity was significantly increased in
PBMCs from cancer and polyp subjects consuming synbiotic. Interestingly PBMCs
derived from placebo polyp subjects also had significantly increased GST activity
(per 106 cells) at the end of the twelve-week period compared to the beginning of
intervention. Szarka et oJ. (1995) reported that GST activity ranged from 0.0258-
0.1387 nmoleslmin per J.1g protein in healthy volunteers. In this study there was a
large inter-individual variability in GST activity with values ranging from 0.009-
0.390 nmoles/min per J.1g protein. Therefore, although there is an indication that
SYnbiotic consumption induces GST activity, the large inter-individual variation in
activity may prove difficult when employing GST activity as a biomarker in
intervention studies. Large scale studies with a number of baseline sampling times
would be of use in determining if GST activity is suitable as an intervention
biomarker.
Studies have shown that GST activity of blood lYmphocytes from high cancer risk
individuals is significantly lower than that of blood lYmphocytes from control
individuals (Szarka et oJ. 1995). In this study we found that GST activity in PBMCs
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from cancer subjects was not significantly different from that in PBMCs derived
from polyp subjects. Although we consider that polyp subjects are at a lower cancer
risk than cancer subjects and therefore would eXPeCt polyp subjects to have lower
GST activity it would be interesting to compare GST levels in polyp, cancer and
healthy subjects to determine if this parameter is useful as a biomarker of cancer
risk.
Carcinoembyronic antigen (CEA) is a high molecular weight glycoprotein belonging
to the immunoglobulin superfamily of molecules. It has been postulated to playa
role in a number of biological processes including cell adhesion, immunity and
apoptosis. After CEA, CA 19-9 is the most widely used tumour marker. It is the best
available marker for pancreatic cancer but it is less sensitive than CEA for detecting
colorectal carcinoma. Because of their widespread use as diagnostic tools for colon
cancer we investigated if synbiotic intervention influenced the levels of CEA and
CAI9-9.
The levels of CEA and CA19-9 were within the normal range for the majority of
subjects. In the synbiotic cancer group SYN-21 had an elevated CEA and equivocal
CA19-9 level at T3, however this is to be expected as this subject was diagnosed
with metastatic disease during the intervention. There were no significant effects of
synbiotic intervention on the levels of CEA and CA19-9 in this study. In fact the
individual with metastatic disease was identified by CEA and CA19-9 indicating that
synbiotic intervention did not influence the usefulness of these markers as diagnostic
tools.
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In conclusion, twelve-week consumption of a synbiotic combination of
lActobacillus rhamnosus 00, Bifidobacterium lactis Bb12 and SynergyOl
significantly reduced the proliferative activity of the colorectal mucosa of polyp
subjects, indicating a potential reduction in cancer risk. GST activity in PBMCs from
synbiotic fed cancer subjects increased, indicating the induction of a putative cancer
protective state due to synbiotic consumption. Synbiotic consumption did not
influence the tumour promoting activities (tight junction integrity and invasive
potential) of FW in either cancer or polyp subjects. However FW derived from polyp
subjects significantly increased tight junction integrity compared to FW derived
from cancer subjects indicating that the composition and or activity of FW from
polyp subjects is significantly different from that of cancer subjects. CEA and CA19-
9 were unaltered in this study showing that synbiotic intervention does not adversely
affect these commonly used diagnostic tools.
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Chapter 5
The genotoxic potential of faecal water and in
vivo genotoxic damage in cancer and polyp
subjects: can synbiotics modulate genotoxic
damage?
Abstract
Increased genotoxic damage is associated with increased cancer risk. Animal and
human studies have shown that pre-, pro- and synbiotics can protect against
genotoxic damage in vivo and reduce the genotoxic potential of faecal water (FW).
Studies have also shown that dietary intervention (e.g. vegetables) can modulate the
level of DNA damage in peripheral blood mononuclear cells (PBMCs). In
azoxymethane treated rats synbiotic consumption reduced the genotoxic potential of
FW with a concomitant reduction in the number of colonic tumours. The aim of this
study was to determine if synbiotic consumption could influence the level of in vivo
DNA damage (colonic mucosa and PBMCs) and the DNA damaging potential of
FW. We also investigated if the level of genotoxic damage was different in cancer
and polyp subjects. We found that synbiotic consumption protects against genotoxic
damage in the colon and modulates the genotoxic potential of FW in a cancer
protective and health promoting manner. There was no difference in the genotoxic
potential of FW of cancer and polyp subjects but the levels of DNA damage in the
mucosa and in PBMCs of these two groups were different. We also found that
gender and smoking status playa role in susceptibility to genotoxic damage.
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Introduction
The human colon is continually exposed to a complex mixture of compounds, which
are either of direct dietary origin or the result of digestive, microbial and excretory
processes. Cells of the colonic mucosa are in intimate contact with the contents of
the gut lumen, which contains compounds that may be either damaging to or
protective of the mucosa. Damage to cells of the mucosa leads to increased
proliferative activity to replace damaged cells and therefore increased risk of tumour
development. It is therefore useful to develop methods to analyse the mutagenic
burden to which the colonic mucosa is exposed, identify components of the luminal
contents, which may protect the mucosa and employ this information to develop
strategies to reduce the mutagenic burden in the colon.
Traditionally the Ames test, where mutagenicity is determined based on the ability of
the test substance to induce mutations in Salmonella typhimurium, was used to
investigate the mutagenic potential of compounds associated with cancer (Bruce et
al. 1977). However, the ability of this test to identify human carcinogens is limited
as the mutagenic potential of substances is evaluated using prokaryotic cells. In
recent years, the use of methods, which measure genotoxic damage in eukaryotic
cells, has proven to be more promising as an indicator ofcancer risk.
Genotoxic agents cause cellular DNA damage but are not cytotoxic to the cell. One
of the most commonly used methods to assess genotoxic damage is the
microgelelectrophoresis assay or comet assay, which was developed by Ostling &
Johanson (1984), and modified by Singh et al. (1988) as the alkaline comet assay.
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This method has been used to study the genotoxic potential of many substances by
determining the extent of DNA damage in cell lines following in vitro incubation
with the substance of interest (Pool-Zobel & Leucht 1997; Pool-Zobel et ale 2000).
In vivo genotoxic damage can be determined in cells derived from tissues of interest.
Pool-Zobel et ale (1999) demonstrated that the comet assay is sufficiently sensitive to
detect genotoxic damage in small numbers of cells derived from human biopsy
material.
The level of genotoxic damage is associated with the risk of colon cancer. PooI-
Zobel & Leucht (1997) reported that substances associated with cancer risk such as
N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and dinitrosocaffeidine (DNe)
induced genotoxic damage in freshly derived colon cells from healthy subjects.
Hambly et al. (1997) fed DMH treated, human flora-associated (HFA) rats, diets
containing high and low risk factors for colon cancer. DNA damage was
significantly higher in colon cells from animals on the high-risk diet.
Pre-, pro and synbiotic consumption has been associated with reduced genotoxicity.
Studies have shown that some lactic acid bacteria inhibit MNNG and DMH induced
genotoxicity in colon cells isolated from rats (Pool-Zobel et ale 1996; Wollowski et
al. 1999). Zsivkovits et ale (2003) reported that bacterial strains commonly used in
yoghurt production protect against hetero-cyclic amine induced DNA damage in
colon and liver cells of rats.
Faecal water (FW), which is the aqueous phase of faeces, contains most of the free
reactive and soluble factors, which likely interact with the mucosa in vivo (Rafter et
ale 1987). The genotoxic potential of FW is considered a measure of the potential of
247
the dissolved factors to induce damage in the colonic mucosa. Many colonic tumours
arise from damage to the colonic mucosa, which is a result of the interactions with
gut luminal contents. Studies have shown that there is an inter- and intra-individual
variation of faecal water genotoxicity even in subjects consuming the same diet
(OJ3wald et al. 2000; Woods et al. 2002). However, OJ3wald et al. (2000) conclude
that despite this variation FW genotoxicity is suitable as a biomarker for application
in intervention studies when each subject is analysed as his or her own control.
Diets considered high risk for colon cancer have been reported to increase the
genotoxic potential of FW in healthy volunteers (Rieger et al. 1999). Lactic acid
bacteria have been shown to modulate the genotoxic potential of FW. The genotoxic
potential of FW from rats treated with AOM was significantly reduced in animals
fed a synbiotic (SynergyOl, Bb12 and LOG) compared to controls and this correlated
with a reduction in tumour incidence in the synbiotic fed group (Klinder et al. 2004).
The genotoxic potential of FW derived from tumour bearing rats was significantly
higher than the genotoxic potential of FW derived from non tumour bearing rats.
Burns & Rowland (2004) investigated the effect of incubating a genotoxic FW
sample from a human subject with six different strains of lactic acid bacteria on the
DNA damaging potential of the FW. They found that DNA damage induced by FW
in HT-29 cells was significantly reduced by all strains except Strep. thermophilus
and that Lactobacillus plantarum and Bb12 showed the greatest protective effect.
Another putative non-invasive biomarker of cancer risk is genotoxic damage in
lYmphocytes. Duthie et al. (1996) reported that vitamin supplementation reduced
DNA damage in human lYmphocytes. The first demonstration that consumption of
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whole foods (in this case vegetable juices) influenced lymphocyte DNA damage was
shown by Pool-Zobel et al. (1997) who reported that consumption of carotenoid-
containing vegetable juices which are considered cancer protective by 23 healthy
male subjects reduced genotoxic damage in lymphocytes. Other studies have
confirmed that dietary intervention can modulate genotoxic damage in lymphocytes.
Reduced DNA damage was reported after intervention with tomato puree (Riso et al.
1999), soy milk (Mitchell & Collins 1999) and with fruit juices (Bub et al. 2003).
However other investigators using bread (Pool-Zobel et al. 2000) or vegetables and
fruits (Moller et al. 2003) have not observed the same protective effect.
This could indicate that differences in the bioavailability of the active ingredients
may limit the sensitivity of the comet assay biomarker when using only lymphocytes
as the surrogate tissue. Further studies comparing DNA damage in both lymphocytes
and colon cells will determine the usefulness of lymphocytes as surrogate tissues.
The aims of this study were:
1) To investigate the influence of twelve-week consumption of a synbiotic
combination of Lactobacillus rhamnosus 00, Bifidobacterium lactis Bb12 and
SynergyCl on in vivo genotoxic damage by measuring DNA damage in biopsies
and lymphocytes.
2) To investigate the influence of synbiotic intervention on the genotoxic potential
of faecal water and to assess if the genotoxic potential of FW is associated with
in vivo DNA damage as measured in biopsies and PBMCs.
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3) To assess if exposure to genotoxins in cancer subjects who had undergone
previous curative resection is significantly different from that of polypectomised
subjects.
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Methods
Work described in this chapter was conducted in collaboration with Dr Annett
Klinder, Dr Michaela May and Prof. Beatrice L. Pool-Zobel of the Department of
Nutritional Toxicology, Friedrich-Schiller University ofJena, Gennany.
DNA Damage in Biopsies
2 rectal biopsies from each subject were obtained by sigmoidoscopy for each of two
time points one at the beginning of intervention (week 0) and the other at the
cessation of feeding (week 12). Biopsies were immediately placed in a collection
tube containing Hanks Balanced Salt Solution, (HBSS; 8.0 gil NaCI; 0.4 gil KCI;
0.06 gil Na2HP04_2H20; 0.06 gil K2HP04; 1 gil glucose; 0.35 gil; NaHC03; 4.8 gil
HEPES; pH 7.4) and kept on ice until further processing.
Biopsies were washed several times in HBSS, minced using a fine edge scissors and
incubated in 3mls HBSS supplemented with 2 mglml proteinase K (Sigma,
Steinheim, Gennany) and 1 mglml collagenase P (Boehringer, Mannheim, Gennany)
for 30 mins in a water-bath at 3'rC with agitation. Following incubation the
suspension was supplemented with 12ml fresh HBSS, centrifuged at 400 x g for
5mins, and the pellet resuspended in 200f.11 of HBSS. Viability and yield of cells
were detennined by trypan blue exclusion.
Cell concentration was adjusted to 0.2x106 cellslml and 50f.11 of cells were mixed
with 350f.11 of 0.7% low melting point agarose. 50f.11 of this agarose/cell suspension
was then pipetted to each well of a trevigen slide (Trevigen, U.S.) and spread with
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the pipette tip. Slides were allowed to dry for 10 mins on a cool box (5°C - 10°C)
and treated with lysis solution (100 mM Na2EDTA, 1 % Triton X- 100, 2.5 M NaCI;
1 % N-Iauroyl sarcosin sodium salt, 10 % DMSO, 10 mM Tris, pH 10) for Ihr at 4°C
in the dark.
Slides were then placed in an electrophoresis chamber and soaked in electrophoresis
buffer (l mM Na2EDTA, 300mM NaOH pH13) for 20 mins at 4°C to allow alkaline
unwinding. Electrophoresis was performed for 20 mins at 300mA, 2SV at 4°C.
Slides were then fixed in absolute ethanol for 5 mins and allowed to dry for 10 mins
at room temperature. Slides were stored at 4°C in the dark until analysed.
Slides were stained with SYBR Green 1 (Sigma) and microscopical analysis
revealed images of more or less damaged DNA ("comets") (Figures l(a-c)). The
comets are a consequence of DNA migration within the electrical field (Singh et al.
1988). DNA damage was quantified by measuring the proportion and extent of DNA
migration using the image analysis system of Perceptive Instruments (Halstead; UK).
50 DNA spots (individual biopsy cells) were evaluated per slide and six slides were
analysed for each sample. DNA damage was expressed as tail intensity (% DNA in
the tail) and tail moment (% DNA in the tail x tail length). The percentage of
undamaged DNA (intact cells) on each slide was also measured.
DNA Damaging Potential of Faecal Water
Microscope slides were coated with 50JlI of 0.7% low melting point agarose (LMP)
followed by 8SJlI of0.5% normal melting point (NMP) agarose and kept overnight at
4°C. The following day HT29clone19a cells were harvested and adjusted to a
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concentration of 2 x 106 cells/ml. The cell line HT29clone19a is a subclone of the
HT29 human colon cancer cell line and was produced by permanent differentiation
with 5mM sodium butyrate (Augeron & Laboisse 1984). Cells were incubated with
either 50% FW or with DMEM as control at 3t>C for 30 minutes with agitation.
Following FW incubation cell numbers and viabilities were determined with trypan
blue in 20,,11 aliquots of the suspension. The remaining cells were pelleted by
centrifuging for 5 mins at 400 x g. The supernatant was discarded and the cell pellet
was mixed with 75J.LI of LMP agarose and distributed onto the pre-coated
microscope slides. Further steps were performed as originally described by Singh et
01. (1988) and modified by Pool-Zobel & Leucht (1997). Briefly slides were placed
in lysis solution (100 mM Na2EDTA, 1 % Triton X 100, 2.5 M NaCI; 1 % N-Iauroyl
sarcosin sodium salt, 10 % DMSO, 10 mM Tris, pH 10) for at least 60 minutes at
4°C. Following this slides were placed in the microgel electrophoresis chamber
containing alkaline solution (1 mM Na2EDTA, 300 mM NaOH, pH 13) to allow
alkaline unwinding. After 20 minutes of DNA unwinding, electrophoresis was
performed at 25 V, 300 rnA for 20 minutes. Afterwards slides were washed with
neutralisation buffer (O.4M Tris, pH 7.5) and stained with ethidium bromide
(Sigma).
DNA damage was quantified using the same method as used to assess DNA damage
in biopsies. 50 DNA spots were evaluated per slide and three slides were analysed
for each sample.
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DNA Damage in PBMCs
PBMCs were isolated by density gradient centrifugation and cell number was
adjusted to Ixl06 cellslml in cryoprotective medium (90% FBS, 10% DMSO), and
stored under liquid nitrogen until analysed.
Microscope slides were pre-coated with agarose as described for faecal water
samples. Cryopreserved PBMCs were thawed quickly at 3rC, centrifuged at 400 x g
for 8 mins to remove cryoprective medium and resuspended in 1ml PBS. Cell
numbers and viabilities were determined with trypan blue exclusion. The remaining
cells were pelleted by centrifuging at 400 x g for 8 mins, the supernatant discarded
and the PBMCs were mixed with (0.5%) LMP agarose. The volume of LMP agarose
used was dependant on the number of viable cells recovered from the cryoprotective
medium. If there were less than 3x105 cells the pellet was resuspended in 150fJI
agarose. At higher cell numbers cell concentration was adjusted to 2xlOscellslmi and
then resuspended in 150J.11. 50fJI of agarose/cell suspension was distributed in
triplicate onto pre-coated microscopes slides. Lysis, electrophoresis, neutralisation
and analysis steps were performed as described for faecal water samples.
Strategy for Analysis of Genotoxic Data Taking Account of Gender and
Whether or not Subjects Smoked
Initial data analysis included all subjects and there were no exclusions based on
smoking status or gender. However increased DNA damage in subjects who smoke
compared to non-smokers has consistently been reported. Piperakis et al. (1998)
reported that smoking was associated with a higher level of DNA damage in
lymphocytes in Greek males. A Chinese study found that both smokers and
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employees in a cigarette factory had increased DNA damage in whole blood
compared to control subjects who were non-smokers and not occupationally exposed
to tobacco dust (Zhu et al. 1999). O~wald et al. (2003) reported that buccal
leucocytes isolated from smokers had more DNA damage than the same cells
isolated from non-smokers. Based on these reports we excluded smokers from our
analysis.
Data from studies investigating basal DNA damage in men compared to women has
yielded conflicting results. Some studies have shown no effect of gender on DNA
damage while others have reported that DNA damage is higher in men than in
women (Bajpayee et al. 2002). It is probable that hormonal influences or sex-related
differences in metabolic activation or inactivation may be contributing factors which
may affect endogenous genotoxin production and thus mask effects of simultaneous
intervention. Therefore we further analysed our data excluding smokers and females.
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Results
DNA Damage in Biopsies
Colorectal biopsies were obtained from cancer and polyp subjects at the beginning
(week 0) and the end of intervention (week 12). The level of DNA damage in
biopsies was assessed in single cells derived from colorectal biopsies using the
comet assay.
Following enzYmatic digestion the yield and viability of cells derived from
colorectal biopsies was determined using trypan blue exclusion. The yield (mean ±
SD) was 10.38 ± 15.14 million cells per 2 biopsies and viability (mean ± SD) was
93.42% ± 3.591.
Cancer subjects
Synbiotic consumption influenced genotoxic damage in biopsies from cancer
subjects (including smokers). Tail intensity (TI) (Figure 2(b)) and tail moment (TM)
(Figure 2(d)) in cancer subjects consuming placebo (n=12) were significantly
increased at week 12 compared to week 0 (TI p=O.0488, TM p=0.0396). This
increase in DNA damage was not observed in cancer subjects consuming the
synbiotic product (n=17) suggesting a protective effect of synbiotic consumption
(Figures 2(a) & 2(c)). The percentage of intact cells in both groups was unaltered
(Figures 2(e) & 2(/)).
Exclusion of smokers from analysis yielded the same results as when smokers were
included. Tail intensity (TI) (Figure 3(b)) and tail moment (TM) (Figure 3(d)) were
significantly increased at week 12 compared to week 0 (TI p=O.0488, TM p=O.0396)
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in the placebo group of non-smoking cancer subjects (n=12) and this increase was
not observed in non-smoking cancer subjects consuming the synbiotic product
(n=15) (Figures 3(a) & 3(c)). The percentage of intact cells in both groups was
unaltered (Figures 3(e) & 3(/)).
In contrast when smokers and females were excluded from analysis there was a trend
towards increase in DNA damage in biopsies from male non-smoking cancer
subjects consuming placebo (n= I0) however this increase did not reach significance
(TI, JrO.772 TM, ~0.0716) (Figures 4(b) & 4(d)). The percentage of intact cells
was unaltered (Figures 4(/)). In biopsies from the synbiotic group of male non-
smoking cancer subjects (n=7) tail intensity, tail moment and the percentage of intact
cells was unaltered during the twelve-week intervention period (Figures 4(a), 4(c) &
4(e)).
Polyp subjects
There was a significant reduction in tail intensity (JrO.0476) (Figure 5(a)) and tail
moment (P=ij.0135) (Figure 5(c)) in biopsies from polyp subjects (including
smokers) consuming synbiotics (n=17) at week 12 compared to week O. In polyp
subjects consuming placebo (n=15) tail moment (JrO.0388) but not tail intensity was
significantly reduced at week 12 compared to week 0 (Figure 5(b) & 5(d)). The
reduction was not as pronounced as in the synbiotic consuming subjects (Figures
5(a) & 5(c)). The percentage of intact cells in both groups was unaltered (Figures
5(e) & 5(/)).
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Similar results were observed when smokers were excluded from analysis. Tail
intensity (p=O.0496) and tail moment (p=O.O 164) were significantly reduced in
biopsies from non-smoking subjects consuming sYnbiotic (n=15) at week 12
compared to week 0 (Figures 6(a) & 6(c)). In placebo non-smoking polyp subjects
(n=14) tail moment (p=O.0312) but not tail intensity was significantly reduced at
week 12 compared to week 0 (Figures 6(b) & 6(d)). The reduction was not as
pronounced as in the synbiotic consuming subjects (Figures 6(a) & 6(c)). The
percentage of intact cells in both groups was unaltered (Figures 6(e) & 6(/)).
Male non-smoking polyp subjects
In biopsies from male non-smoking polyp subjects consuming placebo (n=12) tail
intensity (Figure 7(b)) tail moment (Figure 7(d)) and the percentage of intact cells
(Figure 7(/)) were not altered during the twelve-week intervention period. In
biopsies from sYnbiotic non-smoking polyp subjects (n=6) tail intensity (Figure
7(a)) and the percentage of intact cells (Figure 7(e)) were not significantly different
at week 12 compared to week O. Tail moment however was reduced (p=O.0803) at
week 12 compared to week 0 (Figure 7(c)).
The initial level of genotoxic damage in biopsies from cancer and polyp subjects was
analysed. Tail intensity, tail moment and the percentage of intact cells was not
significantly different in biopsies from cancer subjects compared to polyp subjects at
week 0 (Table 1). Similar results were observed in non-smokers (male and female)
(Table 2) and in non-smoking males (Table 3). Interestingly DNA damage in
biopsies from cancer subjects at all time points (weeks 0 and 12) was significantly
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higher than in polyp subjects at all times (Table 1). The same result was observed
when smokers were excluded from the analysis (Table 2). However when smoking
subjects and females were excluded there was no difference in DNA damage in
biopsies in male non-smoking cancer and polyp subjects (Table 3).
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Figure 2(a)
Tail intensity in biopsies from cancer subjects consuming synbiotic (n=17) at the
beginning (week 0) and the end of intervention (week 12). Tail intensity was
unchanged at week 12 compared to week O. Results are expressed as mean ± S.E.
Figure 2(b)
Tail intensity in biopsies from cancer subjects consuming placebo (n=12) at the
beginning (week 0) and the end of intervention (week 12). Tail intensity was
significantly increased at week 12 compared to week O. Results are expressed as
mean± S.E.
Figure 2(c)
Tail moment in biopsies from cancer subjects consuming synbiotic (n=17) at the
beginning (week 0) and the end of intervention (week 12). Tail moment was
unchanged at week 12 compared to week O. Results are expressed as mean ± S.E.
Figure 2(d)
Tail moment in biopsies from cancer subjects consuming placebo (n=12) at the
beginning (week 0) and the end of intervention (week 12). Tail moment was
significantly increased at week 12 compared to week O. Results are expressed as
mean± S.E.
Figure 2(e)
The percentage of intact cells (non comet images) in biopsies from cancer subjects
consuming synbiotic (n=17) at the beginning (week 0) and the end of intervention
(week 12). There was no change at week 12 compared to week O. Results are
expressed as mean ± S.E.
Figure 2(f)
The percentage of intact cells (non comet images) in biopsies from cancer subjects
consuming placebo (n=12) at the beginning (week 0) and the end of intervention
(week 12). There was no change at week 12 compared to week O. Results are
expressed as mean ± S.E.
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Figure3(a)
Tail intensity in biopsies from non-smoking cancer subjects consuming synbiotic
(n=15) at the beginning (week 0) and the end of intervention (week 12). Tail
intensity was unaltered at week 12 compared to week O. Results are expressed as
mean± S.E.
Figure3(b)
Tail intensity in biopsies from non-smoking cancer subjects consuming placebo
(n=12) at the beginning (week 0) and the end of intervention (week 12). Tail
intensity significantly increased at week 12 compared to week O. Results are
expressed as mean ± S.E.
Figure3(c)
Tail moment in biopsies from non-smoking cancer subjects consuming synbiotic
(n=15) at the beginning (week 0) and the end of intervention (week 12). Tail moment
was unaltered at week 12 compared to week O. Results are expressed as mean ± S.E.
Figure3(d)
Tail moment in biopsies from non-smoking cancer subjects consuming placebo
(n=12) at the beginning (week 0) and the end of intervention (week 12). Tail moment
was significantly increased at week 12 compared to week O. Results are expressed as
mean± S.E.
Figure3(e)
The percentage of intact cells (non comet images) in biopsies from non-smoking
cancer subjects consuming synbiotic (n=15) at the beginning (week 0) and the end of
intervention (week 12). There was no change at week 12 compared to week O.
Results are expressed as mean ± S.E.
Figure 3(f)
The percentage of intact cells (non comet images) in biopsies from non-smoking
cancer subjects consuming placebo (n=12) at the beginning (week 0) and the end of
intervention (week 12). There was no change at week 12 compared to week O.
Results are expressed as mean ± S.E.
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Figure 4(a)
Tail intensity in biopsies from male non-smoking cancer subjects consuming
synbiotic (n=7) at the beginning (week 0) and the end of intervention (week 12). Tail
intensity was unaltered at week 12 compared to week O. Results are expressed as
mean± S.E.
Figure4(b)
Tail intensity in biopsies from male non-smoking cancer subjects consuming placebo
(n=10) at the beginning (week 0) and the end of intervention (week 12). Tail
intensity was increased at week 12 compared to week O. Results are expressed as
mean± S.E.
Figure4(c)
Tail moment in biopsies from male non-smoking cancer subjects consuming
synbiotic (n=7) at the beginning (week 0) and the end of intervention (week 12). Tail
moment was unaltered at week 12 compared to week O. Results are expressed as
mean± S.E.
Figure4(d)
Tail moment in biopsies from male non-smoking cancer subjects consuming placebo
(n=10) at the beginning (week 0) and the end of intervention (week 12). Tail moment
was increased at week 12 compared to week O. Results are expressed as mean ± S.E.
Figure 4(e)
The percentage of intact cells (non comet images) in biopsies from male non-
smoking cancer subjects consuming synbiotic (n=7) at the beginning (week 0) and
the end of intervention (week 12). There was no change at week 12 compared to
week O. Results are expressed as mean ± S.E.
Figure 4(f)
The percentage of intact cells (non comet images) in biopsies from male non-
smoking cancer subjects consuming placebo (n=10) at the beginning (week 0) and
the end of intervention (week 12). There was no change at week 12 compared to
week O. Results are expressed as mean ± S.E.
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Figure 5(a)
Tail intensity in biopsies from polyp subjects consuming synbiotic (n=17) at the
beginning (week 0) and the end of intervention (week 12). Tail intensity was
significantly decreased at week 12 compared to week O. Results are expressed as
mean± S.E.
Figure 5(b)
Tail intensity in biopsies from polyp subjects consuming placebo (n=15) at the
beginning (week 0) and the end of intervention (week 12). Tail intensity was
unaltered at week 12 compared to week O. Results are expressed as mean ± S.E.
Figure 5(c)
Tail moment in biopsies from polyp subjects consuming synbiotic (n=17) at the
beginning (week 0) and the end of intervention (week 12). Tail moment significantly
reduced at week 12 compared to week O. Results are expressed as mean ± S.E.
Figure 5(d)
Tail moment in biopsies from polyp subjects consuming placebo (n=15) at the
beginning (week 0) and the end of intervention (week 12). Tail moment was
significantly reduced at week 12 compared to week O. Results are expressed as mean
±S.E.
Figure 5(e)
The percentage of intact cells (non comet images) in biopsies from polyp subjects
consuming synbiotic (n=17) at the beginning (week 0) and the end of intervention
(week 12). There was no change at week 12 compared to week O. Results are
expressed as mean ± S.E.
Figure 5(f)
The percentage of intact cells (non comet images) in biopsies from polyp subjects
consuming placebo (n=15) at the beginning (week 0) and the end of intervention
(week 12). There was no change at week 12 compared to week O. Results are
expressed as mean ± S.E.
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Figure 6(a)
Tail intensity in biopsies from non-smoking polyp subjects consuming synbiotic
(n=15) at the beginning (week 0) and the end of intervention (week 12). Tail
intensity was significantly reduced at week 12 compared to week O. Results are
expressed as mean ± S.E.
Figure 6(b)
Tail intensity in biopsies from non-smoking polyp subjects consuming placebo
(n=14) at the beginning (week 0) and the end of intervention (week 12). Tail
intensity was unaltered at week 12 compared to week O. Results are expressed as
mean± S.E.
Figure 6(c)
Tail moment in biopsies from non-smoking polyp subjects consuming synbiotic
(n=15) at the beginning (week 0) and the end of intervention (week 12). Tail moment
was significantly reduced at week 12 compared to week o. Results are expressed as
mean± S.E.
Figure 6(d)
Tail moment in biopsies from non-smoking polyp subjects consuming placebo
(n=14) at the beginning (week 0) and the end of intervention (week 12). Tail moment
was significantly reduced at week 12 compared to week O. Results are expressed as
mean± S.E.
Figure 6(e)
The percentage of intact cells (non comet images) in biopsies from non-smoking
polyp subjects consuming synbiotic (n=15) at the beginning (week 0) and the end of
intervention (week 12). There was no change at week 12 compared to week O.
Results are expressed as mean ± S.E.
Figure 6(J)
The percentage of intact cells (non comet images) in biopsies from non-smoking
polyp subjects consuming placebo (n=14) at the beginning (week 0) and the end of
intervention (week 12). The percentage of intact cells was significantly increased at
week 12 compared to week o. Results are expressed as mean ± S.E.
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Figure 7(a)
Tail intensity in biopsies from male non-smoking polyp subjects consuming
synbiotic (n=6) at the beginning (week 0) and the end of intervention (week 12). Tail
intensity was unaltered at week 12 compared to week O. Results are expressed as
mean± S.E.
Figure 7(b)
Tail intensity in biopsies from male non-smoking polyp subjects consuming placebo
(n=12) at the beginning (week 0) and the end of intervention (week 12). Tail
intensity was unaltered at week 12 compared to week O. Results are expressed as
mean± S.E.
Figure 7(c)
Tail moment in biopsies from male non-smoking polyp subjects consuming
synbiotic (n=6) at the beginning (week 0) and the end of intervention (week 12). Tail
moment was reduced at week 12 compared to week O. Results are expressed as mean
±S.E.
Figure 7(d)
Tail moment in biopsies from male non-smoking polyp subjects consuming placebo
(n=12) at the beginning (week 0) and the end of intervention (week 12). Tail moment
was unaltered at week 12 compared to week O. Results are expressed as mean ± S.E.
Figure 7(e)
The percentage of intact cells (non comet images) in biopsies from male non-
smoking polyp subjects consuming synbiotic (n=6) at the beginning (week 0) and the
end of intervention (week 12). There was no change at week 12 compared to week O.
Results are expressed as mean ± S.E.
Figure 7(f)
The percentage of intact cells (non comet images) in biopsies from male non-
smoking polyp subjects consuming placebo (n=12) at the beginning (week 0) and the
end of intervention (week 12). There was no change at week 12 compared to week O.
Results are expressed as mean ± S.E.
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Table 1
In vivo DNA damage (tail intensity, tail moment and the % of intact cells) in
biopsies from cancer and polyp subjects (including smokers) at the beginning of
intervention and at all time points. DNA damage in biopsies was not significantly
different in cancer and polyp subjects at the beginning of intervention. However
DNA damage was significantly lower in polyp subjects compared to cancer subjects
at all times. Results are expressed as mean ± S.E.
Table 2
In vivo DNA damage (tail intensity, tail moment and the % of intact cells) in
biopsies from non-smoking cancer and polyp subjects at the beginning of
intervention and at all time points. DNA damage in biopsies was not significantly
different in cancer and polyp subjects at the beginning of intervention. However
DNA damage was significantly lower in polyp subjects compared to cancer subjects
at all times. Results are expressed as mean ± S.E.
Table 3
In vivo DNA damage (tail intensity, tail moment and the % of intact cells) in
biopsies from cancer and polyp subjects (including smokers) at the beginning of
intervention and at all time points. DNA damage in biopsies was not significantly
different in cancer and polyp subjects at the beginning of intervention and at all
times. Results are expressed as mean ± S.E.
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Table 1:
All subjects (incl smokers)
Geootoxic Biomarker Caocer Subjects Polyp Subjects P value
(Week 0) (Week 0)
Biopsy (TI) 12.16 ± 1.21 (n=29) 12.62 ± 1.06 (n=32) o.s.
Biopsy (TM) 3.988 ± 0.554 (n=29) 4.296 ± 0.536 (n=32) o.s.
Biopsy (% IC) 62.49 ± 2.00 (n=29) 63.97 ± 2.01 (n=32) o.s.
Cancer Subjects Polyp Subjects
(All Times) (All Times)
Biopsy (TI) 15.03 ± 1.27 (n=29) 11.11 ± 0.66 (0=32) 1.0041
Biopsy (TM) 5.304 ± 0.557 (0=29) 3.407 ± 0.313 (0=32) 0.0029
Biopsy (% IC) 58.78 ± 1.83 (n=29) 62.54 ± 1.96 (n=32) 0.0845
Table 2:
Non-smokers
Geootoxic Biomarker Caocer Subjects Polyp Subjects P value
(Week 0) (Week 0)
Biopsy (TI) 12.21 ± 1.28 (n=27) 11.25 ± 0.80 (n=29) n.s.
Biopsy (TM) 4.049 ± 0.585 (n=27) 3.256 ± 0.370 (n=29) n.s.
Biopsy (% IC) 62.43 ± 2.08 (n=27) 57.93 ± 2.22 (n=29) n.s.
Cancer Subjects Polyp Subjects
(All Times) (All Times)
Biopsy (TI) 15.09± 1.28 (0=27) 11.55 ± 0.67 (0=29) •.014~
Biopsy (TM) 5.304 ± 0.573 . (0=27) 3.550 ± 0.332 (0=29) 1.0081
Biopsy (% IC) 58.73 ± 1.92 (n=27) 61.75 ± 1.58 (n=29) o.s.
Table 3:
Male non-smokers
Geootoxic Biomarker Caocer Subjects Polyp Subjects Pvalue
(Week 0) (Week 0)
Biopsy (TI) 10.29 ± 1.02 (n=17) 12.69 ± 1.29 (n=18) o.s.
Biopsy (TM) 3.077 ± 0.447 (n=17) 4.398 ± 0.774 (n=18) o.s.
Biopsy (%IC) 64.29 ± 2.23 (n=17) 63.42 ± 2.41 (n=18) o.s.
Caocer Subjects Polyp Subjects
(All Times) (All Times)
Biopsy (TI) 13.74 ± 1.43 (n=17) 11.08 ± 0.82 (n=18) o.s.
Biopsy (TM) 4.803 ± 0.712 (n=17) 3.406 ± 0.444 (n=18) o.s.
Biopsy (%IC) 60.06 ± 2.31 (n=17) 63.15 ± 1.80 (n=18) o.s.
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DNA Damaging Potential of Faecal Water (FW)
Faecal samples were obtained from cancer and polyp subjects at the beginning of
(week 0), mid-way through (week 6) and the end of intervention (week 12). FW was
prepared by ultracentrafugation and sterile filtration as described previously.
HT29clone19a cells were treated with FW and the DNA damaging potential of FW
was assessed using the comet assay. Following incubation with FW the viability of
HT29clone19a cells was assessed by trypan blue. Cell viability was 97.0 I% ± 4.031
(mean ± SO) well within the accepted range of >75% (Henderson et al. 1998)
indicating that the FW samples tested were not cytotoxic to HT29clone19a cells.
Cancer subjects
Synbiotic consumption did not influence the genotoxic potential of FW derived from
cancer subjects. Tail intensity, tail moment and the percentage of intact cells in
HT29clone19a cells following incubation with FW derived from both synbiotic
(n=17) and placebo cancer subjects (n=14) were not significantly altered during the
twelve week intervention period (Figures 8(a-J)). Similar results were observed with
FW derived from synbiotic (n=15) and placebo (n=14) non-smoking cancer subjects
(Figures 9(a-J)) and placebo (n=9) and synbiotic (n=8) male non-smoking cancer
subjects (Figures 10(a-J)).
Polyp subjects
FW derived from the placebo group of polyp subjects (n=20) increased DNA
damage in HT29clone19a cells. The percentage of intact cells was significantly
reduced at week 6 (p=0.0185) and week 12 (p=0.035I ) compared to week 0 (Figure
11(/)). There was a significant increase in tail intensity (p=0.0354) at week 6 and an
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increase although not reaching significance at week 12 (p=O.0547) compared to
week 0 (Figure ll(b)). There was a trend towards increased tail moment at week 6
(p=O.0662) and week 12 (p=O.735) but this increase did not reach significance
(Figure ll(d)). FW derived from polyp subjects consuming the synbiotic (n=17) did
not influence DNA damage in HT29c1one19a cells at weeks 6 and 12 compared to
week 0 (Figure ll(a), ll(e), ll(e)).
Similar but more pronounced results were observed in non-smoking synbiotic (n=15)
and placebo (n=19) polyp subjects (Figures 12(a-J)). Interestingly the increase in
DNA damage in HT29clone19a cells was most pronounced following incubation
with FW derived from male non-smoking placebo polyp subjects (n=14). Tail
intensity (p=O.0025) and tail moment (p=O.0067) were significantly increased at
week 12 compared to week 0 Figures (13(b) &13(d) and the percentage of intact
cells was significantly decreased at week 6 (p=O.0308) and week 12 (p=O.0053)
compared to week 0 Figure (13(f)). In contrast FW derived from male non-smoking
synbiotic polyp subjects (n=7) did not influence DNA damage.
The genotoxic potential of FW derived from cancer and polyp subjects at the
beginning of intervention and at all time points was analysed. There was no
significant difference in the genotoxic potential of FW derived from cancer subjects
compared to polyp subjects at the beginning of intervention or at all time points
(Table 4). Similar results were observed in non-smokers (male and female) (Table 5)
and in non-smoking males (Table 6).
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Figure 8(a)
Tail intensity in HT29clone19a cells induced by FW from cancer subjects
consuming synbiotic (n=17) at the beginning (week 0), mid-way through (week 6),
and the end of intervention (week 12). Tail intensity was unaltered at weeks 6 and 12
compared to week O. Results are expressed as mean ± S.E.
Figure8(b)
Tail intensity in HT29clone19a cells induced by FW from cancer subjects
consuming placebo (n=14) at the beginning (week 0), mid-way through (week 6),
and the end of intervention (week 12). Tail intensity was unaltered at weeks 6 and 12
compared to week O. Results are expressed as mean ± S.E.
Figure8(c)
Tail moment in HT29clone19a cells induced by FW from cancer subjects consuming
synbiotic (n=17) at the beginning (week 0), mid-way through (week 6), and the end
of intervention (week 12). Tail moment was unaltered at weeks 6 and 12 compared
to week O. Results are expressed as mean ± S.E.
Figure 8(d)
Tail moment in HT29clone19a cells induced by FW from cancer subjects consuming
placebo (n=14) at the beginning (week 0), mid-way through (week 6), and the end of
intervention (week 12). Tail moment was unaltered at weeks 6 and 12 compared to
week O. Results are expressed as mean ± S.E.
Figure 8(e)
The percentage of intact cells (non comet images) in HT29clone19a cells induced by
FW from cancer subjects consuming synbiotic (n=17) at the beginning (week 0),
mid-way through (week 6), and the end of intervention (week 12). There was no
change at weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 8(f)
The percentage of intact cells (non comet images) in HT29clone19a cells induced by
FW from cancer subjects consuming placebo (n=14) at the beginning (week 0), mid-
way through (week 6), and the end of intervention (week 12). There was no change
at weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
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Figure 9(a)
Tail intensity in HT29clone19a cells induced by FW from non-smoking cancer
subjects consuming sYnbiotic (n=15) at the beginning (week 0), mid-way through
(week 6), and the end of intervention (week 12). Tail intensity was unaltered at
weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 9(b)
Tail intensity in HT29clone19a cells induced by FW from non-smoking cancer
subjects consuming placebo (n=14) at the beginning (week 0), mid-way through
(week 6), and the end of intervention (week 12). Tail intensity was unaltered at
weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 9(c)
Tail moment in HT29clone19a cells induced by FW from non-smoking cancer
subjects consuming sYnbiotic (n=15) at the beginning (week 0), mid-way through
(week 6), and the end of intervention (week 12). Tail moment was unaltered at
weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 9(d)
Tail moment in HT29clone19a cells induced by FW from non-smoking cancer
subjects consuming placebo (n=14) at the beginning (week 0), mid-way through
(week 6), and the end of intervention (week 12). Tail moment was unaltered at
weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 9(e)
The percentage of intact cells (non comet images) in HT29clone19a cells induced by
FW from non-smoking cancer subjects consuming sYnbiotic (n=15) at the beginning
(week 0), mid-way through (week 6), and the end of intervention (week 12). There
was no change at weeks 6 and 12 compared to week O. Results are expressed as
mean± S.E.
Figure 9(f)
The percentage of intact cells (non comet images) in HT29clone19a cells induced by
FW from non-smoking cancer subjects consuming placebo (n=14) at the beginning
(week 0), mid-way through (week 6), and the end of intervention (week 12). There
was no change at weeks 6 and 12 compared to week O. Results are expressed as
mean± S.E.
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Figure lOra)
Tail intensity in HT29clone19a cells induced by FW from male non-smoking cancer
subjects consuming synbiotic (n=8) at the beginning (week 0), mid-way through
(week 6), and the end of intervention (week 12). Tail intensity was unaltered at
weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure lO(b)
Tail intensity in HT29clone19a cells induced by FW from male non-smoking cancer
subjects consuming placebo (n=9) at the beginning (week 0), mid-way through
(week 6), and the end of intervention (week 12). Tail intensity was unaltered at
weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure lO(e)
Tail moment in HT29clone19a cells induced by FW from male non-smoking cancer
subjects consuming synbiotic (n=8) at the beginning (week 0), mid-way through
(week 6), and the end of intervention (week 12). Tail moment was unaltered at
weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 1O(d)
Tail moment in HT29clone19a cells induced by FW from male non-smoking cancer
subjects consuming placebo (n=9) at the beginning (week 0), mid-way through
(week 6), and the end of intervention (week 12). Tail moment was unaltered at
weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure lOre)
The percentage of intact cells (non comet images) in HT29clone19a cells induced by
FW from male non-smoking cancer subjects consuming synbiotic (n=8) at the
beginning (week 0), mid-way through (week 6), and the end of intervention (week
12). There was no change at weeks 6 and 12 compared to week O. Results are
expressed as mean ± S.E.
Figure lO(j)
The percentage of intact cells (non comet images) in HT29clone19a cells induced by
FW from male non-smoking cancer subjects consuming placebo (n=9) at the
beginning (week 0), mid-way through (week 6), and the end of intervention (week
12). There was no change at weeks 6 and 12 compared to week O. Results are
expressed as mean ± S.E.
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Figure 11(a)
Tail intensity in HT29clone19a cells induced by FW from polyp subjects consuming
sYnbiotic (n=17) at the beginning (week 0), mid-way through (week 6), and the end
of intervention (week 12). Tail intensity was unaltered at weeks 6 and 12 compared
to week O. Results are expressed as mean ± S.E.
Figure 11(b)
Tail intensity in HT29clone 19a cells induced by FW from polyp subjects consuming
placebo (n=20) at the beginning (week 0), mid-way through (week 6), and the end of
intervention (week 12). Tail intensity was increased at weeks 6 and 12 compared to
week O. Results are expressed as mean ± S.E.
Figure 11(e)
Tail moment in HT29clone19a cells induced by FW from polyp subjects consuming
sYnbiotic (n=17) at the beginning (week 0), mid-way through (week 6), and the end
of intervention (week 12). Tail moment was unaltered at weeks 6 and 12 compared
to week O. Results are expressed as mean ± S.E.
Figure 11(d)
Tail moment in HT29c1one19a cells induced by FW from polyp subjects consuming
placebo (n=20) at the beginning (week 0) at the beginning (week 0), mid-way
through (week 6), and the end of intervention (week 12). Tail moment was increased
at weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 11(e)
The percentage of intact cells (non comet images) in HT29clone19a cells induced by
FW from polyp subjects consuming sYnbiotic (n=17) at the beginning (week 0), mid-
way through (week 6), and the end of intervention (week 12). There was no change
at weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 11(f)
The percentage of intact cells (non comet images) in HT29clone19a cells induced by
FW from polyp subjects consuming placebo (n=20) at the beginning (week 0), mid-
way through (week 6), and the end of intervention (week 12). The percentage of
intact cells was reduced at weeks 6 and 12 compared to week O. Results are
expressed as mean ± S.E.
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Figure 12(a)
Tail intensity in HT29clone19a cells induced by FW from non-smoking polyp
subjects consuming synbiotic (n=15) at the beginning (week 0), mid-way through
(week 6), and the end of intervention (week 12). Tail intensity was unaltered at weeks
6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 12(b)
Tail intensity in HT29c1one19a cells induced by FW from non-smoking polyp
subjects consuming placebo (n=19) at the beginning (week 0), mid-way through
(week 6), and the end of intervention (week 12). Tail intensity was increased at weeks
6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 12(c)
Tail moment in HT29clone19a cells induced by FW from non-smoking polyp subjects
consuming sYnbiotic (n=15) at the beginning (week 0), mid-way through (week 6),
and the end of intervention (week 12). Tail moment was unaltered at weeks 6 and 12
compared to week O. Results are expressed as mean ± S.E.
Figure 12(d)
Tail moment in HT29clone19a cells induced by FW from non-smoking polyp subjects
consuming placebo (n=19) at the beginning (week 0), mid-way through (week 6), and
the end of intervention (week 12). Tail moment was increased at weeks 6 and 12
compared to week O. Results are expressed as mean ± S.E.
Figure 12(e)
The percentage of intact cells (non comet images) in HT29c1oneI9a cells induced by
FW from non-smoking polyp subjects consuming sYnbiotic (n=15) at the beginning
(week 0), mid-way through (week 6), and the end of intervention (week 12). There
was no change at weeks 6 and 12 compared to week O. Results are expressed as mean
±S.E.
Figure 12(j)
The percentage of intact cells (non comet images) in HT29c1one19a cells induced by
FW from non-smoking polyp subjects consuming placebo (n=19) at the beginning
(week 0), mid-way through (week 6), and the end of intervention (week 12). The
percentage of intact cells was reduced at weeks 6 and 12 compared to week O. Results
are expressed as mean ± S.E.
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Figure 13(a)
Tail intensity in HT29clone 19a cells induced by FW from male non-smoking polyp
subjects consuming synbiotic (n=7) at the beginning (week 0), mid-way through
(week 6), and the end of intervention (week 12). Tail intensity was unaltered at
weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 13(b)
Tail intensity in HT29clone19a cells induced by FW from male non-smoking polyp
subjects consuming placebo (n=14) at the beginning (week 0), mid-way through
(week 6), and the end of intervention (week 12). Tail significantly intensity
increased at week 12 compared to week O. Results are expressed as mean ± S.E.
Figure 13(c)
Tail moment in HT29clone19a cells induced by FW from male non-smoking polyp
subjects consuming sYnbiotic (n=7) at the beginning (week 0), mid-way through
(week 6), and the end of intervention (week 12). Tail moment was unaltered at
weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 13(d)
Tail moment in HT29clone19a cells induced by FW from male non-smoking polyp
subjects consuming placebo (n=14) at the beginning (week 0), mid-way through
(week 6), and the end of intervention (week 12). Tail moment was significantly
increased at week 12 compared to week O. Results are expressed as mean ± S.E.
Figure 13(e)
The percentage of intact cells (non comet images) in HT29clone19a cells induced by
FW from male non-smoking polyp subjects consuming sYnbiotic (n=7) at the
beginning (week 0), mid-way through (week 6), and the end of intervention (week
12). There was no change at weeks 6 and 12 compared to week O. Results are
expressed as mean ± S.E.
Figure 13(f)
The percentage of intact cells (non comet images) in HT29clone19a cells induced by
FW from male non-smoking polyp subjects consuming placebo (n=14) at the
beginning (week 0), mid-way through (week 6), and the end of intervention (week
12). The percentage of intact cells was significantly decreased at weeks 6 and 12
compared to week O. Results are expressed as mean ± S.E.
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Table 4
DNA damage (tail intensity, tail moment and the % of intact cells) in HT29clone19a
cells induced by FW derived from cancer and polyp subjects (including smokers) at
the beginning of intervention and at all times (average 3 time-points). The DNA
damaging potential of FW was not significantly different in cancer and polyp
subjects at all times. Results are expressed as mean ± S.E.
Table 5
DNA damage (tail intensity, tail moment and the % of intact cells) in HT29clonel9a
cells induced by FW derived from non-smoking cancer and polyp subjects at the
beginning of intervention and at all times (average 3 time-points). The DNA
damaging potential of FW was not significantly different in cancer and polyp
subjects at all times. Results are expressed as mean ± S.E.
Table 6
DNA damage (tail intensity, tail moment and the % of intact cells) in HT29clone19a
cells induced by FW derived from male non-smoking cancer and polyp subjects at
the beginning of intervention and at all times (average 3 time-points). The DNA
damaging potential of FW was not significantly different in cancer and polyp
subjects at all times. Results are expressed as mean ± S.E.
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Table 4:
All subjects (incl smokers)
GeDotoxic Biomarker CaDcer Subjects Polyp Subjects P value
(Week 0) (Week 0)
FW (TI) 18.00 ± 1.82 (n=31 ) 16.59 ± 1.63 (n=37) D.S.
FW (TM) 6.254 ± 0.736 (n=31) 5.476 ± 0.554 (n=37) D.S.
FW (%IC) 59.26 ± 3.42 (n=31) 59.64 ± 3.23 (n=37) D.S.
CaDcer Subjects Polyp Subjects
(All Times) (All Times)
FW (TI) 19.11 ± 1.23 (n=31 ) 19.20 ± 1.17 (n=37) D.S.
FW (TM) 6.420 ± 0.461 (n=31 ) 6.424 ± 0.426 (n=37) D.S.
FW (%IC) 56.67 ± 2.28 (n=31 ) 54.31 ± 2.08 (n=37) D.S.
Table 5:
Non-smokers
GeDotoxic Biomarker CaDcer Subjects Polyp Subjects P value
(Week 0) (Week 0)
FW (TI) 18.03 ± 1.95 (n=29) 16.86 ± 1.63 (n=34) n.s.
FW (TM) 6.30 ± 0.79 (n=29) 5.50 ± 0.57 (n=34) n.s.
FW (%IC) 59.56 ± 3.54 (n=29) 58.61 ± 3.30 (n=34) n.s.
CaDcer Subjects Polyp Subjects
(All Times) (All Times)
FW (TI) 18.82 ± 1.26 (n=29) 18.86 ± 1.56 (n=34) D.S.
FW (TM) 6.48 ± 0.49 (n=29) 6.28 ± 0.43 (n=34) D.S.
FW (%IC) 57.32 ± 2.27 (n=29) 54.41 ± 2.10 (n=34) D.S.
Table 6:
Male non-smokers
GeDotoxic Biomarker CaDcer Subjects Polyp Subjects P value
(Week 0) (Week 0)
FW (TI) 15.1 7 ± 2.02 (n=17) 16.05 ± 2.27 (n=21 ) D.S.
FW (TM) 5.24 ± 0.83 (n=17) 5.22 ± 0.78 (n=21) D.S.
FW (%IC) 63.22 ± 3.97 (n=17) 61.30 ± 4.56 (n=21) D.S.
CaDcer Subjects Polyp Subjects
(All Times) (All Times)
FW (TI) 18.83± 1.76 (n=17) 19.94 ± 1.53 (n=21 ) D.s.
FW (TM) 6.44 ± 0.66 (n=17) 6.72 ± 0.58 (n=21 ) D.S.
FW (%IC) 56.69 ± 2.93 (n=17) 52.36 ± 2.75 (n=21) D.S.
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DNA Damage in PBMCs
DNA damage in PBMCs isolated from whole blood at week 0, week 6 and week 12
was assessed by comet assay. PBMCS were cryopreserved following isolation and
stored under liquid nitrogen until analysed. PBMCs were thawed at 3'PC and
viability assessed by trypan blue exclusion. Average viability was 94.73% ± 7.426
within accepted standards. Although the majority of samples contained greater than
90% viable cells a small number contained less viable cells and overall viabilities
ranged from 29.3% to 100% and this must be remembered when interpreting the
data.
Cancer subjects
Genotoxic damage in PBMCs was unaltered during the twelve-week intervention
period in cancer subjects. Tail intensity and tail moment in PBMCs derived from
cancer subjects (synbiotic n=18, placebo n=15) showed no difference at weeks 6 and
12 compared to week 0 (Figures 14 (a-d)). The same outcome was observed in non-
smoking cancer subjects (synbiotic n=16, placebo n=15) (Figures 15 (a-d)) and male
non-smoking cancer subjects (synbiotic n=18, placebo n=10) (Figures 16 (a-d)).
Polyp subjects
Genotoxic damage in PBMCs was significantly reduced in both the synbiotic and
placebo groups of polyp subjects at the end of the twelve-week intervention period.
Tail intensity (p=0.0306) and tail moment (P=O.0246) were significantly decreased at
week 12 compared to week 6 in the synbiotic group (n=18) of polyp subjects
(Figures 17(a) & 17(c)). In the placebo group (n=19) tail intensity (P=O.0049) and
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tail moment (p=O.0085) were significantly decreased at week 12 compared to week 0
(Figures l7(b) & l7(d)).
Similarly for non-smoking polyp subjects in the synbiotic group (n=15) tail intensity
(p=O.0509) and tail moment (p=O.0429) in PBMCs were decreased at week 12
compared to week 6 (Figures l8(a) & l8(c)). Similarly in the non-smoking placebo
group (n=17) there was a significant reduction in tail intensity (p=O.0202) and tail
moment (p=O.0329) at week 12 compared to week 0 (Figures l8(b) & l8(d)). In
PBMCs from male non-smoking polyp subjects tail intensity (p=O.0212) and tail
moment (p=O.388) were significantly reduced at week 12 compared to week 0 in the
synbiotic group of polyp subjects (n=7). In the placebo polyp subjects (n=12) there
was a trend towards lower DNA damage at week 12 compared to week 0 but this
reduction was not statistically significant (tail intensity p=O.0567, tail moment
p=O.0708) (Figures 19 (a-d)).
DNA damage in PBMCs from cancer and polyp subjects at the beginning of
intervention and at all three time points was analysed. DNA damage in PBMCs was
significantly higher (p<O.05) in polyp subjects compared to cancer subjects at week
o and at all three time points (Table 7). Similar results were observed in non-
smokers (male and female) (Table 8) and in non-smoking males (Table 9).
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Figure 14(a)
Tail intensity in PBMCs from cancer subjects consuming synbiotic (n=18) at the beginning (week 0), mid-way through (week 6), and the end of
intervention (week 12). Tail intensity was unaltered at weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 14(b)
Tail intensity in PBMCs from cancer subjects consuming placebo (n=15) at the beginning (week 0), mid-way through (week 6), and the end of
intervention (week 12). Tail intensity was unaltered at weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 14(c)
Tail moment in PBMCs from cancer subjects consuming synbiotic (n=18) at the beginning (week 0), mid-way through (week 6), and the end of
intervention (week 12). Tail moment was unaltered at weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 14(d)
Tail moment in PBMCs from cancer subjects consuming placebo (n=15) at the beginning (week 0), mid-way through (week 6), and the end of
intervention (week 12). Tail moment was unaltered at weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
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Figure 15(a)
Tail intensity in PBMCs from non-smoking cancer subjects consuming synbiotic (n=18) at the beginning (week 0), mid-way through (week 6),
and the end of intervention (week 12). Tail intensity was unaltered at weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 15(b)
Tail intensity in PBMCs from non-smoking cancer subjects consuming placebo (n=15) at the beginning (week 0), mid-way through (week 6),
and the end of intervention (week 12). Tail intensity was unaltered at weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 15(c)
Tail moment in PBMCs from non-smoking cancer subjects consuming synbiotic (n=18) at the beginning (week 0), mid-way through (week 6),
and the end of intervention (week 12). Tail moment was unaltered at weeks 6 and 12 compared to week O. Results are expressed as mean ± S.E.
Figure 15(d)
Tail moment in PBMCs from non-smoking cancer subjects consuming placebo (n=15) at the beginning (week 0), mid-way through (week 6),
and the end of intervention (week 12). Tail moment was unaltered at weeks 6 and 12 compared to week o. Results are expressed as mean ± S.E.
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Figure 16(a)
Tail intensity in PBMCs from male non-smoking cancer subjects consuming synbiotic (n=18) at the beginning (week 0), mid-way through (week
6), and the end of intervention (week 12). Tail intensity was unaltered at weeks 6 and 12 compared to week O. Results are expressed as mean ±
S.E.
Figure 16(b)
Tail intensity in PBMCs from male non-smoking cancer subjects consuming placebo (n=15) at the beginning (week 0), mid-way through (week
6), and the end of intervention (week 12). Tail intensity was unaltered at weeks 6 and 12 compared to week O. Results are expressed as mean ±
S.E.
Figure 16(c)
Tail moment in PBMCs from male non-smoking cancer subjects consuming synbiotic (n=18) at the beginning (week 0), mid-way through (week
6), and the end of intervention (week 12). Tail moment was unaltered at weeks 6 and 12 compared to week O. Results are expressed as mean ±
S.E.
Figure 16(d)
Tail moment in PBMCs from male non-smoking cancer subjects consuming placebo (n=15) at the beginning (week 0), mid-way through (week
6), and the end of intervention (week 12). Tail moment was unaltered at weeks 6 and 12 compared to week O. Results are expressed as mean ±
S.E.
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Figure 17(a)
Tail intensity in PBMCs from polyp subjects consuming synbiotic (n=18) at the beginning (week 0), mid-way through (week 6), and the end of
intervention (week 12). Tail intensity was significantly decreased at week 12 compared to week 6. Results are expressed as mean ± S.E.
Figure 17(6)
Tail intensity in PBMCs from polyp subjects consuming placebo (n=19) at the beginning (week 0), mid-way through (week 6), and the end of
intervention (week 12). Tail intensity was significantly decreased at week 12 compared to week O. Results are expressed as mean ± S.E.
Figure 17(c)
Tail moment in PBMCs from polyp subjects consuming synbiotic (n=18) at the beginning (week 0), mid-way through (week 6), and the end of
intervention (week 12). Tail moment was significantly decreased at week 12 compared to week 6. Results are expressed as mean ± S.E.
Figure 17(d)
Tail moment in PBMCs from polyp subjects consuming placebo (n=19) at the beginning (week 0), mid-way through (week 6), and the end of
intervention (week 12). Tail moment was was significantly decreased at week 12 compared to week O. Results are expressed as mean ± S.E.
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Figure l8(a)
Tail intensity in PBMCs from non-smoking polyp subjects consuming synbiotic (n=15) at the beginning (week 0), mid-way through (week 6),
and the end of intervention (week 12). Tail intensity was decreased at week 12 compared to week 6. Results are expressed as mean ± S.E.
Figure l8(b)
Tail intensity in PBMCs from non-smoking polyp subjects consuming placebo (n=17) at the beginning (week 0), mid-way through (week 6), and
the end of intervention (week 12). Tail intensity was significantly decreased at week 12 compared to week O. Results are expressed as mean ±
S.E.
Figure l8(c)
Tail moment in PBMCs from non-smoking polyp subjects consuming synbiotic (n=15) at the beginning (week 0), mid-way through (week 6),
and the end of intervention (week 12). Tail moment was significantly decreased at week 12 compared to week 6. Results are expressed as mean
± S.E.
Figure l8(d)
Tail moment in PBMCs from non-smoking polyp subjects consuming placebo (n=17) at the beginning (week 0), mid-way through (week 6), and
the end of intervention (week 12). Tail moment was significantly decreased at week 12 compared to week O. Results are expressed as mean ±
S.E.
301
18 18
Placebo Polyp Subjects
(non-smokers)
15
Synbiotic Polyp Subjects
(non-smokers)
15
~ 1] ---L Paired t test I0.0509'0 Fl P value
~
c:
10
!
'0
,= r=9
c: I r+-,(1) InPaired t test I0.0202....
'co
,=
P value
....
'co 5
....
0" " " , 0" " " ,
Week 0 Week 6 Week 12 Week 0 Week 6 Week 12
Synbiotic Polyp Subjects
(non-smokers)
Week 12
Paired t test I
P value 0.0329
Week 6
Placebo Polyp Subjects
(non-smokers)
....
c:
~ 3
~ 2
'co
....
1
0
Week 0Week 12
Paired t test I
P value 0.0429
Week 6
5
4
....
c: 3~
~
'co
2
....
1
0
Week 0
Figure 19(a)
Tail intensity in PBMCs from male non-smoking polyp subjects consuming synbiotic (n=7) at the beginning (week 0), mid-way through (week
6), and the end of intervention (week 12). Tail intensity was significantly decreased at week 12 compared to week O. Results are expressed as
mean± S.E.
Figure 19(b)
Tail intensity in PBMCs from male non-smoking polyp subjects consuming placebo (n=12) at the beginning (week 0), mid-way through (week
6), and the end of intervention (week 12). Tail intensity was decreased at week 12 compared to week O. Results are expressed as mean ± S.E.
Figure 19(c)
Tail moment in PBMCs from male non-smoking polyp subjects consuming sYnbiotic (n=7) at the beginning (week 0), mid-way through (week
6), and the end of intervention (week 12). Tail moment was significantly decreased at week 12 compared to week O. Results are expressed as
mean± S.E.
Figure 19(d)
Tail moment in PBMCs from male non-smoking polyp subjects consuming placebo (n=12) at the beginning (week 0), mid-way through (week
6), and the end of intervention (week 12). Tail moment was decreased at week 12 compared to week O. Results are expressed as mean ± S.E.
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Table 7
DNA damage (tail intensity and tail moment) in PBMCs from cancer and polyp
subjects (including smokers) at the beginning of intervention and at all times
(average 3 time-points). DNA damage in PBMCS was significantly lower in cancer
subjects compared to polyp subjects at the beginning of intervention and at all three
time points. Results are expressed as mean ± S.E.
Table 8
DNA damage (tail intensity and tail moment) in PBMCs from non-smoking cancer
and polyp subjects at the beginning of intervention and at all times (average 3 time-
points). DNA damage in PBMCS was significantly lower in cancer subjects
compared to polyp subjects at the beginning of intervention and at all three time
points. Results are expressed as mean ± S.E. .
Table 9
DNA damage (tail intensity and tail moment) in PBMCs from male non-smoking
cancer and polyp subjects at the beginning of intervention and at all times (average 3
time-points). DNA damage in PBMCS was significantly lower in cancer subjects
compared to polyp subjects at the beginning of intervention and at all three time
points. Results are expressed as mean ± S.E.
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Table 7:
All subjects (incl smokers)
Genotoxic Biomarker Cancer Subjects Polyp Subjects P value
(Week 0) (Week 0)
PBMC (TI) !.530 ± 0.470 (n=33) '.843 ± 0.800 (n=37) 1.018"
PBMC (TM) 1.327 ± 0.150 (n=33) 2.068 ± 0.259 (n=37) O.019a
Cancer Subjects Polyp Subjects
(All Times) (All Times)
PBMC (TI) 5.780 ± 0.418 (0=33) '.760 ± 0.630 (n=37) 8.011"
PBMC (TM) 1.413 ::i:: 0.128 (8=33) 2.056 ::i:: 0.211 (n=37) 1.0113
Table 8:
Non-smokers
Genotoxic Biomarker Cancer Subjects Polyp Subjects P value
(Week 0) (Week 0)
PBMC (TI) ~.580 ± 0.500 (n=31) '.662 ± 0.884 (n=33) 6.0483
PBMC (TM) 1.353 ::i:: 0.158 (n=31) L995::i::0.286 (n=33) 1.0585
Cancer Subjects Polyp Subjects
(All Times) (All Times)
PBMC (TI) !.911 ± 0.441 (n=31) '.815 ± 0.710 (n=33) 1.0253
PBMC (TM) 1.453 ::i:: 0.136 _~. (n=31) Z.067 ::i:: 0.239 (8=33} 8.0281
Table 9:
Male non-smokers
Genotoxic Biomarker Cancer Subjects Polyp Subjects P value
(Week 0) (Week 0)
PBMC (TI) ~.631 ± 0.662 (0=19) 8.890::i:: 1.328 (n=l9) ••0341
PBMC (TM) A.414::i:: 0.222 (D=lt) a..J76 ::i:: 0.435 (D=19) I-0S"-
Cancer Subjects Polyp Subjects
(All Times) (All Times)
PBMC (TI) 5.840 ::i:: 0.504 (0=-19) '.600 ::i:: 0.725 (0-19) '.0498
PBMC (TM) 1.447::i:: 0.153 (n=19) 1.964 ::i:: 0.227 (n=19) 0.0615
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Discussion
Cancer arises from an accumulation of mutations in a single cell and is often referred
to as a disease of DNA. Mutations may arise as a result of errors in DNA replication
or as a result of exposure to environmental mutagens such as ultra violet radiation
and dietary mutagens. The colonic mucosa is constantly exposed to the contents of
the gut lumen, which contains compounds that may be either damaging to or
protective of the mucosa. DNA damage followed by ineffective repair leads to
permanent mutations altering gene expression and activity.
Studies have shown that DNA damage is higher in the colon of rats fed diets
containing high risk factors for colon cancer than in the colons of rats fed low risk
factors and that lactic acid bacteria can inhibit DNA damage, (Pool-Zobel et al.
1996; Hambly et al. 1997; Zsivkovits et al. 2003).
In the current study we evaluated the influence of a synbiotic combination of
Lactobacillus rhamnosus 00, Bifidobacterium lactis Bb12 and SynergyCl on in vivo
genotoxic damage by measuring DNA damage in biopsies and lYmphocytes. In
placebo cancer subjects DNA damage in biopsies was significantly increased after
the twelve-week intervention period but this increase was not observed in the
synbiotic consuming cancer subjects. Similar results were seen when subjects who
smoke were excluded from the analysis. These results indicate that in cancer subjects
synbiotic consumption is protective against DNA damage in the colonic mucosa.
This protection may be due to binding of genotoxic substances in the gut lumen by
probiotic bacteria preventing these substances from coming in contact with the
colonic mucosa. Interestingly when both smokers and females were excluded from
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analysis there was a trend towards increased DNA damage in the placebo cancer
group but this increase did not reach significance. This suggests that the colonic
mucosa of females is more susceptible to genotoxic damage as the most significant
increase was observed when females were included in the analysis. This gender
difference is not unexpected and studies have shown gender related differences in
genotoxic damage. The number of females in this study, however, was small and
further work is needed to confirm this observation.
In polyp subjects genotoxic damage was significantly decreased following sYnbiotic
consumption, however there was also a decrease although less pronounced in the
placebo group. It may be that in vivo genotoxic damage in polypectomised subjects
is reduced over time and intervention with sYnbiotics may hasten this reduction. In
contrast when females and smokers were excluded from analysis there was no
change in DNA damage in placebo subjects but there was a trend towards reduction
in the synbiotic subjects but this reduction was not as significant as when smokers
and females were included in the analysis. This suggests that the level of DNA
damage decreases over time at a greater rate in female polyp subjects than in male
polyp subjects. This result is in contrast to the cancer subjects where female subjects
were more susceptible to DNA damage. It may be that the level or activity of
genotoxins to which the colonic mucosa is exposed is different in female cancer and
female polyp subjects, however a larger scale study would be required to investigate
if this is true.
The initial level of genotoxic damage in biopsies from cancer and polyp subjects was
also analysed. There was no difference in DNA damage in biopsies from cancer
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subjects compared to polyp subjects at the beginning of intervention. Interestingly
DNA damage in biopsies from cancer subjects was significantly higher than in polyp
subjects at the end of intervention. This result indicates that the increase in DNA
damage in the colonic mucosa of cancer subjects over time is significantly greater
than that observed in polyp subjects. A similar result was observed when smokers
were excluded from the analysis. However when smoking subjects and females were
excluded there was no difference in DNA damage in biopsies from male non-
smoking cancer and polyp subjects indicating the colonic mucosa of females is more
susceptible to DNA damage than the mucosa of males.
We also investigated the influence of synbiotic consumption on the genotoxic
potential of FW. Diets considered high risk for colon cancer have been reported to
increase the genotoxic potential of FW in healthy volunteers (Rieger et ale 1999). In
the current study there was no effect of synbiotic intervention on the genotoxic
potential of FW during the twelve-week intervention period. However FW derived
from the placebo group of polyp subjects increased DNA damage in HT29clone19a
cells during the twelve-week intervention period and this increase was most
pronounced in the male non-smoking subjects. In the synbiotic group of polyp
subjects there was no change in the genotoxic potential of FW suggesting that
synbiotic consumption prevented the increase in genotoxicity seen in the placebo
group of subjects. This result suggests that synbiotic consumption in polyp subjects
modulates the genotoxic potential of FW and that this effect is most pronounced in
male non-smoking subjects.
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The genotoxic potential of FW derived from cancer and polyp subjects at the
beginning of intervention and at all time points was analysed. There was no
significant difference in the genotoxic potential of FW derived from cancer subjects
compared to polyp subjects. We would have expected FW genotoxicity to be higher
in cancer subjects as these subjects had significantly more DNA damage in the
colonic mucosa than polyp subjects. There are a number of possible explanations for
this result. It may be that in vivo DNA damage in the cancer subjects was caused by
factors other than those in the FW. It may also be that the colonic mucosa of cancer
subjects is more susceptible to genotoxic damage than the mucosa of polyp subjects.
Further large scale studies investigating the relationship between in vivo DNA
damage and the genotoxic potential of FW are needed to determine if FW
genotoxicity is useful as a biomarker ofcancer risk.
Dietary intervention has been reported to modulate genotoxic damage in
lYmphocytes (Pool-Zobel et al. 1997). In the current study genotoxic damage in
PBMCs was unaltered during the twelve-week intervention period in cancer subjects.
In contrast, DNA damage in PBMCs was significantly reduced at week 12 compared
to week 6 in the sYnbiotic groups of polyp subjects and in non-smoking polyp
subjects. In male non-smoking polyp sYnbiotic subjects DNA damage was
significantly decreased at week 12 compared to week O. Interestingly, DNA damage
was significantly reduced at the end of the intervention period in all placebo polyp
and in non-smoking placebo polyp subjects. There was also a trend towards lower
damage in the male non-smoking placebo polyp subjects but this decrease was not
statistically significant. This reduction in DNA damage correlates with induction of
GST activity (chapter 4). These results indicate that genotoxic damage in PBMCs
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may normally decrease over time in polyp subjects, however in male non-smoking
subjects sYnbiotic intervention hastens this decrease.
Comparison of DNA damage in PBMCs from cancer and polyp subjects revealed
that there was more damage in PBMCs from polyp subjects than in PBMCs from
cancer subjects. In contrast the level of DNA damage in the colonic mucosa of
cancer subjects was significantly higher than in polyp subjects. Therefore in this
study the level of DNA damage in the colon, was not mirrored by the level of
damage in the PBMCs. It may be that there is a relationship between DNA damage
in the colon and in the PBMCs and further studies to investigate this relationship
should be performed.
In conclusion synbiotic consumption protects against in vivo genotoxic damage of
the colonic mucosa in cancer and polyp subjects and reduces the genotoxic potential
of FW derived from polyp subjects. In polyp subjects DNA damage in PBMCs
decreases over time, however sYnbiotic consumption may positively influence this
reduction in a subset of subjects e.g. male non-smokers. Cancer subjects have
significantly higher DNA damage in the colonic mucosa and significantly lower
damage in PBMCs than polyp subjects. These markers may prove useful as
biomarkers of cancer risk., however large-scale studies comparing the levels of the
markers in healthy and diseased states are needed. Gender, smoking status and
genetic polymorphisms seem to play a role in susceptibility to genotoxic damage.
Future studies should be designed and sufficient participants enrolled to control for
such factors.
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Chapter 6
Study of the effect(s) of synbiotic cons·umption
on other potential biomarkers for cancer
Abstract
The normal gut flora has many beneficial effects on the host (e.g. vitamin synthesis)
but is also involved in the metabolism of carcinogens ingested in the diet to both
active and inactive compounds. Imbalance in the composition of the gastrointestinal
flora has been associated with increased risk ofcolon cancer. Pre-, pro- and synbiotic
consumption has been reported to alter the composition and the metabolic activity of
the gut flora. Consumption of pre- and probiotics has also been reported to
beneficially affect cholesterol levels in animals and humans. In this study we
investigated the influence of synbiotic consumption on the composition of the faecal
flora, the concentration of short chain fatty acids (SCFAs), faecal calprotectin, the
cytotoxic potential of FW, and cholesterol levels. Lactobacilli, bifidobacteria and
enterococci numbers were increased with decreases in the levels of Clostridium
perfringens and coliforms being recorded following twelve weeks of synbiotic
consumption. No effects on the levels of faecal calprotecin, FW cytotoxicity, SCFAs
or cholesterol following synbiotic consumption were observed. Interestingly the
initial numbers of faecal lactobacilli and enterococci were lower while the cytotoxic
potential of FW and the concentration of propionic, isobutyric and isovaleric acids
were significantly higher in cancer subjects than in polyp subjects at the beginning of
the study. We conclude that there are differences in the composition and metabolic
activity of the gastrointestinal flora of cancer and polyp subjects and that synbiotic
consumption increases the numbers of beneficial bacteria. However in this study this
increase in bacterial numbers was not associated with a change in SCFAs or the
cytotoxic potential of FW. It may be that a longer period of intervention is required
for such changes to occur.
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Introduction
The gastrointestinal (GI) tract is home to a rich flora of greater than 500 different
bacterial species the vast majority «400 species) of which reside in the large
intestine (colon). Obligate anaerobes predominate in the large intestine (99.9% of the
total flora). Genera such as Bacteroides, Eubacterium, Bifidobacterium and
Peptostreptococcus dominate at levels ofapprox. 1010-1011cfu/g. Enterobacteriaceae,
streptococci and lactobacilli are also present at levels of 108cfulg, (Naidu et al.
1999).
The normal gut flora has many beneficial effects on the host including vitamin
synthesis, and improved absorption of minerals by the host e.g. calcium, magnesium
and iron. The flora is also involved in the conversion of pro-drugs to their active
form and the metabolism of carcinogens ingested in the diet to both active and
inactive compounds. Imbalance in the composition of the GI flora has been
associated with increased risk of colon cancer (Gorbach & Goldin 1990).
Modulating the composition of the GI flora has been proposed as a possible
mechanism for reduction ofcancer risk.
The consumption of pre-, pro- and synbiotics has been reported to shift the
composition of the gut flora to a more beneficial composition. Most studies in this
area have shown that pre-, pro or synbiotic consumption increases bifidobacteria and
lactobacilli numbers, (Kruse et al. 1999; Tuohy et al. 2001). However some studies
have demonstrated that pre-, pro- or synbiotic consumption can also affect other
members ofthe gut flora.
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Spanhaak et al. (1998) demonstrated that consumption of a milk fennented by
Lactobacillus case; strain shirota significantly increased lactobacilli and
bifidobacteria and decreased the numbers of clostridium although not significantly.
Gibson et al. (1995) demonstrated that consumption of the prebiotics, oligofructose
and inulin, significantly increased the numbers of faecal bifidobacteria, while
decreasing the numbers of bacteroides, clostridia, fusobacteria and Gram positive
cocci. The protective role of pre-, pro-, and synbiotics against colon carcinogenesis
has been demonstrated in animal studies (Femia et al. 2002; Gallaher & Khil 1999;
Goldin et al. 1996).
The inflammatory protein calprotectin found in faeces is often used as a biomarker
for inflammation. Elevated levels of faecal calprotectin have been found in patients
with colonic polyps and colon cancer (Kristinsson et al. 1998; Roseth et al. 1993;
Tibbie et al. 200 I) and active inflammatory bowel disease (Roseth et al. 1993;
Tibbie et aI. 2000). Calprotectin is a calcium-binding protein found mainly in
neutrophils. Immunohistochemical examination of colorectal cancer specimens has
shown calprotectin reactivity confined to neutrophils with no reactivity in neoplastic
cells, (Roseth et al. 1993; Tibbie et al. 2000). The amount ofcalprotectin in faeces is
dependent on the integrity of the colonic tight junctions. If tight junction integrity is
impaired neutrophils containing calprotectin migrate from the blood stream through
the leaky junctions and into the gut lumen. Berstad et al. (2000) demonstrated a
correlation between increased intestinal penneability and calprotectin concentrations
in gut lavage fluid of IBD patients.
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Despite the growing acceptance of calprotectin as a marker of inflammation its' use
as a risk marker for colon cancer is not yet fully proven and some studies have found
no correlation between faecal calprotectin levels and carcinogenesis. A study
performed by (Limburg et aJ. 2003) in colonoscopy patients with a personal history
of colorectal neoplasia, family history of colorectal cancer, or iron deficiency
anaemia found that faecal calprotectin levels did not differ significantly between
subjects with, versus subjects without colorectal neoplasms. Poullis et aJ. (2004)
reported a significant positive relationship between faecal calprotectin and cancer
risk factors such as increasing age, obesity, physical inactivity, and an inverse
relationship with fiber intake and vegetable consumption. Bruzzese et aJ. (2004)
reported that, in children with either active inflammatory bowel disease or cystic
fibrosis, consumption of Lactobacillus rhamnosus GG significantly reduced faecal
calprotectin levels.
Many of the substances to which the colonic mucosa is exposed induce cytotoxic
damage leading to cell death. Stimulation of proliferation in the colon is, in part, to
compensate for the loss of cells due to cytotoxic mechanisms, an increase in mitotic
activity could increase the risk of colon cancer. The cytotoxic potential of faecal
water is now accepted as a risk marker for colon cancer (Lapre & Van der Meer
1992; Lipkin 1991) and in vitro faecal water cytotoxicity towards colon cells is often
employed as a biomarker in intervention studies.
van Muster et aJ. (1994) demonstrated that the consumption of resistant starch (a
prebiotic) significantly decreased proliferation in rectal biopsies and the cytotoxicity
of faecal water in healthy volunteers. Glinghammar et aJ. (1997) demonstrated that a
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shift from a dairy-product rich diet (low cancer risk) to a dairy product-free diet
(high risk) increased cytotoxicity of FW from healthy volunteers; however the
genotoxic potential of FW was unaltered. The exact mechanism by which dairy
products lower cancer risk is unknown however it may be speculated that, in this
study, the increase in cytotoxicity seen in volunteers on the dairy product free diet
may have been due to the reduction ofcalcium in the diet.
Short-chain fatty acids (SCFAs) are the major end products of bacterial metabolism
in the human large intestine. They are formed by bacterial fermentation of
polysaccharides, oligosaccharides, proteins, peptides and glycoproteins (Cummings
& Macfarlane 1991). SCFAs provide between 10-30% of basal metabolic
requirements for liver cells, colonocytes and peripheral tissues (Dunne 2001).
Acetate, propionate and butyrate are the principal SCFAs produced in the colon
although formate, valerate, caproate, isobutyrate and isovalerate are produced in
lesser amounts (Macfarlane & Macfarlane 2003). SCFAs contribute to normal large
bowel function and prevent pathology through their actions in the lumen and on the
colonic musculature and vasculature and through their metabolism by colonocytes
(Topping & Clifton 2001). Segal et aJ. (1995) reported that total faecal SCFA
concentration was significantly higher in healthy black South African subjects
(lower CRC incidence) than in healthy white South African subjects (higher CRC
incidence).
Butyrate has been associated with many biological properties in the colon and is
thought to directly enhance cell proliferation in normal cells and suppress
proliferation in transformed cells. In addition, apoptosis may be increased in
transformed cells but inhibited in normal cells when butyrate is present (Hague et al.
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1995; Hass et al. 1997; Marchetti et al. 1997). Butyrate has been reported to reduce
hydrogen peroxide induced DNA damage in freshly isolated rat colon cells
(Abrahamse et al. 1999) and human colonocytes (Rosignoli et aI. 2001). Butyrate is
known to reduce risk factors involved in the aetiology of colon cancer and adenoma
development (Smith et al. 1998).
Emenaker et al. (2001) reported that incubation with acetate, proprionate and
butyrate reduced the invasiveness of cells isolated from surgical specimens of
patients resected for invasive colorectal cancer and that this reduction seemed to be
dependent on inhibition of urokinase plasminogen activator (uPA) and the
stimulation of tissue inhibitor matrix metalloproteinase (TIMP)-I and TIMP-2
protein activities. Acetate, proprionate and butyrate also demonstrated the ability to
modulate the expression of genes associated with cancer such as mutant p53, Bcl-2,
bax, p21 and PCNA.
Probiotics have been shown to reduce cholesterol and triacylglycerol plasma
concentrations, (Kiessling et al. 2002; Taranto et aI. 1998). Cholesterol absorption is
dependant on the solubilisation of cholesterol with bile acids. Probiotics are thought
to influence cholesterol levels due to deconjugation of bile acids by bacterial
enzymes (bile salt hydrolase) giving rise to deconjugated bile salts which are less
soluble and less efficiently reabsorbed from the intestinal lumen than their
conjugated counterparts, leading to larger amounts of free bile acids being excreted
in the faeces. Also, free bile salts are less efficient in the solubilisation and
absorption of lipids in the gut. Therefore, the deconjugation of bile acids by probiotic
bacteria could lead to a reduction in serum cholesterol either by increasing the
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demand ofcholesterol for de novo synthesis of bile acids to replace that lost in faeces
or by reducing cholesterol solubility and, thereby, absorption of cholesterol
throughout the intestinal lumen. Gilliland et aJ. (1985) reported a significant
relationship between cholesterol assimilation by lactobacilli and their degree of bile
deconjugation.
A meta-analysis performed by Agerholm-Larsen et aJ. (2000) found that probiotic
intervention significantly decreased total and LDL cholesterol. du Toit et aJ. (1998)
performed a feeding trial with a mix of three lactobacilli strains in minipigs and
found that serum cholesterol levels were decreased three weeks after beginning
intervention. The effects of consumption of probiotics and prebiotics on serum lipid
levels in humans was reviewed by Pereira & Gibson (2002). They concluded that in
hyperlipidemic subjects probiotic consumption reduces total cholesterol levels,
whereas in normal subjects, effects on serum triglycerides are the dominant feature.
The aims of this study were:
1) To investigate if sYnbiotic consumption can alter the composition of the
gastrointestinal flora.
2) To determine if sYnbiotic consumption alters the physiochemical environment of
the gut lumen e.g. short-chain fatty acids.
3) To determine if sYnbiotic consumption protects against damage and
inflammation of the colonic mucosa e.g. cytotoxic potential of FW and
calprotectin expression.
4) To investigate if sYnbiotic consumption can influence cholesterol levels.
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Table 1: Selective media employed for the culture ofdifferent bacteria
BaeIe..~,~_~~ple~1_
Lactobacilli Rogosa Agar 1.32ml/L of glacial acetic acid
Bifidobacteria MRS Agar 0.2% lithium chloride
0.3% sodium proprionate
0.05% cysteine hydrochloride
5% sheeps blood
Enterococci KF Streptococcus Agar 10ml/L 1% TIC,
(2,3,5-Triphenyltetrazolium chloride)
Clostridium OPSP Agar Perfringens A Selective Supplement,
perfringens SR076E (Oxoid)
Perfringens B Selective Supplement,
SR077E (Oxoid)
Coliforms MacConkey agar No.3
Bacteroides Wilkins & Chalgren Anaerobic supplement SR108 (Oxoid)
Agar 5% horse blood
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Methods
Work described in this chapter was conducted in collaboration with Pemilla
Karlsson and Prof. Joseph Rafter of the Department of Medical Nutrition, Karolinska
Institutet, Huddinge, Sweden, Dr Jan Van Loo and Dr Nadine Jonkers of Orafti,
Tienen, Belgium and Dr Tony Fitzgerald of the Biochemistry Department, The
Mercy University Hospital, Cork.
Faecal Flora Analysis
Subjects provided faecal samples at the beginning (week 0), mid way through (week
6) and at the end of intervention (week 12). Total stool from one passage was
collected in a plastic container and mixed using a sterile wooden spatula. An aliquot
was used to make a faecal slurry with sterile 60% PBS / 40% Glycerol / 0.05%
cysteine. Faecal slurries were stored at -80°C until required.
Faecal slurries were thawed at room temperature, serially diluted 10-fold in sterile
PBS /0.05% cysteine and either spread-plated or pour-plated in appropriate dilutions
on suitable media (Table 1).
Plates were incubated in gas pakjars (BBL) with C02 generating kits (Anaerocult A;
Merck), for 48 to 72 hrs at 3rC. Mac Conkey agar No.3 and OPSP plates were
incubated for 18-24 hours at 3rc. Colony identities were confirmed by Gram stain.
Microbial numbers were calculated as colony forming units per g of wet weight of
faeces. The identity of colonies on MRS blood plates however was further
investigated as this medium is not fully selective for Bifidobacteria.
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Bifidobacteria are characterized by a unique hexose metabolism that occurs via a
phosphoketolase pathway often termed the 'bifid shunt'. Fructose-6-phosphate
phosphoketolase (F6PPK) is a key enzyme of the 'bifid shunt' and its presence is the
most common diagnostic test for this genus, as it is not present in other Gram-
positive intestinal bacteria.
Representative colonies were selected from MRS blood plates and inoculated into
MRS broth supplemented with 0.05% cysteine and grown anaerobically for 48hrs at
3t>C. Iml of turbid culture was centrifuged at 1700 x g for 5 mins. The pellet was
washed twice in Iml of 0.05M phosphate buffer with 0.05% cysteine HCL, pH6.5
(0.5% PBIHCL). The washed pellet was resuspended in 200fJ.I of 0.5% PBIHCL, and
0.25% Triton X-IOO, mixed vigorously for two minutes to induce cell lysis, and
incubated at room temperature for 10mins. Following incubation 50fJ.I of a sodium
fluoride (6mg/ml) / sodium iodoacetate (I Omg/ml) solution and 50fJ.I of a fructose-6-
phosphate solution (80mg/ml) were added. Samples were mixed on a vortex and
incubated for Ihour at 3t>C. 300fJ.I of 13.9% (w/v) hydroxylamine HCL (freshly
neutralized with NaOH to pH 6.5) was added, followed by incubation for IOmins at
room temperature. Finally 200fJ.I of 15% trichloroacetic acid, 200fJ.I of 4M HCL, and
200fJ.I of 5% FeCh.6H20 in O.IM HCL was added. Immediate development of a
purple colour indicated a positive result for the presence of F6PPK. A yellow colour
indicates a negative result. Only colonies with the same colony morphology as the
F6PPK positive colonies were counted as Bifidobacteria.
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Calprotectin
Frozen faecal samples were thawed at room temperature. Approximately 100 mg
(40-120 mg) faecal sample was collected with a disposable inoculation loop and
placed into a 15 ml screw cap tube. The weight of the faeces was recorded and the
loop handle was broken off, leaving the loop with faeces and 4-6 cm of the handle
inside the tube (to act as agitator). Pre-diluted extraction buffer (Nycomed, Norway)
containing urea and citrate was added in a weight/volume ratio of 1:50. The tubes
were mixed on a vortex for 30 sec followed by homogenisation for 30 min at 1400
rpm on a shaker (lka-Vibrax-VXR, IKA). 1 ml of the homogenate was transferred to
a microcentrifuge tube (Eppendort) and centrifuged for 20 min at 10000 x g. After
centrifugation 0.5 ml of the supernatant was transferred to a new microcentrifuge
tube and analysed immediately or stored at -20°C until analysis.
The calprotectin concentrations of faecal supernatants were assessed by a
calprotectin enzYme linked immunosorbent assay (Oslo, Norge). Standards and
positive controls supplied in the kit were included in each run of the assay according
to manufacturer's instructions. The faecal supernatants were diluted 1:50 in assay
buffer (0.15M NaCl, 0.5mM MgC12, 50mM TRIS, 2.5mM KCI, 0.25 mM
Merthiolate, 0.05% Tween 20, pH 8, supplemented with 10g/L bovine serum
ablumin) and IOOIlI of each sample was added in duplicate to cells of a 96 well
microtiter plate that had previously been coated with POlyclonal antibody to
calprotectin.
The plate was then incubated at room temperature for 45mins followed by washing
four times with washing solution (0.15M NaCI, 0.5mM MgC12, 50mM Tris, 2.5mM
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KC1, 0.25 mM merthiolate, 0.05% Tween 20, pH 8). 100fll conjugate (purified rabbit
anti-human calprotectin IgG antibodies conjugated with alkaline phosphatase) were
added to each well and the plate was incubated for 45mins at room temperature. At
the end of the incubation period the plate was washed four times with washing
solution as above and 100fll of substrate solution (p-nitrophenylphosphate dissolved
in 1% diethanole amine, MgCh 0.01 gIL, merthiolate 0.01 gIL, pH 9.5) were added to
each well.
After 15 min incubation in the dark at room temperature the optical density was read
at 405 nm in a spectrophotometer. The calprotectin concentrations in the faecal
samples were calculated from the standard curve obtained with the standards of
known concentration. The concentrations of extracted calprotectin were expressed as
flglg of stool.
Cytotoxicity
The Alamar Blue cytotoxicity kit (Alamar, USA) was used to examine cytotoxic
effects of faecal water in cells. HT-29 cells (2.5 x 104 cells/well) were seeded in
wells of 96-well plates and cultured for 36 hours at 3'PC in a humidified atmosphere
containing 5% C02 in air. Medium was removed and deoxycholic acid (DCA) and
faecal water diluted (1:10, 1:20, and 1:30) in 0.1 % Dulbecco's Modified Eagle
Medium (DMEM) and each sample was added to eight wells of the 96 well plate.
After 24 hours, the test agents were removed and a 10% solution of Alamar Blue dye
was added. The cells were incubated for 3 hours with Alamar Blue, thereafter the
colour change was measured spectrophotometrically at 600 and 570 om
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(SPECTRAmax 250, Molecular Devices Corporation). The mean absorbance ofeach
well was calculated and % cell death was expressed as:
~ absorbance in sample well x 10~
lmaximal absorbance in DMEM well (negative control) )
Faecal Short-Chain Fatty Acids (SCFAs)
Faecal samples were obtained at week 0, week 6 and week 12 and stored at -80°C
until analysed. Faecal SCFAs were determined using gas chromatography and flame
ionisation detection (GC VEGA 6000, Carlo Elba, Milano, Italy).
Faecal samples were weighed and diluted with an internal standard solution (2-
methyl valerie acid, 0.010/0). The solution was acidified with 0.5 ml H2S04 (pH 2),
and SCFAs were extracted by shaking with 2.0 ml diethylether and subsequent
centrifugation (10 min at 600 x g). The ether phase was injected directly onto a pre-
heated (150oC) column (BT21-FFAPP 25 m x 0.53 mm x 0.5 mm, Achrom NV/SA,
Belgium), using N2 as the carrier gas and the detection temperature was set at 230°C.
Peaks were integrated using the Atlas software (ThermoLab Systems, The
Netherlands).
Cholesterol
Blood was collected in serum-gel blood collection tubes (Sarstedt). The tubes were
centrifuged at 300 x g for 5mins and the upper serum layer was removed, aliquoted
and stored at -80°C until analysed. Serum total cholesterol, HDL cholesterol, and
triglycerides were determined enzymatically on an Olympus Chemistry- Immuno
Analyzer in the Biochemistry Department, Mercy University Hospital. LDL
cholesterol was calculated from the Friedewald formula, (Friedewald et ale 1972).
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Results
Faecal Flora Analysis
Subjects provided faecal samples at the beginning (week 0), mid way through (week
6) and at the end of intervention (week 12). The composition of the faecal flora was
assessed using standard plate count methods.
Synbiotic consumption modified the composition of the faecal flora. In cancer
. subjects consuming synbiotic (n=19) there was a trend towards increase in the
numbers of lactobacilli (p=O.0674) and enterococci (p=0.0558) although this
increase did not reach significance. Bifidobacteria were significantly increased at
weeks 6 (p=0.0045) and 12 (p=0.0009) compared to week O. The numbers of
coliforms were significantly lower (p=0.0262) at week 12 compared to week 0 while
there was no change in the numbers of Clostridium perfringens and bacteroides
(Figure 1).
In contrast the numbers of lactobacilli, enterococci, coliforms, Clostridium
perfringens and bacteroides in cancer subjects consuming placebo (n=14) were not
altered during the twelve-week intervention period. There was however a significant
reduction in the numbers of bifidobacteria at weeks 6 (p=0.0093) and 12 (p=O.0046)
compared to week 0 (Figure 2).
Similarly synbiotic consumption in polyp subjects (n=19) altered the composition of
the gut flora. The numbers of lactobacilli at week 12 (p=0.0204) and bifidobacteria
at weeks 6 (p=O.0143) and 12 (p<O.OOOI) were significantly increased compared to
week O. Clostridium perfringens were significantly decreased at week 12 (p=O.0303)
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and coliforms at week 6 (p=0.0410) compared to week O. The numbers of
enterococci and bacteroides were unaltered (Figure 3).
The faecal flora of polyp subjects consuming placebo (n=18) was not significantly
altered during the twelve-week intervention period. There was however a trend
towards higher numbers of bacteroides at week 12 compared to week 0 (Figure 4).
Initial bacterial numbers in cancer (sYnbiotic & placebo) subjects and polyp
(synbiotic & placebo) subjects at week 0 were analysed (Table 2). Lactobacilli
(p=O.0401) and enterococci (p=0.0029) levels were significantly lower in cancer
subjects compared to polyp subjects. Bifidobacteria, Clostridium perfringens,
coliforms and bacteroides levels were not significantly different.
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Figure 1
Faecal flora composition of cancer subjects consuming synbiotic (n=19) at the beginning (week 0), mid-way through (week 6) and the
end of intervention (week 12). Bifidobacteria levels at weeks 6 and 12, lactobacilli levels at week 6 and enterococci levels at week 12
were increased while coliforms decreased compared to week O.
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Figure 2
Faecal flora composition of cancer subjects consuming placebo (n=14) at the beginning (week 0), mid-way through (week 6) and the end of
intervention (week 12). Bifidobacteria levels at weeks 6 and 12 were significantly decreased compared to week O.
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FigureJ
Faecal flora composition of polyp subjects consuming synbiotic (n=19) at the beginning (week 0), mid-way through (week 6) and the end of
intervention (week 12). Bifidobacteria levels at weeks 6 and 12 and lactobacilli levels at week 12 were increased while Clostridium perfringens
at week 12 and coliforms at week 6 were decreased compared to week O.
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Figure 4
Faecal flora composition of polyp subjects consuming placebo (n=18) at the beginning (week 0), mid-way through (week 6) and the end of
intervention (week 12). Bacteroides were significantly increased at week 12 compared to week o. Other members of the flora were unaltered.
337
Place bo Po Ivp Subjects
-Week 0
10.0, a:::::J Week 6
Week 12
p=O.059
r:E-rlr:E-
j 7051 rw, ~I I I~
'5
C) 5.0-I II I I II I I II I I IrfrtF
2.5-
0.0 II I , " , , " , , " , , " , , " , , ,
Lactobacilli Bifidobacteria Enterococci CI.perfringens Coliforms
Bacterium
Bacteroides
Table 2
Comparison of faecal flora composition in all cancer subjects compared to all polyp
subjects at the beginning of intervention. Lactobacilli and enterococci were
significantly higher in polyp subjects compared to cancer subjects. Results are
expressed as mean ± standard error. Statistical significance was assessed using an
un-paired t-test.
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Table 2
Biomarker Cancer Subjects Polyp Subjects P value
(units) Week 0 Week 0
Faecal Flora
Lactobaci II i l059± 0.241 1.956± 0.3]2 1.0401(cfu/g wet weight of faeces) (0=30) (0=36)
Bifidobacteria 7.676 ± 0.244 7.243 ± 0.193
(cfu/g wet weight of faeces) (n=32) (n=37) n.s.
Enterococci '.588 ± 0.1" 1.407 ± 0.111
•.oo2t(cfu/g wet weight of faeces) (n=32) (0=40)
Clostridium perfringens 4.561 ± 0.360 4.133 ± 0.337
(cfu/g wet weight of faeces) (n=21 ) (n=37) n.s.
Coliforms 6.024 ± 0.251 6.123 ± 0.176
(cfu/g wet weight of faeces) (n=32) (n= 39) n.s.
Bacteroides 7.232 ± 0.193 7.558 ± 0.200
(cfu/g wet weight of faeces) (n=32) (n=39) n.s.
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Figure 5
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Calprotectin
Faecal calprotectin levels were assessed by ELISA at weeks 0, 6 and 12. There was
no significant change in faecal calprotectin levels in cancer or polyp subjects ,
subjects during the twelve week intervention period (Figure 5).
Initial calprotectin levels in the cancer (synbiotic & placebo) subjects and polyp
(synbiotic & placebo) subjects at week 0 were not significantly different (Table 4).
Results are expressed as mean ± standard error. Statistical significance was assessed
using an un-paired t-test.
Table 4
Calprotectin
(flglg of faeces)
Cancer Subjects
Week 0
48.40 ± 7.76
(n=36)
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Polyp Subjects
Week 0
65.29 ± 12.96
(n=43)
P value
n.s.
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Cytotoxicity
FW was isolated from faecal samples at the beginning (week 0), mid-way (week 6)
and the end of intervention (week 12). The cytotoxic effect of FW in HT-29 cells ,
was assessed using the Alamar Blue cytotoxicity kit. The cytotoxic potential of FW
(% cell death) was unaltered in the cancer synbiotic (n=16) and placebo subjects
(n~12) and in the polyp sYnbiotic (n=16) and placebo (n=18) subjects during the
twelve week intervention period (Figure 6).
The cytotoxicity of FW derived from cancer (sYnbiotic & placebo) and polyp
(sYnbiotic & placebo) subjects at the beginning of intervention (week 0) was
analysed (Table 5). The percentage cell death was significantly higher following
incubation with FW derived from cancer subjects compared to FW derived from
polyp subjects indicating the FW from cancer subjects was more cytotoxic than FW
from polyp subjects. Results are expressed as mean ± standard error. Statistical
significance was assessed using an un-paired t-test.
Table 5
Cytotoxicity
(% cell death)
Cancer Subjects
Week 0
b.78±5.64
(Ja=33)
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Polyp Subjects
Week 0
18.86 ± 3."
(Ja=37)
P value
Short-Chain Fatty Acids (SCFAs)
Faecal SCFAs were detennined using gas chromatography and flame ionisation
detection. In polyp subjects consuming both synbiotic (n=8) and placebo (n=ll)
there was no significant change in the total SCFA levels or in the individual levels of
acetic, propionic, isobutyric, butyric, isovaleric, valeric or hexonic acids during the
twelve week period (Tables 6(a) &(b)).
SCFA levels were also unaltered in cancer subjects during the twelve-week period,
however the numbers of subjects in this analysis were small (synbiotic n=3, placebo
n=2) due to small sample size (Tables 6(c) & (d)).
Initial SCFA concentration in the cancer (synbiotic & placebo) subjects and polyp
(synbiotic & placebo) subjects at week °were analysed (Table 7). The concentration
of proprionic (p=O.0358), isobutyric (p=O.0113) and isovaleric (p=O.0161) acids in
faeces was significantly higher in cancer subjects compared to polyp subjects. In
polyp subjects the concentration of acetic acid and total acids tended to be lower and
hexonic acid tended to be higher compared to cancer subjects but the difference did
not reach significance. However the statistical power of this analysis was limited due
to the small number of subjects in the cancer group (n=5 cancer, n=19 polyp).
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Table 6 (a)
Short chain fatty acid (SCFA) concentrations in faeces from synbiotic polyp subjects
at the beginning (week 0), mid-way through (week 6) and the end of intervention
(week 12). There was no effect of synbiotic consumption on SCFA concentrations.
Results are expressed as mean ± standard error.
Table 6 (b)
Short chain fatty acid (SCFA) concentrations in faeces from placebo polyp subjects
at the beginning (week 0), mid-way through (week 6) and the end of intervention
(week 12). SCFA concentrations were unaltered during the twelve-week intervention
period. Results are expressed as mean ± standard error.
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Table 6(a): SCFA
Syobiotic Polyp Subjects (0=8)
SCFA(mglg) Week 0 Week 6 Week 12 Pvalue
Acetic Acid 347.0 ± 70.52 374.0 ± 78.00 342.1 ± 75.32 D.S.
Propionic Acid 109.9 ± 23.54 137.5±37.31 108.6 ± 23.23 D.S.
Isobutyric Acid 16.81 ± 2.37 19.91 ± 3.82 14.10 ± 2.40 D.S.
Butyric Acid 195.3 ± 65.73 192.3 ± 61.78 190.9 ± 59.40 D.S.
Isovaleric Acid 26.75 ± 3.56 31.75 ± 6.69 23.98 ± 4.06 D.S.
Valerie Acid 22.69 ± 4.85 18.95 ± 6.46 19.50±6.14 D.S.
Hexonic Acid 3.62 ± 1.66 3.81 ± 1.86 6.40 ± 4.38 D.S.
Total Acids 722.0 ± 158.6 778.2 ± 181.2 705.6 ± 161.4 D.S.
Table 6(b): SCFA
Placebo Polyp Subjects (0=11)
SCFA (mg I g) Week 0 Week 6 Week 12 P value
Acetic Acid 380.5 ± 55.87 396.1 ± 41.92 367.7 ± 48.36 D.S.
Propionic Acid 132.5 ± 22.47 136.9 ± 17.92 134.6 ± 19.89 D.S.
Isobutyric Acid 14.04 ± 0.99 16.22 ± 1.09 16.82 ± 2.00 D.S.
Butyric Acid 171.1 ± 45.70 167.4 ± 35.62 171.8 ± 33.13 D.S.
Isovaleric Acid 22.55 ± 1.85 25.64 ± 2.15 27.91 ± 3.48 D.S.
Valerie Acid 30.00 ± 4.48 31.36 ± 4.38 30.23 ± 5.12 D.S.
Hexonic Acid 6.46 ± 3.16 11.41 ± 8.02 5.55 ± 3.67 D.S.
Total Acids 757.0 ± 122.7 785.0 ± 95.48 754.7 ± 104.1 D.S.
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Table 6 (c)
Short chain fatty acid (SCFA) concentrations in faeces from synbiotic cancer
subjects at the beginning (week 0), mid-way through (week 6) and the end of
intervention (week 12). There was no effect of sYnbiotic consumption on SCFA
concentrations. Results are expressed as mean ± standard error.
Table 6 (d)
Short chain fatty acid (SCFA) concentrations in faeces from placebo cancer subjects
at the beginning (week 0), mid-way through (week 6) and the end of intervention
(week 12). SCFA concentrations were unaltered during the twelve-week intervention
period. Results are expressed as mean ± standard error.
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Table 6 (c): SCFA
Synbiotic Cancer Subjects (n=3)
SCFA(mg/g) Week 0 Week 6 Week 12 P value
Acetic Acid 466.0 ± 74.10 323.7± 131.1 316.0 ± 92.65 D.S.
Propionic Acid 181.0 ± 79.00 109.3 ± 36.92 120.0 ± 44.31 D.S.
Isobutyric Acid 20.07 ± 5.80 12.10 ± 2.90 11.00 ± 2.89 D.S.
Butyric Acid 126.0 ± 71.53 127.6± 103.1 115.7 ± 86.8 D.S.
Isovaleric Acid 34.33 ± 11.41 18.90 ± 5.23 17.47 ± 6.00 D.S.
Valerie Acid 17.90 ± 7.90 11.90 ± 8.13 11.17 ± 7.54 D.S.
Hexonic Acid 1.230 ± 0.573 0.407 ± 0.139 0.548 ± 0.217 D.S.
Total Acids 846.5 ± 156.4 603.9 ± 274.6 591.8 ± 205.7 D.S.
Table 6 (d): SCFA
Placebo Cancer Subjects (n=2)
SCFA(mg/g) Week 0 Week 6 Week 12 P value
Acetic Acid 577.5 ± 30.5 554.0 ± 123.0 507.0 ± 132.0 D.S.
Propionic Acid 260.5 ± 57.5 267.0 ± 82.0 246.0 ± 102.0 D.S.
Isobutyric Acid 28.00 ± 0.09 24.50 ± 9.50 28.50 ± 16.50 D.S.
Butyric Acid 240.5 ± 44.5 215.5 ± 9.5 193.5 ± 44.5 D.S.
Isovaleric Acid 40.50 ± 1.50 41.50± 12.50 48.00 ± 27.00 D.S.
Valerie Acid 58.50 ± 1.50 62.50 ± 5.50 43.00± 4.00 D.S.
Hexonic Acid 0.925 ± 0.575 1.060 ± 0.740 1.050 ± 0.050 D.S.
Total Acids 1206 ± 128 1166 ± 222 1067 ± 326 D.S.
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Table 7
SCFA concentration in the cancer (synbiotic & placebo) subjects and polyp
(synbiotic & placebo) subjects at the beginning of intervention (week 0). Proprionic,
isobutyric and isovaleric acids in faeces were significantly higher in cancer subjects
compared to polyp subjects. Results are expressed as mean ± standard error.
Statistical significance was assessed using an un-paired t-test.
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Table 7
Short Chain Fatty Acids Cancer Subjects Polyp Subjects Pvalue
(units) Week 0 Week 0
Acetic Acid 510.6 ± 49.9 366.4 ± 42.8
(mg/g of faeces) (n=5) (n=19) n.s.
Propionic Acid 112.8=*:50" l22.9 =*: 16.1
'.03!t(mg/g of faeces) (n=5) (n=19)
Isobutyric Acid 13.24 ± 3.71 .5.21 =*: 1.1'
"old(mg/g of faeces) (0=5) (0=19)
Butyric Acid 171.8 ± 50.2 181.3 ± 37.2
(mg/g of faeces) (n=5) (n=19) n.s.
Isovaleric Acid 16.80=*:6.'- *'-.32 =*: I..
"0161(mg/g of faeces) (0=5) (0=19)
Valerie Acid 34.14 ± 10.86 26.92 ± 3.32
(mg/g of faeces) (n=5) (n=19) n.s.
Hexonic Acid 1.108 ± 0.370 5.265 ± 1.943
(mg/g of faeces) (n=5) (n=19) n.s.
Total Acids 990.5 ± 129.5 742.3 ± 94.8
(mg/g of faeces) (n=5) (n=19) n.s.
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Cholesterol
There was no effect ofsynbiotic intervention on serum levels of total, HDL and LDL
cholesterol and triglycerides. Total cholesterol levels were slightly, but not
significantly above the normal level of <5.5 mmol/L in all subjects (Table 8(a)).
HDL (Table 8(b)) and LDL (Table 8(c)) cholesterol levels were within the
recommended normal range of <1.5mmollL and <4.0mmollL respectively for all
subjects. Triglyceride levels were slightly elevated above the recommended normal
level of<I.7mmol/L (Table 8(d)).
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Table 8(a)
Total cholesterol in synbiotic and placebo cancer and polyp subjects at the beginning
(week 0), mid-way through (week 6) and the end of intervention (week 12). Total
cholesterol levels were unaltered during the twelve-week intervention period.
Normal levels are <5.5 mmoVL. Results are expressed as mean ± standard error.
Table 8(b)
HDL cholesterol in synbiotic and placebo cancer and polyp subjects at the beginning
(week 0), mid-way through (week 6) and the end of intervention (week 12). HDL
cholesterol levels were unaltered during the twelve-week intervention period.
Normal levels are >1.5 mmoVL. Results are expressed as mean ± standard error.
Table 8(c)
LDL cholesterol in synbiotic and placebo cancer and polyp subjects at the beginning
(week 0), mid-way through (week 6) and the end of intervention (week 12). LDL
cholesterol levels were unaltered during the twelve-week intervention period.
Normal levels are <4.0 mmoVL. Results are expressed as mean ± standard error.
Table 8(d)
Triglyceride levels in synbiotic and placebo cancer and polyp subjects at the
beginning (week 0), mid-way through (week 6) and the end of intervention (week
12). Triglyceride levels were unaltered during the twelve-week intervention period.
Normal levels are <1.7 mmoVL. Results are expressed as mean ± standard error.
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Table 8(a): Total cholesterol (mmol/L)
Total Cholesterol Week 0 Week 6 Week 12 P value
Synbiotic Cancer (n=14) 5.750 ± 0.378 5.829 ± 0.234 5.736 ± 0.245 D.S.
Placebo Cancer (n=12) 6.008 ± 0.405 5.817 ± 0.410 5.733 ± 0.340 D.S.
Synbiotic Polyp (n=18) 5.828 ± 0.201 5.900 ± 0.187 5.694 ± 0.171 D.S.
Placebo Polyp (n=21) 5.614 ± 0.247 5.729 ± 0.220 5.757 ± 0.211 D.S.
HDL Cholesterol
Table 8(b): HDL cholesterol (mmol/L)
Week 0 Week 6 Week 12 P value
Synbiotic Cancer (n=14) 1.279 ± 0.101 1.314 ± 0.103
Placebo Cancer (n=12) 1.458 ± 0.120 1.400 ± 0.097
Synbiotic Polyp (n=18) 1.350 ± 0.068 1.333 ± 0.076
Placebo Polyp (n=20) 1.315 ± 0.070 1.355 ± 0.068
1.321 ± 0.098
1.408 ± 0.104
1.356 ± 0.066
1.360 ± 0.069
D.S.
D.S.
D.S.
D.S.
Table 8(c): LDL cholesterol (mmol/L)
LDL Cholesterol Week 0 Week 6 Week 12 P value
Synbiotic Cancer (n=13) 3.462 ± 0.39 3.523 ± 0.213 3.377 ± 0.273 D.S.
Placebo Cancer (n=9) 3.467 ± 0.480 3.511 ± 1.336 3.367 ± 0.340 D.S.
Synbiotic Polyp (n=17) 3.600 ± 0.177 3.665 ± 0.184 3.559 ± 0.1 52 D.S.
Placebo Polyp (n=19) 3.489 ± 0.201 3.384 ± 0.217 3.474 ± 0.221 D.S.
Table 8(d): Triglycerides (mmol/L)
Triglycerides Week 0 Week 6 Week 12 Pvalue
Synbiotic Cancer (n=14) 2.149 ± 0.354 2.244 ± 0.320 2.211 ± 0.277 D.S.
Placebo Cancer (n=12) 2.752 ± 0.458 2.372 ± 0.338 2.707 ± 0.485 D.S.
Synbiotic Polyp (n=17) 1.832 ± 0.253 1.954 ± 0.272 1.743 ± 0.236 D.S.
Placebo Polyp (n=20) 1.872 ± 0.265 2.376 ± 0.287 2.298 ± 0.50 I D.S.
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Discussion
The human gastrointestinal tract contains more than 500 different bacterial species,
the greatest concentration being found in the colon. Imbalance in the gastrointestinal
flora has been associated with increased risk of colon cancer (Gorbach & Goldin
1990). Many studies have shown that pre-, pro- and synbiotic consumption can
modulate the gut flora, in general increasing the levels of beneficial bacteria such as
bifidobacteria and lactobacilli and decreasing the levels of detrimental bacteria such
as C. perfringens and coIiforms. A protective role of pre-, pro-, and sYnbiotics
against colon carcinogenesis has been demonstrated in animal studies (Femia et al.
2002; Gallaher & Khil 1999; Goldin et al. 1996) however studies in humans are
limited.
In the current study we report that a synbiotic combination of Lactobacillus
rhamnosus GG, Bifidobacterium /actis Bb12 and SYnergyCl modulated the flora of
cancer and polyp subjects. Lactobacilli and bifidobacteria in cancer and polyp
subjects and enterococci in cancer subjects were increased by synbiotic consumption
with concomitant decreases in coliforms in cancer subjects and C. perfringens in
polyp subjects. In the placebo group of cancer subjects there was a reduction in
bifidobacteria the cause of which is unknown. These results correlate with other
studies reporting increases in lactobacilli and bifidobacteria (Kruse et a/. 1999;
Tuohy et al. 2001) and decreases in clostridia and coIiforms (Spanhaak et al. 1998),
following probiotic consumption. We also compared the initial levels of faecal
bacteria in cancer and polyp subjects and found that polyp subjects have
significantly higher levels of lactobacilli and enterococci than cancer subjects.
355
Elevated levels of faecal calprotectin have been found in patients with colonic
polyps and colon cancer (Kristinsson et aJ. 1998; Roseth et aJ. 1993; TibbIe et aJ.
2001) and active inflammatory bowel disease (Roseth et aJ. 1993; TibbIe et al.
2000). In this study there was no influence of sYnbiotic consumption on faecal
calprotectin levels. This lack of effect may be due to the fact that calprotectin levels
in our study group were not significantly elevated compared to the normal level of
<60 J.lglg. Calprotectin levels at the beginning of intervention were 48.40 ± 7.76 Jlg/g
for all cancer (sYnbiotic and placebo) and 65.29 ± 12.96 Jlg/g for all polyp (sYnbiotic
and placebo) and were not elevated compared to normal levels. This indicates that in
this study subjects did not have active intestinal inflammation and therefore
calprotectin levels were not elevated.
Studies have shown that subjects at high risk of colon cancer have a high mucosal
proliferative activity as compared to controls. This increase in proliferative activity
is to replace cells killed either by apoptosis or by cytotoxic damage. In vitro· faecal
water cytotoxicity towards colon cells is often employed as a biomarker in
intervention studies. Studies have shown that dietary interventions such as
consumption of prebiotics or shifting from dairy product rich to a dairy product free
diet influences FW cytotoxicity (Glinghammar et aJ. 1997; van Muster et aJ. 1994).
However in this study there was no significant effect of sYnbiotic intervention on the
cytotoxic potential of FW derived from cancer or polyp subjects. Interestingly FW
derived from cancer subjects was more cytotoxic than FW derived from polyp
subjects suggesting that the colonic mucosa of cancer subjects is exposed to a higher
level of cytotoxicity than the mucosa of polyp subjects which may lead to increased
proliferative activity and increased cancer risk.
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Short chain fatty acids (SCFAs) are produced from carbohydrate fermentation by
colonic bacteria and are a major source of energy for liver cells, colonocytes and
peripheral tissues. Low faecal SCFA concentrations have been associated with
increased cancer risk (Segal et aI. 1995). We have previously shown that
consumption of the syobiotic combination employed in this study increase caecal
butyrate in azoxymethane treated rats (Femia et al. 2002). In this study however
syobiotic consumption did not influence the faecal levels of acetic, propionic,
isobutyric, butyric, isovaleric, valeric, hexonic or total short chain fatty acids.
The concentration of propionic, isobutyric and isovaleric acids were significantly
higher in cancer subjects compared to polyp subjects at the beginning of
intervention. However the number of cancer subjects for which data is available is
small and a larger study group would be required to confirm this result. Also >95%
of SCFA are produced and absorbed in the colon and the use of faecal measurements
may not be a true indication of SCFAs produced in the colon (Dunne 2001; Topping
& Clifton 2001). Measurement of SCFAs in colonic contents sampled at endoscopy
would provide a truer representation of the colonic SCFA profile.
One beneficial effect that has been suggested to result from human consumption of
pre- and probiotics is a reduction in serum cholesterol levels, as suggested by the
results of several human and animal studies. However results from human studies are
not always consistent (Taylor & Williams 1998). In this study there was no effect of
syobiotic intervention on serum levels of total, HDL and LDL cholesterol and
triglycerides and although cholesterol levels were not optimal in our study group
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levels were not significantly outside the normal range to warrant medical
intervention.
In conclusion consumption of a synbiotic combination of Lactobacillus rhamnosus
GG, Bifidobacterium lactis Bb12 and SynergyCl modulated the flora of cancer and
polyp subjects increasing the numbers of beneficial bacteria such as lactobacilli and
bifidobacteria and reducing putrefactive bacteria such as coliforms and CI
perfringens. This change in the composition of the gut flora did not alter the
expression of faecal calprotectin, the concentration of faecal SCFAs, the cytotoxic
potential of FW or serum cholesterol levels suggesting that these parameters may not
be suitable biomarkers in an intervention trial of this type. However comparison of
cancer vs. polyp subjects at the beginning of intervention showed that the number of
lactobacilli and enterococci, were lower and the cytotoxic potential of FW and the
concentration of propionic, isobutyric and isovaleric acids are significantly higher in
cancer subjects than in polyp subjects. Further investigation of these parameters may
help identify subjects at risk ofcancer.
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Chapter 7
Gene expression profiles of the colonic mucosa
in normal, cancer and polyp subjects and the
influence of synbiotic consumption on gene
•expression
Abstract
The progression from normal epithelium to adenoma, invasive carcinoma and
metastasis is a multi-step process involving several genetic changes. Genes
implicated in this process include those associated with proliferation, apoptosis and
DNA repair. Studies of gene expression profiles of normal, adenoma and tumour
tissues have identified genes which are differentially expressed in diseased states
compared to normal. The aim of this study was to determine the gene expression
profile in rectal biopsies from normal, cancer and polyp subjects and to identify
genes which are highly expressed in the colonic mucosa. We also investigated the
subsequent effect of synbiotic consumption on gene expression in cancer and polyp
subjects. Using cDNA array analysis of 588 cancer associated genes we have
identified 14 genes which are highly expressed in the colonic mucosa of normal,
cancer and polyp subjects as well as genes which are highly expressed in subsets of
subjects. We have also identified 30 genes, which are expressed at significantly
different levels in cancer, polyp and normal subjects. Synbiotic consumption
modulated the expression of genes associated with differentiation and tight junction
integrity such as TEK, MT3, PDGFRA and protocadherin 1 and may indicate
potential mechanisms by which synbiotics reduce cancer risk by modulating
intestinal barrier integrity and cytoprotective gene expression. Further analysis of
expression profiles of these genes in a larger number of subjects over a number of
time-points are needed to confirm the highly and differentially expressed genes
identified in this study as well as the influence of synbiotic consumption on gene
expression and will determine if analysis of these genes are useful as markers of
cancer risk or as intervention markers.
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Introduction
The adenoma-carcinoma sequence, initially postulated by Fearon and Vogelstein
accounts for approximately 90% of cases of colorectal cancers (Vogelstein et al.
1988). This sequence refers to the multi-step progression from normal epithelium to
hyperprolferative epithelium, to focally dysplastic crypts, to tubular adenoma, to
dysplastic or villous adenoma and finally onto invasive carcinoma and metastasis.
Several gene changes have been identified to be present at different stages of this
cascade. Two major molecular patterns of change exist, namely chromosomal
instability (85%) and microsatellite instability (15%) (Kinzler & Vogelstein 1998;
Lengauer & Issa 1998; Lindblom 2001). Changes that occur due to chromosomal
instability include alteration in chromosome number (aneuploidy) and detectable loss
of portions of chromosomes 5q, 18q, 17p, and mutations in the k-ras oncogene. Loss
of 5q involves the APe gene, which is an example of one of the earliest changes in
tumour evolution. Microsatellite instability cancers are tumours with a mostly intact
chromosome complement, but due to defects in DNA repair mechanisms, important
cancer-associated genes remain unchecked. In 1990 Fearon and Vogelstein
published 'A Genetic Model for Colorectal Carcinogenesis', describing some of the
molecular events in the carcinogenic process and suggesting the possible sequence in
which these events occur (Figure 1).
The knowledge gained from the study of cancer genetics has lead to the
identification of markers that can aid early diagnosis and that are relatively specific
to malignant and premalignant disease. These changes can be detected in colorectal
biopsies but also non-invasively, by detection in the stools, as cells containing these
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abnormal DNA sequences are shed into the gastrointestinal lumen by exfoliation
(Duffy 1995).
These genetic changes can be detected using several different traditional techniques,
such as subtractive hybridization and PCR for individual genes, but these methods
are often time-consuming and limited in the number of genes which can be
investigated at anyone time. With the advent of microarray technology, the
investigation of the expression of thousands of genes can be performed within a
single patient sample.
Various studies have reported the expression profiles of colorectal normal tissue,
adenomas and adenocarcinoma. Notterman et ale (2001) used an oligonucleotide
array (GeneChip, Affymetrix) and found that only 1.8% of 4000 genes were
differentially expressed in the tumours compared to matched normal tissue. This low
level of difference may be due to the close relationship of the tissues studied. They
were also able to successfully distinguish adenoma from adenocarcinoma and
normal tissue by means of a hierarchical clustering algorithm. Kitahara et ale (2001)
studied the different patterns of expression of 9216 genes in normal and neoplastic
colorectal tissue. Overall both of these studies identified one to two hundred genes
involved in tumour progression, but only three of these genes were held in common.
These genes, pyroline 5-carboxylate reductase, BENE and carbonic anhydrase II,
were differentially expressed in adenocarcinoma and normal tissue in both studies.
There were however many differences in materials and methodology in these
studies, which highlights the importance of study design and interpretation of data
sets.
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A study conducted using gene array analysis of left-sided colorectal tumours showed
that most genetic changes occur at an early stage of cancer development and far
fewer genes change their expression at the stage of spread to lYmPh nodes or distant
metastasis (Birkenkamp-Demtroder et a/. 2002).
Using laser mediated microdissecton and RNA amplification, another group studied
gene changes in areas of low grade dysplasia within colonic adenomas and found up-
regulation of proliferation associated genes such as ras-oncogene related p21-rae1
and PAPK p38a and also found down-regulation in apoptosis related genes; FAST
kinase and p53 which reveals an extra insight into the early steps towards colorectal
cancer (Lechner et a/. 2003). Bertucci et a/. (2004) classified tumours by identifying
sets of genes that discriminated between normal and tumour tissues, tumours
associated or not with lYmph node invasion or genetic instability, and tumours from
the right or left colon. This group also identified a gene set that divided patients by
prognosis; with significantly different 5-year survival (l00% in one group and 40%
in the other group; p=O.005). Protein expression was also studied which confirmed
the up-regulation of the protein NM23 in colorectal cancer and a down-regulation in
poor prognosis tumours.
In terms of pharmacogenetic studies, two publications in Nature Genetics observed
differential expression of genes among the 60 cell lines used in the National Cancer
Institute's screen for anticancer drugs (Ross et a/. 2000; Scherfet a/. 2000). However
the clinical relevance of these genes needs to be confirmed in large groups of
patients.
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Gene array analysis has lead to the unfolding of several new aspects in the field of
cancer research including diagnosis, patient stratification and therapy. All factors of
the genetic pathway in colorectal cancer are potential targets for therapy. However it
is important to remember that microarray data should not to be thought of as an
endpoint but as a hypothesis-driven tool to further advance our understanding of the
cancer process and to enable the discovery of new therapies and new biomarkers.
Studies have shown that probiotics can modulate gene expression. Sheil (2003)
reported that co incubation of human peripheral blood mononuclear cells (PBMCs)
with different probiotic strains led to profound changes in cytokine gene expression.
Although a proportion of genes were consistently altered following exposure to
Lactobacilli and Bifidobacteria, in general changes in gene expression were strain
specific.
The aims of this study were:
1) To investigate the influence of twelve-week consumption of this synbiotic
combination of Lactobacillus rhamnosus GG, Bifidobacterium lactis Bb12 and
SYnergycl on the expression of588 cancer associated genes.
2) To generate gene expression profiles for the colonic mucosa of normal, polyp
and cancer subjects, and identify genes highly expressed in the colonic mucosa.
3) To identify genes useful as biomarkers of cancer risk or as markers for
intervention studies.
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Methods
Work described in this chapter was performed in collaboration with Dr Mary
Bennett and Dr John MacSharry of the Department of Medicine, University College
Cork, Cork.
cDNA gene expression was performed on colorectal biopsies from normal, cancer
and polyp subjects (Figure 2).
Total RNA Extraction
2 rectal biopsies from cancer and polyps subjects were obtained by sigmoidoscopy at
the beginning (week 0) and the end of intervention (week 12), placed in a collection
tube containing 'RNA later' (Ambion) and transported on ice to the laboratory.
Biopsies were also obtained from normal subjects at one time-point. Biopsies were
stabilised overnight in 'RNA later' at 4°C and subsequently transferred to -80°C.
Total RNA was extracted using a commercially available kit, (Stratagene,
Absolutely RNA, 400800) as per manufacturers instructions. Briefly biopsies were
disrupted in lysis buffer using a homogeniser (Powergen 125, Fisher Scientific) and
the lysate was applied to an RNA binding spin column. Following washing, RNAse
free DNAse was applied to the column to remove contaminating DNA and incubated
at 3rc for 15mins. Additional washes removed the DNase and impurities, and total
RNA was eluted in a low ionic strength buffer and stored at -80°C.
RNA was quantified by spectrophotometry and RNA integrity was examined by
running RNA in an ethidium bromide stained 2% agarose gel in TBE. Absence of
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contaminating DNA was confinned by perfonning a Polymerase Chain Reaction
(PCR) for G3PDH. If this reaction yields a product contaminating DNA is present.
Gene Expression Analysis
Gene expression in biopsies was investigated using an Atlas1M human cancer cDNA
expression array (BD Biosciences, Clontech) which contains 588 double spotted
cDNAs.
• 33p eDNA synthesis
Radio-labelled cDNA was synthesized from total RNA by RT-PCR using [a_33p]
dATP (Amersham). Briefly 2.5J1g of total RNA in 2fll DEPC (Diethyl
pyrocarbonate) treated H20 was incubated with Ifll of CDS primer mix (Clontech)
at 70°C for two minutes followed by 2 minutes at 48°C. Following incubation the
reverse transcription reagents (Table 1) were added to the RNA/CDS primer mix
which was then incubated at 48°C for an hour to allow the cDNA synthesis reaction
to occur. This reaction was tenninated by the addition of Ifll lOX tennination buffer
(0.1 M EDTA [pH8.0], Img/ml glycogen).
Table 1: Volume ofreverse transcription reagents added to RNA/CDS primer mix
Re\'ersc Transcription Rca~cnts Stock Solution Volume
5X Reaction Buffer (Clonteeh) 250mM Iris-Hel lpH8.3 j, 2J.ll
375mM KCL, 15mM MgCb
lOX dNTP Mix (Clontech) 5mM each dCTP, dGTP, dTTP 1J,ll
ra 33Pl dATP (Amersham Life Science) (>2,5000 Ci/mmol, 10)1Ci/J.l1) 3.5)11
DTT (Clontech) 100mM 0.5J,l1
MMLV reverse transcriptase (Clontech) 100 U/J,ll hll
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• Column Chromatography
The 33P-Iabeled cDNA probe was purified from unincorporated 33P-Iabeled
nucleotide by column chromatography using the NucleoSpin Extraction Kit
supplied, which involves a number of wash steps and the purified 33P-Iabeled cDNA
probe was collected. 33p incorporation was determined by scintillation count. Counts
within the range of2-10 x 106 cpm indicate successful incorporation.
• Hybridisation
0.5mg of sheared salmon testes DNA (Sigma) was denatured at 95-1 OO°C for 5 mins
and the chilled immediately on ice. The Atlas nylon membranes were then
prehybridised with 5ml warm ExpressHyb and the salmon testes DNA for 30 mins at
68°C in roller bottles rotating at 5-7rpm. The purified 33P-Iabeled cDNA was mixed
with I I III of lOX denaturing solution (I M NaOH, 10mM EDTA) and incubated at
68°C for 20 mins. Following this 5111 of Cot-I DNA and I I5III of 2X neutralising
solution (l M NaH2P04 [pH7]) were added and a final 10 minute incubation at 68°C
performed. The denatured probe was then added to the prehybridisation solution in
the roller bottles and hydridisation was performed overnight at 68°C. The next day
the membranes were washed 4 times (30 mins each) with prewarmed wash solution
1 (2X SSC, 1% SDS), 68°C followed by 1 wash (30 mins) with wash solution 2
(O.lX SSC, 0.5% SDS) at 68°C rotating at 12-15 rpm and a final 5 min wash with
200ml of 2X SSC. The membranes were then wrapped in cling film and
exposed to a phosphorimaging screen (Molecular Dymnamics) for 5 days. Phosphor
screens were scanned using a Storm 860 scanner (Molecular Dynamics, Amersham
Biosciences). The screens were then scanned at 50J.U11 pixel size using a storm
phosphorimager (Molecular Dynamics, Amersham Biosciences).
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• Array Analysis
Array images were analysed using Phoretixl'M Array Software (Nonlinear dynamics).
The background was subtracted and the intensity was normalised to negative control
spots and to the housekeepil]g gene p-actin and expression was expressed as a
percentage of p-actin expression. The normalised data was imported to Microsoft
Excel (Microsoft Corporation) and genes which were expressed at greater than 40%
of p-actin in 8 cancer and 6 polyp subjects at the beginning (week 0) and end (week
12) of intervention and in the 6 normal subjects were considered to be highly
expressed in the colonic mucosa.
To identify genes differentially expressed in cancer, polyp and normal subjects the
ratios of difference of each gene for cancer versus normal, polyp versus normal and
cancer versus polyp subjects was determined and significantly different genes were
identified by unpaired t- test. For this analysis one cancer subject was excluded
(Syo-39) as the level of gene expression in this subject was much higher than other
cancer subjects and was considered an outlier (Appendix I).
In cancer and polyp subjects consuming syobiotic and placebo the ratios of
difference in gene expression at the beginning compared to the end of intervention
was also calculated.
Finally genes were classified and grouped according to function which was
determined using Genecards (http://bioinformatics.weizmann.ac.iVcards), Entrez
Gene (www.ncbLnlm.nih.gov/entrezlquery.fcgi?db=gene), and the PubMed database
(www.ncbi.nlm.nih.gov/entrezlquery.fcgi?db=PubMed).
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Results
eDNA array analysis of 588 cancer associated genes was performed on biopsies
from cancer, polyp and normal subjects.
Constitutive Genes
Genes expressed at a level above 40% of beta actin expression in all subjects at all
times were considered to be highly expressed. 14 genes were identified as highly
expressed in the colonic mucosa of all subjects (6 polyp and 8 cancer subjects at
weeks 0 and 12 and 6 normal subjects) (Table 2).
Table 2
Gene Symbol Gene Name
Differentiation
Cell cycle
CDK6 cyclin-dependent kinase 6
NME2 protein expressed in non-metastatic cells 2 (NM23B)
UBC ubiquitin C
RPL13A ribosomal protein L13a
RPS9 ribosomal protein S9
apoptosis
GAPD ~lyceraldehyde-3-phosphatedehydrogenase
Cell Cell Interaction
RHOA ras homolog gene family, member A
ARHGDIB Rho GOP dissociation inhibitor (GOI) alpha
CD9 C09 antigen (p24)
CDH5 cadherin 5, type 2, VE-cadherin (vascular epithelium)
CD59 CD59 antigen p18-20
Cell Structure
KRT19 keratin 19
VIM vimentin
ACTB actin, beta
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Further analysis revealed some genes although not highly expressed in all subjects
were highly expressed in subsets of subjects (Table J). Interestingly there were no
highly expressed genes unique to cancer subjects.
TableJ
Gene Symbol Gene Name
Highly Expressed in Cancer & Polyp Subjects
HLA-C major histocompatibility complex, class I, C
KRT8 keratin 8
Highly Expressed in Cancer & Normal Subjects
JUP junction plakoglobin
K-Alpha-l tubulin, alpha, ubiquitous
Highly Expressed in Normal Subjects
GRB2 growth factor receptor-bound protein 2
LITAF LPS-induced TNF-alpha factor
FNI fibronectin 1
Highly Expressed in Polyp Subjects
RHOC ras homolog gene family, member C
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pm
n.s. • non significant
Differentially Expressed Genes
Ratios of difference of gene expression for all 588 genes in cancer versus nonnal,
polyp versus nonnal and cancer versus polyp subjects were calculated. For this
analysis one cancer subjects was excluded (Syn-39) as an outlier because the level of
gene expression in this subject was much higher than other cancer subjects
(Appendix I). Genes with a ratio of difference of 1.4 or above were identified
(Appendix II) and statistical analysis (unpaired t-test) revealed 30 genes, which are
expressed at significantly different levels in cancer, polyp and nonnal subjects
(Table 4).
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U46461
64595
U07707
L06139
L20688
X78817
X03663
DVL111
RAC2
EPS15
TEK
ARHGDIB
ARHGAP4
Increased expression
Decreased expression
No chan
'hie 5: Genes in which expression was changed at the end of intervention (Wk 12) compared to the beginning of intervention eWk. 0) in two or more subjects
1\1\ u.enesare nonnaliscd to the housekeeping gene ~actin and expressed as % of f>-actin. For a full list of gene names see
Influence of Synbiotic Intervention on Gene Expression
cDNA array analysis was perfonned on biopsies from cancer (synbiotic n=4, placebo
n=4) and polyp (sYnbiotic n=3, placebo n=3) subjects at the beginning and after
twelve weeks intervention. For each subject the ratios of expression at the beginning
of intervention (week 0) compared to the end of intervention (week 12) were
calculated. Genes with ratios of difference of 1.5 or greater were considered
significantly different. Table 5 shows 40 genes in which major changes in expression
occurred in two or more subjects at the end of the twelve-week intervention period
compared to the beginning.
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Discussion
The aetiology of colorectal cancer is heterogeneous, with environment or genetics
playing varying key roles in different patients (Potter 1999). The influence of genetic
factors is well documented and there are several rare genetic syndromes (HNPCC,
FAP) that carry a markedly increased risk for CRC. However about 80% of
colorectal cancer cases are sporadic with no evidence of a heritable component.
Although the genetic process of sporadic cancer is not understood, genes described
in the Fearon and Vogelstein cascade (APe, genes on 18q, ras, and p53), have been
confirmed as affected in sporadic cancers.
Tumour development and progression involves the accumulation of numerous
genetic alterations and occurs over a long time period. Techniques commonly used
to measure gene expression such as Reverse Transcription PolYmerase Chain
Reaction (RT-PeR) and Northern blot analysis etc are time consuming and often
require large amounts of RNA. These techniques are further limited in the number of
genes which can be investigated at anyone time. However in recent years the advent
of cDNA microarray analysis technology has provided the means by which the
expression of the entire human genome can be determined.
By employing gene array analysis of 588 cancer related genes we have generated an
expression profile for the colorectal mucosa. We have identified 14 genes which are
highly expressed in the coIorectal mucosa of normal, previously re-sected colon
cancer and polypectomised subjects. A number of these genes are involved in the
cell cycle and apoptosis (CDK6, NME2, UBC, RPL13A, RPS9 and GAPD). Genes
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involved in cell-cell interactions were also highly expressed (RHOA, ARHGDIB,
CD9, CDH5 and CD59), as were structural genes (KRT19, VIM and ACTB).
Interestingly, we found two genes (HLA-C and KRT8), which were highly expressed
in cancer and polyp subjects but not in nonnal subjects. The genes JUP and K-
Alpha-l were highly expressed in cancer and nonnal subjects but were not found at
these levels in polyp subjects. We also identified highly expressed genes, which
were unique to nonnal (GRB2, LITAF, FNl) and polyp (RHOC) subjects. There
were no highly expressed genes unique to cancer subjects. Further analysis of these
genes and others in a larger number of subjects over a number of time-points are
needed to confinn the expression of highly genes identified in this study and will
detennine if analysis of these genes are useful as markers ofcancer risk.
Analysis of the expression of 588 genes in cancer, polyp and nonnal subjects
revealed 30 genes, which were significantly differentially expressed in these
subjects. VEGF which is a growth factor involved in angiogenesis was more highly
expressed in both cancer and polyp subjects than in nonnal subjects. Cell cycle
genes such as cyclin G1, MAP2K6 and integrin alpha 3 were more highly expressed
in nonnal subjects than in cancer and polyp subjects. Cyclin G1 is a member of the
cyclin family, which playa role in the cell cycle by regulating the activities of
cyclin-dependent protein kinases (CDKs) and CDK inhibitors. Transcriptional
activation of cyclin G1 can be induced by tumour protein p53, transfonning growth
factor B (TGF-B), BMP-4, p63, and p73. MAP2K6 encodes a protein, which
phosphorylates and activates p38 mitogen-activated protein kinase (p38 MAPK) in
response to inflammatory cytokines or environmental stress. Qi et al. (2004) reported
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that p38 MAPK activation selectively induced cell death in K-ras-mutated human
colon cancer cells. Integrin alpha 3 is a receptor for fibronectin, laminin, collagen,
epiligrin and thrombospondin. Integrin alpha 3 has been shown to be upregulated in
oesophageal adenocarcinoma tissue compared to normal oesophageal tissue
(Hourihan et ale 2003).
In contrast to cell cycle genes, genes involved in apoptosis (caspase 9, MAP3KI4
and BIRC4) were more highly expressed in cancer and polyp subjects than in normal
subjects. Caspase 9 is involved in the activation cascade of caspases responsible for
apoptosis. The caspase 9 protein is processed by caspase APAF1 and this step is
thought to be one of the earliest in the caspase activation cascade. MAP3K14 is
involved in the activation of the transcription factor Nuclear factor of kappaB (NF-
lCB) which plays a role in the regulation of cell proliferation, apoptosis and cell
migration. NF-lCB activation also leads to production of enzymes such as inducible
nitric oxide sYnthase (iNOS) and cyclooxygenase-2 (Cox-2), which enhance the
production of reactive oxygen species, leading to additional DNA damage (Karin et
ale 2002). BIRC4 is known to inhibit apoptosis by binding to tumour necrosis factor
receptor-associated factors TRAFI and TRAF2. BIRC4 also inhibits caspase 9.
MAP3KI4 also plays a role in apoptosis as well as inducing nitric oxide sYnthase
(iNOS) and cyclooxygenase-2 (Cox-2) production through NF-lCB activation, leading
to the production of reactive oxygen species and additional DNA damage.
Interestingly genes, which code for cell signalling and communication proteins
(BMP4, ephrin-B2, interleukin I, alpha, IGFBP4) are more highly expressed in
polyp and in some cases cancer subjects compared to normal subjects. These genes
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are known to be involved in the regulation ofapoptosis and proliferation. BMP4 is a
member of the bone morphogenetic protein family, which is part of the transforming
growth factor-beta superfamily. Nishanian et aI. (2004) reported that BMP4 is
involved in signalling in apoptosis and as a negative regulator of proliferation
through interaction with the Wnt signalling pathway. Ephrin-B2 encodes a member
of the ephrin and EPH-related receptor family, which is the largest subfamily of
receptor protein-tyrosine kinases. Recently, it has been demonstrated that over-
expression of specific Ephs and ephrins is associated with a poor prognosis in human
tumours. EphB and the ephrin-B subfamilies are coexpressed in human colorectal
cancer, and ephrin-B2 is expressed at higher levels in human colorectal cancer than
in adjacent normal mucosa (Liu et aI. 2002). IL-l alpha is involved in the
inflammatory response and induction ofapoptosis. Abdul & Hoosein (2002) reported
that IL-l alpha expression was observed in three of the seven colon cancer cell lines
and was associated with high CEA secretion and aggressive growth behavior.
IFGBP4 is a member of the insulin-like growth factor binding protein (lGFBP)
family, which bind insulin-like growth factors (IGFs) I and II. IGF-II is expressed
commonly in colorectal tumours. IGFBP-4 counteracts the tumour promoting
activities of IGF-II by binding this growth factor (Diehl et aJ. 2005).
Genes coding for proteins classed as intracellular transducers, effectors and
modulators such as PTPRF, PAK2, RHOQ, RHOB and ARHGAPI were also more
highly expressed in polyp subjects than normal subjects and tended to be increased
in cancer subjects compared to normal subjects although this increase did not reach
significance. PTPFR is a member of the protein tyrosine phosphatase (PTP) family,
which are signalling molecules that regulate a variety of cellular processes including
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cell growth, differentiation, mitotic cycle, and oncogenic transfonnation. Recently
PTPRF has been identified as a putative molecular marker for assessing the
metastatic potential of prostate cancer (Trojan et ale 2005). PAK2 is a member of the
p21 activated kinases (PAK) which are critical effectors that link Rho GTPases to
cytoskeleton reorganisation and nuclear signalling. The protein encoded by this gene
is activated by proteolytic cleavage during caspase-mediated apoptosis, and may
playa role in regulating the apoptotic events in the dying cell. Huang et al. (2004)
reported that Pak2 negatively regulates the oncogenic activities of Myc and suggest
that this negative regulation of Myc is due to the tumour suppressive activity of
Pak2. RHOQ and RHOB are plasma membrane bound small GTPases involved in
mitogen-activated protein kinase (MAPK) cascades, cell cycle progression and
transfonnation. RhoB mediates apoptosis in neoplastically transfonned cells after
DNA damage and has been reported to modulate COX-2 transcription and COX-2
mRNA stability (Shao et ale 2000). ARHGAPI is a GTPase activator for the Rho,
Rae and Cdc42 proteins. Another gene in the intracellular transducers, effectors and
modulators group is caveolin 1 which is more highly expressed in cancer subjects
than in nonnal subjects. Caveolin 1 encodes one of the principal proteins of
caveolae, the vesicular invaginations of the plasma membrane. Several reports have
suggested that caveolin-l may have a role in cellular transfonnation and
tumourigenesis and is over-expressed in colon cancers (Fine et ale 2001; Patlolla et
ale 2004). However some investigators have reported that caveolin 1 is down
regulated in human colon cancer (Bender et ale 2000).
Genes coding for matrix metalloproteinases and their inhibitiors (MMP3, A2M and
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TIMP3) were identified as being differentially expressed in cancer and polyp
subjects compared to normal subjects. MMP3 is a member of the matrix
metalloproteinase (MMP) family involved in the breakdown of extracellular matrix
in normal physiological processes, such as embryonic development, reproduction,
and tissue remodelling, as well as in disease processes, such as arthritis and
metastasis. MMP3 encodes an enzyme which degrades fibronectin, laminin,
collagens III, IV, IX, and X, and cartilage proteoglycans. The enzyme is thought to
be involved in wound repair, progression of atherosclerosis, and tumour initiation.
(Roeb et al. 2004) reported that MMP-3, MMP-7 and MMP-13 were more highly
expressed in tumour tissue than in distant normal tissue. A2M is a protease inhibitor
and cytokine transporter, which inhibits proteases such as trypsin, thrombin and
collagenase. This gene has been found to be differentially expressed in normal and
tumour tissue in hepatocellular carcinoma (Kurokawa et al. 2003). TIMP3 is a
member of the tissue inhibitor of metalloproteinase (TIMP), gene family, which are
natural inhibitors of MMPs. TIMP3 is known to act on MMP-l, MMP-2, MMP-3,
MMP-7, MMP-9, MMP-13, MMP-14 and MMP-15.
Villin 2 is more highly expressed in cancer subjects than in normal subjects and is
involved in connecting major cytoskeletal structures to the plasma membrane and
plays a role in cell surface structure adhesion, migration, and organization.
Nishizuka et aI. (2003) suggested that villin 2 may be suitable as a diagnostic marker
for colon cancer.
Genes involved in DNA synthesis, recombination and repair (POLA, MLHl,
PRKOC, CDKN2B and DNASE1L1) were more highly expressed in polyp subjects
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compared to nonnal and cancer subjects. POLA is a key replication enzyme,
primarily responsible for the sYnthesis of DNA. MLH1 was identified as a locus
frequently mutated in hereditary nonPOlYPOsis colon cancer (HNPCC). It is a human
homolog of the E. coli DNA mismatch repair gene mutL, consistent with the
characteristic alterations in microsatellite sequences found in HNPCC. PRKDC
encodes a Serineffhreoine kinase involved in DNA double-strand break repair. The
protein must be bound to DNA to express its catalytic properties. CDKN2B encodes
a cyclin-dependent kinase inhibitor, which fonns a complex with CDK4 or CDK6,
and prevents the activation of the CDK kinases, therefore functioning as a cell
growth regulator that controls cell cycle G1 progression. DNASE1L1 gene encodes a
member of the deoxyribonuclease family and is thought to be a lysosomal type of
endonuclease.
Comparison of gene expression in cancer and polyp subjects at the end of the
twelve-week intervention period revealed a number of genes, which were altered by
sYnbiotic consumption. In cancer subjects, sYnbiotic consumption altered the
expression of genes involved in the cell cycle such as cell division cycle 34, cyclin
02, tumor protein p73 and MT3. CDC34 encodes a gene, which is required for
ubiquitin-mediated degradation of cell cycle G1 regulators, and for the initiation of
DNA replication. Cyclin 02 regulates the activities of CDKs and CDK inhibitors,
fonns a complex with and functions as a regulatory subunit of CDK4 or CDK6,
whose activity is required for cell cycle G1/S transition. Cyclin 02 has also been
shown to interact with and be involved in the phosphorylation of tumour suppressor
protein Rb. Tumour protein p73 is involved in the apoptotic response to DNA
damage and when overproduced, activates transcription from p53-responsive
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promoters and induces apoptosis. It has been suggested that p73 has tumour
suppressor properties however over-expression of p73 causes progression in some
tumour types. MT3 expression deficiency has been implicated in carcinogenesis,
however there is also a possible involvement of MT3 over expression and resistance
of tumours to anti-cancer therapy.
Interestingly in the placebo group of cancer subjects there was an increase in four
cell cycle genes, which were not altered in the sYnbiotic group (COC27, COC2L5,
cyclin DI and RBBP5). COC27 has been shown to interact with mitotic checkpoint
proteins including Mad2, p55COC and BUBRI, and thus may be involved in
controlling the timing of mitosis. COC2L5 is a member of the cyclin-dependent
serine/threonine protein kinase family, which play an essential role as master
switches in cell cycle control however the exact function of COC2L5 has not yet
been determined. Cyclin D1 has a similar function to cyclin D2 as a regulatory
subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/8 transition
and cyclin DI also interacts with the tumour suppressor protein Rb. RBBP5 encodes
a protein which is among several proteins that bind directly to retinoblastoma
protein, a cell proliferation regulator. RBBP5 binds preferentially to
underphosphorylated retinoblastoma protein and has been reported to be coamplified
with MDM4 in malignant gliomas (Riemenschneider et al. 1999).
In the cancer group of sYnbiotic subjects the expression of a number of genes
encoding cell receptors was altered (POOFRA, protocadherin 1 and OPCML). The
POOFRA gene encodes a cell surface tyrosine kinase receptor for members of the
platelet-derived growth factor (POOF) family. POOFRA binds both POOFA and
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PDGFB. The protocadherin 1 encoded protein is a membrane protein found at cell-
cell boundaries and involved in cell adhesion. OPCML is a member of the IgLON
family of immunoglobulin and encodes a plasma membrane protein, which binds
opioids in the presence of acidic lipids and is thought to play a role in cell contact.
The expression of these genes were unaltered in the placebo group of cancer
subjects, however there was an increase in the expression of LAMRI, integrin beta 8
and integrin alpha 6. LAMRI encodes a receptor for the laminin family of
extracellular matrix glycoproteins which are the major noncollagenous constituent of
basement membranes and are involved in cell adhesion, differentiation, migration,
signalling and metastasis. LAMR1 has been reported to be more highly expressed in
colon carcinoma tissue than in normal colon tissue. Integrin beta 8 is a member of
the integrin family of transmembrane proteins and is a receptor for fibronectin.
Integrin alpha 6 combines with integrin beta-I to form a receptor for laminin on
platelets and also combines with integrin beta-4 as a receptor for laminin in epithelial
cells. Increased expression is associated with colon cancer metastasis to the liver.
In cancer subjects synbiotic consumption also altered the expression of TNFSF8,
interleukin 13, MSTI, HGF, TEK, MMPII and VEGF. TNFSF8 encodes a cytokine
that belongs to the TNF ligand family, is a ligand for TNFRSF8/CD30 and induces
proliferation of T cells. Interleukin 13 encodes an immunoregulatory cytokine
produced primarily by activated Th2 cells. IL-13 inhibits inflammatory cytokine
production and synergises with IL-2 in regulating IFN-y synthesis. IL-13 was
upregulated in two of the four symbiotic subjects and down-regulated in the other
two subjects. Interestingly PBMCs derived from cancer symbiotic subjects produced
more IFN-y at the end of intervention compared to the beginning. MSTI is a
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pleiotropic growth factor that signals via the Ron receptor tyrosine kinase. HGF
regulates cell growth, cell motility, and morphogenesis by activating a tyrosine
kinase signaling cascade after binding to the proto-oncogenic c-Met receptor. Its
ability to stimulate mitogenesis, cell motility, and matrix invasion gives it a central
role in angiogenesis, tumorogenesis, and tissue regeneration. TEK encodes a protein
tyrosine-kinase transmembrane receptor for angiopoietin I and possibily regulates
endothelial cell proliferation, differentiation and the proper patterning of endothelial
cells during blood vessel formation. MMPII encodes an enzyme, which is activated
intracellularly by furin within the constitutive secretory pathway in contrast to most
MMP's, which are secreted as inactive pro-proteins, and are activated when cleaved
by extracellular proteinases. Also in contrast to other MMP's, this enzyme cleaves
alpha I-proteinase inhibitor but weakly degrades structural proteins of the
extracellular matrix. VEGF encodes a growth factor, which is active in angiogenesis,
vasculogenesis and endothelial cell growth and induces endothelial cell proliferation,
promotes cell migration, inhibits apoptosis, and induces permeabilisation of blood
vessels.
In contrast to cancer subjects sYnbiotic consumption in polyp subjets altered the
expression of only two genes. TFDPI can stimulate E2F transcription. The E2F
transcription factor family regulates the expression of various cellular promoters,
particularly those involved in the cell cycle and seems to playa role in both
proliferation and apoptosis. FRZB acts as a soluble Wnt-binding protein that
antagonizes Wnt signalling. FRZB has been reported to be expressed in normal
colonic tissue from subjects with colon cancer but not in the tumour tissue. FRZB is
not expressed in the normal colonic mucosa (BYUD et ale 2005).
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Interestingly we have identified a number of genes unique to the placebo polyp
group in which expression levels are changed after 12 weeks. These included genes
involved in cell cycle and apoptosis such as cell division cycle 34, cyclin D2,
caspase 4, MCL1 and BAKI, cell receptors IGFBP2 and desmoglein 2, intracellular
transducers / effectors or modulators such as DVL1LI, RAC2, ARHGDIB,
ARHGAP4, CSFIR and other genes such as FAU, MMP9 and TGF-p induced.
Reduced expression of these genes is interesting in light of the proliferation results
where sYDbiotic consumption reduced the proliferative activity of the the colonic
mucosa in polyp subjects. It may be that these genes are involved in proliferation and
that sYDbiotic consumption prevents this reduction in gene expression therefore
reducing the proliferative activity of the colonic mucosa.
In conclusion by using cDNA array analysis of 588 cancer associated genes we have
identified 14 genes which are highly expressed in the colonic mucosa of normal,
cancer and polyp subjects as well as genes which are highly expressed in subsets of
subjects. We have also identified 30 genes, which are expressed at significantly
different levels in cancer, polyp and normal subjects. Further analysis of these genes
and others in a larger number of subjects over a number of time-points are needed to
confirm the expression of constitutive and differentially expressed genes identified
in this study and will determine if analysis of these genes are useful as markers of
cancer risk.
Analysis of gene expression in cancer and polyp subjects before and after
intervention with either a sYDbiotic or placebo revealed a number of genes, the
expression of which were altered by sYDbiotic consumption. Changes in genes
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associated with differentiation and tight junction integrity such as TEK, MT3,
PDGFRA and protocadherin I in subjects who consumed synbiotic may indicate
potential mechanisms by which synbiotics reduce cancer risk by modulating
intestinal barrier integrity and cytoprotective gene expression. The reduced
expression 15 genes in the placebo polyp group and the possible association with
proliferation warrants further investigation.
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Chapter 8
Conclusion
Conclusion
Colorectal cancer is the fourth most common cause of death from cancer in the
world and the second most common (behind lung cancer) in developed countries.
The lifetime colorectal cancer risk in the general population is 5%, but this figure
rises dramatically with age: by the age of 70, approximately half the Western
population will have developed an adenoma (Fodde et 01.2001).
Cancer develops over a long period of time and symptoms of colorectal cancer
generally present at a late stage in the disease process. This long time period poses a
difficult problem in identifying subjects at risk of CRC and also when studying the
relationship between suspected aetiological agents of colon cancer and the end point
of tumour formation. The currently available biochemical markers for CRC such as
CEA and CA19-9 are not markers of cancer risk and therefore are not particularly
useful in cancer risk lowering studies or in evaluating the effectiveness of prevention
strategies.
Traditionally colorectal cancer risk has been assessed by monitoring the frequency of
polyp relapse, by measuring proliferation or apoptosis in the colonic mucosa or the
presence of aberrant crypt foci. Although assessment of these parameters has proven
useful in the detection of early stage and recurrent disease, the invasive endoscopic
examination and sampling required for their analysis means that measurement of
these markers is time consuming and expensive and can not be extended to the
general population.
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In order to identify at risk subjects as well as early stage cancers, there is a real need
for the development of new, non-invasive, reliable markers, predictive of tumour
formation, which are altered by changing risk. The ideal biomarker of cancer risk
identifies an early alteration during the premalignant phase of neoplasia and predicts
with a degree of sensitivity and specificity the future progression and likely
prognostic outcome of the disease.
The aim of this study was to investigate a range of potential CRC biomarkers, and to
assess their suitability as biomarkers of CRC risk. The influence of sYDbiotic
consumption on these parameters was used to determine their usefulness as
biomarkers in intervention studies. It was decided to investigate these potential
biomarkers in two study populations from different disease backgrounds; cancer
subjects who had defined surgically resected frank cancer and polyp subjects who
had previously had polyps removed. Both the cancer and polyp subjects had
undergone pre-neoplastic changes, however the cancer subjects had progressed to
frank cancer while polyp subjects were considered to be at an intermediate stage.
Before beginning the intervention study it was confirmed that the probiotics
employed in this study had the ability to transit the gastrointestinal tract in the
presence of the prebiotic so that any observed effect could be associated with
sYDbiotic consumption. In the intervention study sYDbiotic consumption had a
beneficial effect on the gut flora increasing the numbers of lactobacilli and
bifidobacteria while decreasing the numbers of putrefactive bacteria such as
coliforms and Cl. perfringens recovered from the faeces. The altered composition of
the faecal flora did not however alter the expression of faecal calprotectin, the
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concentration of faecal SCFAs, the cytotoxic potential of FW or serum cholesterol
levels during the twelve week intervention period suggesting that these parameters
may not be suitable biomarkers in an intervention trial of this type. However
significant differences in the number of lactobacilli and enterococci, the cytotoxic
potential of FW and the concentration of propionic, isobutyric and isovaleric acids in
cancer subjects compared to polyp subjects were observed suggesting that these
parameters may be useful as biomarkers ofcancer risk.
Natural killer cell activity, IL-12 production by PBMCs and the level ofPGE2 in FW
was identified as being significantly different in cancer subjects as compared to
polyp subjects. NK cell activity was found to be significantly higher in polyp
subjects compared to cancer subjects in this study. Previous studies have reported
that high NK cell activity of PBMCs is associated with reduced cancer risk (Imai et
aJ. 2000). IL-12 production by PBMCs from cancer subjects was significantly higher
than production by PBMCs from polyp subjects in this study. Two studies by O'Hara
et aI. (1998a,b) showed that CRC patients have lower preoperative levels of IL-12
compared to healthy controls and lower levels of IL-12 production was associated
with advanced disease. In the current study the levels of PGE2 in FW of cancer
subjects was significantly higher than in FW from polyp subjects. Similarly
Lauritsen et aJ. (1984) reported that the levels of PGE2 in FW from patients with
active ulcerative colitis is significantly higher than in FW from healthy volunteers.
NK cell activity, IL-12 production and the levels ofPGE2 in FW may have potential
as biomarkers for cancer risk, however further analysis in a larger study population
is needed.
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Prebiotics and probiotics have been reported to have numerous influences on the
immune system (Blum & Schiffrin 2003; Cross 2002; Erickson & Hubbard 2000).
In contrast in the current study synbiotic consumption did not significantly modulate
the systemic immune system. It is however possible that modulation of the immune
system by synbiotics occurred in a site specific manner and future studies should
investigate the immune response in tissues such as the Peyer's patch and the
mesenteric lYmph node.
One of the most commonly used cancer risk biomarkers is the proliferative activity
of the colonic mucosa. In the current study sYnbiotic intervention significantly
reduced proliferation in the colonic mucosa of polyp subjects suggesting a protective
effect of sYnbiotics on cancer risk. Interestingly sYnbiotic intervention did not
influence the tumour promoting activities (tight junction integrity and invasive
potential) of FW ofeither cancer or polyp subjects. However FW derived from polyp
subjects significantly increased tight junction integrity (TER) compared to FW
derived from cancer subjects indicating that the composition and / or activity of FW
from polyp subjects is significantly different from that of cancer subjects. Also of
note was the finding that the activity of the detoxifying enzYme glutathione-S-
transferase (GST) was increased in cancer subjects indicating the induction of a
putative cancer protective state due to synbiotic consumption. The levels ofCEA and
CA19-9 were unaltered by sYnbiotic consumption showing that synbiotic
intervention does not adversely affect these commonly used diagnostic tools, thus
allowing these markers to be used to monitor possible recurrence ofdisease when the
sYnbiotic is included in the diet.
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The level of genotoxic damage in the colon and in PBMCs and the genotoxic
potential of FW are other putative cancer risk biomarkers which have received much
attention in recent years. A high level of genotoxic damage in the colon is associated
with increased risk of colon cancer (Hambly et ale 1997; Pool-Zobel & Leucht 1997)
as is highly genotoxic FW (O~wald et al. 2000; Rieger et al. 1999). Dietary
intervention studies as well as studies with pre-, pro- and synbiotics have been
shown to inhibit DNA damage in the colon as well as reduce the genotoxic potential
ofFW.
In the current study sYnbiotic consumption was found to protect against in vivo
genotoxic damage of the colonic mucosa in cancer and polyp subjects, reduce the
genotoxic potential of FW derived from polyp subjects, as well as influence the level
of DNA damage in PBMCs derived from polyp subjects. Cancer subjects have
significantly higher DNA damage in the colonic mucosa and significantly lower
damage in PBMCs than polyp subjects. Therefore it seems reasonable to further
investigate the usefulness of in vivo genotoxic damage as well as the genotoxic
potential of FW as both biomarkers of cancer risk and intervention markers.
However large-scale studies comparing the levels of the markers in healthy and
diseased states are needed, and, as gender, smoking status and genetic
polYffiorphisms seem to playa role in susceptibility to genotoxic damage future
studies should be designed, and sufficient participants enrolled, to control for such
factors.
Current knowledge points to the fact that cancer develops from the accumulation ofa
number of mutations in a single cell. In recent years, the advent ofeDNA microarray
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technology has greatly improved the potential for investigating the molecular
mechanisms of cancer and the identification of molecular markers of cancer risk. In
the current study we used eDNA array analysis to identify genes which are highly
expressed in the colonic mucosa of normal, cancer and polyp subjects. We also
identified genes which were differentially expressed in cancer, polyp and normal
subjects.
Synbiotic consumption in cancer subjects modulated the expression of genes
involved in differentiation and tight junction integrity such as TEK, MT3, PDGFRA
and protocadherin I as well as cell cycle and apoptosis genes. Interestingly the
expression of 15 other genes was reduced in the placebo polyp group but the
expression of these same genes were unaltered in the synbiotic group. The possible
association of this altered gene expression and the reduction in proliferative activity
in the synbiotic polyp group warrants further investigation.
In summary, several putative biomarkers of cancer risk have been identified
including immune parameters (NK cell activity, PGE2 in FW, IL-12 production by
PBMCs), the tumour promoting (TER) and genotoxic potential of FW, the level of
genotoxic damage in the colonic mucosa and the composition and metabolic activity
(SCFA) of the microflora. Synbiotic consumption altered the composition of the
microflora to a more beneficial type and modulated gene expression in both cancer
and polyp subjects. Synbiotic consumption also significantly reduced the
proliferative activity and genotoxic damage in the colonic mucosa, the genotoxic
potential of FW and the level of DNA damage in PBMCs in polyp subjects. In
cancer subjects synbiotic consumption protected against further DNA damage in the
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colonic mucosa and induced the activity of the detoxifying enzyme GST. These
results suggest that polyp subjects are more amenable to the protective effects of
syobiotics than cancer subjects although beneficial effects are also seen in this group.
Syobiotics offer great potential as a preventative strategy. Future studies in humans
should further elucidate the mechanisms involved in their preventative action and
their possible role as an early intervention strategy. Studies should be randomised,
double-blinded and placebo controlled, and performed in a well-defined population.
Careful syobiotic selection from well characterised Pre- and probiotics, based on the
ability to ameliorate disease progression is essential.
Most cancer risk studies are performed in subjects who have either a personal or
family history of cancer and are generally older than 40. Recently researchers have
suggested the need for long-term trials (20 to 30 years) in the general population
beginning at a much younger age. They hypothesise that many of the changes which
predispose to cancer occur at an early age and that traditional trials do not detect
these alterations (Dickersin 2005). Such trials, however will be time consuming and
expensive and the availability of reliable non-invasive, reproducible biomarkers will
be essential, especially with regard to subject recruitment and compliance.
The identification and use of proven CRC biomarkers will be essential in assessing
syobiotic efficacy in cancer risk lowering studies. Progress in the area of detection of
cancer and the development of early preventive measures, such as synbiotics, will
lead to a dramatic change in the morbidity and mortality patterns of colorectal cancer
in the developed world.
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Appendix III
Accession Gene Symbol Gene Name
Number
Tnll1Krtption Acttvaton & Repl'e!lSOn
U76638 BAR01 BRCA1 associated RING domain 1
M96577 E2F1 E2F transcnptlon factor 1
Y10479 E2F3 E2F transcnptlon factor 3
U15642 E2F5 E2F transcnptlon factor 5, p130-bindil'lQ
M6:829 EGR1 ea1y Qrowth response 1
M91196 homeo box D3 rlO'Tleo box 03
011117 ICSBP1 Interferon consen8U8 sequence binding protein 1
X· 4454 IRF1 Interferon reguatory factor 1
X'7620 NME1 non-metastatic cells 1 protein (NM23A) expressed In
L16785 NME2 non-metaslatlc cells 2. protein (NM23B) expressed In
M9f684 PURA Ipunne-nch element blndlnQ protem A
X06538 RARA rellnolc aCid re:;eplor alpha
X07282 RARB retlnolC aCid re;;eptor beta
M2<:857 RARG retlnolC aCid receptor gamma
M97935 S'AT1 signal transducer and activator of trar"1scription 1, 91 kO
M9/934 S'AT2 slqnal transducer and activator of lrar,scnpllon 2, 1131<0
U47686 S""AT5B slqnal transdJeer and activator of trars·~npllon 5B
U59863 TANK TRAF famlty 'Tlember-assoclated NFKB actlV8tor
L23aS9 TFDP1 lranscnptlon factor 0p-1
U18422 TFDP2 transcnptlon factor Dp-2 (E2F dimerization partner 2)
Cell Cycle
U33286 CSE1L CSE1 chromosome segregation 1-like (yeast)
L34J75 FRAP1 FK506 binding proleln 12-rapamycln associated protein 1
AFOO7111 Mdm2 Mclm2, lransfo'med 3T3 cell double ml'1ute 2. p53 ~lndlnQ protein (mouse)
Z12J20 Mdrn4 Mdm4, transformed 3T3 cell double minute 4 p53 btndinQ protein (mouse)
U63295 SIAH1 seven In absertla homolog 1 (Or08Ophlla)
Y11416 tumor protein p73 tumor protem p73
C.l'cJill6
X51688 eyclln A2 cyclin A2
M2~753 eyclln B1 cyehn B1
M14091 eyclin C eyehn C
X59798 eyclln 01 cyehn 01 (PRA01: parathyroid adenomatosis 1)
013639 'eychn D2 cyehn 02
M9:'287 eyclln 03 cyehn D3
M73812 eyclln E1 eyelin E1
U47413 leyclln G1 eyehn G1
U47414 eyclln G2 eyehn G2
U11791 leyClln H cvclin H
Cell cycIN'egM11Uill1l1rUuua
L29222 CDC-like kinase 1 CDC-like kinase 1
L29216 CDC-like kinase 2 CDC-like kinase 2
L29220 CDC-like kinase 3 CLC-hke kinase 3
M6E520 COK2 cychn-dependent kinase 2
X66357 COK3 cychn-dependenl kinase 3
M14505 COK4 ICVClln-dependent kinase 4
IX66364 COK5 leyclin-dependent kinase 5
Appendix Ill: Full list ofgene symbols and corresponding gene names
Accession Gene Symbol IGene Name
Number I
Cd} cych-r¥Uatilllllriusa
X66365 CDK6 cyclin-dependent kinase 6
L20320 CDK 7 cychn-dependent kinase 7 (M015 homolOQ, Xenopus laevis cdk-activating kinase)
L25i376 CDK9 cychn-dependent kinase 9 (CDC2-related kinase)
L33264 CDK10 :cyclln-dependent kinase (CDC2-hke) 10
X66358 CDKL1 Icychn-dep~ndent klnase-hke 1 (CDC2-related kinase)
X05360 CDC2 cetl dIVISion cycle 2 G1 to Sand G2 to M
M8C629 CDC2L5 ce'l diVIsion cycle 2-like 5 (chohnesterase-related cell divlsion controller)
X60188 MAPK3 extracellular signal-regulated kinase 1 (ERK1) Insuhn-stlmulated MAP2 kinase; MAP kinase 1 (MAPK 1); p44-MAPK' microtubule-as
U02687 FLT3 fms-relatedJyroslne kinase 3
X59727 MAPK4 ml1ogen-activated protein kinase 4
X80692 MAPK6 mnogen-actlvated protein kinase 6
U25278 MAPK7 mitogen-activated protein k'nase 7
X79483 MAPK12 mitogen-activated protein k,nase 12
L35253 MAfJK14 mitogen-activated protein k nase 14
L05t324 MAP2K1 mitogen-activated protein knase kinase 1
U25265 MAP2K5 mitogen-activated protein knase kinase 5
U39657 MAP2k6 mnogen-actlvated protein knase kinase 6
U78876 MAP3K3 mitogen-activated protein k,nase kinase kinae 3
U01038 PLK1 lpolo-hke kinase (Drosophila)
CDK ;lIltibitOl'l
U09579 CDKN1A ICYciin-dep~ndentkinase inhibitor 1A (p21 Cip1)
U22398 CDKN1C Icychn-dependent kinase Inhibitor 1C CP57, KIP2)
L27211 CDKN2A Icychn-dependent kinase Inhibitor 2A melanoma p16 inhibits CDK4)
U17075 CDKN28 Icychn-dependent kinase Inhibitor 28 (p15 Inhibits CDK4)
U40343 CDKND Icychn-dep~ndent kinase Inhlbrtor 2D (p19 Inhibits CDK4)
U10564 WEE1 WEE1+ homolog (5 pombel
Otll6 Cd} Cycl~CtMlToU
U77949 CDC6 CDC6 cell divlsion cycle 6 homolog (5 cerevislae)
572::>08 CDC10 CCC10 cell dlv,slon cycle 10 homolog (S cerevlslae)
U18291 CDC16 CC:C16 cell dlv'slOn cycle 16 homolog (S cerevlslae)
U63131 CDC37 CCC37 cell dIVISIOn cycle 37 homolog (5 cerevlslae)
()tIm C«JC~ CtMlToU
557153 AR!D4A retinoblastoma binding protein 1
M81933 CDC25A ceti diVlSlon c;ycle 25A
M81934 CDC258 cetl diVISion cycle 258
M34065 CDC25C ceq diVISion cycle 25C
UOOO01 CDC27 ceq diVISion cycle 27
X80343 CDK5R1 cyclln-dependent kinase 5, regulatory subunit 1 (p35)
U34051 CDK5R2 tcyclin-dep~ndent kinase 5, regulatory subunit 2 (p39)
U66469 CGRRF1 ce : Qrowth regJlatory WIth ring finger domain
L13'398 GAS1 growth arrest-specific 1
566431 JARID1A ret:noblastoma binding protein 2
D13365 MT3 metallothlonelr: 3 (growth Inhlbrtory factor (neurotrophic))
063878 NED05 neJral precursor cell expressed, developmentally dcmn-regulated 5
U49070 PIN1 tproteln (peptld'/I-pro/yl crsll'ans Isomerase) NIMA-Interactlng 1
X85134 RBBP5 retinoblastoma binding protein 5
Appendix III: Full list ofgene symbols and corresponding gene names
IAccession Gene Symbol GeM Name
Number
Other Cal CycJ~CtMI1'oU
X85133 RB8P6 retinoblastoma binding protein 6
U58334 T~,3BP2 tumor protelrl p53 binding protein, :2
CeU Adhesion Receptor~Protelns
IM81104 CD34 CD34 antigen
Z24680 GARP glycoprotein A repetitions predominant
.\JaJrix AdltaiOff R«:qtor, fNJtrix adlluion r«qJlors
M24795 !CD36 CD36 anttgen (collagen type I receptor, thrombospondin receptor)
M14219 deconn decorin
IX56654 desmogleln 1 desmogleln 1
IZ26317 desmoglein :2 desmogleln 2
U43901 LAMR1 larllnln receptor 1 (671<0, nbo&omal protein SA)
U14588 paxilin paxJllin
L12350 th'ombospondin 2 thrornbospondln 2
c~lJ..( 'ell AdhUiOfi R«qJlors
!M34064 cadnenn 2 cadhenn 2, type 1, N-cadhenn (neuronal)
X63'329 cadnerin 3 cadhenn 3 type 1 P-caChenn (placental)
L34:J59 cad'1enn 4 cadhenn 4 type 1 R-cadhenn (retinal)
IX79981 cad'1erin 5 cadhenn 5, type 2, VE-cadhenn (vascular epithelium)
1031784 cad'1enn 6 cadhenn 6, type 2, K-cadhenn (fetal kidney)
L34060 cad'1enn 8 cadhenn 8, type 2
L.j4056 cad'1enn 11 cadhenn 11, type 2, OB-cadhenn (osteoblast)
L34057 cad'1enn 12 cadhenn 12, type 2 (N-cad'1enn 2)
L34058 cad'1enn 13 cadhenn 13 H-cadhenn (heart)
083542 cad'1enn 15 cadhenn 15, M-cadhenn (myotubule
D~3866 catenln alpha 1 ca:enln (cadhenn-assoclated protein alpha 1 (1021<0)
M94151 calenln alpha 2 ca'enln (cadhenn-assoclaled protein alpha 2
X87838 calenln beta 1 ca:enln (cadhenn-aS8OClated protein , beta 1 (881<0)
X72925 desmocolhn 1 desmocolhn 1
X56807 desmocolhn 2 desmocolhn 2
X83929 desmocolhn 3 desmocolhn 3
~F7830 desmoplakJn desmoplakin (OPt DPII)
U53786 envoplakln erlvoplakln
M74387 L1CAM L1 cell adhesion molecule (hydrocephalus stenosis of aqueduct of SyMus 1 MASA (mental retardation aphasia shumino Qait
X 1 6841 NCAM1 neural cell adhe6lOO molecule 1
U72661 nlnJunn 1 nlnJunn 1
L34774 OPCML op,oid binding protein/cell adheslOf'l molecule-like
U52111 ple)(In B3 plexln B3
AAA36418 protocadherin 1 protocadherin 1 (cadherin-Iike 1)
L11373 PCDHGC3 protocadhenn gamma subfamily C 3
U60800 SEMAD4 sema domain Immunoglobulin domain (Ig), transmembrane domain (TM) and short ic domain (semaDhorin) 4D
X85978 TAX1 TAX1 axonln-1fTAQ1
Intl!grUu
X68742 inlegnn, alpha 1 Integrin, alpha 1
M2E249 Integnn, alpha 2 Integnn, alpha 2 (CD49B alpha 2 subunit of VLA-2 receptor)
M59911 integnn, alpha 3 Integnn alpha 3 (antigen CD49C alpha 3 subunit of VLA-3 receptor)
I~12002 integnn, alpha 4 integrin, alpha 4 (antlgerl CD49D, alpha 4 subunit of VLA-4 receptor)
Appendix Ill: Full list ofgene symbols and corresponding gene names
Accession Gene Symbol GeneNarne
Number
It.ugriJu
X06256 Integnn, alpha 5 inteQrin, alpha 5 (f1bronectin receptor alpha ooIvPePtide)
X53586 Integnn, alpha 6 InteQnn, alpha 6
X74295 Integnn, alpha 7 integnn, alpha 7
L36531 mtegnn, alpha 8 Integnn alpha 8
025303 Inteqnn, alpha 9 Integnn alpha 9
L25851 Integnn, alpha E Inteqnn alpha E (antigen C0103, human mucosal lymphocyte antiaen 1, alpha polypeptide)
M34189 integnn, beta 1 Integnn beta 1 (fibronectln receptor beta POlypeptide, anhaen C029 Includes MOF2 MSK12)
JOT03 Integnn, beta 3 Integnn beta 3 (platelet glycoprotein lila antlQen CD61)
U37139 Integnn beta 3 (BP) Integnn beta 3 binding protem (beta3-endonexJn)
X53587 Inteqnn beta 4 Integnn, beta 4
J05633 integnn beta 5 Integnn, beta 5
M3~198 integnn. beta 6 mtegnn beta 6
M6::-880 integnn, beta 7 integnn. beta 7
M73780 integr,n beta 8 integrin, beta 8
IImmune :system Yro ems
IM34671 ICl)'.)9 ICD59 antigen 016-20 (antigen identified bY monoclonalantibodl8816.3A5, EJ16, EJ30 EL32 and G344)
IM11886 HLA-C major histocompatibility complex, class I, c.;
[M21626 !TRAV14DV4 T cell receptor alpha variable 14/delta variable <4
Oncogenes &: Twnor Suppresson
IU23435 abl-,nteractor '2 ab'-Interactor 2
IM7 4 088 APe adenomatosIs pOlypOSIS call
IU43 746 [BRCA2 breast cancer 2, early onset
X03663 CSF1R coony stlmulaLng factor 1 receptor formertv McDollOU(jh feline sarcoma VIral (v-fm8) oncogene homolog
X76132 OCC de'eted In colo'ectal carcinoma
IU49089 IDLG3 discs. large (O'osophlla) homolog 3 (neuroendocrine-dlg)
IAF010314 IENC1 ec:odermal-neural cortex ('{lith BTB-Iike domalO)
IXOO588 IEGFR epdermal growth factor receptor (erythroblastlc leukemia wal (v-ert>-b) oncogene hOITlOIog, avian)
M9f·487 FOLH1 folate hydrola~Jp!ostate-Sf>eClfic membrane antigen) 1
M1f,722 FGR Gardner-Rasheed feline sarcoma VlraIJv-fgr) oncogene homolog
L29511 GRB2 [growth factor receptor-bound protein 2
AFOO1954 ING1 Inhlbrtor of growth family, member 1
M2f'039 JUNB un B proto-oncogene
U43527 KISS1 KISS-1 metastaSls-suppressor
X06182 KIT v-kit Hardy-Zuckerman 4 feitne sarcoma viral oncogene homoloa
X13967 L1F leukemia Inhibitory factor (cholinergIC differentiation factor)
AF010312 L1TAF LPS-Induced TNF-alpha fa·:;tor
J02958 MET met proto-oncogene (hepatocyte growth factor receptor)
U35113 MTA1 metastasIs associated 1
U68162 MPL myeloprolrferat·ve leukemia virus oncogene
AF010315 p53-lnduced prdein ,p53-lnduced p'oteln
X02811 PCX:;FB iplalelet-denved growth factor beta POlYpeptide (SImian sarcoma viral (v-sis) oncogene homoIoa)
089667 prefoldtn 5 Iprefoldln 5
AF010310 PROOH Iproline dehydrogenase (Olodase) 1
AF010316 PTGES Iprostaglandln E synthase
AF010309 TP5313 IQUinone OXidoreductase homolog
l25080 RHOA ras homolog gene family, member A
Appendix Ill: Full list ofgene symbols and corresponding gene names
Accession Gene Symbol IGene Name
Number I
Oncogenes 4 Tumor Suppresson
L25081 RHOC ras homolog gene family member C
085815 RHOO ras homolog gene family member 0
X95282 RHOE ras homoloq gene family member E
X61587 RHOG ras homolOQ Qene family member G (rho G)
Z35227 RHOH ras homolOQ gene family member H
M31213 oncogene RET ret proto-oncogene (multiple endocnne neoplasta and medullary thyroid carcinoma 1 Hirachaprung dISease)
M15400 RB' retinoblastoma 1 (Including osteosarcoma)
X74594 RBL2 retinoblastoma-like 2 (P130)
U16296 TIAM1 T-<:ell lymphoma InvaSion and metastasi8 1
Z29'J83 TPBG trophoblast Qly:;oproteln
M14694 tumor protein p53 tumor protew p53 (Li-Fraumeni syndrome)
M3~296 ABL2 v-ab! Abelson munne leukemia wal oncogene homolog 2 (arg, Abelson-related gene)
M63167 AKT1 v-ak! munne trymoma VIral oncogene romolog 1
Mn198 AKT2 v-ak! munne !t·y'moma VIral oncogene romolog 2
M11730 ERBB2 v-erb-b2 erythroblastlc leukemia VIral orCOQene homoloQ 2 neurolglioblastoma deriVed oncoaene homolog (avllSn)
M2S366 ERE3B3 v-erb-b2 erythroblastlc leukemia IIlral orcogene homolOQ 3 (aVIan)
L07368 ERBB4 v-erb-a erythroolastlc leukemia wal oncogene homolog 4 (BVlan)
KOO650 FOS v-fos FBJ munne osteosarcoma VIral orcogene homolog
M54968 KRAS2 v-KI-ras2 Kirsten rat sarcoma 2 VIral on:;ogene homolog
M1:)228 MYCN v-myc myeloeytomatosls VIral related oncogene, neuroblastoma derived (avian)
M9E712 BRAF v-raf munne sa 'coma wal oncogene homolog B1
X03484 RAF1 v-raf-1 munneeukemla VIral oncOQene homolog 1
NM 00541 SRC v-src sarcoma ~Schmldt-RLJPPInA-2) wal oncogene homolog (avian)
M15990 YES1 v-yes-1 Yamaguchi sarcoma wal oncogene homolog 1
EltraceUular Matrix Proteins
M55172 aqqrecan 1 aqqrecan 1 (chondroitin sulfate n 1 lame lKIcreaating n, antigen identified bv monoclonal antibodY A0122
J04599 bioi/can blqlycan
U16306 CSPG2 chondroitin sulfate n 2 (ver6lCan)
X02761 fibronectln 1 fib'onectln 1
M8t289 HSPG2 heoaran sulfate proteoglycan 2 (perlecan)
X,8565 tenaSCln C hexabrachlOn (tenascln C cytotactin)
U86759 netnn 2-lIke netnn 2-lIke (ctilcken)
M3C269 nldc>Qen nldogen (enact,n)
J03040 SPARC se::;reted protein acidic, cystetne-rich (osteonectin)
X98085 tenasctn R tenascln R (restnctln lanuStn)
X'4787 thrombospondin 1 thrombospond,n 1
X03168 vitrcnectln vitronectln (serum spreading factor aomatomedln B complement S-proteln)
TroOkIdnWTargetJn, Proteins
X55525 COL1A2 co.\agen, ype I alpha 2
X'6468 COL2A1 COllagen, ype II alpha 1 (primary osteoarthritis, soondvloeptphyseal clysplasia, canaenital)
X'4420 COL3A1 coHagen YDe III alpha 1 (Ehlers-Danlos syndrome type IV autosomal dominant)
X05610 COL4A2 COlIaqen YDe IV, alpha 2
M92993 COL4A3 colaqen ype IV, alpha 3 (Goodpasture antigen)
021337 COL4A6 cOlaqen ype IV, alpha 6
X~5879 COL6A1 colagen ype 1/1, alpha 1
M3457Q COL6A2 coilaqen, :ype VI, alpha 2
Appendix III: Full list of gene symbols and corresponding gene names
Accession Gene Symbol IGene He....
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Tnd'lkldn&lTargetinJ Proteins
X52022 GOL6A3 colagen type VI alpha 3
X57527 COL8A1 colagen type VIII, alpha 1
J04177 C0L11A1 colagen type XI alpha 1
U32169 Col11 A2 co'iaQen type XI alpha 2
M9~642 COL16A1 co:laQen type XVI alpha 1
L22548 COL IBM cOilagen type XVIII alpha 1
M61916 lam1mn, beta 1 larllnln beta 1
S77512 lam1ntn, beta 2 larllmn, beta 2 (Iamlnln S)
X70904 lamnln, alpha 4 laMlnln alpha 4
J03~02 lamnln, gamma 1 laMlmn Qamma 1 (formerty LAMB2)
X97442 TMP21 transmembrane tralTicklng protem
MetaboUJm
X01677 GAPD glvceraldehyde-3-phosphate dehydrogenase
U90313 GST01 glutathlone-S-transferase liKe, Qlutathlone transferase omega
V00530 HPFH1 hypoxanthine phosphonbosyltransferase 1 (Le&Ch-Nyhan syndrome)
Y07604 NM~4 non-metastatic cells 4 protem expressed In
M13267 SOD1 SUperoXlde dlsmutase 1 soluble (amyotrophic lateral sclerolale 1 (adult))
Rlhosomal ProteIns
X65923 FAU Finkel-Biskis-Reilly murine sarcoma virue (FBR-MuSV) ubiQuitously expressed (fox derived); ribosomal protein S30
X56932 nbosomal protem L13a r'bosomal protein l13a
U14971 nbosomal protein S9 r'bosomal protem S9
Apoptosls As..o;oclated Proteins
Death Receptor-.-luodated Pr(Jl~ns & AtltJplon
U84388 CRADO CASP2 and RIPK1 domain containina adaotor with deeth domain
U82938 SIVA CD27 -btndlng :Slva) protein
AF015956 DA.:O( death-associated protein 6
L41690 TRAOO ThFRSF1 A-associated via death domain
U78798 TRf,F6 ThF receptor-associated factor 6
U90875 TNF"RSF10A tumor necr06ls factor receptor superfamily, member 10a
Casl'iUG
U13699 casoase 1 caspase 1 apopt08ls-related cysteine protease (Interleukin 1 beta convertase)
U13021 casoase 2 caspase 2 apcptOSls-related cySteine protease (neural precursor cell expressed developmentally down-regulated 2)
U13737 casoase 3 caspase 3 apoptOSls-related cySteine protease
U28014 caS;)8se 4 caspase 4 apcptOSls-related cysteine protease
U20537 cas;J8se 6 caspase 6 apcptosls-related cysteine protease
U37448 cas:)ase 7 caspase 7 apcptOSls-related evstelne ~lrotease
X98176 casoase 8 caspase 8, apcptOSls-related evstelne protease
U56390 casnase 9 caspase 9 apcptOSls-related cysteine ~lrotease
U60519 caS:J8se 10 caspase 10 apopt08ls-related cysteine protease
BCU fiurtily Prot....
U23765 BAK BCL2-antagonl8tlkiller 1
U66879 BAD BCl2-antagon'st of cell death
S83171 BAG1 BCl2-assoclated athanoqene
L22474 BAX BCl2-assoclated X protein
M14745 BCL2 B-cell ClUlymphoma 2
IU29680 ,BCL2A1 IBCL2-related protein A1
Appendix Ill: Full list ofgene symbols and corresponding gene names
IAccesslon Gene Symbol Gene Name
Number
8('1.2 FlUffily Prot..
U59747 BCL212 BCL2-like 2
U34584 BIK BCL2-lnteractlng killer (alXlPtosls-lnducing)
882185 BRAG-1 brain-related aPOptosls gene (BRAG-1) BcI-2 homolog
L08246 MC~1 myeloid cell leukemia sequence 1 (BCL2-related)
Death KilUUG
X761 04 DAPK1 death-aSSOCiated protein kinase 1
Y10256 MAP3K14 mltogen-act,.vated protein k,nase kinase kinase 14
X66363 PC~K1 peTAIRE protein kinase 1
XE6360 PCTK2 peTAIRE protein kinase 2
X66362 PCTK3 PeTAIRE protem kinase 3
Other .4popttni6-,4..od4Ied ProteillS
U45879 BIRC2 baculoVifal lAP repeat-containing 2
U45878 BIRC3 baculovlral lAP repeat-containing 3
U45880 BIRC4 baculovlral lAP repeat-contalnlnq 4
U75285 BIRC5 baculoVifal iAP repeat-contalnlnq 5 (survivin)
AF010127 CFLAR CA8P8 and i=ADD-like apoptosls regulator
U18321 DAP3 death associated protein 3
U91985 DFFA DNA fragmentation factor, 45 kD, alpha polypeptide
840706 DDIT3 Df'.A-damage-"lduclble transcnpt 3
8,8385 PDCD2 programmed cell death 2
AF022385 PDCD10 proQrammed cell death 10
U25994 RPK1 receptor (TNFR8F -Interacting aenne-threonine kinase 1
Rl\A processing, tumo\er, and tr.msport
U12431 ELAVL2 IELAV (embryOniC lethal abnormal vi6ion Drosophila)-Iike 2 (Hu antigen B)
Cell Receptors
Growth Factor & CIIDMldllt RecqJtorr
L17075 ACVRL1 actlVln A receptor type II-like 1
M6C459 EPOR erythropoietin receptor
X68203 FLT4 fms-related tyrosine kinase 4
L37382 FZD2 fnzzled homoloq 2 (DrosoPhila)
U28811 GLG1 IQo'QI apparatus protein 1
X04434 IGF1R Insulin-like qrowth factor 1 receptor
YC0285 IGF2R Insulin-like growth factor 2 'eceptor
M3E410 IGFBP2 Insulin-like growth factor binding protein 2 (36kD)
U12140 NTRK2 neJrotrophlc 1'I'oslne kinase, receptor type 2
U05012 NTRK3 neJrotrophlc 1'I'oslne kinase, receptor type 3
M98437 Notc2 homoloQ 2 Notc2 homolog 2 NeurogeniC locus notch homoloQ protein 2 Dfl!Cunsor )
U77493 Notch homoloq 2 Notch homoloq 2 (Drosophila)
U95299 Notch homolog 4 Notch homoloq 4 (Drosoph"la)
U43148 PTCH lpatched homo!OQ Drosophila)
M21574 PDGFRA p1atelet-denved growth factor receptor alpha polypeptide
M21616 POGFRB platelet-denved growth factor receptor beta polypeptide
L07594 TGFBR3 transforming growth factor, beta receptor III (betaglycan, 3001<0)
X85960 TRK-fused gene TRK-fused gere
AF016268 TNFR8F10B tumor necrOSIS factor receptor superfamily, member 10b
Y09392 TNFR8F25 tumor necrOSIS factor receptor superfamily, member 12 (translocating chain-association membrane protetn)
Appendix Ill: FuIllist of gene symbols and corresponding gene names
Accession Gene Symbol GeMMaI'M
Number
GroWl" Factor cI Clterwlcillt R«q1Ion
M33294 TNFRSF1A tumor necrosis factor receptor superfami V, member 1A
M3:'315 TNFRSF1B tumor necrosIs factor receptor superfaml y, member 1B
X60592 TNFRSF5 turner necrOSIs factor receptor superfaml y, member 5
Z70519 TNFRSF6 tUmOl' necrosIS factor receptor superfami Iy, member 6
Fc;rr«epton
M37722 FGFR1 fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2 Pfeiffer syndrome)
U11814 FGFR2 flb'oblast growth factor receptor 2 (bactena-expressed kinase, keratlnocyte growth factor reeeotor craniofacial dv808t08ia 1
M58051 FGFR3 fibroblast growth factor receptor 3 (achondroplasIa, thanatophorlc dwarfism)
Ephrill rt«plon
M59371 Ept-.A2 EphA2
L40636 EphB1 EphB1
L41939 Ept-H2 EphB2
U07695 Ept-B4 EphB4
InterleJI/cj1l R.c«pton
M63099 inte1eukln 1 receptor Inter1eukin 1 receptor antagonist
M20566 inte1eukln 6 receptor Interteukln 6 receptor
Inttrferoll rtcq1ton
J03171 IFNAR1 Interferon (alpha beta and omega) receptor 1
X,7722 IFNAR2 Interferon (alpha beta and omega) receptor 2
A09781 IFNGR Interferon-ga'11'Tla receptor (IFNGR)
J03143 IFNGR1 Interferon gam'11a receptor 1
U05875 IFNGR2 Interferon gamma receptor 2 (Interferon gamma transducer 1)
HorlllOfl. R«qJton
X52173 RXRA retinoid X receptor alpha
M84820 RXRB retinoid X receptor beta
Prottill KilUUD
X61656 KDR kinase Insert domain receptor (8 type III receptor tyrosine kinase)
U33635 P""'K7 PTK7 protein t'/roslne kinase 7
YC9028 NTRK1 neJrotrophlc tyrOSine kinase, receptor type 1
017517 TYR03 TYR03 proteIn tyrosine kinase
Orhn' Rt«pIor.
X95425 EPHA5 ephrin type-A receptor 5 precursor' tyrosine-protein kinase reeeotor EHK1, EPH homology kinase-1, HEK7
U43318 FZD5 frIZZled homolog 5 (DrosophIla)
U82169 FlD9 fnzzled homolog 9 (Drosophila)
X02492 GIP3 Interferon alpha-Inducible protein (clone IFI-6-16)
X-3916 lRP1 lOY" denSIty lipoprotein-related proteIn 1 (alpha-2-macroglobuhn receotor)
U04441 LRP2 lOY" denSity IIlX1proteln-related protein 2
M14764 NGFR nerve growth factor receptor (TNFR suroerfamitv, member 16)
U08839 PLAUR plasminogen actrvator urokinase receptor
X87B52 SEX gene SEX gene
X60957 TIE tvr'JSlne kInase with immuroglobulin and eoidermal arowth factor hornoIogy domains
Cell ~. -""' EnnceUular Communkatloo Protelm
i'ieJIro~tida
L19063 GOOF Qlial cell derived neurotrophIC factor
X52599 NGFB nerve growth factor. beta polypeptide
M7 3980 Notch homolog 1 Notch homolog 1 translocation-associated (Drosophila)
5':1541 NTF6G nedrotrophln 6 gamma pseudogene
IX536~5 neurotrophln 3 neurotrophln 3
Appendix III: Full list ofgene symbols and corresponding gene names
Accession Gene Symbol IGene Name
Number I
Urowtll Factor., CytokblG & CilmtokillU
M30704 ar'1phlregulin amphlregulinJschwannoma-demiedQrowth factor)
M1E530 Bcell growth factor 1 B-cell growth factor 1 f12KD)
M61176 BOf~F braln-denved r,eurotrophlc factor
M73238 CN-;FR ciliary neurotrOphiC factor
M9~934 CTGF connective tissue growth factor
U15979 DLK1 de:ta-IIke 1 homolog (Drosophila)
M6C278 DTR dlphthena toxin receptor (hepann-blnding epidermal growth factor-like growth factor)
U49262 DVL3 dIShevelled, ds'1 homol~ 3 (Drosophila)
X04571 EGF ep;dermal growth factor (beta-urogastrone)
U04806 FLT3LG fms-related tyrosine kinase 3 ligand
M86492 GM;:"B gila maturation factor bela
D49493 GDF10 growth differentiation factor 10
U46010 HGF heoatocyte growth factor (hepapotetin A scatter factor)
016431 HOOF heoatoma-derlved growth factor_ (hl9J1-mobllitv oroup protein 1·like)
014012 HGF activator HGF activator
A25270 IK cytoklne IK cytoklne down-regulator c:I HLA II
M59964 KITl..G KIT ligand
M74178 MST1 macrophage stimulating 1 (hepatocyte C1rowth factor-like)
X72755 CXCL9 monoklne Induced by gamma Interferon
L12260 neuregulin 1 ne'Jreguiln 1
X54936 PGF Iplacental growth factor, vascular endothelial orowth factor-related oroteln
X06374 POOFA associated pratE Iplatelet-denved growth factor alpha polvpeptlde
M57399 IplelOtrophln Ipl~lotrophln (hepann binding growth factor 8 neurite Qrowth-promotinc factor 1)
M54995 PPBP Ipro-platelet basIC protein {Includes platelet basic protein beta-thromboglobUlin connective ti88Ue-actiwting peptide III ne
L42379 IQulescln Q6 IQUIescln Q6
L26J81 SEMA3A sema domain ,mmun~lobulln domain (Ig) 8hort baSIC domain secreted (semaphorin) 3A
ABCOO220 SEMA3C sema domain, ,mmunoglobulin domain (10) short baSIC domain secreted (semaphorin\ 3C
U33920 SEMA3F sema domalnmmunoglobulln domain (IQ) short baSIC domain, secreted (semaphonn) 3F
X02530 CXCL10 small IndUCible cytoklne subfamily B (Cya-X-Cys) member 10
L38518 SHH sonic hedgehog homolog (Drosophila)
L36034 CXCL12 str:::>maI cell-derlVed facto' 1
M9E956 TDGF3 teratocarclnoma-denved~owth factor 3 pseudogene
L36052 th rombopoietln thrombopoiettr (myeloproliferative leukemia virus oncoaene liaand meaakarvocvte arowth and de'.'elopment factor)
K03222 TGFA transforming growth factor, alpha
X02812 TGFB1 transforming g'owth factor, beta 1 (Camuratl-Enaelmann disease)
M1~}154 TGFB2 transforming g'owth factor, beta 2
J03241 TGFB3 transforming growth factor, beta 3
L07414 TNFSF5 tumor necrosIS factor ligand superfaml '/If, member 5 (hyper-lgM sYndrome)
038122 TNFSF6 tumor necrosIs factor ligand superfarr1 1~, member 6
L08096 TNFSF7 tumor necrosIS factor IIgard superfaml ~. member 7
L09753 TNFSF8 tumor necrosIs factor Iigar,d superfaml ~. member 8
U57059 TNFSF10 tumor necrosIs factor ligand superfaml ~. member 10
Fibroblllst U,uwtll Flletor
X51943 FGF1 fibroblast growth factor 1.(aCIdic)
M27968 FGF2 fibroblast growth factor 2(baSIc)
IX14445 IFGF3 fibroblast growth factor 3 (munne mammary tumor virus Integration site (v-int-2) oncogene hOmOlOg)
Appendix III: Full list ofgene symbols and corresponding gene names
Accession OeneSymbol OeneName
Number
fibroblJut Gruwtll FtlClOI'
M37B25 FGF5 fibroblast growth factor 5
X63454 FGF6 flb'oblast grO'Nth factor 6
M6CB2B FGF7 flb'oblast grO'Nth factor 7 (keratinocyte growth factor)
U36223 FGFB flb'oblast grO'Nth factor B (androgen-induced)
014838 FGF9 fibcoblast grO'Nth factor 9 (gila-activating factor)
U66197 FGF12 flb'oblast grO'Nth factor 12
L03B40 FGFR4 fibroblast grO'Nth factor receptor 4
B,me Morplao,..«ic Protein
M22488 BMP1 bone morphogenetic protein 1
M2::'489 BMP2 bone morphogenetic protem 2
M2::491 BMP3 bone morphogenetic protem 3 (osteogenic)
030751 BMP4 bo'le morphogenetic protem 4
M6G314 BMPS bone morphogenetic protem 5
M6C315 BMP6 bone morphogenetic protem 6
M6C316 BMP7 bone morphogenetic protem 7 (osteogenIC protein 1)
M97016 BMPBA bone morphogenetIC protem B (osteogeniC proteIn 2)
Epllnll'
M57730 ephnn-A1 lephrin-A1
U:'6403 ephnn-A5 ephnn-A5
U09304 ephnn-B1 ephnn-B1
L38734 ephnn-B2 ephnn-B2
U66406 ephnn-B3 lephnn-B3
Interleukilll
X02B51 Inte'leukln 1 alpha mter1eukin 1, alpha
K02770 Inte'leukln 1 beta Interleukln 1 beta
A'4844 Inte'leukln 2 Interteukln 2
M14743 Inte1eukln 3 Interteukln 3 (colony·ltimulating factor multiple)
M13982 Inte1eukln 4 Interteukln 4
XQ4688 Inte1eukln 5 Inteneukln 5 rcolony-stlmulatlng factor eoeinOPhil)
X04602 Inte1eukln 6 11terteukln 6 (Interferon, beta 2)
J04156 Inte1eukln 7 I1terleukln 7
X'7543 Inte1eukln 9 Interteukln 9
M5/627 Inte'leukln 10 mterleukln 10
M5/765 In1e1eukln 11 Interteukin 11
MI3~291 Inte1eukln 12A tnterleukln 12A{natural killer cell stimulatory factor 1 CYtotoxic Iy 11~1 ""'y e maturatIOn factor 1 p35)
Mf3~290 Inte1eukln 12B I1terteukln 128 (natural killer cell stimulatory factor 2 eytOtOXIC tvmohocvte maturatIOn factor 2 p40)
L06301 Inte'teukln 13 Interteukln 13
L15344 Inte1eukln 14 Interleukln 14
U14407 Inte'teukln 15 Interleukln 15
U32659 Inte1eukln 17 mter1eukln 17 (eytotoxic T- e-associated serine esterase 8)
llIterfertHf
M28622 IFN31 Interferon, beta 1, fibroblast
JOO~~09 Interferon, alpha 10 Interferon, alpha 10
lX01992 interferon gamma mterferon, gamma
Appendix Ill: Full list ofgene symbols and corresponding gene names
IAcceSslon )GeneSymbof
Number
Gene Name
M27544
M31159
M62403
M6:062
M62402
JnAllUt~Grtm1Jl Facioi' Hilldillg Protein
IGF1 Iinsulin-like growth factor 1 (somatomedln C)
IGFBP3 Iinsulin-like growth factor binding protein 3
IGFBP4 Iinsulin-like growth factor binding protein 4
IGFBP5 Iinsulin-like growth factor binding protein 5
IGFBP6 Iinsulin-like growth factor binding protein 6
Ollrc'1' Extraceblltlr ComntMlIictUion ProlalU
U83508 langlOpClletin 1 langlOpClletln 1
M3E690 ICoo antlQen (p24) ICCJ9 antigen (P24)
U24163 IFRZB Ifnzzled-related protein
AF028593 !Jagged 1 IJa~lged 1 (Alagille syndrome)
AF003521 IJagged 2 lJagged 2
U94354 ILFNG Ilunatic fringe homolog (Drosophila)
M2:639 IMiF Imacrophage migration Inhlbltory factor (glycosytatlCln-inhibiting factor)
U94352 IMFNG Imanlc fnnge homolOQ (DrosoPhila)
U41745 IPDAP1 IPDGFA associated protein 1
AF017986 ISFRP2 lsecreted fnzzled-related protein 2
AF017988 ISFRP5 lsecreted frizzled-related protein 5
X07876 IWNT2 IWlngless-type MMTV Integration site famity member 2
Z71621 IWNT2B IWlngless-type MMTV Integration site family, member 2B
L20861 IWNT5A IWlngless-type rAMTV Integration site family, membe' 5A
X91940 IWNT8B IwmQless-type MMTV Integration site family, member 8B
X97057 IWNT10B Iwmgless-type MMTV Integration site family, member 10B
IntraceUuJar TransduceniJ1.:fTeetol's/Modulaton
M76125
U24166
L11353
YC0815
L06139
U77845
U07707
U12535
U69276
AKC26432
U40282
M63959
U84401
U12597
U21092
lJ69108
L05148
IAF'OOO-g74
AXL IAXL receptor t/roslne kinase
MAPRE1 Imlcrotubule-assoclated protein, RPIEB famity, member 1
neurofibromin 2 IneeJrofibromin 2 (bllaterai acoustic neuroma)
P""PRF Iproteln tyrosine phosphatase, receptor type, F
TEK ITEK tyrosme knase, endothel.aITvenou8 malfOrmations, multiPlecutaneousand mucosal)
TRIP ITRAF Interacting protein
Adaptor & R«q1IONtuociatt'd Prolans
EPS15 lep',dermal growth factor receptor pathway substrate 15
EPS8 lepidermal growth factor receptor pathway substrate 8
GRB10 Igrowth factor receptor-bound protein 10
HCK lhemopoletlc cell kinase
ILK Iintegnn-linked kinase
LRPAP1 !low density lipoprotein-related protein-a88OCiated protein 1 (alpha-2-macroglobulin receptor-888OCiated protein 1)
SMO Ismoothened homolog (Drosophila)
TRAF2 ITNF receptor-associated factor 2
TRAF3 ITNF receptor-associated factor 3
TRAF5 ITNF receptor·assoclated factor 5
ZAP70 Izeta-challl (TCR) associated protein kinase (70 kD)
TRIP6 (zyxin related protein ZRP-1
Appendix III: Full list ofgene symbols and corresponding gene names
IAccesslon aeneSymbol IGene Name
Number I
INtracdJMlJu Kilian NdWOI'kM~ (no""'«qnOl' prota" kilUUu)
X58957 BTl< Bruton agammaglobulinemia tyrosine kJnase
X86779 FAST kinase FAST kinase
L26318 MAPK8 mitogen-activated protein kinase 8
L31951 MAPK9 mitogen-activated protew kinase 9
U34819 MAPK10 mitogen-activated protew knase 10
U24152 PAK1 IP21/Cdc42lRac1-actlVated kinase 1 (STE20 homoloa, veast\
U24153 PAK2 Ip21 (CDKN1 A)-actIVated kinase 2
U43522 PAK2B Iproteln tyrosine kinase 2 beta
L13616 P~K2 PTK2 protein tyrosine k,nase 2
U43195 ROCK1 Rho-associated coiled-coli containing orotein kJnase 1
G-ProtaIU
M35543 cell dlllisioncycle 42 cell dIVision cycle 42 (GTP bindingj)fotein 251<0)
YC7923 GTP-blndlng protein GTP-blndlng protein
X06820 RHOB ras homolog gene family member B
X95456 RHON GTP-blndlng protein Rho7
M31470 RHOQ likely ortholo~ of mouse TC10-alpha
M29870 RAC1 ras-related C3 botulinum tOXin substrate 1 (rho family small GTP binding protein Rac1)
M6<:595 RAC2 ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2)
L24564 RRAD Ras-related associated wrth diabetes
GTPGDP cI G-PrOlan GTPfU~ Aeth'il)' ,\(ofbd41ors
Z18951 caveohn 1 caveohn 1 caveolae protem, 22kD
U32114 caveohn 2 caveohn 2
U11690 fac,oQemtal dysplnla faCloqemtal dysplasia (Aarskog-Scott syndrome)
U59752 PSCD2 Ipleckstnn homology, Sec7 and COiled/coil domains 2-like
U02570 ARHGAP1 Rt'o GTPase actiVating protein 1
X/8S17 ARHGAP4 Rt',o GTPase actiVating p'ote,n 4
X69550 ARHGOIA Rro GOP diSSOCiation Inhibitor (GOD alpha
L20i)88 ARHGOIB Rt'o GOP dISS(>c,atlon Inhlbrtor (GO!} beta
U82532 ARHGOIG Rt'o GOP dissociation inhibrtor (GOI) gamma
Phosplwlipa6a & PIIoqIIoinosilol Kintua
U38545 Iphosphohpase 01 Iphosphohpase 01 phophalldytcholine-soecific
M86400 YWi-JAZ tyrosine 3-morooxygenaseltryptophan 5-monooxvaenaae actIVation protein zeta POlYPeptide
Otlu, Intracdllllar TrtUUdI4urs. EfJ~etors.JfodMlIJJors
L22005 cell dl\l1Slon cycle 34 cell dl\l1slon cycle 34
U46461 OVL1L1 diShevelled, ds"l homolog 1 (Drosophila)
U56976 PDE1B IphosphodleSterase 1B calmodulin
Pnlteln Turnover
Serine ProtlJ/Ues
049742 HARP2 hyaluronan binding protein 2
X05199 ,plae.mlnogen Iplasmlnoqen
M1t518 PLAT Iplasmlnoqen actlV8tor, tissue
M15476 PLAU !pIasmlnogen actIVator uroklnase
MnaUoprotdNuu
X05231 MMP1 matrix metalloproteinase 1 (interstitial collagenase)
J03210 MMP2 matnx metalloprotelnase 2 (gelallnase A 72kO gelatinase, 721<0 type IV collagenase)
IX05232 MMP3 matnx metalloprote,nase 3 (stromelysln 1, progelatlnase)
Appendix III: Full list ofgene symbols and corresponding gene names
Accession OeneSymbol OeneName
Number
oW ttaUopt'oIftNuG
X07819 M~D7 matrix metalloproteinase 7 (matrilysin uterine)
J05556 Ml,.1P8 matnx metalloprotelnase 8 (neutrophil collaqenase)
J05070 Ml,.1D9 matnx metalloprotelnase 9 (~elatmase B 92kO getatinase, 921<0 type IV collagenase)
X07820 MM D10 matnx metalloprotelnase 10 stromelYSIn 2)
X57766 Ml,.1D11 matnx metalloprotelnase 11 stromelysln 3)
L23808 Ml,.1D12 matnx metalloprotelnase 12 macrophage elastase)
X/5308 MM D13 matnx metalloprotelnase 1:; collagenase 3)
026512 Ml,.1D14 matnx metalloprotelnase 14 membrane-Inserted
Z48482 MMP15 matnx metalloprotelnase 15 membrane-Inserted
085511 MMP16 matnx metalloprotelnase 16 membrane-Inserted
X89576 MM D17 matnx metalloprotelnase 17 membrane-inserted
X92521 MM D19 matnx metalloprotelnase 19
U41766 ADAM9 a dlslntegnn and metalloprotelnase domain 9 (meltnn qamma)
U69611 ADAM17 a dlslntegnn and metalloprotelnase domain 17 (tumor necrosIs factor alpha, converting enzyme)
ProttQS~ Inltibiton
M11313 A2M alpha-2-macroglobulin
M68516 SERPINA5 se'lne (or cysteine) proteinase Inhibitor clade A (alpha-1 antiprotetnase, antitrypsin), member 5
M18D82 SERPINB2 serine (or cysteine) proteinase Inhibitor clade B (ovalbumin) member 2
X04429 SERPINE1 se'tne (or cysteine) proteinase Inhibitor clade E (nexln, plasmlnoqen actIVator inhibitor type 1), member 1
X03124 TIMP1 tissue Inhibitor of metalloorotemase 1 (erythrOId potentiating activity, collagenase Inhibitor)
J05593 TIMP2 tissue Inhibitor of metalloorotelnase 2
Z30183 TIMP3 tissue Inhibitor of metalloprotelnase 3 (SOl'8bv fundus dv&troohv. oeeudoinflammatorv)
U76456 TIMP4 tissue Inhibitor of metalloprotelnase 4
OtJrers lI.voWed ill Prolan T"rnm'c
L20471 BSG baslgln (OK blood group)
M26880 ublQultin C ub'qultln C
()1oskeletonlM~' Proteins
XOO351 beta actin aC~ln beta
U29343 RHAMM hyaluronan-medlated motility receptor (RHAMM)
M23410 Uunctlon plakoglobin !Junction p1akoclobln
M77349 TGF -13 Induced transforming growth factor, beta-induced 68kD
KOO558 aloha tubulin tubulin, alpha UbIQUItous
X~,1521 Vlllln 2 Vlll'n 2 (ezrin)
X94991 IZV'Xln Izyxin
IntemwJi4le FiIaIlWlll Prote/ni
M63618 OS: bullous pemphigoid ant~_ 1j230124OkD)
M9t,D63 Icytokeratin 2 Icytokeratln 2
U:,9167 desmln desmln
M98776 keratin 1 keratin 1 (epldermolytic hyper1<eratosis)
Mgs061 keratIn 2A keratin 2A (eptdermallchthyoslS bullosa c:I Siemens)
Xf7683 keratin 4 keratIn 4
M21389 keratin 5 keratin 5 bul108a simplex Dowtlng-MearalKobnerlWeber- types)
JOD269 keratIn 6A keratin 6A
L42592 keratin 68 keratIn 68
X03212 keratin 7 keratIn 7
M34225 keratin 8 keratIn 8
Z29D74 keratin 9 keratin 9 ic palmoplantar keratoderma)
Appendix Ill: Full list ofgene symbols and corresponding gene names
Accession Gene Symbol IGeneN.me
Number I
Int~nrwIiat~FUll"'" holM'
M19156 keratin 10 keratin 10 (e ic hyperl<eratosis keratosis palmaris et plantaris)
078367 keratin 12 ke'atln 12 (Meesmann comeal dystrophy)
X52426 keratin 13 ke'atln 13
JOO124 keratin 14 ke'atln 14 (e bullosa simplex. DowlinQ-Meara, Koehner)
M26326 kerattn 18 ke'atln 18
YC0503 keratin 19 keratin 19
M21772 K16 CK16 type I cytoskeletal16 keratin cytokeratin 16 (K16 CK 16); pseudo-keratin K16 type I
X56134 vunentln vimentln
D!\A Svnthesls, Recomhination & Repair
D.\'. I RepaClllion: Polymeras~s, RepliCllli1H1 Factors & To~.
M15796 PCNA prollferatlnO cell nuclear antlQen
X06745 POLA po:ymerase (DNA directed) alpha
M62488 RPA1 replication protein A1 (70kD)
M87338 RFC2 replication factor C activator 1 2 4OkO)
L07541 RFC3 replication factor C activator 1 3 381(0)
M87339 RFCA replication factor C activator 1 4 371(0)
lO754O RFC5 replication factor C actIVator 1 5 36 5kO)
J03250 TOP1 tor>Olsomerase (DNA) I
J04088 TOP2A tOr>Olsomerase (DNA) " alpha (170kO)
D.Y..t DtJma~ Si/lflJllJlI/lIRqJDir Protftfll & DNA Ligases
U33841 ATM ataxia telangedasla mutated (Includes complementation oroups A C and 0)
M13194 ERCC1 eXGISIOn repair cross-compiementlng 'odent repair defiCiency, complementation group 1 includes overlapPing antisense sequence)
X52221 ERCC2 eXCISion repair cross-compiementlng rodent repair defiCiency, complementation group 2 xeroderrra plgmentosum D)
M31899 ERCC3 eX,;ISlon repair cross-compiementlng 'odent repair defiCiency, complementation grouP 3 xeroderrra plomentosum croup B complement
L20046 ERCC5 excIsion repair cross-compiementlng rodent repair defiCiency, complementation croup 5 xeroderma ptgmentosum complementation 9
X84740 L1G3 ligase III, DNA ATP-deperdent
X83441 L1G4 ligase IV, DNA, ATP-dependent
U07418 MLH1 mutl homolog 1 colon cancer, nonpolyposiS type 2 (E coli)
U04045 MSH2 mutS homolog 2 colon cancer, nonpalYpOSls type 1 (E coli)
U54777 MSH6 mutS homolog 6 (E coli)
M29971 MGMT 0-6-methylguanlne-DNA methyltransferase
U35835 PRKDC ,protein kinase DNA-actlVa~ed. catalytic polypeptide
0::'1235 RAD23A RAD23 homolc)Q A (S cerevlslae)
U63139 RAD50 RAD50 homolog (S cereVlslae)
013804 RAD51 RAD51 homolog (RecA t-.omolog, E. coli) (S cereYlSiae)
U12134 RAD52 RAD52 homolog (S oereVlslae)
M32865 G2:'P1 thyroid autoantoen 70kO (Ku antiaen)
D,"': I~~ifiRqJDir hotftfll & DSA Ligas~s
M30938 XRCC5 X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoinina: Ku autoentlQen, 8OkO\
M7 4524 UBE2A ublQultln-conluqatlno enzyme E2A (RAD6 homolOQ)
M36089 XRCC1 X.ray repair complementlnQ defectIVe repair In Chinese hamster cells 1
Otlrn DNA Symlt.u, R«ombiflllliofl & Rtpair Protft'lS
X90392 ONASE1L1 IdeoXYribonuclease I-like·
M6C974 GAD045A Igrowth arrest and DNA-damage-tnducible alpha
IX74262 IRBBP4 Iretlnoblastoma binding protein 4
Appendix III: Full list ofgene symbols and corresponding gene names
Accession Gene Symbol GeneNafTle
Number
An~enk racton
M32977 VEGF vascular endothelial growth factor
U43142 VEGFC vascular endot'1elial growth factor C
U48801 VEGFB vascular endothelIal Qrowth factor B
J05081 endothehn 3 endothelin 3
M6t'199 endothehn 2 endothelin 2
U01134 FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factorlva8cular permeability factor receptor)
FUJK1IonaIlv Unclassified
U32907 LRRC17 137 kDa leucine-rich repeat (LRR) protein
U37688 RATS1 IRATS1
1025216 LRRC14 IKlAAOO14 gene product
Appendix III: Full list ofgene symbols and corresponding gene names
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